WO2011053821A1 - Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same - Google Patents

Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same Download PDF

Info

Publication number
WO2011053821A1
WO2011053821A1 PCT/US2010/054797 US2010054797W WO2011053821A1 WO 2011053821 A1 WO2011053821 A1 WO 2011053821A1 US 2010054797 W US2010054797 W US 2010054797W WO 2011053821 A1 WO2011053821 A1 WO 2011053821A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
hydrogen
agonist
alkyl
compound
Prior art date
Application number
PCT/US2010/054797
Other languages
French (fr)
Inventor
Hamid Hoveyda
Éric MARSAULT
Helmut Thomas
Graeme Fraser
Sylvie Beaubien
Axel Mathieu
Julien Beignet
Marc-André BONIN
Serge Phoenix
David Drutz
Mark Peterson
Sophie Beauchemin
Martin Brassard
Martin Vézina
Original Assignee
Tranzyme Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tranzyme Pharma, Inc. filed Critical Tranzyme Pharma, Inc.
Priority to CN2010800600814A priority Critical patent/CN102812037A/en
Priority to JP2012537129A priority patent/JP2013509434A/en
Priority to CA2778990A priority patent/CA2778990A1/en
Priority to EP10774101A priority patent/EP2493910A1/en
Priority to AU2010313282A priority patent/AU2010313282A1/en
Publication of WO2011053821A1 publication Critical patent/WO2011053821A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to novel conformationally-defined macrocyclic compounds that have been demonstrated to function as antagonists or inverse agonists of the ghrelin (growth hormone secretagogue) receptor (GRLN, GHS-Rla).
  • GHLN growth hormone secretagogue receptor
  • the invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the compounds.
  • These novel macrocyclic compounds are useful as therapeutics for a range of indications including metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disordersand inflammatory disorders.
  • ghrelin is a recently characterized 28-amino acid peptide hormone that has been shown to mediate a variety of important physiological functions.
  • a novel characteristic of the structure is the presence of an rc-octanoyl group on Ser thai appears to be relevant to ghrelin' s activity.
  • GPCR G protein-coupled receptor
  • hGHS-Rla type 1 growth hormone secretatogue receptor
  • GPCR G protein-coupled receptor
  • GHS-Rla has recently been reclassified as the ghrelin receptor (GRLN) in recognition of its endogenous ligand (Davenport, A.P. ; et al. Pharmacol Rev, 2005, 57, 541- 546).
  • GH growth hormone
  • GHRH growth hormone-releasing hormone
  • GRF growth hormone releasing factor
  • GHS growth hormone-releasing peptides
  • GHS were projected to have utility in a variety of other disorders, including the treatment of wasting conditions (cachexia) as seen in HIV patients and cancer-induced anorexia, musculoskeletal frailty in the elderly, and growth hormone deficient diseases.
  • wasting conditions cachexia
  • musculoskeletal frailty in the elderly
  • growth hormone deficient diseases a number of potent, orally available GHS.
  • ghrelin has been found to have multiple other physiological functions apart from the stimulation of GH release, including regulation of food intake and appetite, promotion of weight gain, control of energy balance, and modulation of gastrointestinal (GI) motility, gastric acid secretion and glucose homeostasis.
  • GI gastrointestinal
  • the hormone has also been linked to control of circadian rhythm and memory.
  • Ghrelin appears to also play a role in bone metabolism and inflammatory processes.
  • WO 2004/09124 and WO 2005/68639 describe modified virus particles derived from short peptide sequences from the N-terminus of ghrelin that can be used as vaccines for treatment of obesity. Another vaccine approach for obesity is described in WO 2004/024183.
  • WO 01/56592 and US 2001/020012 describe the use of ghrelin antagonists for the regulation of food intake.
  • WO 2004/004772 describes the use of GHS-R antagonists as a treatment for diabetes, obesity and appetite control. Their use for treatment of intestinal inflammation has also been described (Intl. Pat. Appl. Publ. WO 2004/084943; U.S. Pat. Appl. Publ. 2007/0025991).
  • no specific examples of compounds, apart from ghrelin peptide and its analogues, for this purpose are presented in these applications.
  • thermoregulation, sleep, appetite, food intake, obesity and other ghrelin-mediated conditions through reduction of ghrelin expression is described in U.S. Pat. Appl. Publ. 2010/0196396.
  • Ghrelin antagonists and inverse agonists have also been considered for playing a role in the reduction of the incidence of the following obesity-associated conditions including diabetes, complications due to diabetes such as retinopathy, cardiovascular diseases, hypertension, dyslipidemia, osteoarthritis and certain forms of cancer.
  • diabetes complications due to diabetes such as retinopathy, cardiovascular diseases, hypertension, dyslipidemia, osteoarthritis and certain forms of cancer.
  • transgenic rats engineered without the GRLN (GHS-Rla) receptor have exhibited reduced food intake, diminished fat deposition, and decreased weight.
  • GRS-Rla GRLN
  • the hormone's involvement in a number of physiological processes, including regulation of cardiovascular function and stress responses as well as growth hormone release may indicate potential drawbacks to this strategy.
  • complete lack of ghrelin may not be desirable, but suppression may be sufficient to control obesity and other metabolic disorders.
  • Ghrelin plays a key role in the regulation of insulin release and glycemia and hence modulators of the ghrelin receptor have application to the treatment of diabetes and metabolic syndrome.
  • Ghrelin reduces glucose stimulated insulin secretion, decreases insulin sensitivity, increases resting/fasting blood glucose levels, shifts energy metabolism from fat to glucose, and indirectly antagonizes insulin dependent CNS regulation of food intake and glucose homeostasis.
  • Asnicar, M Smith, R.G. Neuroendocrinal. 2007, 86, 215-228; Dezaki, K.; Sone, H.; Yada, T. Pharmacol. Ther. 2008, 118, 239-249; Tong, J.; Prigeon, R.L.; Davis, H.W.; et al. Diabetes 2010, 59, 2145-2151.
  • Ghrelin antagonists and/or inverse agonists hence would have beneficial effects for the treatment or prevention of diabetes and related conditions, such as metabolic syndrome.
  • GHS-Rl a receptor and inhibit receptor activation by native ghrelin.
  • This same molecule is a full agonist with respect to stimulating weight gain and food intake.
  • This and related peptidic ghrelin analogues effectively separate the GH-modulating activity of ghrelin from the effects of the peptide on weight gain and appetite.
  • the macrocyclic ghrelin agonists described in WO 2006/009645 and WO 2006/009674 report the separation of the Gl effects from the GH-release effects in animal models.
  • ghrelin-O-acyltransferase (Romero, A.; Kirchner, H.; Heppner, K.; et al. Eur. J. Endocrinol. 2010, 163, 1 -8; Intl. Pat. Appl. Publ. WO 2008/079705; Gutierrez, J.A.; Solenberg, P.J.; Perkins, D.R.; et al. Proc. Natl. Acad. Sci.
  • GOAT is responsible for the postradiational modification that incoporates the n-octanoyl moiety on Ser 3 of ghrelin.
  • this acylated form is the active species in vivo. Pentapeptide (Yang, J.; Zhao, T.J.; Goldstein, J.L.; et al. Proc. Natl Acad. Sci. 2008, 105, 10750- 10755), small molecule (BK11 14, U.S. Pat. Appl. Publ. 2010/0086955) and bisubstrate (Intl. Pat. Appl. Publ.
  • WO 2010/039461 inhibitors of GOAT have been reported, but this approach is still not yet proven in humans.
  • Prader-Willi syndrome the most common form of human syndromic obesity, is characterized paradoxically by GH deficiency and high ghrelin levels that are not decreased after feeding.
  • Antagonists of the ghrelin receptor would have a role in treating this syndrome as well.
  • NAFLD non-alcoholic steatohepatitis
  • NAFLD can occur with or without inflammation of the liver or liver cell injury or damage, and without a history of excessive alcohol ingestion. It has been suggested that NAFLD represents the hepatic manifestation of metabolic syndrome, but may also predict the development of metabolic syndrome. Although NAFLD has been found in patients without risk factors, individuals with conditions such as diabetes, obesity, hypertension and hypertriglyceridemia are at greatest risk of developing the condition. An inextricable relationship exists between central obesity, steatosis and insulin resistance. Adipokines and ghrelin have been implicated in the pathogenesis of nonalcoholic fatty liver disease through their metabolic and/or anti-inflammatory activity. Emerging data shows a relationship between NAFLD, ghrelin and adipokines.
  • Ghrelin was elevated in patients with NAFLD, primarily those with normal body weight. Peripheral ghrelin induces lipid accumulation in specific abdominal depots, liver and skeletal muscle without affecting superficial subcutaneous white adipose tissue. These effects may be augmented by suppression of spontaneous growth hormone (GH) secretion. In addition, peripheral ghrelin and des-acyl ghrelin induce adipogenesis in bone marrow. Peripheral ghrelin defends accumulated fat in abdominal locations associated with the development of metabolic syndrome (Wells, T. Prog. Lipid Res. 2009, doi: 10.1016/j .plipres .2009.04.002). Studies have shown that ghrelin may influence adipocyte metabolism and stimulate adipogenesis. (Depoortere, 1. Regul. Pept. 2009, 156, 13-23.). Ghrelin antagonists would therefore be useful in the treatment or prevention of NAFLD and NASH.
  • GH spontaneous growth hormone
  • Such agents may have potential for diabetic hyperphagia.
  • Hyperphagia and altered fuel metabolism result from uncontrolled diabetes mellitus in humans. This has been suggested to occur through a combination of elevated ghrelin levels and decreased leptin through the NPY/AGRP pathway.
  • levels of ghrelin are essential ly the same in healthy and diabetic subjects, the different levels of ghrelin in diabetic hyperphagia could make it difficult to remain on diet therapies and an antagonist could be useful in assisting control.
  • Ghrelin levels are elevated in cirrhosis and with complications from chronic liver disease, although unlike levels of insulin-like growth factor-1 (IGF- 1 ), they do not correlate to liver function.
  • IGF- 1 insulin-like growth factor-1
  • Ghrelin antagonists could be useful in . controlling these liver diseases.
  • ghrelin and its receptor are overexpressed in numerous cancers. Antagonists would have potential application to treatment of cancer.
  • Intl. Pat. Appl. Publ. WO 02/90387 has described the use of interventionist strategies targeting GHS-Rl a as an approach to treatment of cancers of the reproductive system.
  • Ghrelin antagonists therefore would have utility for treatment of alcohol-related disorders (Leggio, L. Drug News Perspect. 2010, 23, 157- 166.) and other addictive disorders, such as drug dependence (Intl. Pat. Appl. Publ. WO 2009/020419).
  • ghrelin antagonists only a limited number of small molecule ghrelin antagonists have yet been reported in the patent or scientific literature including diaminopyrimidiues, tetralin carboxamides, isoxazole carboxamides, ⁇ -carbolines, oxadiazoles, pyrazoles, benzofuranylindolones and benzenesulfonamides. (U.S. Pat. Appl.
  • WO 2005/1 14180 describes a number of individual compounds containing heteroaryl core structures, such as isoazoles, 1,2,4-oxadiazoles and 1 ,2,4-triazoles, as "functional ghrelin antagonists" and their uses as therapeutic agents for the treatment of obesity and diabetes.
  • heteroaryl core structures such as isoazoles, 1,2,4-oxadiazoles and 1 ,2,4-triazoles, as "functional ghrelin antagonists" and their uses as therapeutic agents for the treatment of obesity and diabetes.
  • Other heterocyclic structures, some of which displayed antagonist activity, are reported in WO 2005/035498; WO 2005/097788 and US 2005/0187237.
  • ghrelin antagonists are primarily peptidic in nature (WO 2004/09616, WO 02/08250, WO 03/04518, US 2002/0187938, Pinilla, L.; Barreiro, M.L.; Tena-Sempere, ML; Aguilar E. Neuroendocrinology 2003, 77, 83-90) although antagonists based on nucleic acids have also been disclosed (WO 2004/013274; WO 2005/49828; Helmling, S.; Maasch, C; Eulberg, D.; et al. Proc. Natl Acad.
  • the compounds of the present invention are structurally distinct from all of these previously reported ghrelin antagonist structures.
  • the present invention provides novel conformationally-defincd macrocyclic compounds that can function as antagonists or inverse agonists of the ghrelin (growth hormone secretagogue) receptor (GRLN, GHS-R 1 a).
  • GHLN growth hormone secretagogue receptor
  • the present invention relates to compounds according to formu
  • T is selected from and , wherein (NA) indicates the site of bonding of to NR4 a of formula (I) and (NR) indicates the site of bonding to NR 4c of formula (I);
  • Ri is selected from the group consisting of -(CH 2 ) S CH 3 , -CH(CI I 3 )(CH 2 ) t CH ,
  • R N and Ri 2 are optionally present and, when present, are independently selected from the group consisting of C
  • 7 is hydrogen or methyl; and Rj s is selected from the group consisting of hydrogen, C
  • R 2a is selected from the group consisting of -CH 3 , -CH 2 CH 3 , -CH(CH ) 2 , -CF 3 , -CF 2 H and -CH 2 F;
  • R 2b is selected from the group consisting of -H and -CH 3 ;
  • R 3a is selected from the group consisting of hydrogen, C
  • R 3b is selected from the group consisting of hydrogen and C
  • R 4a , R 4b , R 4c and R 4( j are independently selected from the group consisting of hydrogen and Q-C4 alkyl;
  • R5 when Y
  • 6 , is selected from the group consisting of hydrogen, C] -C4 alkyl and acy! ; or, when Y ] is C( 0), is selected from the group consisting of hydroxyl, alkoxy and amine;
  • R6 is selected from the group consisting of hydrogen, Cj -C 4 alkyl, oxo and trifluoromethyl
  • R 7 is selected from the group consisting of hydrogen, C[-C 4 alkyl, hydroxyl, alkoxy and trifluoromethyl
  • R 7 and X together form a five or six-membered ring
  • Rio is selected from the group consisting of hydrogen, C
  • R26, R?8 and R2 are independently selected from the group consisting of hydrogen, C
  • R27 is selected from the group consisting of hydrogen, C r C 4 alkyl, hydroxyl, alkoxy and trifluoromethyl; or R 27 and X43 together form a five or six-membered ring
  • R30 is selected from the group consisting of hydrogen, C
  • Ar is selected from the group consisting of:
  • Mi, M 2 , M 3 , M 4 , M 5 , M 6 , M 7 , Mg and M M arc independently selected from the group consisting of O, S and NR
  • X40, X 4 i and X42 are independently selected from the group consisting of hydrogen, hydroxyl, alkoxy, amino, halogen, cyano, trifluoromethyl and C)-C 4 a!kyl;
  • Lj, L 2 , L 3 , L 4 and L 6 are independently selected from the group consisting of CH and N;
  • L5 is selected from the group consisting of CR
  • Xi is selected from the group consisting of hydrogen, halogen, trifluoromethyl and C1-C4 alkyl; or X
  • X 2 , X 3 and X 4 are independently selected from the group consisting of hydrogen, halogen, trifluoromethyl and C1-C4 alkyl;
  • X43 and X44 are optionally present and, when present, are independently selected from the group consisting of C
  • z 0, 1, 2 or 3;
  • Z is selected from the group consisting of
  • (Ar)-CR 8b CR -(Lc) and -(Ar)-C ⁇ C-(L ⁇ 5), wherein (Ar) indicates the site of bonding to the phenyl ring and (L 6 ) the site of bonding to L 6 , R 8a and R3 ⁇ 4 are independently selected from the group consisting of hydrogen, Cj-C 4 alkyl, hydroxyl, alkoxy, oxo and trifluoromethyl; Rgb and R 9h are independently selected from the group consisting of hydrogen, C
  • compositions comprising: (a) a compound of the present invention; and (b) a pharmaceutically acceptable carrier, excipient or diluent.
  • compositions comprising (a) a compound of the present invention; (b) one or more additional therapeutic agents ;and (c) a pharmaceutically acceptable carrier, excipient or diluent.
  • the additional therapeutic agent is selected from the group comprising a GLP-1 agonist, a DPP-TV inhibitor, an amylin agonist, a PPAR-a agonist, a PPAR- ⁇ agonist, a PPAR- ⁇ / ⁇ dual agonist, a GDTR or GPR l 19 agonist, a FTP- I B inhibitor, a peptide YY agonist, an 1 ⁇ ⁇ -hydroxysteroid dehydrogenase (1 ⁇ -HSD)-!
  • a sodium-dependent renal glucose transporter type 2 (SGLT-2) inhibitor a glucagon antagonist, a glucokinase activator, an a-glucosidase inhibitor, a glucocorticoid antagonist, a glycogen synthase kinase 3 ⁇ (GSK-3 ) inhibitor, a glycogen phosphorylase inhibitor, an AMP- activated protein kinase (AMPK) activator, a fructose- 1 ,6-biphosphatase inhibitor, a sulfonyl urea receptor antagonist, a retinoid X receptor activator, a 5- ⁇
  • kits comprising one or more containers containing pharmaceutical dosage units comprising an effective amount of one or more compounds of the present invention packaged with optional instructions for the use thereof.
  • the present invention provides methods of modulating GRLN receptor activity in a mammal comprising administering an effective GRLN receptor activity modulating amount of a compound of the present invention.
  • the compound is a ghrclin receptor antagonist or a GRLN receptor antagonist.
  • the compound is a ghre!in receptor inverse agonist or a GRLN receptor inverse agonist.
  • the compound is both a ghrelin receptor antagonist and a ghrelin receptor inverse agonist or a GRLN receptor antagonist and a GRLN receptor inverse agonist.
  • aspects of the present invention further relate to methods of preventing and/or treating disorders such as metabolic and/or endocrine disorders, obesity and obesity- associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.
  • disorders such as metabolic and/or endocrine disorders, obesity and obesity- associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.
  • the metabolic disorder is obesity, diabetes, metabolic syndrome, non-alcoholic fatty acid liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) or steatosis.
  • NAFLD non-alcoholic fatty acid liver disease
  • NASH non-alcoholic steatohepatitis
  • steatosis is obesity, diabetes, metabolic syndrome, non-alcoholic steatohepatitis (NASH) or steatosis.
  • the appetite or eating disorder is Prader-Willi syndrome or hyperphagia.
  • the addictive disorder is alcohol dependendence, drug dependence or chemical dependence.
  • the present invention also relates to compounds of formula I useful for the preparation of a medicament for prevention and/or treatment of the disorders described herein.
  • Figure 1 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1319.
  • Figure 2 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1350.
  • Figure 3 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1636.
  • Figure 4 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1383.
  • Figure 5 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1390.
  • Figure 6 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1401.
  • Figure 7 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1300.
  • Figure 8 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1505.
  • Figure 9 shows a graph presenting results of a study to assess the in vivo activity of an exemplary compound of the present invention, compound 1505, specifically the effect on body weight in the Zucker fatty rat model.
  • Figure 10 shows a graph presenting results of a study to assess the in vivo activity of an exemplary compound of the present invention, compound 1505, specifically the effect on cumulative food consumption in the Zucker fatty rat model.
  • Figure 11 shows a graph presenting results of a study to assess the in vivo activity of an exemplary compound of the present invention, compound 1712, specifically the effect on acute cumulative food consumption in the ob/ob mouse model.
  • Figure 12 shows a graph presenting results of a study to assess the in vivo activity of an exemplary compound of the present invention, compound 848, specifically the effect on cumulative food consumption in the ob/ob mouse model.
  • Figure 13 shows a series of graphs presenting results of a study to assess the in vivo activity of an exemplary compound of die present invention, compound 1848, specifically the effect on selected metabolicm parameters.
  • alkyl refers to straight or branched chain saturated or partially unsaturated hydrocarbon groups having from 1 to 20 carbon atoms, and in some instances, ] to 8 carbon atoms.
  • lower alkyl refers to alkyl groups containing 1 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, isopropyl, /erf-butyi, 3-hexenyl, and 2-butynyl.
  • unsaturated is meant the presence of 1 , 2 or 3 double or triple bonds, or a combination of the two. Such alkyl groups may also be optionally substituted as described below.
  • C 2 -C4 alkyl indicates an alkyl group that contains 2, 3 or 4 carbon atoms.
  • cycloalkyl refers to saturated or partially unsaturated cyclic hydrocarbon groups having from 3 to 15 carbon atoms in the ring, and in some instances, 3 to 7, and to alkyl groups containing said cyclic hydrocarbon groups.
  • examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopropylmethyl, cyclopentyl, 2-(cyclohexyl)ethyl, cycloheptyl, and cyclohexenyl.
  • Cycloalkyl as defined herein also includes groups with multiple carbon rings, each of which may be saturated or partially unsaturated, for example decalinyl, [2.2.1]-bicycloheptanyl or adamantanyl. All such cycloalkyl groups may also be optionally substituted as described below.
  • aromatic refers to an unsaturated cyclic hydrocarbon group having a conjugated pi electron system that contains 4n+2 electrons where n is an integer greater than or equal to 1.
  • Aromatic molecules are typically stable and are depicted as a planar ring of atoms with resonance structures that consist of alternating double and single bonds, for example benzene or naphthalene.
  • aryl refers to an aromatic group in a single or fused carbocyclic ring system having from 6 to 35 ring atoms, and in some instances, 6 to 10, and to alkyl groups containing said aromatic groups.
  • aryl groups include, but are not limited to, phenyl, 1 -naphthyl, 2-naphthyl and benzyl.
  • Aryl as defined herein also includes groups with multiple aryl rings which may be fused, as in naphthyl and anthracenyl, or unfused, as in biphenyl and terphenyl.
  • Aryl also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated or aromatic, for example, indanyl or tetrahydronaphthyl (tetralinyl). All such aryl groups may also be optionally substituted as described below.
  • heterocycle refers to saturated or partially unsaturated monocyclic, bicyclic or tricyclic groups having from 3 to 15 atoms, and in some instances, 3 to 7, with at least one heteroatoin in at least one of the rings, said hcteroatom being selected from O, S or N.
  • Each ring of the heterocyclic group can contain one or two O atoms, one or two S atoms, one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom.
  • the fused rings completing the bicyclic or tricyclic heterocyclic groups may contain only carbon atoms and may be saturated or partially unsaturated.
  • heterocyclic also refers to alkyl groups containing said monocyclic, bicyclic or tricyclic heterocyclic groups. Examples of heterocyclic rings include, but are not limited to, 2- or 3-piperidinyi, 2- or 3-piperazinyl, 2- or 3-morpholinyl. All such heterocyclic groups may also be optionally substituted as described below
  • heteroaryl refers to an aromatic group in a single or fused ring system having from 5 to 15 ring atoms, and in some instances, 5 to 10, which have at least one heteroatom in at least one of the rings, said heteroatom being selected from O, S or N.
  • Each ring of the heteroaryl group can contain one or two O atoms, one or two S atoms, one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom.
  • the fused rings completing the bicyclic or tricyclic groups may contain only carbon atoms and may be saturated, partially unsaturated or aromatic.
  • the N atoms may optionally be quatemized or oxidized to the N-oxide.
  • Heteroaryl also refers to alkyl groups containing said cyclic groups.
  • Examples of monocyclic heteroaryl groups include, but are not limited to pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyi, and triazinyi .
  • bicyclic heteroaryl groups include, but are not limited to indolyl, benzothiazolyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazo!yl, benzopyranyl, indolizinyl, benzofuranyl, isobenzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxaliny!, indazolyl, purinyl, pyrrolopyridiny.l, furopyridinyl, thienopyridinyl, dihydroisoindolyl, and tetrahydroquinolinyl.
  • tricyclic heteroaryl groups include, but are not limited to carbazolyl, benzindolyl, phenanthrollinyl, acridinyl, phenanthridinyl, and xanthenyl. Ail such heteroaryl groups may also be optionally substituted as described below.
  • hydroxyl refers to the group -OH.
  • alkoxy refers to the group -OR a , wherein R ;i is alkyl, cycloalkyl or heterocyclic. Examples include, but are not limited to methoxy, ethoxy, teri-butoxy, cyclohexyloxy and tetrahydropyranyloxy.
  • aryloxy refers to the group -OR b wherein R
  • Examples include, but are not limited to phenoxy, benzyloxy and 2-naphihyloxy.
  • amino acyl indicates an acyl group that is derived from an amino acid.
  • amino refers to an -NR d R e group wherein R d and R e arc independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl.
  • R ⁇ j and R E together form a heterocyclic ring of 3 to 8 members, optionally substituted with unsubstituted alkyl , unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryLoxy, acyl, amino, amido, carboxy, carboxyalkyl, carboxyaryl, mercapto, sulfinyl, suifonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heteroatoms selected from O, S or N.
  • Rf and R g together form a heterocycl ic ring of 3 to 8 members, optionally substituted with unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyaikyl, carboxyaryl, mercapto, sulfinyl, sulfonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heteroatoins selected from O, S or N.
  • Rj and R together form a heterocyclic ring of 3 to 8 members, optionally substituted with unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyaikyl, carboxyaryl, mercapto, sulfinyl, sulfonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heleroatoms selected from O, S or N.
  • Carboxyaikyl refers to the group -CC ⁇ k , wherein 3 ⁇ 4s alkyl, cycloalkyl or heterocyclic.
  • Carboxyaryl refers to the group -CO 2 RTM, wherein R m is aryl or heteroaryl.
  • cyano refers to the group -CN.
  • halo refers to fluoro, fluorine or fluoride, chloro, chlorine or chloride, bromo, bromine or bromide, and iodo, iodine or iodide, respectively.
  • mercapto refers to the group -SR n wherein R n is hydrogen, alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl .
  • nitro refers to the group -N0 2 .
  • trifluoromethyl refers to the group -CF3.
  • aminosulfonyl refers to the group wherein R q2 is hydrogen, alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl; and R q 3 is alkyl, cycloalkyl, heterocyclic, aryi or heteroaryl.
  • R v and R s together form a heterocyclic ring of 3 to 8 members, optionally substituted with unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyalkyl, carboxyaryl, mercapto, sulfinyl, sulfonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heteroatoms selected from O, S or N.
  • R x and R y together form a heterocyclic ring or 3 to 8 members, optionally substituted with unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyalkyl, carboxyaryl, mercapto, sulfinyl, sulfonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heteroatoms selected from O, S or N.
  • R z , R aa and R bb are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl.
  • R aa and R bb together with the nitrogen atom to which they are each bonded form a heterocyclic ring of 3 to 8 members, optionally substituted with unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyalkyl, carboxyaryl, mercapto, sulfinyl, sulfonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heteroatoms selected from O, S or N.
  • optionally substituted is intended to expressly indicate that the specified group is unsubstituted or substituted by one or more suitable substituents, unless the optional substituents are expressly specified, in which case the term indicates that the group is unsubstituted or substituted with the specified substituents.
  • various groups may be unsubstituted or substituted (i.e., they are optionally substituted) unless indicated otherwise herein (e.g., by indicating that the specified group is unsubstituted).
  • R cc , R dd , R ee , Rj T , R gg , R hh , R ;i , R , R mm , R p , R qq and R 1T are independently selected from hydrogen, unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl or unsubstituted heteroaryl; and wherein R kk and R flesh attorney are independently selected from unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl or unsubstituted heteroaryl.
  • substituted for aryl and heteroaryl groups includes as an option having one of the hydrogen atoms of the group replaced by
  • substitution is made provided that any atom's normal valency is not exceeded and that the substitution results in a stable compound.
  • such substituted group may not be further substituted or, if substituted, the substituent comprises only a limited number of substituted groups, for example 1 , 2, 3 or 4 such substituents.
  • stable compound or “stable structure” is meant to mean a compound that is sufficiently robust to survive isolation to a useful degree of purity and formulation into an efficacious therapeutic agent.
  • amino acid refers to the common natural (genetical ly encoded) or synthetic amino acids and common derivatives thereof, known to those skil led in the art.
  • standard or “proteinogenic” refers to the genetically encoded 20 amino acids in their natural configuration.
  • unnatural or “unusual” refers to the wide selection of non-natural, rare or synthetic amino acids such as those described by Hunt, S. in Chemistry and Biochemistry of the Amino Acids, Barrett, G.C., Ed., Chapman and Hall: New York, 1985.
  • residue with reference to an amino acid or amino acid derivative refers to a group of the formula:
  • AA is an amino acid side chain
  • n 0, 1 or 2 in this instance.
  • fragment with respect to a dipeptide, tripeptide or higher order peptide derivative indicates a group that contains two, three or more, respectively, amino acid residues.
  • amino acid side chain refers to any side chain from a standard or unnatural amino acid, and is denoted R A A.
  • R A A amino acid side chain
  • the side chain of alanine is methyl
  • the side chain of valine is isopropyl
  • the side chain of tryptophan is 3-indolylmethyl.
  • agonist refers to a compound that duplicates at least some of the effect of the endogenous ligand of a protein, receptor, enzyme or the like.
  • antagonist refers to a compound that inhibits at least some of the effect of the endogenous ligand of a protein, receptor, enzyme or the like.
  • inverse agonist refers to a compound that decreases, at least to some degree, the baseline functional activity of a protein, receptor, enzyme or the like, such as the constitutive signaling activity of a G protein-coupled receptor or variant thereof.
  • An inverse agonist can also be an antagonist.
  • baseline functional activity refers to the activity of a protein, receptor, enzyme or the like, including constitutive signaling activity, in the absence of the endogenous ligand.
  • growth hormone secretagogue refers to any exogenoissly administered compound or agent that directly or indirectly stimulates or increases the endogenous release of growth hormone, growth hormone-releasing hormone, or somatostatin in an animal, in particular, a human.
  • a GHS may be peptidic or non-peptidic in nature, with an agent that can be administered orally preferred, in addition, an agent that induces a pulsatile response is preferred.
  • modulator refers to a compound that imparts an effect on a biological or chemical process or mechanism.
  • a modulator may increase, facilitate, upregulate, activate, inhibit, decrease, block, prevent, delay, desensitize, deactivate, down regulate, or the like, a biological or chemical process or mechanism.
  • a modulator can be an "agonist,” an "antagonist,” or an "inverse agonist.”
  • Exemplary biological processes or mechanisms affected by a modulator include, but are not limited to, receptor binding and hormone release or secretion.
  • Exemplary chemical processes or mechanisms affected by a modulator include, but are not limited to, catalysis and hydrolysis.
  • variable when applied to a receptor is meant to include dimers, trimers, tetramers, pentamers and other biological complexes containing multiple components. These components can be the same or different.
  • peptide refers to a chemical compound comprised of two or more amino acids covalently bonded together.
  • peptidomimetic refers to a chemical compound designed to mimic a peptide, but which contains structural differences through the addition or replacement of one of more functional groups of the peptide in order to modulate its activity or other properties, such as solubility, metabolic stability, oral bioavailability, lipophilicity, permeability, etc. This can include replacement of the peptide bond, side chain modifications, truncations, additions of functional groups, etc.
  • non-peptide peptidomimetic When the chemical structure is not derived from the peptide, but mimics its activity, it is often referred to as a "non-peptide peptidomimetic.”
  • protecting group refers to any chemical compound that may be used to prevent a potentially reactive functional group, such as an amine, a hydroxyl or a carboxyl, on a molecule from undergoing a chemical reaction while chemical change occurs elsewhere in the molecule. A number of such protecting groups are known to those skilled in the art and examples can be found in "Protective Groups in Organic Synthesis," Theodora W. Greene and Peter G.
  • amino protecting groups include, but are not limited to, phthalimido, trichloroacetyl, benzyloxycarbonyl, ierr-butoxycarbonyi, and adamanlyloxy- carbonyt.
  • Preferred amino protecting groups are carbamate amino protecting groups, which are defined as an amino protecting group that when bound to an amino group forms a carbamate.
  • Preferred amino carbamate protecting groups are allyloxycarbonyl (Alloc or Aloe), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), ierr-butoxycarbonyi (Boc) and a,a-dimethyl-3,5-dimethoxybenzyloxycarbonyl (Ddz).
  • allyloxycarbonyl Alloc or Aloe
  • benzyloxycarbonyl Cbz
  • 9-fluorenylmethoxycarbonyl Fmoc
  • ierr-butoxycarbonyi Boc
  • Ddz a,a-dimethyl-3,5-dimethoxybenzyloxycarbonyl
  • hydroxyl protecting groups include, but are not limited to, acetyl, tert- butyldimethylsilyl (TBDMS), trityl (Trt), tenf-butyl, and tetrahydropyranyl (THP).
  • carboxyl protecting groups include, but are not limited to methyl ester, terr-butyl ester, benzyl ester, trimethylsiiylethyl ester, and 2,2,2-trichloroethyl ester.
  • solid phase chemistry refers to the conduct of chemical reactions where one component of the reaction is covalently bonded to a polymeric material (solid support as defined below). Reaction methods for performing chemistry on solid phase have become more widely known and established outside the traditional fields of peptide and oligonucleotide chemistry.
  • solid support refers to a mechanically and chemically stable polymeric matrix utilized to conduct solid phase chemistry. This is denoted by "Resin,” “P-” or the following symbol: ⁇
  • polystyrene polyethylene, polyethylene glycol, polyethylene glycol grafted or covalently bonded to polystyrene (also termed PEG-polystyrene, TentaGelTM, Rapp, W.; Zhang, L.; Bayer, E. In Innovations and Persepctives in Solid Phase Synthesis. Peptides, Polypeptides and Oligonucleotides; Epton, R., Ed.; SPCC Ltd.
  • polyacrylate (CLEARTM), polyacrylamide, polyurethane, PEGA polyethyleneglycol poiy(N,N-dimethyiacrylamide) co-polymer, Meldal, M. Tetrahedron Lett. 1992, 33, 3077- 3080], cellulose, etc.
  • CLARTM polyacrylate
  • polyacrylamide polyurethane
  • PEGA polyethyleneglycol poiy(N,N-dimethyiacrylamide) co-polymer
  • Meldal M. Tetrahedron Lett. 1992, 33, 3077- 3080
  • cellulose etc.
  • These materials can optionally contain additional chemical agents to form cross-linked bonds to mechanically stabilize the structure, for example polystyrene cross-linked with divinylbenezene (DVB, usually 0.1-5%, or 0.5-2%).
  • DVD divinylbenezene
  • This solid support can include as non-limiting examples aminomethyl polystyrene, hydroxymethyl polystyrene, benzhydrylamine polystyrene (BHA), methy!benzhydrylamine (M B HA) polystyrene, and other polymeric backbones containing free chemical functional groups, most typically, -NH? or -OH, for further derivatization or reaction.
  • the term is also meant to include "Ultraresins" with a high proportion ("loading") of these functional groups such as those prepared from polyethyleneimines and cross-linking molecules (Barth, M. ; Rademann, J. J. Comb. Chem. 2004, 6, 340-349).
  • resins are typically discarded, although they have been shown to be able to be reused such as in Frcchet, J.M.J.; Haque, K.E. Tetrahedron Lett. 1975, 16, 3055.
  • the materials used as resins are insoluble polymers, but certain polymers have differential solubility depending on solvent and can also be employed for solid phase chemistry.
  • polyethylene glycol can be utilized in this manner since it is soluble in many organic solvents in which chemical reactions can be conducted, but it is insoluble in others, such as diethyl ether.
  • reactions can be conducted homogeneously in solution, then the product on the polymer precipitated through the addition of diethyl ether and processed as a solid. This has been termed "liquid-phase" chemistry.
  • linker when used in reference to solid phase chemistry refers to a chemical group that is bonded covalently to a solid support and is attached between the support and the substrate typically in order to permit the release (cleavage) of the substrate from the solid support. However, it can also be used to impart stability to the bond to the solid support or merely as a spacer element. Many solid supports are available commercially with linkers already attached.
  • the term "effective amount” or "effective” is intended to designate a dose that causes a relief of symptoms of a disease or disorder as noted through clinical testing and evaluation, patient observation, and the like, and/or a dose that causes a detectable change in biological or chemical activity as detected by one skilled in the art for the relevant mechanism or process. As is generally understood in the art, the dosage will vary depending on the administration routes, symptoms and body weight of the patient but also depending upon the compound being administered.
  • Administration of two or more compounds "in combination” means that the two compounds are administered closely enough in time that the presence of one alters the biological effects of the other.
  • the two compounds can be administered simultaneously (concurrently) or sequentially. Simultaneous administration can be carried out by mixing the compounds prior to administration, or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration.
  • the phrases "concurrent administration”, “administration in combination”, “simultaneous administration” or “administered simultaneously” as used herein, means that the compounds are administered at the same point in time or immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time.
  • pharmaceutically active metabolite is intended to mean a pharmacologically active product produced through metabolism in the body of a specified compound.
  • solvate is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound.
  • examples of solvates include compounds of the invention in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.
  • the macrocyclic compounds of the invention have been shown to possess ghrelin modulating activity, and in particular embodiments, as antagonists or inverse agonists,
  • a series of macrocyclic peptidomimetics recently has been described as modulators of the ghrelin receptor and their uses for the treatment and prevention of a range of medical conditions including metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders outlined (U.S. Pat. Nos. 7,452,862, 7,476,653 and 7,491,695; Intl. Pat. Appl. Publ. Nos.
  • TZP- 101 a ghrelin agonist
  • the compounds of the present invention differ in structural composition and chiral configuration when compared to these agonists.
  • the macrocyclic compounds of the present invention have been found to possess such desirable pharmacological characteristics, while maintaining sufficient binding affinity and or selectivity for the ghrelin receptor, as illustrated in the Examples. These combined characteristics are superior to the macrocyclic ghrelin antagonist compounds previously described and make them more suitable for development as pharmaceutical agents, particularly for use as orally administered agents or for chronic uses.
  • Novel macrocyclic compounds of the present invention include those of formula (I):
  • component T is selected from
  • the compound can have any of the structures defined in Table 1 . These structures are based upon the structural formula (A):
  • T A elements of Table 1 are as follows:
  • N A indicates the site of bonding to NR a of formula (A)
  • N B indicates the site of bonding to NR C of formula (A)
  • Pg is a nitrogen protecting group
  • the present invention includes isolated compounds.
  • An isolated compound refers to a compound that, in some embodiments, comprises at least 10%, at least 25%, at least 50% or at least 70% of the compounds of a mixture.
  • the compound, pharmaceutically acceptable salt thereof or pharmaceutical composition containing the compound exhibits a statistically significant binding and/or antagonist activity and or inverse agonist activity when tested in biological assays at the human ghrelin receptor.
  • the compounds of formula (I) herein disclosed have asymmetric centers.
  • the inventive compounds may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates, and mixtures thereof are intended to be within the scope of the present invention. However, the inventive compounds are used in optically pure form.
  • the terms "S” and "R” configuration as used herein are as defined by the IUPAC 1974 Recommendations for Section E, Fundamentals of Stereochemistry ⁇ Pure Appi Chem. 1976, 45, 13-30.).
  • the compounds may be prepared as a single stereoisomer or a mixture of stereoisomers.
  • the non-racemic forms may be obtained by either synthesis or resolution.
  • the compounds may, for example, be resolved into the component enantiomers by standard techniques, for example formation of diastereomeric pairs via salt formation.
  • the compounds also may be resolved by covalently bonding to a chiral moiety.
  • the diastereomers can then be resolved by chromatographic separation and/or crystallographic separation. In the case of a chiral auxiliary moiety, it can then be removed.
  • the compounds can be resolved through the use of chiral chromatography. Enzymatic methods of resolution could also be used in certain cases.
  • an “optically pure” compound is one that contains only a single enantiomer.
  • the term “optically active” is intended to mean a compound comprising at least a sufficient excess of one enantiomer over the other such thai the mixture rotates plane polarized light. The enantiomeric excess (e,e.) indicates the excess of one enantiomer over the other.
  • Optically active compounds have the ability to rotate the plane of polarized light.
  • D and L or R and S are used to denote the absolute configuration of the molecule about its chiral ccnter(s).
  • the prefixes "d” and “1" or (+) and (-) are used to denote the optical rotation of the compound ⁇ i.e. , the direction in which a plane of polarized light is rotated by the optically active compound).
  • the "1" or (-) prefix indicates that the compound is levorotatory (i. e. , rotates the plane of polarized light to the left or counterclockwise) while the "d” or ⁇ +) prefix means that the compound is dextrarotatory (i.e. , rotates the plane of polarized light to the right or clockwise).
  • the sign of optical rotation, (-) and (+) is not related to the absolute configuration of the molecule, R and S .
  • a compound of the invention having the desired pharmacological properties will be opticaily active and is comprised of at least 90% (80% e.e.), at least 95% (90% e.e.), at least 97.5% (95% e.e.) or at least 99% (98% e.e.) of a single isomer.
  • Embodiments of the present invention further provide intermediate compounds formed through the synthetic methods described herein to provide the compounds of formula (I).
  • the intermediate may possess utility as a therapeutic agent and/or reagent for further synthesis methods and reactions.
  • the compounds of formula (I) can be synthesized using traditional solution synthesis techniques or solid phase chemistry methods, in either, the construction involves four phases: first, synthesis of the building blocks comprising recognition elements for the biological target receptor, plus one tether moiety, primarily for control and definition of conformation. These building blocks are assembled together, typically in a sequential fashion, in a second phase employing standard chemical transformations. The precursors from the assembly are then cyclized in the third stage to provide the macrocyclic structures. Finally, the post-cyclization processing fourth stage involving removal of protecting groups and optiona! purification provides the desired final compounds. Synthetic methods for this general type of macrocyclic structure are described in Intl. Pat. Appls.
  • the macrocyclic compounds of formula (I) may be synthesized using solid phase chemistry on a soluble or insoluble polymer matrix as previously defined.
  • solid phase chemistry a preliminary stage involving the attachment of the first building block, also termed "loading," lo the resin must be performed.
  • the resin utilized for the present invention preferentially has attached to it a linker moiety, L.
  • linkers are attached to an appropriate free chemical functionality, usually an alcohol or amine, although others are also possible, on the base resin through standard reaction methods known in the art, such as any of the large number of reaction conditions developed for the formation of ester or amide bonds.
  • linker moieties for the present invention are designed to allow for simultaneous cleavage from the resin with formation of the macrocycle in a process generally termed "cyclization-release.”
  • van Maarseveen J.H. Comb. Chem. High Throughput Screen. 1998, 1, 185-214; James, I.W. Tetrahedron 1999, 55, 4855-4946; Eggenweiler, H.-M. Drug Discovery Today 1998, 3, 552-560; Backcs, B.J.; Ellman, J.A. C rr. Opin. Chem. Biol. 1997, 1, 86-93.
  • 3-thiopropionic acid linker Hojo, FL; Aimoto, S. Bull. Chem. Soc. Jpn. 1991, 64, 111- 1 17; Zhang, L.; Tam, J. J. Am. Chem. Soc. 1999, 121, 331 1 -3320.
  • the thioester strategy proceeds through a modified route where the tether component is actually assembled during the cyclization step.
  • assembly of the building blocks proceeds sequentially, followed by cyclization (and release from the resin if solid phase).
  • An additional post-cyclization processing step is required to remove particular byproducts of the RCM reaction, but the remaining subsequent processing is done in the same manner as for the thioester or analogous base-mediated cyclization strategy.
  • steps including the methods provided herein may be performed independently or at least two steps may be combined. Additionally, steps including the methods provided herein, when performed independently or combined, may be performed at the same temperature or at different temperatures without departing from the teachings of the present invention.
  • the present invention provides methods of manufacturing the compounds of the present invention comprising (a) assembling building block structures, (b) chemically transforming the building block structures, (c) cyclizing the building block structures including a tether component, (d) removing protecting groups from the building block structures, and (e) optionally purifying the product obtained from step (d).
  • assembly of the building block structures may be sequential.
  • the synthesis methods are carried out using traditional solution synthesis techniques or solid phase chemistry techniques.
  • Reagents and solvents were of reagent quality or better and were used as obtained from commercial suppliers, including Sigma-Aldrich (Milwaukee, WI, USA), Lancaster (part of Alfa Aesar, a Johnson Matthey Company, Ward Hill, MA), Acros Organics (Geel, Belgium), Alfa Aesar (part of Johnson Matthey Company, Ward Hill, MA), Fisher Chemical (part of Thermo Fisher, Fairlawn, NJ), TCI America (Portland, OR), Digital Specialty Chemicals (Toronto, ON, Canada), unless otherwise noted. DMF, DCM, DME and THF used are of DriSolv ® (EM Science, E.
  • Concentrated/evaporated/removed under reduced pressure/vacuum indicates evaporation utilizing a rotary evaporator under either water aspirator pressure or the stronger vacuum provided by a mechanical oil vacuum pump as appropriate for the solvent being removed.
  • “Dry pack” indicates chromatography on silica gel that has not been pre- treated with solvent, generally applied on larger scales for purifications where a large difference in R exists between the desired product and any impurities.
  • Flash chromatography refers to the method described as such in the literature (Still, W. C; Kahn, M.; Mitra, A. J. Org. Chem.
  • the solvent choice is important not just to solubilize reactants as in solution chemistry, but also to swell the resin.
  • Certain solvents interact differently with the polymer matrix depending on its nature and can affect this swelling property.
  • polystyrene with DVB cross-links
  • swells best in nonpolar solvents such as DCM and toluene
  • other resins such as PEG-grafted ones like TentaGel
  • appropriate choices can be made by one skilled in the art.
  • polystyrene-DVB resins are employed with DMF and DCM common solvents.
  • the volume of the reaction solvent required is generally 1 -1 .5 mL per 100 mg resin.
  • appropriate amount of solvent refers to this quantity.
  • the recommended quantity of solvent roughly amounts to a 0.2 M solution of building blocks (linkers, amino acids, hydroxy acids, and tethers, used at 5 eq relative to the initial loading of the resin). Reaction stoichiometry was determined based upon the "loading" (represents the number of active functional sites, given as mmol / g) of the starting resin.
  • the reaction can be conducted in any appropriate vessel, for example round bottom flask, solid phase reaction vessel equipped with a fritted filter and stopcock, or Teflon-capped jar.
  • the vessel size should be such that there is adequate space for the solvent, and that there is sufficient room for the resin to be effectively agitated taking into account that certain resins can swell significantly when treated with organic solvents.
  • the solvent/resin mixture should fill about 60% of the vessel.
  • the volume of solvent used for the resin wash is a minimum of the same volume as used for the reaction, although more is generally used to ensure complete removal of excess reagents and other soluble residual by-products.
  • Each of the resin washes specified in the Examples should be performed for a duration of at least 5 min with agitation (unless otherwise specified) in the order listed.
  • the number of washings is denoted by "nx" together with the solvent or solution, where n is an integer. In the case of mixed solvent washing systems, both are. listed together and denoted solvent 1/solvent 2.
  • the ratio of the solvent mixtures DC /MeOH and THF/MeOH used in the washing steps is (3: 1 ) in all cases. Other mixed solvents are as listed.
  • drying in the "standard manner” means that the resin is dried first in air (1 h), and subsequently under vacuum (oil pump usually) until full dryness is attained (minimum 30 min, to O/N).
  • Amino acids, Boc- and Fmoc-protectcd amino acids and side chain protected derivatives, including those of N-methyl and unnatural amino acids were obtained from commercial suppliers [for example Advanced ChemTech (Louisville, KY, USA), Anaspec (San Jose, CA, USA), Astatech (Princeton, NJ, USA), Bachem (Bubendorf, Switzerland), Chemlmpex (Wood Dale, IL, USA), Novabiochem (subsidiary of Merck KGaA, Darmstadt, Germany), PepTech (Burlington, MA, USA), Synthetech (Albany, OR, USA)] or synthesized through standard methodologies known to those in the art.
  • Ddz-amino acids were either obtained commercially from Orpegen (Heidelberg, Germany) or Advanced ChemTech (Louisville, KY, USA) or synthesized using standard methods utilizing Ddz-OPh or Ddz-N 3 .
  • Bts-amino acids were synthesized by known methods.
  • N-Alkyl amino acids in particular N-methyl amino acids, are commercially available from multiple vendors (Bachem, Novabiochem, Advanced ChemTech, Chemlmpex).
  • N-alkyl amino acid derivatives were accessed via literature methods.
  • An improved synthesis of Fmoc-N-MeSer and Fmoc-N-MeThr has been reported.
  • a//(j-Threoninc and ⁇ -hydroxyvaline can be synthesized by known procedures (Shao, H.; Goodman, M. J. Org. Chem. 1996, 61, 2582; Blaskovich, M. A.; Evindar, G.; Rose, N. G. W.; Wilkinson, S.; Luo, Y.; Lajoie, G.. J. Org. Chem. 1998, 63, 3631 ; Dettwiler; J.E.
  • Exemplary tethers (T) for the compounds of the invention include, but are not limited to, the following:
  • T33a (R) T38a (R> T40a (R) T33b (S) T38b (S) T40b (S)
  • Pg and Pg 2 are nitrogen protecting groups, such as, but not limited to, Boc, Fmoc, Cbz, Ddz and Alloc.
  • ⁇ and U C NMR spectra were recorded on a Varian Mercury 300 MHz spectrometer (Varian, Inc., Palo Alto, CA) and are referenced internally with respect to the residual proton signals of the solvent unless otherwise noted.
  • HPLC analyses were performed on a Waters Alliance ® system 2695 running at 1 mL/min using an Xterra ® MS C18 column (or comparable) 4.6 x 50 mm (3.5 ⁇ ) and the indicated gradient method.
  • a Waters 996 PDA provided UV data for purity assessment (Waters Corporation, Milford, MA).
  • an LCPackings Dionex Corporation, Sunnyvale, CA
  • splitter 50:40: 10
  • the first part (50%) was diverted to a mass spectrometer (Micromass ® Platform II MS equipped with an APCI probe) for identity confirmation.
  • the second part (40%) went to an evaporative light scattering detector (ELSD, Polymer Laboratories, now part of Varian, Inc., Palo Alto, CA, PL-ELS- 1000TM) for purity assessment and the last portion (10%) went to a chemiluminescence nitrogen detector (CLND, Antek ® Model 8060, Antek instruments, Houston, TX, part of Roper Industries, Inc., Duiuth, GA) for quantitation and purity assessment.
  • ELSD evaporative light scattering detector
  • CLND chemiluminescence nitrogen detector
  • Antek ® Model 8060 Antek instruments, Houston, TX, part of Roper Industries, Inc., Duiuth, GA
  • Each detector could also be used separately depending on the nature of the analysis required. Data was captured and processed utilizing the most recent version of the Waters Millennium ® software package.
  • Preparative HPLC purifications were performed on final deprotected macrocycles using the Waters FractionLynx system, on an XTcrra MS C I.8 column (or comparable) 19 x 100mm (5 ⁇ ).
  • the injections were done using an At-Column-Dilution coni ' iguration with a Waters 2767 injector/collector and a Waters 515 pump running at 2 mL/min.
  • the mass spectrometer, HPLC, and mass-directed fraction collection are controlled via MassLynx software version 3.5 with FractionLynx.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides novel conformationalIy- defined macrocyclic compounds of formula (I) that have been demonstrated to be selective modulators of the ghrelin receptor (GRLN, growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity- associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.

Description

Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and
Methods of Using the Same
Cross Reference to Related Application
This application claims priority to U.S. Provisional Application serial number
61/256,727, filed October 30, 2009, the disclosure of which is incorporated herein by reference in its entirety.
Field of the Invention
The present invention relates to novel conformationally-defined macrocyclic compounds that have been demonstrated to function as antagonists or inverse agonists of the ghrelin (growth hormone secretagogue) receptor (GRLN, GHS-Rla). The invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the compounds. These novel macrocyclic compounds are useful as therapeutics for a range of indications including metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders, central nervous system disordersand inflammatory disorders.
Background of the Invention
The improved understanding of various physiological regulatory pathways enabled through the research efforts in genomics and proteomics has begun to impact the discovery of novel pharmaceutical agents. In particular, the identification of key receptors and their endogenous ligands has created new opportunities for exploitation of these receptor/ligand pairs as therapeutic targets. For example, ghrelin is a recently characterized 28-amino acid peptide hormone that has been shown to mediate a variety of important physiological functions. (Kojima, M.; Hosoda, H.; et al. Nature 1999, 402, 656-660.) A novel characteristic of the structure is the presence of an rc-octanoyl group on Ser thai appears to be relevant to ghrelin' s activity. This peptide has been demonstrated to be the endogenous ligand for a previously orphan G protein-coupled receptor (GPCR), type 1 growth hormone secretatogue receptor (hGHS-Rla). (Howard, A.D.; Feighner, S.D.; Cully, D.F.; et al. Science 1996, 273, 974-977.) GHS-Rla has recently been reclassified as the ghrelin receptor (GRLN) in recognition of its endogenous ligand (Davenport, A.P. ; et al. Pharmacol Rev, 2005, 57, 541- 546).
Even prior to the isolation of this receptor and its endogenous peptide ligand, a significant amount of research was devoted to finding agents that can stimulate growth hormone (GH) secretion. The proper regulation of human GH has importance not only for proper body growth, but also for a range of other critical physiological effects. GH and other GH-stimulating peptides, such as growth hormone-releasing hormone (GHRH) and growth hormone releasing factor (GRF), as well as their derivatives and analogues, are administered via injection. Therefore, to better take advantage of these positive effects, attention was focused on the development of orally active therapeutic agents that would increase GH secretion, termed GH secretagogues (GHS). Additionally, use of these agents was expected to be able to more closely mimic the pulsatile physiological release of GH.
Beginning with the identification of the growth hormone-releasing peptides (GHRP) in the late 1970's (Bowers, C.Y. Curr. Opin. Endocrinol Diabetes 2000, 7, 168- 174; Camanni, F. ; Ghigo, E.; Arvat, E. Front. Neurosci. 1998, 19, 47-72; Locatelli, V.; Torsello, A. Pharmacol Res. 1997, 36, 415-423), a host of agents have been studied for their potential to act as GHS. In addition to their stimulation of GH release and concomitant positive effects in that regard, GHS were projected to have utility in a variety of other disorders, including the treatment of wasting conditions (cachexia) as seen in HIV patients and cancer-induced anorexia, musculoskeletal frailty in the elderly, and growth hormone deficient diseases. Many efforts over the past 25 years have yielded a number of potent, orally available GHS. (Cordido, F.; Isidro, ML.; Nemina, R.; Sangiao-Alvarellos, S. Curr. Drug Disc. Tech. 2009, 6, 34-42; Isidro, M.L.; Cordido, F. Comb. Chem. High Throughput Screen. 2006, 9, 178- 180; Smith, R.G.; Sun, Y.X. ; Beatancourt, L.; Asnicar, M. Best Tract. Res. Clin. Endocrinol. Metab. 2004, 18, 333-347; Fehrentz, J.-A.; Martinez, J.; Boeglin, D.; Guerlavais, V.; Deghenghi, R. IDrugs 2002, 5, 804-814; Svensson, J. Exp. Opin. Ther. Patents 2000, 10, 1071 - 1080; Nargund, R.P.; Patchett, A.A.; Bach, M.A. ; Murphy, M.G. ; Smith, R.G. J. Med. Chem. 1998, 41, 3103-3127; Ghigo, E; Arvat, E.; Camanni, F. Ann. Med. 1998, 30, 159- 168.) These include small peptides, such as hexarelin (Zentaris) and ipamorelin (Novo Nordisk), as well as small molecules such as capromorelin (Pfizer), L-252,564 (Merck), M -0677 (Merck), NN703 (tabimorelin, Novo Nordisk), G-7203 (Genentech), S-37435 ( aken) and SM- 130868 (Sumitomo). However, clinical tests with such agents have rendered disappointing results due to, among other things, lack of efficacy over prolonged treatment or undesired side effects, including irreversible inhibition of cytochrome P450 enzymes. (Zdravkovic Μ,; Olse, A.K.; Christiansen, T.; et al. Eur. J. Clin. Pharmacol. 2003, 58, 683- 688.)
The cloning of the human receptor, which was actually enabled through the use of a synthetic GHS, and the subsequent identification of ghrelin have opened a variety of new chemical areas for investigation on both agonists and antagonists (Carpino, P.A. Exp. Opin. Ther. Patents 2002, 12, 1599- 1618). in particular, the ghrelin peptide has been found to have multiple other physiological functions apart from the stimulation of GH release, including regulation of food intake and appetite, promotion of weight gain, control of energy balance, and modulation of gastrointestinal (GI) motility, gastric acid secretion and glucose homeostasis. The hormone has also been linked to control of circadian rhythm and memory. Ghrelin appears to also play a role in bone metabolism and inflammatory processes. (Van der Lely, A.J.; Tschop, M.; Heiman, M.L.; Ghigo, E. Endocrine Rev. 2004, 25, 426-457; Inui, A.; Asakawa, A. ; Bowers, C.Y.; Mantovani, G. ; Laviano, A. ; Meguid, M.M.; Fujimiya, M. FASEB J. 2004, 18, 439-456; Diano, S. Farr, S.A.; Benoit, S .C. ; et al. Nat. Neuroscience 2006, 9, 381 -388; Kojima, K.; Kangawa, K. Nat. Clin. Pract. Endocrinol. Metab. 2006, 2, 80-88; aiya, H.; Miyazato, M.; Kangawa, K.; Peter, R.E. ; Unniappan, S. Coinp. Biochem. Physiol. A 2008, 149, 109-128.)
Due to these myriad physiological effects, modulation of the ghrelin receptor has come under increasing study for therapeutic indications apart from those related to the GH secretory function (Dodge, J. A.; Heiman, M.L. Ann. Rep. Med. Chem. 2003, 38, 81-88.). For example, Intl. Pat. Appl. WO 2006/009645 and WO 2006/009674 describe the use of macrocyclic compounds as ghrelin modulators for use in the treatment of gastrointestinal (GI) disorders. Similarly, WO 2006/020930 and WO 2006/023608 describe structurally distinct ghrelin agonists (growth hormone secretagogues) for use in such GI disorders. In addition, Intl. Pat. Appl. WO 2004/09124 and WO 2005/68639 describe modified virus particles derived from short peptide sequences from the N-terminus of ghrelin that can be used as vaccines for treatment of obesity. Another vaccine approach for obesity is described in WO 2004/024183.
Not surprisingly due to the role of ghrelin in the control of appetite and feeding, particular interest has also been sparked in the development of ghrelin antagonists and inverse agonists as new anti-obesity pharmaceutical agents, as indeed has modulation of a number of peptide hormones and their receptors. (Crowley, V.E.F.; Yeo, G.S .H. ; O-Rahilly, S. Nat. Rev. Drug Disc. 2002, 1, 276-286; Spanswick, D.; Lee, K. Exp. Opin. Emerging Drugs 2003, 8, 217-237; Horvath, T.L.; Castaheda, T.; Tang-Christensen, M. ; Pagotto, U.; Tschop, M.H. Curr. Pharm. Design 2003, 9, 1383-1395; Higgins, S.C.; Gueorguiev, M.; Korbonits, M, Ann. Med. 2007, 39, 116-136; Carpino, P.A.; Ho, G. Exp. Opin. Ther. Pat. 2008, 18, 1253-1263; Soares, J.-B.; Roncon-Aibuquerque, R,, Jr.; Leite-Moreira, A. Exp. Opin. Ther. Targets 2008, 12, 1177-1189; Ukkola, O. Curr. Prot. Pept. Sci. 2009, 10, 2-7; Constantino, L.; Barlocco, D. Fut. Med. Chem.. 2009, 1, 157-177; Chollet, C; Meyer, K.; Beck-Sickinger, A.G. J. Pept. Sci. 2009, 15, 711-730.) In contrast to ghrelin agonists, with the precedence in the search for GHS, the field of research on ghrelin antagonists and inverse agonists is significantly less mature. U.S. Patent Application Publ. 2003/021 1967 and WO 01/87335 address the use of ghrelin antagonists as treatments for a variety of disease states including obesity and related disorders. Similarly, WO 01/56592 and US 2001/020012 describe the use of ghrelin antagonists for the regulation of food intake. Likewise, WO 2004/004772 describes the use of GHS-R antagonists as a treatment for diabetes, obesity and appetite control. Their use for treatment of intestinal inflammation has also been described (Intl. Pat. Appl. Publ. WO 2004/084943; U.S. Pat. Appl. Publ. 2007/0025991). However, no specific examples of compounds, apart from ghrelin peptide and its analogues, for this purpose are presented in these applications. More recently, oxadiazole ghrelin antagonists have been reported which are also claimed to be effective in improving cognition, memory and other CNS disorders (WO 2005/1 12903). Modulation of thermoregulation, sleep, appetite, food intake, obesity and other ghrelin-mediated conditions through reduction of ghrelin expression is described in U.S. Pat. Appl. Publ. 2010/0196396.
Ghrelin antagonists and inverse agonists have also been considered for playing a role in the reduction of the incidence of the following obesity-associated conditions including diabetes, complications due to diabetes such as retinopathy, cardiovascular diseases, hypertension, dyslipidemia, osteoarthritis and certain forms of cancer. Indeed, in addition to the anti-obesity effects seen in animal studies, transgenic rats engineered without the GRLN (GHS-Rla) receptor have exhibited reduced food intake, diminished fat deposition, and decreased weight. However, the hormone's involvement in a number of physiological processes, including regulation of cardiovascular function and stress responses as well as growth hormone release, may indicate potential drawbacks to this strategy. Hence, complete lack of ghrelin may not be desirable, but suppression may be sufficient to control obesity and other metabolic disorders. It should be noted that recent studies with ghrelin knockout mice reveal that these animals do not exhibit the expected modifications in size and food intake among other physiological characteristics. (Sun,Y.; Ahmed, S.; Smith, R.G. Mol. Cell Biol. 2003, 23, 7973-7981; Wortley, K.E.; Anderson, K.D.; Garcia, K.; et al. Pr c. Natl Acad. Sci. USA 2004, 101, 8227-8232.)
Ghrelin plays a key role in the regulation of insulin release and glycemia and hence modulators of the ghrelin receptor have application to the treatment of diabetes and metabolic syndrome. (Yada, T.; Dezaki, K. Sone, H.; et al. Curr. Diab, Rev. 2008, 4, 18-23; Pulkkinen, L.; Ukkola, O.; Kolehmainen, M.; Uusitupa, M. Int. J. Pept. 2010, doi: 10.1155/2010/248948.) Ghrelin reduces glucose stimulated insulin secretion, decreases insulin sensitivity, increases resting/fasting blood glucose levels, shifts energy metabolism from fat to glucose, and indirectly antagonizes insulin dependent CNS regulation of food intake and glucose homeostasis. (Sun, Y.; Asnicar, M; Smith, R.G. Neuroendocrinal. 2007, 86, 215-228; Dezaki, K.; Sone, H.; Yada, T. Pharmacol. Ther. 2008, 118, 239-249; Tong, J.; Prigeon, R.L.; Davis, H.W.; et al. Diabetes 2010, 59, 2145-2151.). Ghrelin antagonists and/or inverse agonists hence would have beneficial effects for the treatment or prevention of diabetes and related conditions, such as metabolic syndrome.
Recently, BIM-28163 has been reported to function as an antagonist at the GRLN
(GHS-Rl a) receptor and inhibit receptor activation by native ghrelin. However, this same molecule is a full agonist with respect to stimulating weight gain and food intake. This and related peptidic ghrelin analogues effectively separate the GH-modulating activity of ghrelin from the effects of the peptide on weight gain and appetite. (Halem, H.A.; Taylor, J.E.; Dong, J.Z.; et al. Eur. J. Endocrinol. 2004, 151, S71-S75.) Analogously, the macrocyclic ghrelin agonists described in WO 2006/009645 and WO 2006/009674 report the separation of the Gl effects from the GH-release effects in animal models.
in addition to the ghrelin receptor itself, another component of the ghrelin biological pathway, the enzyme ghrelin-O-acyltransferase (GOAT), has been suggested as an anti- obesity target. (Romero, A.; Kirchner, H.; Heppner, K.; et al. Eur. J. Endocrinol. 2010, 163, 1 -8; Intl. Pat. Appl. Publ. WO 2008/079705; Gutierrez, J.A.; Solenberg, P.J.; Perkins, D.R.; et al. Proc. Natl. Acad. Sci. 2008, 705, 6320-6325.) GOAT is responsible for the postradiational modification that incoporates the n-octanoyl moiety on Ser3 of ghrelin. As mentioned previously, this acylated form is the active species in vivo. Pentapeptide (Yang, J.; Zhao, T.J.; Goldstein, J.L.; et al. Proc. Natl Acad. Sci. 2008, 105, 10750- 10755), small molecule (BK11 14, U.S. Pat. Appl. Publ. 2010/0086955) and bisubstrate (Intl. Pat. Appl. Publ. WO 2010/039461) inhibitors of GOAT have been reported, but this approach is still not yet proven in humans. Prader-Willi syndrome, the most common form of human syndromic obesity, is characterized paradoxically by GH deficiency and high ghrelin levels that are not decreased after feeding. (Cummings, D.E. ; Clement, .; Pumell, J.Q.; et al, Not. Med. 2002, 8, 643- 644.) Antagonists of the ghrelin receptor would have a role in treating this syndrome as well.
Figure imgf000008_0001
characterized by the formation of significant lipid deposits in liver hepatocytes. NAFLD is the most common liver problem in industrialized Western countries, affecting 20-40% of the general population. In patients with type II diabetes, prevalence of NAFLD may be as high as 70% and in obese individuals NAFLD prevalence is 58-74%. NAFLD can progress to non- alcoholic steatohepatitis (NASH), which increases the potential for development of liver cirrhosis. (Angulo, P. New Engl. J. Med. 2002, 346, 1221-1231 ; Perlemuter, G.; Bigorgnc, A.; Cassard-Doulcier, A.-M.; Naveau, S. Nat. Clin. Pract. Endocrinol. Metab. 2007, J, 458- 469; Younossi, Z.M. Aliment. Pharmacol. Ther. 2008, 28, 2- 12; Ali, R. ; Cusi, K. Ann. Med. 2009, 41 , 265-278; Mal guarnera, M.; Di Rosa, M.; Nicoletti, F.; Malaguaracra, L. J. Mol. Med. 2009, 87, 679-695.)
NAFLD can occur with or without inflammation of the liver or liver cell injury or damage, and without a history of excessive alcohol ingestion. It has been suggested that NAFLD represents the hepatic manifestation of metabolic syndrome, but may also predict the development of metabolic syndrome. Although NAFLD has been found in patients without risk factors, individuals with conditions such as diabetes, obesity, hypertension and hypertriglyceridemia are at greatest risk of developing the condition. An inextricable relationship exists between central obesity, steatosis and insulin resistance. Adipokines and ghrelin have been implicated in the pathogenesis of nonalcoholic fatty liver disease through their metabolic and/or anti-inflammatory activity. Emerging data shows a relationship between NAFLD, ghrelin and adipokines. Ghrelin was elevated in patients with NAFLD, primarily those with normal body weight. Peripheral ghrelin induces lipid accumulation in specific abdominal depots, liver and skeletal muscle without affecting superficial subcutaneous white adipose tissue. These effects may be augmented by suppression of spontaneous growth hormone (GH) secretion. In addition, peripheral ghrelin and des-acyl ghrelin induce adipogenesis in bone marrow. Peripheral ghrelin defends accumulated fat in abdominal locations associated with the development of metabolic syndrome (Wells, T. Prog. Lipid Res. 2009, doi: 10.1016/j .plipres .2009.04.002). Studies have shown that ghrelin may influence adipocyte metabolism and stimulate adipogenesis. (Depoortere, 1. Regul. Pept. 2009, 156, 13-23.). Ghrelin antagonists would therefore be useful in the treatment or prevention of NAFLD and NASH.
Similarly, such agents may have potential for diabetic hyperphagia. Hyperphagia and altered fuel metabolism result from uncontrolled diabetes mellitus in humans. This has been suggested to occur through a combination of elevated ghrelin levels and decreased leptin through the NPY/AGRP pathway. Although levels of ghrelin are essential ly the same in healthy and diabetic subjects, the different levels of ghrelin in diabetic hyperphagia could make it difficult to remain on diet therapies and an antagonist could be useful in assisting control. (Lshii, S. ; Kamegai, J. ; Tamura, H.; Shimizu, T.; Sugihara, H.; Oikawa, S. Endocrinology 2002, 143, 4934-4937; Sindelar, D. K., Mystkowski, P., Marsh, D. J., Palmiter, R. D.; Schwartz, M. W Diabetes 2002, 51, 778-783.)
Ghrelin levels are elevated in cirrhosis and with complications from chronic liver disease, although unlike levels of insulin-like growth factor-1 (IGF- 1 ), they do not correlate to liver function. (Tacke, F.; Brabant, G. ; Kruck, E.; Horn, R. ; et al. J. epatology 2003, 38, 447-454.) Ghrelin antagonists could be useful in . controlling these liver diseases. Further, ghrelin and its receptor are overexpressed in numerous cancers. Antagonists would have potential application to treatment of cancer. Intl. Pat. Appl. Publ. WO 02/90387 has described the use of interventionist strategies targeting GHS-Rl a as an approach to treatment of cancers of the reproductive system.
For metabolic disorders such as obesity, it has been speculated that due to the critical nature of the food intake process for the survival of the organism, a single agent with a single target may not be sufficient for long term weight control since alternative or redundant pathways can be used to circumvent the affected pathway. Hence, the best therapeutic strategy may be to simultaneously apply multiple agents that target different pathways involved in the feeding appetite control process (see for example Intl. Pat. Appl . Pub). WO 2006/052608). Indeed, some successful weight-loss therapeutics have been combinations of drugs.
Recently, antagonism of ghrelin has been demonstrated to reduce alcohol consumption. (Kaur, S .; Ryabinin, A.E. Alcohol. Clin. Exp. Res. 2010, 34, 1525-1534.) This is consistent with studies that have shown altered plasma ghrelin levels in alcoholic patients (Wurst, F.M. ; Graf, L ; Ehrenthal, H.D. ; et al. Alcohol. Clin. Exp. Res. 2007, 31, 2006-2020; Badaoui, A.; De Saeger, C; Duchemin, J.; Gihousse, D. ; de Timary, P. ; Starkel, P. Eur. j. Clin. Invest. 2008, 38, 397^103) and reduced alcohol intake in ghrelin knockout mice (Jerlhag, E.; Egecioglu, E. ; Landgren, S.; et al. Proc. Natl. Acad. Set. USA 2009, 106, 1 1318- 11323). Relatedly, reduction of food intake in mice with a disrupted gene or treated with a ghrelin antagonist suggests ghrelin involvement in the incentive and reward system associated with food. (Egecioglu, E.; Jerlhag, E.; Salome, N.; et al. Addict. Biol. 2010, 15, 304-311 ; Perello, M.; Sakata, I.; Bimbaum, S.; et al. Biol. Psychiatry 2010, 67, 880-886.) Further, dopamine release upon the presence of rewarding food was absent in ghrelin knockout mice. In addition, the ghrelin signaling system appears to be required for a reward from drugs of abuse. (Jerlhag, E.; Egecioglu, E.; Dickson, S.L.; Engel, J. A. Psychopharmacol. 2010, 211, 415-422.) Amphetamine- or cocaine-induced stimulation and dopamine release were reduced upon treatment with a ghrelin antagonist. Ghrelin antagonists therefore would have utility for treatment of alcohol-related disorders (Leggio, L. Drug News Perspect. 2010, 23, 157- 166.) and other addictive disorders, such as drug dependence (Intl. Pat. Appl. Publ. WO 2009/020419). Despite the potential therapeutic uses for ghrelin antagonists, only a limited number of small molecule ghrelin antagonists have yet been reported in the patent or scientific literature including diaminopyrimidiues, tetralin carboxamides, isoxazole carboxamides, β-carbolines, oxadiazoles, pyrazoles, benzofuranylindolones and benzenesulfonamides. (U.S. Pat. Appl. Publ. US 2005/0171 31; US 2005/0171132; Intl. Pat. Appl. Publ. WO 2005/030734; WO 2005/112903; WO 2005/48916; WO 2008/008286; WO 2010/092288; WO 2010/092289; Zhao, H.; Xin, Z.; Liu, G.; et al. . Med. Chem. 2004, 47, 6655-6657; Xin, Z.; Zhao, H.; Serby, M.D.; ct al. Bioorg. Med. Chem. Lett. 2005, 15, 1201-1204; Zhao, H.; Xin, Z.; Patel, J.R.; et al. Bioorg. Med, Chem. Lett. 2005, 15, 1825-1828; Liu, B.; Liu, G.; Xin, Z.; et al. Bioorg. Med. Chem. Lett. 2004, 14, 5223-5226; Pasternak, A,; Goble, S.D.; deJesus, R.K.; et al. Bioorg. Med. Chem. Lett. 2009, 19, 6237-6240). WO 2005/1 14180 describes a number of individual compounds containing heteroaryl core structures, such as isoazoles, 1,2,4-oxadiazoles and 1 ,2,4-triazoles, as "functional ghrelin antagonists" and their uses as therapeutic agents for the treatment of obesity and diabetes. Other heterocyclic structures, some of which displayed antagonist activity, are reported in WO 2005/035498; WO 2005/097788 and US 2005/0187237.
The remaining known ghrelin antagonists are primarily peptidic in nature (WO 2004/09616, WO 02/08250, WO 03/04518, US 2002/0187938, Pinilla, L.; Barreiro, M.L.; Tena-Sempere, ML; Aguilar E. Neuroendocrinology 2003, 77, 83-90) although antagonists based on nucleic acids have also been disclosed (WO 2004/013274; WO 2005/49828; Helmling, S.; Maasch, C; Eulberg, D.; et al. Proc. Natl Acad. Sci USA 2004, 101, 13174- 13179; Shearman, L.P.; Wang, S.P.; Helmling, S.; et ai. Endocrinology 2006, 147, 1517- 1526). The compounds of the present invention are structurally distinct from all of these previously reported ghrelin antagonist structures. The 14-amino acid compound, vapreotide, a small somatostatin mimetic, was demonstrated to be a ghrelin antagonist. (Deghenghi R, Papotti M, Ghigo E, Muccioli G, Locatelli V. Endocrine 2001, 14, 29-33.) The binding activity of analogues of the cyclic neuropeptide cortistatin to the growth hormone secretatogue receptor has been disclosed (WO 03/00451 8). These compounds exhibit an IC50 of 24-33 11M. In particular, one of these analogues, EP-01492 (cortistatin 8) has been advanced into preclinical studies for the treatment of obesity as a ghrelin antagonist. (Deghenghi R, Broglio F, Papotti M, et al. Endocrine 2003, 22, 13- 1.8; Sibilia, V.; Muccioli, G.; Deghenghi, R.; et al. J. Neuroendocrinal. 2006, 18, 122- 128.)
A l imited series of peptides as ghrelin antagonists containing the very specific short octanoylated sequence known to be critical for binding to GHS-Rl a has been reported (U.S. Pat. Appl. No. 2002/0187938; Intl. Pat. Appl. No. WO 02/08250). Action of [ D-Lys3]-GHRP- 6 has been described as a ghrelin antagonist. (Pinilla, L.; Barreiro, M.L. ; Tena-Sempere, ML; Aguilar E. Neuroendocrinology 2003, 77, 83-90) More recently, the substance P peptide derivative, L-756,867 (EP-80317, [D-Arg' ^-Phe^D-Trp^JLeu 1 'j-substance P), a weak ghrelin antagonist, was demonstrated to be a potent inverse agonist (Kd/i = 45 11M) to open another potential approach to the treatment of obesity targeting the ghrelin receptor. (Hoist, B. ; Schwartz, T.W. Trends Pharmacol. Sci. 2004, 25, 1 13-1 17; Hoist, B . ; Cygankiewicz, A.; Jensen, T.H. ; Ankersen, M. ; Schwartz, T.W. Mol. Endocrinol. 2003, 17, 2201-2210; Cheng, K.; Wei, L.; Chaung, L.-Y.; et al. J. Endocrinol. 1997, 152, 155- 158.) However, the use of this particular agent likely would be limited due to its poor selectivity since it also interacts at the neurokinin- 1 and bombesin receptors.
The use of inverse agonists has been suggested to even be of more relevant use for the control of appetite due to the high constitutive activity of the ghrelin receptor. (Hoist, B.; Holliday, N. D.; Bach, A. ; Elling, C.E. ; Cox, H.M.; Schwartz, T.W. J. Biol. Chem. 2004, 279, 53806-53817.) However, only the L-756,867 peptide and a single pyrrole compound, TM27810, (WO 2004/056869) have been reported to date as inverse agonists.
In fact, it has been argued that it is actually beneficial to have compounds that act as both ghrelin receptor antagonists and inverse agonists in order to best control feeding (Hoist, B. Schwartz, T. J. Clin. Invest. 2006, 116, 637-641). The recent observation that humans possessing a mutation in the ghrelin receptor that impairs constitutive activity are of short stature illustrates the importance of the constitutive activity to the normal in vivo function of this receptor. (Pantel, J.; Legendre, M. Cabrol, S. ; et al. J. Clin. Invest. 2006, 116, 760-768.) As shown in the Examples, some compounds of the present invention act as both ghrelin receptor antagonists and inverse agonists.
Although a limited series of macrocyclic peptidomimetics has been previously described as antagonists and inverse agonists of the ghrelin receptor and their uses for the treatment of a variety of disorders summarized (Intl. Pat. Appl. Publ. Nos. WO 2006/046977; 2006/137974), the compounds of the present invention are shown to possess unexpected and more favorable pharmacological properties.
Accordingly, with so few examples of ghrelin antagonists or inverse agonists suitable for pharmacological intervention, there is a need for additional compounds that modulate the ghrelin receptor and suppress ghrelin release.
Summary of the Invention
The present invention provides novel conformationally-defincd macrocyclic compounds that can function as antagonists or inverse agonists of the ghrelin (growth hormone secretagogue) receptor (GRLN, GHS-R 1 a).
According to aspects of the present invention, the present invention relates to compounds according to formu
Figure imgf000012_0001
(I)
or a pharmaceutically acceptable salt thereof, wherein:
T is selected from
Figure imgf000013_0001
and , wherein (NA) indicates the site of bonding of to NR4a of formula (I) and (NR) indicates the site of bonding to NR4c of formula (I);
Ri is selected from the group consisting of -(CH2)SCH3, -CH(CI I3)(CH2)tCH ,
-(CH2)UCH(CH3)2, -C(CH3)3, -CH2-C(CH3)3> -CHR ,7OR,R,
Figure imgf000013_0002
wherein s is 0, 1 , 2, 3 or 4; t is 1, 2 or 3; u is 0, 1 or 2; v is 1 , 2, 3 or 4; w is 1, 2, 3 or 4; and R N and Ri2 are optionally present and, when present, are independently selected from the group consisting of C|-C4 alkyl, hydroxyl and alkoxy; R |7 is hydrogen or methyl; and Rj s is selected from the group consisting of hydrogen, C |-C4 alkyl and acy! ;
R2a is selected from the group consisting of -CH3, -CH2CH3, -CH(CH )2, -CF3, -CF2H and -CH2F;
R2b is selected from the group consisting of -H and -CH3;
R3a is selected from the group consisting of hydrogen, C|-C4 alkyl, hydroxyl and alkoxy;
R3b is selected from the group consisting of hydrogen and C |-C4 alkyl ;
R4a, R4b, R4c and R4(j are independently selected from the group consisting of hydrogen and Q-C4 alkyl;
R5, when Y| is O or NR |6, is selected from the group consisting of hydrogen, C] -C4 alkyl and acy! ; or, when Y ] is C(=0), is selected from the group consisting of hydroxyl, alkoxy and amine;
R6 is selected from the group consisting of hydrogen, Cj -C4 alkyl, oxo and trifluoromethyl; R7 is selected from the group consisting of hydrogen, C[-C4 alkyl, hydroxyl, alkoxy and trifluoromethyl; or R7 and X( together form a five or six-membered ring;
Rio is selected from the group consisting of hydrogen, C|-C4 alkyl, 1,1,1- trifluoroefhyl, hydroxyl and alkoxy, with the provisos that when L6 is CH, Rio is also selected from trifluoromethyl, and when L6 is N, Rio is also selected from sulfonyl; or Rio and R¾a together form a five-or six-membered ring;
R26, R?8 and R2 are independently selected from the group consisting of hydrogen, C|-C4 alkyl, hydroxyl, alkoxy and trifluoromethyl; or R28 and R99 together form a three- membered ring;
R27 is selected from the group consisting of hydrogen, CrC4 alkyl, hydroxyl, alkoxy and trifluoromethyl; or R27 and X43 together form a five or six-membered ring
R30 is selected from the group consisting of hydrogen, C|-C4 alkyl, hydroxyl, alkoxy and trifluoromethyl;
Ar is selected from the group consisting of:
Figure imgf000014_0001
and
wherein Mi, M2, M3, M4, M5, M6, M7, Mg and MM arc independently selected from the group consisting of O, S and NR|3, wherein R13 is selected from the group consisting of hydrogen, Ci-C4 alkyl, formyl, acyl and sulfonyl; M8, Mjo and M!2 are independently selected from the group consisting of N and CR!4, wherein Ri4 is selected from the group consisting of hydrogen and C|-C alkyl; X5, X6, X7, X|8, X1 , X21, X22, X24, 25, X26> X27, 28> X29, X30 and X i are independently selected from the group consisting of hydrogen, halogen, trifluoromethyl and CpC4 alkyl; and X ) X , XjO, Xll, X|2J Xl3, Xj4, Xl5> Xl6> Xl7> 205 X23, X¾2, 3> X34, Χ¾5> X36. 7, 38, 39,
X40, X4i and X42 are independently selected from the group consisting of hydrogen, hydroxyl, alkoxy, amino, halogen, cyano, trifluoromethyl and C)-C4 a!kyl;
Lj, L2, L3, L4 and L6 are independently selected from the group consisting of CH and N;
L5 is selected from the group consisting of CR|5ilRi5b, O and NR|5C, wherein Rj5a and i5b are independently selected from hydrogen, C|-C4 alkyl, hydroxyl and alkoxy; and Ri5c is selected from the group consisting of hydrogen, C|-C4 alkyl, acyl and sulfonyl;
Lio is selected from the group consisting of CR35aR35b, O and OC(=0)0, wherein R35a and R3¾ are independently selected from hydrogen, Cj-C4 alkyl, hydroxyl and alkoxy;
Xi is selected from the group consisting of hydrogen, halogen, trifluoromethyl and C1-C4 alkyl; or X| and R7 together form a five or six-membered ring;
X2, X3 and X4 are independently selected from the group consisting of hydrogen, halogen, trifluoromethyl and C1-C4 alkyl;
X43 and X44 are optionally present and, when present, are independently selected from the group consisting of C|-C4 alkyl, hydroxyl, alkoxy and trifluoromethyl; or X4 and R 7 together form a five or six-membered ring; and
Yi is selected from the group consisting of C{=0), O and NR|6, wherein R[6 is selected from the group consisting of hydrogen, C1-C4 alkyl, acyl and sul onyl;
z is 0, 1, 2 or 3; and
Z is selected from the group consisting of
Figure imgf000015_0001
(Ar)-CR8b=CR -(Lc) and -(Ar)-C≡C-(L<5), wherein (Ar) indicates the site of bonding to the phenyl ring and (L6) the site of bonding to L6, R8a and R¾ are independently selected from the group consisting of hydrogen, Cj-C4 alkyl, hydroxyl, alkoxy, oxo and trifluoromethyl; Rgb and R9h are independently selected from the group consisting of hydrogen, C|-C4 alkyl, fluoro, hydroxyl, alkoxy and trifluoromethyl; or Rga and R¾ together form a three-membered ring; or R8a and Rso together form a five- or six-membered ring; or Rga and X4 together form a five- or six-membered ring; or R9a and X4 together form a five- or six-membered ring; or R8[, and X4 together form a five- or six-membered ring; or R% and X4 together form a five- or six- membered ring.
Specific embodiments of the present invention provide for compounds of formula (I) with the structure:
Figure imgf000016_0001

Figure imgf000017_0001
Figure imgf000017_0002
Figure imgf000017_0003
Figure imgf000017_0004
Figure imgf000017_0005
or armaceutically acceptable salt thereof. Further aspects of the present invention provide pharmaceutical compositions comprising: (a) a compound of the present invention; and (b) a pharmaceutically acceptable carrier, excipient or diluent.
In other aspects of the present invention, pharmaceutical compositions are provided comprising (a) a compound of the present invention; (b) one or more additional therapeutic agents ;and (c) a pharmaceutically acceptable carrier, excipient or diluent.
For specific embodiments, the additional therapeutic agent is selected from the group comprising a GLP-1 agonist, a DPP-TV inhibitor, an amylin agonist, a PPAR-a agonist, a PPAR-γ agonist, a PPAR-α/γ dual agonist, a GDTR or GPR l 19 agonist, a FTP- I B inhibitor, a peptide YY agonist, an 1 Ι β-hydroxysteroid dehydrogenase (1 Ιβ-HSD)-! inhibitor, a sodium- dependent renal glucose transporter type 2 (SGLT-2) inhibitor, a glucagon antagonist, a glucokinase activator, an a-glucosidase inhibitor, a glucocorticoid antagonist, a glycogen synthase kinase 3β (GSK-3 ) inhibitor, a glycogen phosphorylase inhibitor, an AMP- activated protein kinase (AMPK) activator, a fructose- 1 ,6-biphosphatase inhibitor, a sulfonyl urea receptor antagonist, a retinoid X receptor activator, a 5-ΗΤ| η agonist, a 5-HT2c agonist, a 5-HTf, antagonist, a cannabioid antagonist or inverse agonist, a melanin concentrating hormone- 1 (MCH-1) antagonist, a melanocortin-4 (MC4) agonist, a leptin agonist, a retinoic acid receptor agonist, a stearoyl-CoA desaturase- 1 (SCD- 1) inhibitor, a neuropeptide Y Y2 receptor agonist, a neuropeptide Y Y4 receptor agonist, a neuropeptide Y Y5 receptor antagonist, a neuronal nicotinic receptor α4β2 agonist a diacyl glycerol acyltransferase 1 (DGAT-1) inhibitor, a thyroid receptor agonist, a lipase inhibitor, a fatty acid synthase inhibitor, a glycerol-3-phosphate acyltransferase inhibitor, a CPT- 1 stimulant, an ct| A- adrenergic receptor agonist, an a2A-adrenergic receptor agonist, a
Figure imgf000018_0001
receptor agonist, a histamine H3 receptor antagonist, a cholecystokinin A receptor agonist and a GABA-A agonist.
Additional aspects of the present invention provide kits comprising one or more containers containing pharmaceutical dosage units comprising an effective amount of one or more compounds of the present invention packaged with optional instructions for the use thereof.
In further aspects, the present invention provides methods of modulating GRLN receptor activity in a mammal comprising administering an effective GRLN receptor activity modulating amount of a compound of the present invention. According to some aspects of the present invention, the compound is a ghrclin receptor antagonist or a GRLN receptor antagonist. In yet another aspect, the compound is a ghre!in receptor inverse agonist or a GRLN receptor inverse agonist. According to another aspect of the present invention, the compound is both a ghrelin receptor antagonist and a ghrelin receptor inverse agonist or a GRLN receptor antagonist and a GRLN receptor inverse agonist.
Aspects of the present invention further relate to methods of preventing and/or treating disorders such as metabolic and/or endocrine disorders, obesity and obesity- associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, genetic disorders, hyperproliferative disorders, central nervous system disorders and inflammatory disorders.
In particular embodiments, the metabolic disorder is obesity, diabetes, metabolic syndrome, non-alcoholic fatty acid liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) or steatosis.
In another specific embodiment, the appetite or eating disorder is Prader-Willi syndrome or hyperphagia.
In still other specific embodiments, the addictive disorder is alcohol dependendence, drug dependence or chemical dependence.
Further aspects of the present invention relate to methods of making the compounds of formula I.
The present invention also relates to compounds of formula I useful for the preparation of a medicament for prevention and/or treatment of the disorders described herein.
Provided in a further embodiment is a macrocyclic compound selected from the group consisting of
Figure imgf000019_0001
and
or a pharmaceutically acceptable salt thereof.
The foregoing and other aspects of the present invention are explained in greater detail in the specification set forth below. Brief Description of the Drawings
Figure 1 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1319.
Figure 2 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1350.
Figure 3 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1636.
Figure 4 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1383.
Figure 5 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1390.
Figure 6 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1401.
Figure 7 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1300.
Figure 8 shows a chemical synthesis scheme for an exemplary compound of the present invention, compound 1505.
Figure 9 shows a graph presenting results of a study to assess the in vivo activity of an exemplary compound of the present invention, compound 1505, specifically the effect on body weight in the Zucker fatty rat model.
Figure 10 shows a graph presenting results of a study to assess the in vivo activity of an exemplary compound of the present invention, compound 1505, specifically the effect on cumulative food consumption in the Zucker fatty rat model.
Figure 11 shows a graph presenting results of a study to assess the in vivo activity of an exemplary compound of the present invention, compound 1712, specifically the effect on acute cumulative food consumption in the ob/ob mouse model.
Figure 12 shows a graph presenting results of a study to assess the in vivo activity of an exemplary compound of the present invention, compound 848, specifically the effect on cumulative food consumption in the ob/ob mouse model.
Figure 13 shows a series of graphs presenting results of a study to assess the in vivo activity of an exemplary compound of die present invention, compound 1848, specifically the effect on selected metabolicm parameters. Detailed Description
The foregoing and other aspects of the present invention will now be described in more detail with respect to other embodiments described herein. It should be appreciated that the invention can be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used in the description of the invention and the appended claims, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. Additionally, as used herein, the term "and/or" includes any and ail combinations of one or more of the associated listed items and may be abbreviated as "/".
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
All publications, U.S. patent applications, U.S. patents and other references cited herein are incorporated by reference in their entireties.
The term "alkyl" refers to straight or branched chain saturated or partially unsaturated hydrocarbon groups having from 1 to 20 carbon atoms, and in some instances, ] to 8 carbon atoms. The term "lower alkyl" refers to alkyl groups containing 1 to 6 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, isopropyl, /erf-butyi, 3-hexenyl, and 2-butynyl. By "unsaturated" is meant the presence of 1 , 2 or 3 double or triple bonds, or a combination of the two. Such alkyl groups may also be optionally substituted as described below.
When a subscript is used with reference to an alkyl or other hydrocarbon group defined herein, the subscript refers to the number of carbon atoms that the group may contain. For example, C2-C4 alkyl indicates an alkyl group that contains 2, 3 or 4 carbon atoms.
The term "cycloalkyl" refers to saturated or partially unsaturated cyclic hydrocarbon groups having from 3 to 15 carbon atoms in the ring, and in some instances, 3 to 7, and to alkyl groups containing said cyclic hydrocarbon groups. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopropylmethyl, cyclopentyl, 2-(cyclohexyl)ethyl, cycloheptyl, and cyclohexenyl. Cycloalkyl as defined herein also includes groups with multiple carbon rings, each of which may be saturated or partially unsaturated, for example decalinyl, [2.2.1]-bicycloheptanyl or adamantanyl. All such cycloalkyl groups may also be optionally substituted as described below.
The term "aromatic" refers to an unsaturated cyclic hydrocarbon group having a conjugated pi electron system that contains 4n+2 electrons where n is an integer greater than or equal to 1. Aromatic molecules are typically stable and are depicted as a planar ring of atoms with resonance structures that consist of alternating double and single bonds, for example benzene or naphthalene.
The term "aryl" refers to an aromatic group in a single or fused carbocyclic ring system having from 6 to 35 ring atoms, and in some instances, 6 to 10, and to alkyl groups containing said aromatic groups. Examples of aryl groups include, but are not limited to, phenyl, 1 -naphthyl, 2-naphthyl and benzyl. Aryl as defined herein also includes groups with multiple aryl rings which may be fused, as in naphthyl and anthracenyl, or unfused, as in biphenyl and terphenyl. Aryl also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated or aromatic, for example, indanyl or tetrahydronaphthyl (tetralinyl). All such aryl groups may also be optionally substituted as described below.
The term "heterocycle" or "heterocyclic" refers to saturated or partially unsaturated monocyclic, bicyclic or tricyclic groups having from 3 to 15 atoms, and in some instances, 3 to 7, with at least one heteroatoin in at least one of the rings, said hcteroatom being selected from O, S or N. Each ring of the heterocyclic group can contain one or two O atoms, one or two S atoms, one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. The fused rings completing the bicyclic or tricyclic heterocyclic groups may contain only carbon atoms and may be saturated or partially unsaturated. The N and S atoms may optionally be oxidized and the N atoms may optionally be quatemized. Heterocyclic also refers to alkyl groups containing said monocyclic, bicyclic or tricyclic heterocyclic groups. Examples of heterocyclic rings include, but are not limited to, 2- or 3-piperidinyi, 2- or 3-piperazinyl, 2- or 3-morpholinyl. All such heterocyclic groups may also be optionally substituted as described below
The term "heteroaryl" refers to an aromatic group in a single or fused ring system having from 5 to 15 ring atoms, and in some instances, 5 to 10, which have at least one heteroatom in at least one of the rings, said heteroatom being selected from O, S or N. Each ring of the heteroaryl group can contain one or two O atoms, one or two S atoms, one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom. The fused rings completing the bicyclic or tricyclic groups may contain only carbon atoms and may be saturated, partially unsaturated or aromatic. In structures where the lone pair of electrons of a nitrogen atom is not involved in completing the aromatic pi electron system, the N atoms may optionally be quatemized or oxidized to the N-oxide. Heteroaryl also refers to alkyl groups containing said cyclic groups. Examples of monocyclic heteroaryl groups include, but are not limited to pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyi, and triazinyi . Examples of bicyclic heteroaryl groups include, but are not limited to indolyl, benzothiazolyl, benzoxazolyl, benzothienyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazo!yl, benzopyranyl, indolizinyl, benzofuranyl, isobenzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxaliny!, indazolyl, purinyl, pyrrolopyridiny.l, furopyridinyl, thienopyridinyl, dihydroisoindolyl, and tetrahydroquinolinyl. Examples of tricyclic heteroaryl groups include, but are not limited to carbazolyl, benzindolyl, phenanthrollinyl, acridinyl, phenanthridinyl, and xanthenyl. Ail such heteroaryl groups may also be optionally substituted as described below.
The term "hydroxyl" refers to the group -OH.
The term "alkoxy" refers to the group -ORa, wherein R;i is alkyl, cycloalkyl or heterocyclic. Examples include, but are not limited to methoxy, ethoxy, teri-butoxy, cyclohexyloxy and tetrahydropyranyloxy.
The term "aryloxy" refers to the group -ORb wherein R|, is aryl or heteroaryl.
Examples include, but are not limited to phenoxy, benzyloxy and 2-naphihyloxy.
The term "acyl" refers to the group -C(=0)-Rc wherein Rc is alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl. Examples include, but are not limited to, acetyl, benzoyl and furoyl.
The term "amino acyl" indicates an acyl group that is derived from an amino acid.
The term "amino" refers to an -NRdRe group wherein Rd and Re arc independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl. Alternatively, R<j and RE together form a heterocyclic ring of 3 to 8 members, optionally substituted with unsubstituted alkyl , unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryLoxy, acyl, amino, amido, carboxy, carboxyalkyl, carboxyaryl, mercapto, sulfinyl, suifonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heteroatoms selected from O, S or N. The term "amido" refers to the group -C(=0)-NRfRg wherein Rf and Rg are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl. Alternatively, Rf and Rg together form a heterocycl ic ring of 3 to 8 members, optionally substituted with unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyaikyl, carboxyaryl, mercapto, sulfinyl, sulfonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heteroatoins selected from O, S or N.
The term "amidino" refers to the group -C(=NRh)NRiRj wherein Rh is selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl; and R\ and Rj are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl. Alternatively, Rj and R, together form a heterocyclic ring of 3 to 8 members, optionally substituted with unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyaikyl, carboxyaryl, mercapto, sulfinyl, sulfonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heleroatoms selected from O, S or N.
The term "carboxy" refers to the group -C02H.
The term "carboxyaikyl" refers to the group -CC^ k, wherein ¾s alkyl, cycloalkyl or heterocyclic.
The term "carboxyaryl" refers to the group -CO2R™, wherein Rm is aryl or heteroaryl. The term "cyano" refers to the group -CN.
The term "formyl" refers to the group -C(~0)H, also denoted -CHO.
The term "halo," "halogen" or "halide" refers to fluoro, fluorine or fluoride, chloro, chlorine or chloride, bromo, bromine or bromide, and iodo, iodine or iodide, respectively.
The term "oxo" refers to the bivalent group =0, which is substituted in place of two hydrogen atoms on the same carbon to form a carbonyl group.
The term "mercapto" refers to the group -SRn wherein Rn is hydrogen, alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl .
The term "nitro" refers to the group -N02.
The term "trifluoromethyl" refers to the group -CF3.
The term "sulfinyl" refers to the group -S(=0)Rp wherein Rp is alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl. The term "sulfonyl" refers to the group -S(=0)2-R i wherein Rq ! is alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl.
The term "aminosulfonyl" refers to the group
Figure imgf000025_0001
wherein Rq2 is hydrogen, alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl; and Rq3 is alkyl, cycloalkyl, heterocyclic, aryi or heteroaryl.
The term "sulfonamido" refers to the group -S(=0)2-NR,Rs wherein Rr and Rs are independently selected from the group consisting of hydrogen, alkyi, cycloalkyl, heterocyclic, aryl or heteroaryl. Alternatively, Rv and Rs together form a heterocyclic ring of 3 to 8 members, optionally substituted with unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyalkyl, carboxyaryl, mercapto, sulfinyl, sulfonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heteroatoms selected from O, S or N.
The term "carbamoyl" refers to a group of the formula -N(Rt)-C(=0)-ORu wherein Rt is selected from hydrogen, alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl; and Ru is selected from alkyl, cycloalkyl, heterocylic, aryl or heteroaryl.
The term "guanidino" refers to a group of the formula -N(Rv)-C(=NRw)-NRxRy wherein Rv, Rw, Rx and Ry are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl. Alternatively, Rx and Ry together form a heterocyclic ring or 3 to 8 members, optionally substituted with unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyalkyl, carboxyaryl, mercapto, sulfinyl, sulfonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heteroatoms selected from O, S or N.
The term "ureido" refers to a group of the formula -N(Rz)-C(=0)-NRMRbb wherein
Rz, Raa and Rbb are independently selected from hydrogen, alkyl, cycloalkyl, heterocyclic, aryl or heteroaryl. Alternatively, Raa and Rbb together with the nitrogen atom to which they are each bonded form a heterocyclic ring of 3 to 8 members, optionally substituted with unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyalkyl, carboxyaryl, mercapto, sulfinyl, sulfonyl, sulfonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heteroatoms selected from O, S or N. The term "optionally substituted" is intended to expressly indicate that the specified group is unsubstituted or substituted by one or more suitable substituents, unless the optional substituents are expressly specified, in which case the term indicates that the group is unsubstituted or substituted with the specified substituents. As defined above, various groups may be unsubstituted or substituted (i.e., they are optionally substituted) unless indicated otherwise herein (e.g., by indicating that the specified group is unsubstituted).
The term "substituted" when used with the terms alkyl, cycloalkyl, heterocyclic, aryl and heteroaryl refers to an alkyl, cycloalkyl, heterocyclic, aryl or heleroaryl group having one or more of the hydrogen atoms of the group replaced by substituents independently selected from unsubstituted alkyl, unsubstituted cycloalkyt, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyalkyl, carboxyaryl, halo, oxo, mercapto, sulfinyl, sulfonyl, suifonamido, amidino, carbamoyl, guanidino, ureido and groups of the formulas -NRccC(=0)Rdd, - eCC(=NRrr)Rgg, -OC(=0)NRh],Rij, -0€(=0)¾, -OC(=0)ORkk, -NRmmS02Rnn, or -NRppS02NRqqRn. wherein Rcc, Rdd, Ree, RjT, Rgg, Rhh, R;i, R , Rmm, R p, Rqq and R1T are independently selected from hydrogen, unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl or unsubstituted heteroaryl; and wherein Rkk and R„„ are independently selected from unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl or unsubstituted heteroaryl. Alternatively, Rgg and Rh , Ry and Rkk or Rpp and Rqq together with the nitrogen atom to which they are each bonded form a heterocyclic ring of 3 to 8 members, optionally substituted with unsubstituted alkyl, unsubstituted cycloalkyl, unsubstituted heterocyclic, unsubstituted aryl, unsubstituted heteroaryl, hydroxy, alkoxy, aryloxy, acyl, amino, amido, carboxy, carboxyalkyl, carboxyaryl, mercapto, sulfinyl, sulfonyl, suifonamido, amidino, carbamoyl, guanidino or ureido, and optionally containing one to three additional heteroatoms selected from O, S or N. in addition, the term "substituted" for aryl and heteroaryl groups includes as an option having one of the hydrogen atoms of the group replaced by cyano, nitro or tiifluoromethyi.
A substitution is made provided that any atom's normal valency is not exceeded and that the substitution results in a stable compound. Generally, when a substituted form of a group is present, such substituted group may not be further substituted or, if substituted, the substituent comprises only a limited number of substituted groups, for example 1 , 2, 3 or 4 such substituents.
When any variable occurs more than one time in any constituent or in any formula herein, its definition on each occurrence is independent, of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
A "stable compound" or "stable structure" is meant to mean a compound that is sufficiently robust to survive isolation to a useful degree of purity and formulation into an efficacious therapeutic agent.
The term "amino acid" refers to the common natural (genetical ly encoded) or synthetic amino acids and common derivatives thereof, known to those skil led in the art. When applied to amino acids, "standard" or "proteinogenic" refers to the genetically encoded 20 amino acids in their natural configuration. Similarly, when applied to amino acids, "unnatural" or "unusual" refers to the wide selection of non-natural, rare or synthetic amino acids such as those described by Hunt, S. in Chemistry and Biochemistry of the Amino Acids, Barrett, G.C., Ed., Chapman and Hall: New York, 1985.
The term "residue" with reference to an amino acid or amino acid derivative refers to a group of the formula:
Figure imgf000027_0001
wherein AA is an amino acid side chain, and n = 0, 1 or 2 in this instance.
The term "fragment" with respect to a dipeptide, tripeptide or higher order peptide derivative indicates a group that contains two, three or more, respectively, amino acid residues.
The term "amino acid side chain" refers to any side chain from a standard or unnatural amino acid, and is denoted RAA. For example, the side chain of alanine is methyl, the side chain of valine is isopropyl and the side chain of tryptophan is 3-indolylmethyl.
The term "agonist" refers to a compound that duplicates at least some of the effect of the endogenous ligand of a protein, receptor, enzyme or the like.
The term "antagonist" refers to a compound that inhibits at least some of the effect of the endogenous ligand of a protein, receptor, enzyme or the like.
The term "inverse agonist" refers to a compound that decreases, at least to some degree, the baseline functional activity of a protein, receptor, enzyme or the like, such as the constitutive signaling activity of a G protein-coupled receptor or variant thereof. An inverse agonist can also be an antagonist.
The term "baseline functional activity" refers to the activity of a protein, receptor, enzyme or the like, including constitutive signaling activity, in the absence of the endogenous ligand.
The term "growth hormone secretagogue" (GHS) refers to any exogenoissly administered compound or agent that directly or indirectly stimulates or increases the endogenous release of growth hormone, growth hormone-releasing hormone, or somatostatin in an animal, in particular, a human. A GHS may be peptidic or non-peptidic in nature, with an agent that can be administered orally preferred, in addition, an agent that induces a pulsatile response is preferred.
The term "modulator" refers to a compound that imparts an effect on a biological or chemical process or mechanism. For example, a modulator may increase, facilitate, upregulate, activate, inhibit, decrease, block, prevent, delay, desensitize, deactivate, down regulate, or the like, a biological or chemical process or mechanism. Accordingly, a modulator can be an "agonist," an "antagonist," or an "inverse agonist." Exemplary biological processes or mechanisms affected by a modulator include, but are not limited to, receptor binding and hormone release or secretion. Exemplary chemical processes or mechanisms affected by a modulator include, but are not limited to, catalysis and hydrolysis.
The term "variant" when applied to a receptor is meant to include dimers, trimers, tetramers, pentamers and other biological complexes containing multiple components. These components can be the same or different.
The term "peptide" refers to a chemical compound comprised of two or more amino acids covalently bonded together.
The term "peptidomimetic" refers to a chemical compound designed to mimic a peptide, but which contains structural differences through the addition or replacement of one of more functional groups of the peptide in order to modulate its activity or other properties, such as solubility, metabolic stability, oral bioavailability, lipophilicity, permeability, etc. This can include replacement of the peptide bond, side chain modifications, truncations, additions of functional groups, etc. When the chemical structure is not derived from the peptide, but mimics its activity, it is often referred to as a "non-peptide peptidomimetic."
The term "peptide bond" refers to the amide [-C(=0)-NH-j functionality with which individual amino acids are typically covalently bonded to each other in a peptide. The term "protecting group" refers to any chemical compound that may be used to prevent a potentially reactive functional group, such as an amine, a hydroxyl or a carboxyl, on a molecule from undergoing a chemical reaction while chemical change occurs elsewhere in the molecule. A number of such protecting groups are known to those skilled in the art and examples can be found in "Protective Groups in Organic Synthesis," Theodora W. Greene and Peter G. Wilts, editors, John Wiley & Sons, New York, 3rd edition, 1999 [ISBN 047 1 1601991- Examples of amino protecting groups include, but are not limited to, phthalimido, trichloroacetyl, benzyloxycarbonyl, ierr-butoxycarbonyi, and adamanlyloxy- carbonyt. Preferred amino protecting groups are carbamate amino protecting groups, which are defined as an amino protecting group that when bound to an amino group forms a carbamate. Preferred amino carbamate protecting groups are allyloxycarbonyl (Alloc or Aloe), benzyloxycarbonyl (Cbz), 9-fluorenylmethoxycarbonyl (Fmoc), ierr-butoxycarbonyi (Boc) and a,a-dimethyl-3,5-dimethoxybenzyloxycarbonyl (Ddz). For a recent discussion of newer nitrogen protecting groups: Theodoridis, G. Tetrahedron 2000, 56, 2339-2358. Examples of hydroxyl protecting groups include, but are not limited to, acetyl, tert- butyldimethylsilyl (TBDMS), trityl (Trt), tenf-butyl, and tetrahydropyranyl (THP). Examples of carboxyl protecting groups include, but are not limited to methyl ester, terr-butyl ester, benzyl ester, trimethylsiiylethyl ester, and 2,2,2-trichloroethyl ester.
The term "solid phase chemistry" refers to the conduct of chemical reactions where one component of the reaction is covalently bonded to a polymeric material (solid support as defined below). Reaction methods for performing chemistry on solid phase have become more widely known and established outside the traditional fields of peptide and oligonucleotide chemistry.
The term "solid support," "solid phase" or "resin" refers to a mechanically and chemically stable polymeric matrix utilized to conduct solid phase chemistry. This is denoted by "Resin," "P-" or the following symbol: ^
Examples of appropriate polymer materials include, but are not limited to, polystyrene, polyethylene, polyethylene glycol, polyethylene glycol grafted or covalently bonded to polystyrene (also termed PEG-polystyrene, TentaGel™, Rapp, W.; Zhang, L.; Bayer, E. In Innovations and Persepctives in Solid Phase Synthesis. Peptides, Polypeptides and Oligonucleotides; Epton, R., Ed.; SPCC Ltd. : Birmingham, UK; p 205), polyacrylate (CLEAR™), polyacrylamide, polyurethane, PEGA polyethyleneglycol poiy(N,N-dimethyiacrylamide) co-polymer, Meldal, M. Tetrahedron Lett. 1992, 33, 3077- 3080], cellulose, etc. These materials can optionally contain additional chemical agents to form cross-linked bonds to mechanically stabilize the structure, for example polystyrene cross-linked with divinylbenezene (DVB, usually 0.1-5%, or 0.5-2%). This solid support can include as non-limiting examples aminomethyl polystyrene, hydroxymethyl polystyrene, benzhydrylamine polystyrene (BHA), methy!benzhydrylamine (M B HA) polystyrene, and other polymeric backbones containing free chemical functional groups, most typically, -NH? or -OH, for further derivatization or reaction. The term is also meant to include "Ultraresins" with a high proportion ("loading") of these functional groups such as those prepared from polyethyleneimines and cross-linking molecules (Barth, M. ; Rademann, J. J. Comb. Chem. 2004, 6, 340-349). At the conclusion of the synthesis, resins are typically discarded, although they have been shown to be able to be reused such as in Frcchet, J.M.J.; Haque, K.E. Tetrahedron Lett. 1975, 16, 3055.
In general, the materials used as resins are insoluble polymers, but certain polymers have differential solubility depending on solvent and can also be employed for solid phase chemistry. For example, polyethylene glycol can be utilized in this manner since it is soluble in many organic solvents in which chemical reactions can be conducted, but it is insoluble in others, such as diethyl ether. Hence, reactions can be conducted homogeneously in solution, then the product on the polymer precipitated through the addition of diethyl ether and processed as a solid. This has been termed "liquid-phase" chemistry.
The term "linker" when used in reference to solid phase chemistry refers to a chemical group that is bonded covalently to a solid support and is attached between the support and the substrate typically in order to permit the release (cleavage) of the substrate from the solid support. However, it can also be used to impart stability to the bond to the solid support or merely as a spacer element. Many solid supports are available commercially with linkers already attached.
Abbreviations used for amino acids and designation of peptides follow the rules of the lUPAC-IUB Commission of Biochemical Nomenclature in J. Biol. Chem. 1972, 247, 977- 983. This document has been updated: Biochem. .]. , 1984, 219, 345-373 ; Eur. J. Biochem. ,
1984, 138, 9-37; 1985, 152, 1 ; Int. J. Pept. Prot. Res. , 1984, 24, following p 84; J. Biol. Chem. , 1985, 260, 14-42; Pure Appl. Chem. , 1984, 56, 595-624; Amino Acids and Peptides,
1985, 16, 387-410; and in Biochemical Nomenclature and Related Documents, 2nd edition, Portland Press, 1992, pp 39-67. Extensions to the rules were published in the JCBN/NC-IUB Newsletter 1985, 1986, 1989; see Biochemical Nomenclature and Related Documents, 2nd edition, Portland Press, 1992, pp 68-69. The term "effective amount" or "effective" is intended to designate a dose that causes a relief of symptoms of a disease or disorder as noted through clinical testing and evaluation, patient observation, and the like, and/or a dose that causes a detectable change in biological or chemical activity as detected by one skilled in the art for the relevant mechanism or process. As is generally understood in the art, the dosage will vary depending on the administration routes, symptoms and body weight of the patient but also depending upon the compound being administered.
Administration of two or more compounds "in combination" means that the two compounds are administered closely enough in time that the presence of one alters the biological effects of the other. The two compounds can be administered simultaneously (concurrently) or sequentially. Simultaneous administration can be carried out by mixing the compounds prior to administration, or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration. The phrases "concurrent administration", "administration in combination", "simultaneous administration" or "administered simultaneously" as used herein, means that the compounds are administered at the same point in time or immediately following one another. In the latter case, the two compounds are administered at times sufficiently close that the results observed are indistinguishable from those achieved when the compounds are administered at the same point in time.
The term "pharmaceutically active metabolite" is intended to mean a pharmacologically active product produced through metabolism in the body of a specified compound.
The term "solvate" is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound. Examples of solvates, without limitation, include compounds of the invention in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.
The macrocyclic compounds of the invention have been shown to possess ghrelin modulating activity, and in particular embodiments, as antagonists or inverse agonists, A series of macrocyclic peptidomimetics recently has been described as modulators of the ghrelin receptor and their uses for the treatment and prevention of a range of medical conditions including metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders outlined (U.S. Pat. Nos. 7,452,862, 7,476,653 and 7,491,695; Intl. Pat. Appl. Publ. Nos. WO 2006/009645, WO 2006/009674, WO 2006/046977, WO 2006/137974 and WO 2008/130464; U.S. Pat. Appl. Publ. Nos. 2006/025566, 2007/021331 , 2008/051383 and 2008/ 94672). One of these compounds, TZP- 101 , a ghrelin agonist, has entered the clinic as a treatment for gastrointestinal dysmotility diorders. (Lasseter, .C. ; Shaughnessy, L.; Cummings, D.; el al. J. Clin. Pharmacol 2008, 48, 193-202). The compounds of the present invention differ in structural composition and chiral configuration when compared to these agonists.
Although binding potency and target affinity are factors in drug discovery and development, also important for development of viable pharmaceutical agents are optimization of pharmacokinetic (PK) and/or pharmacodynamic (PD) parameters. A focus area for research in the pharmaceutical industry has been to better understand the underlying factors which determine the suitability of molecules in this manner, often colloquially termed its "drug-likeness." (Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Adv. Drug Delivery Rev. 1997, 23, 3-25; Muegge, I. Med. Res. Rev. 2003, 23, 302-321 ; Veber, D.F.; Johnson, S.R. ; Cheng, H.-Y.; Smith, B.R.; Ward, K.W. ; Kopple, K.D. ./. Med. Chem. 2002, 45, 2615-2623.) For example, molecular weight, log P, membrane permeability, the number of hydrogen bond donors and acceptors, total polar surface area (TPS A), and the number of rotatable bonds have all been correlated with compounds that have been successful in drug development. Additionally, experimental measurements of plasma protein binding, interaction with cytochrome P450 enzymes, and pharmacokinetic parameters are employed in the pharmaceutical industry to select and advance new drug candidates.
However, these parameters have not been widely explored or reported within the macrocyciic structural class. This creates tremendous challenges in drug development for these molecules. The macrocyclic compounds of the present invention have been found to possess such desirable pharmacological characteristics, while maintaining sufficient binding affinity and or selectivity for the ghrelin receptor, as illustrated in the Examples. These combined characteristics are superior to the macrocyclic ghrelin antagonist compounds previously described and make them more suitable for development as pharmaceutical agents, particularly for use as orally administered agents or for chronic uses.
1. Compounds
Novel macrocyclic compounds of the present invention include those of formula (I):
Figure imgf000033_0001
(I)
or a pharmaceutically acceptable salt thereof, wherein the component T is selected from
Figure imgf000033_0002
and
wherein (NA) indicates the site of bonding of to NR4A of formula (1) and (NB) indicates the site of bonding to NR.4C of formula (I);
In specific embodiments, the compound can have any of the structures defined in Table 1 . These structures are based upon the structural formula (A):
Figure imgf000033_0003
(A) Attorney Docket No. 9412-31 WO
Figure imgf000034_0001
Attorney Docket No. 9412-31 WO
Figure imgf000035_0001
Attorney Docket No. 9412-31 WO
Figure imgf000036_0001
Attorney Docket No. 9412-31 WO
Figure imgf000037_0001
Attorney Docket No. 9412-31 WO
Figure imgf000038_0001
Attorney Docket No. 9412-31 WO
Figure imgf000039_0001
Attorney Docket No. 9412- 31 WO
Figure imgf000040_0001
Attorney Docket No. 9412-31WO
Figure imgf000041_0001
Attorney Docket No. 9412-31 WO
Figure imgf000042_0001
Attorney Docket No. 9412-3 IWO
Figure imgf000043_0001
Attorney Docket No. 9412-3 IWO
Figure imgf000044_0001
A
Attorney Docket No. 9412-31 WO
Figure imgf000045_0001
Attorney Docket No. 9412-3 IWO
Figure imgf000046_0001
Attorney Docket No. 9412-31 WO
Figure imgf000047_0001
Attorney Docket No. 9412-3 IWO
Figure imgf000048_0001
Attorney Docket No. 9412- 31 WO
Figure imgf000049_0001
Attorney Docket No. 9412-31 WO
Figure imgf000050_0001
Attorney Docket No. 9412-31 WO
Figure imgf000051_0001
Attorney Docket No. 9412-31 WO
Figure imgf000052_0001
Attorney Docket No. 9412- 31 WO
Figure imgf000053_0001
Attorney Docket No. 9412-31WO
Figure imgf000054_0001
Attorney Docket No. 9412-3 IWO
Figure imgf000055_0001
Attorney Docket No. 9412-31 WO
Figure imgf000056_0001
Attorney Docket No. 9412-31 WO
Figure imgf000057_0001
Attorney Docket No. 9412- 31WO
Figure imgf000058_0001
Attorney Docket No. 9412-31 WO
Figure imgf000059_0001
Attorney Docket No. 9412-31 WO
Figure imgf000060_0001
Attorney Docket No. 9412- 31 WO
Figure imgf000061_0001
Attorney Docket No. 9412-31 WO
Figure imgf000062_0001
Attorney Docket No. 9412- 31 WO
Figure imgf000063_0001
Attorney Docket No. 9412- 3 IWO
Figure imgf000064_0001
Attorney Docket No. 9412-3 IWO
Figure imgf000065_0001
Attorney Docket No. 9412-31 WO
Figure imgf000066_0001
Attorney Docket No. 9412-31 WO
Figure imgf000067_0001
Attorney Docket No. 9412-3 IWO
Figure imgf000068_0001
Attorney Docket No. 9412-31 WO
Figure imgf000069_0001
Attorney Docket No. 9412-31 WO
Figure imgf000070_0001
Attorney Docket No. 9412- 31 WO
Figure imgf000071_0001
Attorney Docket No. 9412-31 WO
Figure imgf000072_0001
Attorney Docket No. 9412-31 WO
Figure imgf000073_0001
Attorney Docket No. 9412- 31 WO
Figure imgf000074_0001
Attorney Docket No. 9412-3 IWO
Figure imgf000075_0001
Attorney Docket No. 9412-31 WO
Figure imgf000076_0001
Attorney Docket No. 9412-31 WO
Figure imgf000077_0001
Attorney Docket No. 9412-31 WO
Figure imgf000078_0001
Attorney Docket No. 9412-31 WO
Figure imgf000079_0001
Attorney Docket No. 9412-31WO
Figure imgf000080_0001
Figure imgf000081_0001

Attorney Docket No. 9412-31 WO
Figure imgf000082_0001
Attorney Docket No. 9412- 31 WO
Figure imgf000083_0001
Attorney Docket No. 9412-31 WO
Figure imgf000084_0001
Attorney Docket No. 9412-31WO
Figure imgf000085_0001
Attorney Docket No. 9412- 31WO
Figure imgf000086_0001
Figure imgf000087_0001
85
Figure imgf000088_0001
86
Attorney Docket No. 9412-31 WO
Figure imgf000089_0001
Attorney Docket No. 9412-31WO
Figure imgf000090_0001
Figure imgf000091_0001

Attorney Docket No. 9412-31 WO
Figure imgf000092_0001
Attorney Docket No. 9412-31 WO
Figure imgf000093_0001
Attorney Docket No. 9412-31 WO
Figure imgf000094_0001
Attorney Docket No. 9412-3 IWO
Figure imgf000095_0001
Attorney Docket No. 9412-31 WO
Figure imgf000096_0001
Attorney Docket No. 9412-31 WO
Figure imgf000097_0001
Attorney Docket No. 9412-31 WO
Figure imgf000098_0001
Attorney Docket No. 9412-31 WO
Figure imgf000099_0001
Figure imgf000100_0001
Attorney Docket No. 9412-31 WO
Figure imgf000101_0001
Attorney Docket No. 9412-31WO
Figure imgf000102_0001
Attorney Docket No. 9412-31 WO
Figure imgf000103_0001
Attorney Docket No. 9412-3 IWO
Figure imgf000104_0001
Attorney Docket No. 9412- 31 WO
Figure imgf000105_0001
Attorney Docket No. 9412-31 WO
Figure imgf000106_0001
Attorney Docket No. 9412-31 WO
Figure imgf000107_0001
Attorney Docket No. 9412-31 WO
Figure imgf000108_0001
Attorney Docket No. 9412-31 WO
Figure imgf000109_0001
Attorney Docket No. 9412-31 WO
Figure imgf000110_0001
Attorney Docket No. 9412-31 WO
Figure imgf000111_0001
Attorney Docket No. 9412-31 WO
Figure imgf000112_0001
For the compounds in Table 1, Ra = H, Rb = Me, Rc = H, Rd = H for all compounds except the following: Ra = Me, compounds 13 1356; Rb = H, compounds 1353- 1357, 1382; Rc = Me, compounds 1357, 1382, 1388, 1389; Rd = Me, compounds 1353, 1354.
The TA elements of Table 1 are as follows:
Figure imgf000113_0001
T8 T9 T11
Figure imgf000113_0002
T33a (R) T38a (R) T40a (R) T33b (S) T38b (S) T40b (S)
T77 T86 T87
Figure imgf000113_0004
T104a (R,R) T113a (R)
T104b (S,S) T113b (S) T125a (R)
T125b (S)
Figure imgf000114_0001
T100 T104a (R,R) T105
T104b (S,S)
Figure imgf000114_0002
T106 T113a {R) T125a (R)
T113b (S) T125b (S)
Figure imgf000114_0003
T128a (2R.9R) T128c (2S,9R)
T128b (2R,9S) T128d (2S.9S)
Figure imgf000114_0004
T137 T138 T139
Figure imgf000114_0005
Figure imgf000115_0001
T143 T144a (R) T145
T144b (S)
Figure imgf000115_0002
T146a (R)
T146b (S) T147 T148a <8R,9R) T148c (8S,9R)
T148b (8R,9S) T148d (8S,9S)
Figure imgf000115_0003
T149a <R,R) T150a (9R)
T149b (S,S) T151
T150b {9S)
Figure imgf000115_0004
T152 T153 T154
Figure imgf000115_0005
T157
T156a (R)
Figure imgf000115_0006
Figure imgf000116_0001
T161a (R) T162a (R) T163a (R)
T161b (S) T162b (S) T163b <S)
Figure imgf000116_0002
T164a (R) T165a(R) T166
T164b (S) T165b (S)
Figure imgf000116_0003
T167 T168a (R,R) T169a (R)
T168b (S,S) T169b (S)
Figure imgf000116_0004
T173a(R) T174a <R) T175a (R)
T173b{S) T174b (S) T175b (S)
S,9R>
Figure imgf000116_0005
T178b (2R.9S) T178d (2S,9S)
Figure imgf000117_0001
T179a (2R,9R) T179c (2S.9R) T
T179b (2R,9S) T179d (2S,9S) T
Figure imgf000117_0002
T182a (2R.9R) T182c (2S,9R) T183a (2R,9R) T183c (2S,9R)
T182b (2R,9S) T182d (2S,9S) T183b (2R,9S) T183d (2S,9S)
Figure imgf000117_0003
T191a{R) T192a(R)
T191b(S) T192b(S) T193
Figure imgf000118_0001
Figure imgf000118_0002
wherein (NA) indicates the site of bonding to NRa of formula (A), (NB) indicates the site of bonding to NRC of formula (A) and Pg is a nitrogen protecting group.
The present invention includes isolated compounds. An isolated compound refers to a compound that, in some embodiments, comprises at least 10%, at least 25%, at least 50% or at least 70% of the compounds of a mixture. In some embodiments, the compound, pharmaceutically acceptable salt thereof or pharmaceutical composition containing the compound exhibits a statistically significant binding and/or antagonist activity and or inverse agonist activity when tested in biological assays at the human ghrelin receptor.
In the case of compounds, salts, or solvates that are solids, it is understood by those skilled in the art that the inventive compounds, salts, and solvates may exist in different crystal or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulas.
The compounds of formula (I) herein disclosed have asymmetric centers. The inventive compounds may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates, and mixtures thereof are intended to be within the scope of the present invention. However, the inventive compounds are used in optically pure form. The terms "S" and "R" configuration as used herein are as defined by the IUPAC 1974 Recommendations for Section E, Fundamentals of Stereochemistry {Pure Appi Chem. 1976, 45, 13-30.).
Unless otherwise depicted to be a specific orientation, the present invention accounts for all stereoisomeric forms. The compounds may be prepared as a single stereoisomer or a mixture of stereoisomers. The non-racemic forms may be obtained by either synthesis or resolution. The compounds may, for example, be resolved into the component enantiomers by standard techniques, for example formation of diastereomeric pairs via salt formation. The compounds also may be resolved by covalently bonding to a chiral moiety. The diastereomers can then be resolved by chromatographic separation and/or crystallographic separation. In the case of a chiral auxiliary moiety, it can then be removed. As an alternative, the compounds can be resolved through the use of chiral chromatography. Enzymatic methods of resolution could also be used in certain cases.
As generally understood by those skilled in the art, an "optically pure" compound is one that contains only a single enantiomer. As used herein, the term "optically active" is intended to mean a compound comprising at least a sufficient excess of one enantiomer over the other such thai the mixture rotates plane polarized light. The enantiomeric excess (e,e.) indicates the excess of one enantiomer over the other. Optically active compounds have the ability to rotate the plane of polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral ccnter(s). The prefixes "d" and "1" or (+) and (-) are used to denote the optical rotation of the compound {i.e. , the direction in which a plane of polarized light is rotated by the optically active compound). The "1" or (-) prefix indicates that the compound is levorotatory (i. e. , rotates the plane of polarized light to the left or counterclockwise) while the "d" or {+) prefix means that the compound is dextrarotatory (i.e. , rotates the plane of polarized light to the right or clockwise). The sign of optical rotation, (-) and (+), is not related to the absolute configuration of the molecule, R and S .
A compound of the invention having the desired pharmacological properties will be opticaily active and is comprised of at least 90% (80% e.e.), at least 95% (90% e.e.), at least 97.5% (95% e.e.) or at least 99% (98% e.e.) of a single isomer.
Likewise, many geometric isomers of double bonds and the like can also be present in the compounds disclosed herein, and all such stable isomers are included within the present invention unless otherwise specified. Also included in the invention are tautomers and rotamers of formula I.
The use of the following symbols at the right refers to p
0 ^(0, S, NH)
^ R witft the defined substituent K.
The use of the following symbol indicates a single bond or an optional double bond:
Embodiments of the present invention further provide intermediate compounds formed through the synthetic methods described herein to provide the compounds of formula (I). The intermediate may possess utility as a therapeutic agent and/or reagent for further synthesis methods and reactions.
2. Synthetic Methods
The compounds of formula (I) can be synthesized using traditional solution synthesis techniques or solid phase chemistry methods, in either, the construction involves four phases: first, synthesis of the building blocks comprising recognition elements for the biological target receptor, plus one tether moiety, primarily for control and definition of conformation. These building blocks are assembled together, typically in a sequential fashion, in a second phase employing standard chemical transformations. The precursors from the assembly are then cyclized in the third stage to provide the macrocyclic structures. Finally, the post-cyclization processing fourth stage involving removal of protecting groups and optiona! purification provides the desired final compounds. Synthetic methods for this general type of macrocyclic structure are described in Intl. Pat. Appls. WO 01/25257, WO 2004/11 1077, WO 2005/012331, WO 2005/012332, WO 2006/009645, WO 2006/009674, WO 2008/033328, WO 2008/130464 and U.S. Prov. Pat. Appl. 61/254,434 including purification procedures described in WO 2004/111077 and WO 2005/012331. Solution phase synthesis routes, including methods amenable to larger scale manufacture, were described in U.S. Patent Appl. Publ. Nos. 2006/025566 and US 2007/0021331.
In some embodiments of the present invention, the macrocyclic compounds of formula (I) may be synthesized using solid phase chemistry on a soluble or insoluble polymer matrix as previously defined. For solid phase chemistry, a preliminary stage involving the attachment of the first building block, also termed "loading," lo the resin must be performed. The resin utilized for the present invention preferentially has attached to it a linker moiety, L. These linkers are attached to an appropriate free chemical functionality, usually an alcohol or amine, although others are also possible, on the base resin through standard reaction methods known in the art, such as any of the large number of reaction conditions developed for the formation of ester or amide bonds. Some linker moieties for the present invention are designed to allow for simultaneous cleavage from the resin with formation of the macrocycle in a process generally termed "cyclization-release." (van Maarseveen, J.H. Comb. Chem. High Throughput Screen. 1998, 1, 185-214; James, I.W. Tetrahedron 1999, 55, 4855-4946; Eggenweiler, H.-M. Drug Discovery Today 1998, 3, 552-560; Backcs, B.J.; Ellman, J.A. C rr. Opin. Chem. Biol. 1997, 1, 86-93. Of particular utility in this regard for compounds of the invention is the 3-thiopropionic acid linker. Hojo, FL; Aimoto, S. Bull. Chem. Soc. Jpn. 1991, 64, 111- 1 17; Zhang, L.; Tam, J. J. Am. Chem. Soc. 1999, 121, 331 1 -3320.)
Such a process typically provides material of higher purity as only cyclic products are released from the solid support and minimal contamination with the linear precursor occurs as would happen in solution phase. After sequential assembly of all the building blocks and tether into the linear precursor using known or standard reaction chemistry for the formation of ester or amide bonds, base-mediated intramolecular attack on the carbony! attached to this linker, by an appropriate nucleophilic functionality that is part of the tether building block results in formation of the amide or ester bond that completes the cyclic structure as shown (Scheme 1). An analogous methodology adapted to solution phase can also be applied as would likely be preferable for larger scale applications. Scheme 1. Cyclization-release Strategy
Figure imgf000122_0001
et er
Although this description accurately represents the pathway for one of the methods of the present invention, the thioester strategy, another method of the present invention, that of ring-closing metathesis (RCM), proceeds through a modified route where the tether component is actually assembled during the cyclization step. However, in the RCM methodology as well, assembly of the building blocks proceeds sequentially, followed by cyclization (and release from the resin if solid phase). An additional post-cyclization processing step is required to remove particular byproducts of the RCM reaction, but the remaining subsequent processing is done in the same manner as for the thioester or analogous base-mediated cyclization strategy.
Moreover, it will be understood that steps including the methods provided herein may be performed independently or at least two steps may be combined. Additionally, steps including the methods provided herein, when performed independently or combined, may be performed at the same temperature or at different temperatures without departing from the teachings of the present invention.
Accordingly, the present invention provides methods of manufacturing the compounds of the present invention comprising (a) assembling building block structures, (b) chemically transforming the building block structures, (c) cyclizing the building block structures including a tether component, (d) removing protecting groups from the building block structures, and (e) optionally purifying the product obtained from step (d). In some embodiments, assembly of the building block structures may be sequential. In further embodiments, the synthesis methods are carried out using traditional solution synthesis techniques or solid phase chemistry techniques.
A. General Synthetic Information
Reagents and solvents were of reagent quality or better and were used as obtained from commercial suppliers, including Sigma-Aldrich (Milwaukee, WI, USA), Lancaster (part of Alfa Aesar, a Johnson Matthey Company, Ward Hill, MA), Acros Organics (Geel, Belgium), Alfa Aesar (part of Johnson Matthey Company, Ward Hill, MA), Fisher Chemical (part of Thermo Fisher, Fairlawn, NJ), TCI America (Portland, OR), Digital Specialty Chemicals (Toronto, ON, Canada), unless otherwise noted. DMF, DCM, DME and THF used are of DriSolv® (EM Science, E. Merck) or synthesis grade quality except for (i) deprotection, (ii) resin capping reactions and (iii) washing. NMP used for the amino acid (AA) coupling reactions is of analytical grade. DMF was adequately degassed by placing under vacuum for a minimum of 30 min prior to use. Analytical TLC was performed on pre- coated plates of silica gel 60F254 (0.25 mm thickness) containing a fluorescent indicator.
The term "concentrated/evaporated/removed under reduced pressure/vacuum" indicates evaporation utilizing a rotary evaporator under either water aspirator pressure or the stronger vacuum provided by a mechanical oil vacuum pump as appropriate for the solvent being removed. "Dry pack" indicates chromatography on silica gel that has not been pre- treated with solvent, generally applied on larger scales for purifications where a large difference in R exists between the desired product and any impurities. "Flash chromatography" refers to the method described as such in the literature (Still, W. C; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923-2925) and is applied to chromatography on silica gel (230-400 mesh, EM Science) used to remove impurities some of which may be close in Rf to the desired material. Methods specific for solid phase chemistry are detailed separately. B. General Methods for Solid Phase Chemistry
These methods can be equally well applied for the synthesis of single compounds or small numbers of compounds, as well as for the synthesis of libraries of compounds of the present invention.
For solid phase chemistry, the solvent choice is important not just to solubilize reactants as in solution chemistry, but also to swell the resin. Certain solvents interact differently with the polymer matrix depending on its nature and can affect this swelling property. As an example, polystyrene (with DVB cross-links) swells best in nonpolar solvents such as DCM and toluene, while shrinking when exposed to polar solvents like alcohols. In contrast, other resins such as PEG-grafted ones like TentaGel, maintain their swelling even in polar solvents. For the reactions of the present invention, appropriate choices can be made by one skilled in the art. h general, polystyrene-DVB resins are employed with DMF and DCM common solvents. The volume of the reaction solvent required is generally 1 -1 .5 mL per 100 mg resin. When the term "appropriate amount of solvent" is used in the synthesis methods, it refers to this quantity. The recommended quantity of solvent roughly amounts to a 0.2 M solution of building blocks (linkers, amino acids, hydroxy acids, and tethers, used at 5 eq relative to the initial loading of the resin). Reaction stoichiometry was determined based upon the "loading" (represents the number of active functional sites, given as mmol / g) of the starting resin.
The reaction can be conducted in any appropriate vessel, for example round bottom flask, solid phase reaction vessel equipped with a fritted filter and stopcock, or Teflon-capped jar. The vessel size should be such that there is adequate space for the solvent, and that there is sufficient room for the resin to be effectively agitated taking into account that certain resins can swell significantly when treated with organic solvents. The solvent/resin mixture should fill about 60% of the vessel. Take note that all agitations for solid phase chemistry are best conducted with an orbital shaker (for example Forma Scientific, model 430, 160-180 rpm), except for those where scale makes use of gentle mechanical stirring more suitable, to ensure adequate mixing which is generally accepted to be important for a successful reaction.
The volume of solvent used for the resin wash is a minimum of the same volume as used for the reaction, although more is generally used to ensure complete removal of excess reagents and other soluble residual by-products. Each of the resin washes specified in the Examples should be performed for a duration of at least 5 min with agitation (unless otherwise specified) in the order listed. The number of washings is denoted by "nx" together with the solvent or solution, where n is an integer. In the case of mixed solvent washing systems, both are. listed together and denoted solvent 1/solvent 2. The ratio of the solvent mixtures DC /MeOH and THF/MeOH used in the washing steps is (3: 1 ) in all cases. Other mixed solvents are as listed. After washing, drying in the "standard manner" means that the resin is dried first in air (1 h), and subsequently under vacuum (oil pump usually) until full dryness is attained (minimum 30 min, to O/N).
C. Amino acids
Amino acids, Boc- and Fmoc-protectcd amino acids and side chain protected derivatives, including those of N-methyl and unnatural amino acids, were obtained from commercial suppliers [for example Advanced ChemTech (Louisville, KY, USA), Anaspec (San Jose, CA, USA), Astatech (Princeton, NJ, USA), Bachem (Bubendorf, Switzerland), Chemlmpex (Wood Dale, IL, USA), Novabiochem (subsidiary of Merck KGaA, Darmstadt, Germany), PepTech (Burlington, MA, USA), Synthetech (Albany, OR, USA)] or synthesized through standard methodologies known to those in the art. Ddz-amino acids were either obtained commercially from Orpegen (Heidelberg, Germany) or Advanced ChemTech (Louisville, KY, USA) or synthesized using standard methods utilizing Ddz-OPh or Ddz-N3. (Birr, C; Lochinger, W.; Stahnke, G.; Lang, P. Justus Liebigs Ann. Chem. 1972, 763, 162- 172.) Bts-amino acids were synthesized by known methods. (Vedejs, E.; Lin, S.; Klapara, A.; Wang, J. ./. Am. Chem. Soc. 1996, 118, 9796-9797; WO 01 /25257, WO 2004/1 1 1077) N-Alkyl amino acids, in particular N-methyl amino acids, are commercially available from multiple vendors (Bachem, Novabiochem, Advanced ChemTech, Chemlmpex). In addition, N-alkyl amino acid derivatives were accessed via literature methods. (Hansen, D. W., Jr.; Pilipauskas, D. J. Org. Chem.. 1985, 50, 945-950.) An improved synthesis of Fmoc-N-MeSer and Fmoc-N-MeThr has been reported. (Bahekar,R.H.; Jadav, P. A.; Patel, D.N.; Prajapati, V.M.; Gupta, A.A. Jain, M.R.; Patel, P.R. Tetrahedron Lett. 2007, 48, 5003-5005.) a//(j-Threoninc and β-hydroxyvaline can be synthesized by known procedures (Shao, H.; Goodman, M. J. Org. Chem. 1996, 61, 2582; Blaskovich, M. A.; Evindar, G.; Rose, N. G. W.; Wilkinson, S.; Luo, Y.; Lajoie, G.. J. Org. Chem. 1998, 63, 3631 ; Dettwiler; J.E. Lubell, W.D. /. Org. Chem. 2003, 68, 177-179.) Chirai isomers of β-methylphenylalanines and β- methyltyrosines can be accessed using literature methods. (Dharanipragada, R.; Van Hulle, K.; Bannister, A.; Bear, S.; Kennedy, L.; Hruby, V. J. Tetrahedron 1992, 48, 4733-4748; Nicolas, E.; Russell, K. C.; Knollenberg, J.; Hruby, V. J. J. Org. Chem. 1993, 59, 7565- 7571.) Similarly, chirai isomers of 4,4,4-trifluorothreonine with suitable protecting groups can be prepared by the enantioselective synthetic methods described in the literature. (Xiao, N.; Jinag, Z.-H.; Yu, Y.B. Biopolymers (Pept. Sci. ) 2007, 88, 781 -796.) Incorporation of the a//r - isomer of L-threonine (2S,3S) could aiso be accomplished from the syn-L-isomer (2S,3R) based upon a similar transformation used in the synthesis of the natural product ustiloxin D (Wandiess, T.J.; et al. J. Am. Chem. Soc. 2003, 115, 6864-6865.)
D. Tethers
Certain tethers were obtained from the methods previously described in Intl. Pat. Appl. WO 01/25257, WO 2004/111077, WO 2005/012331 , WO 2006/009645, WO 2006/009674 and U.S. Prov. Pat. Appl. 61/254,434.
Exemplary tethers (T) for the compounds of the invention include, but are not limited to, the following:
1.23
Figure imgf000126_0001
T8 T9 T11
Figure imgf000126_0002
T33a (R) T38a (R> T40a (R) T33b (S) T38b (S) T40b (S)
Figure imgf000126_0003
T67 T69 T70
Figure imgf000126_0004
Figure imgf000126_0005
Figure imgf000127_0001
T100 T104a (R,R) T105
T104b (S,S)
Figure imgf000127_0002
T106 T113a (R) T125a (R)
T113b (S) T125b (S)
Figure imgf000127_0003
T128a (2R,9R) T128c (2S,9R)
T128b (2R,9S) T128d (2S.9S)
Figure imgf000127_0004
T137 T138 T139
Figure imgf000127_0005
Figure imgf000128_0001
T144a(R)
T144b (S)
Figure imgf000128_0002
T152 T153 T154
Figure imgf000128_0003
Figure imgf000128_0004
Figure imgf000129_0001
T162b (S) T163 (S>
Figure imgf000129_0002
T164a (R) T165a (R) T166
T164b (S) T165b (S)
Figure imgf000129_0003
T167 T168a (R,R) T169a(R)
T168b (S,S) T169b{S)
Figure imgf000129_0004
T173a(R) T1 4a (R) T175a (R)
T1 3b(S) T1 4b (S) T175b (S)
,9R)
Figure imgf000129_0005
T178b (2R,9S) T178d (2S.9S)
Figure imgf000130_0001
T179a (2R,9R) T1 9c (2S,9R) T180a (2R,9R) T180c (2S.9R) T181a (2R.9R) T181c (2S,9R) T179b <2R,9S) T179d (2S.9S) T180b (2R,9S) T180d (2S.9S) T181b (2R,9S) T181d (2S.9S)
Figure imgf000130_0002
T182a (2R,9R) T182c (2S,9R) T183a (2R,9R) T183c (2S,9R) T184a (R)
T182b (2R,9S) T182d {2S.9S) T183b <2R,9S) T183d (2S.9S) T184b (S)
Figure imgf000130_0003
T191 a (R) T192a (R)
T191 b (S) T192b (S) T193
Figure imgf000131_0001
Figure imgf000131_0002
Figure imgf000131_0003
T216a {R)
T217a (R) T218a (R) T216 (S)
T217b (S) T218b (S)
Figure imgf000131_0004
T219a (R)
T219b (S) T220a (R)
T220b {S}
and wherein Pg and Pg2 are nitrogen protecting groups, such as, but not limited to, Boc, Fmoc, Cbz, Ddz and Alloc.
For representative syntheses of the new tether moieties disclosed herein, the routes presented in the Examples are employed. Although the routes described typically illustrate a specific protection strategy, other suitable protecting groups known in the art can also be empioyed.
E. Solid Phase and Solution Phase Techniques
Specific solid phase techniques, including mixed solid-solution phase procedures, for the synthesis of the macrocyclic compounds of the invention have been described in Intl. Pat. Publ. WO 01/25257, WO 2004/1 11077, WO 2005/012331 , WO 2005/012332, WO 2006/009645, WO 2006/009674, WO 2008/033328, WO 2008/130464 and U.S. Prov. Pat. Appl. 61/254,434 including purification procedures described in WO 2004/111077 and WO 2005/012331. Solution phase synthesis routes, including methods amenable to larger scale manufacture, were described in U.S. Patent Appl. Publ. Nos. 2006/025566 and US 2007/0021331.
3. Analytical Methods
Specific analytical techniques for the characterization of the macrocyclic compounds of the invention have been described in WO 01/25257, WO 2004/1 11077, WO 2005/012331 and WO 2005/012332.
Ή and UC NMR spectra were recorded on a Varian Mercury 300 MHz spectrometer (Varian, Inc., Palo Alto, CA) and are referenced internally with respect to the residual proton signals of the solvent unless otherwise noted. Ή NMR data are presented, using the standard abbreviations, as follows: chemical shift (δ) in ppm (multiplicity, integration, coupling constant(s)). The following abbreviations are used for denoting signal multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, b or br = broad, and m = multiplet. Information about the conformation of the molecules in solution can be determined utilizing appropriate two-dimensional NMR techniques known to those skilled in the art. (Martin, G.E.; Zektzer, A.S. Two-Dimensional. NMR Methods for Establishing Molecular Connectivity: A Chemist's Guide to Experiment Selection, Performance, and interpretation, John Wiley & Sons: New York, 1988, ISBN 0471 187070.)
HPLC analyses were performed on a Waters Alliance® system 2695 running at 1 mL/min using an Xterra® MS C18 column (or comparable) 4.6 x 50 mm (3.5 μιη) and the indicated gradient method. A Waters 996 PDA provided UV data for purity assessment (Waters Corporation, Milford, MA). For certain analyses, an LCPackings (Dionex Corporation, Sunnyvale, CA) splitter (50:40: 10) allowed the flow to be separated in three parts. The first part (50%) was diverted to a mass spectrometer (Micromass® Platform II MS equipped with an APCI probe) for identity confirmation. The second part (40%) went to an evaporative light scattering detector (ELSD, Polymer Laboratories, now part of Varian, Inc., Palo Alto, CA, PL-ELS- 1000™) for purity assessment and the last portion (10%) went to a chemiluminescence nitrogen detector (CLND, Antek® Model 8060, Antek instruments, Houston, TX, part of Roper Industries, Inc., Duiuth, GA) for quantitation and purity assessment. Each detector could also be used separately depending on the nature of the analysis required. Data was captured and processed utilizing the most recent version of the Waters Millennium® software package.
Representative standard HPLC conditions used for the analysis of compounds of the invention are presented below:
Typical Chromato graph: LC Conditions
Column: XTerra RP18, 3.5 μηι, 4.6 x 100 mm (or equivalent)
Detection (PDA): 220-320 nm
Column Temperature: 35±10°C
Injection Volume: ΙΟ μΙ,
Flow Rate: 1 mlJmin
Run Time: 20.0 min
Data Acquisition Time: 17.0 min
Mobile Phase A: Methanol (or Acetonitrile)
Mobile Phase B: Water
Mobile Phase C: 10% TFA in Water
Gradient A4
Figure imgf000133_0001
Gradient B4
Figure imgf000134_0001
Preparative HPLC purifications were performed on final deprotected macrocycles using the Waters FractionLynx system, on an XTcrra MS C I.8 column (or comparable) 19 x 100mm (5 μπι). The injections were done using an At-Column-Dilution coni'iguration with a Waters 2767 injector/collector and a Waters 515 pump running at 2 mL/min. The mass spectrometer, HPLC, and mass-directed fraction collection are controlled via MassLynx software version 3.5 with FractionLynx. Fractions (13 x 125 mm tubes) shown by MS analysis to contain the product were evaporated under reduced pressure, most typically on a centrifugal evaporator system (Genevac HT-4, ThermoSavant Discovery, SpeedVac or comparable) or, alternatively, lyophilized. Compounds were then thoroughly analyzed by LC-MS-UV-ELSD-CLND analysis for identity confirmation, purity and quantity assessment.
Automated medium pressure chromatographic purifications were performed on an Isco CombiFlash 16x system with disposable silica or C18 cartridges that permitted up to sixteen (16) samples to be run simultaneously. MS spectra were recorded on a Waters Micromass Platform II or ZQ system. H MS spectra were recorded with a VG Micromass ZAB-ZF spectrometer. Chemical and biological information were stored and analyzed utilizing the AclivityBase database software (IDBS, Guildford, Surrey, UK).
Analytical data for representative compounds of the invention are summarized in Table 2.
Table 2. Analytical Data for Representative Compounds of the Invention
Figure imgf000134_0002
1301 C32H46N405 566.7 567
1302 C32H46N405 566.7 567
1304 C33H44N405 576.7 577
1305 C28H36N406 524.6 525
1311 C30H43N5O5 553.7 554
1313 C32H44N405 564.7 565
1314 C32H44N405 564.7 565
1315 C32H44N405 564.7 565
1316 C32H44N405 564.7 565
1317 C31H40N4O5 548.7 549
1318 C31H42N405 550.7 551-
1319 C30H40N4O5 536.7 537
1320 C32H42N405 562.7 563
1323 C32H44N405 564.7 565
1324 C30H40N4O6 552.7 553
1325 C31 H41N405F 568.7 569
1326 C31H41N405F 568.7 569
1327 C32H41N405F3 618.7 619
1328 C31H43N505 565.7 566
1329 C28H40N6O5 540.7 541
1330 C30H41N5O5 551.7 552
1331 C29H40N4O6 540.7 541
1332 C29H40N4O5S 556.7 557
1333 C31H43N504 549.7 550 1334 C32H44N405 564.7 565
1335 C33H46N404 562.7 563
1336 C33H46N405 578.7 579
1337 C33H46N405 578.7 579
1338 C32H46N405 566.7 567
1339 C31H44N406 568.7 569
1340 C31H44N406 568.7 569
1341 C31H41 N405F 568.7 569
1342 C32H46N405 566.7 567
1343 C31H43N405F 570.7 571
1344 C32H45N405F 584.7 585
1345 C31H42N405 550.7 551
1346 C32H44N404 548.7 549
1347 C32H46N405 566.7 567
1348 C32H46N405 566.7 567
1349 C32H43N405F3 620.7 621
1350 C30H40N4O6 552.7 553
1351 C31H42N406 566.7 567
1352 C31 H44N406 568.7 569
1353 C31H42N405 550.7 551
1354 C31H44N405 552.7 553
1355 C31H42N405 550.7 551
1356 C31H44N405 552.7 553
1357 C31H44N405 552.7 553 1358 C32H46N405 566.7 567
1359 C31H44N406 568.7 569
1360 C31H43N405F 570.7 571
1361 C31H44N405 552.7 553
1362 C30H42N4O6 554.7 555
1363 C30H41N4O5F 556.7 557
1364 C31H43N405F 570.7 571
1365 C30H41.N4O6F 572.7 573
1366 C30H40N4O5F2 574.7 575
1367 C31H42N405 550.7 551
1368 C31H41N405F 568.7 569
1369 C32H43N405F 582.7 583
1370 C32H46N405 566.7 567
1371 C32H46N406 582.7 583
1372 C31H42N405F2 588.7 589
1373 C32H46N405 566.7 567
1374 C32H43N505 577.7 578
1375 C33H45N505 591.7 592
1376 C30H41N4O5F 556.7 557
1377 C30H41N4O5F 556.7 557
1378 C30H41N4O5F 556.7 557
1379 C31H43N405F 570.7 571
1380 C31H43N405F 570.7 573
1381 C31 H43N405F 570.7 571 1382 C31H42N405 550.7 551
1383 C31H43N406C1 603.1 603
1384 C30H43N5O5 553.7 554
1385 C29H41N505 539.7 540
1387 C31H43N406F 586.7 587
1388 C32H44N405 564.7 565
1389 C32H46N405 566.7 567
1390 C32H46N405 566.7 567
1391 C31H43N405F 570.7 571
1392 C31H42N405F2 588.7 589
1393 C32H46N405 566.7 567
1394 C31H44N405 552.7 553
1395 C30H43N5O5 553.7 554
1396 C31H40N4O5F2 586.7 587
1397 C29H40N4O5 524.7 525
1398 C32H46N405 566.7 567
1399 C29H42N405S 558.7 559
1400 C31H43N405C1 587.1 587
1401 C31H44N406 568.7 569
1402 C31H41N405F3 606.7 607
1403 C31H41N405F3 606.7 607
1404 C32H46N405 566.7 567
1405 C28H41N505S 559.7 560
1406 C33H44N505F 609.7 610 1407 C33H44N505F 609.7 610
1408 C32H44N605 592.7 593
1409 C34H47N505 605.8 606
1411 C31H41N405F3 606.7 607
1412 C32H43N405F3 620.7 621
1413 C34H45N505 603.8 604
1414 C35H46N405 602.8 603
1415 C35H46N405 602.8 603
1416 C33H44N405S 608.8 609
1417 C29H42N405S 558.7 559
1418 C32H46N406 582.7 583
1419 C30H39N4O5F 554.7 555
1420 C31H42N405F2 588.7 589
1421 C31H42N405F2 588.7 589
1422 C31H42N405 550.7 551
1423 C32H45N405F 584.7 585
1424 C32H45N405F 584.7 585
1425 C34H47N405F 610.8 611
1426 C36H49N505 631.8 632
1427 C32H41 N505 575.7 576
1428 C33H44N505F 609.7 610
1429 C33H44N505F 609.7 610
1430 C31 H42N405 550.7 551
1431 C32H45N405F 584.7 585 1432 C30H39N4O5C1 571.1 571
1433 C30H47N4O5C1 579.2 579
1434 C31H42N405FC1 605.1 605
1435 C31H42N405FC1 605.1 605
1436 C31H42N405F2 588.7 589
1437 C31H42N405F2 588.7 589
1438 C30H38N4O5F2 572.6 573
1439 C31 H41N405F3 606.7 607
1440 C31H41N405F3 606.7 607
1441 C32H39N505 573,7 574
1442 C33H42N505F 607.7 608
1443 C33H42N505F 607.7 608
1444 C32H45N406F 600.7 601
1445 C31H42N406 566.7 567
1446 C32H45N406F 600.7 601
1447 C28H38N405S 542.7 543
1448 C29H41N405FS 576.7 577
1449 C29H41N405FS 576.7 577
1450 C31H43N405F 570.7 571
1451 C32H45N405F 584.7 585
1453 C31H44N406 568.7 569
1454 C32H42N505F 595.7 596
1455 C33H44N505F 609.7 610
1456 C32H43N506 593.7 594 14S7 C33 H43N405F 570.7 571
1458 C32H45N405F 584.7 585
1459 C31H44N406 568.7 569
1460 C30H40N4O5FC1 591.1 591
1461 C31H42N405FC1 605.1 605
1462 C30H41N4O6C1 589.1 590
1463 C30H40N4O5F2 574.7 575
1464 C31H42N405F2 588.7 589
1465 C30H41N4O0F 572.7 573
1466 C30H39N4O5F3 592.6 593
1467 C31H41N405F3 606.7 607
1468 C30H40N4O6F2 590.7 591
1469 C32H40N5O5F 593.7 594
1470 C33H42N505F 607.7 608
1471 C32H41N506 591.7 592
1472 C31H43N406F 586.7 587
1473 C32H45N406F 600.7 601
1474 C31H44N407 584.7 585
1475 C28H39N405FS 562.7 563
1476 C29H41N405FS 576.7 577
1477 C28H40N4O6S 560.7 561
1478 C32H45N405F 584.7 585
1479 C33H48N405 580.8 581
1480 C32H45N405F 584.7 585 1481 C34H47N505 605.8 606
1482 C33H48N405 580.8 581
1483 C32H45N405C1 601.2 601
1484 C32H44N405F2 602.7 603
1485 C34H45N505 603.8 604
1486 C30H38N4O5F2 572.6 573
1487 C32H40N5O5F 593,7 594
1488 C30H38N4O5F2 572.6 573
1489 C32H40N5O5F 593.7 594
1490 C30H38N4O5F2 572.6 573
1491 C32H40N5O5F 593.7 594
1492 C30H37N4O5F3 590.6 591
1493 C30H39N4O5F3 592.6 593
1494 C32H39N505F2 611.7 612
1495 C32H41N505F2 613.7 614
1496 C31H41N405F3 606.7 607
1497 C33H43N505F2 627.7 628
1498 C30H42N5O5F 571 .7 572
1499 C32H44N605 592.7 593
1500 C31H43N406F 586.7 587
1501 C33H41N505 587.7 588
1502 C33H45N506 607.7 608
1503 C31H43N406F 586.7 587
1504 C33H45N506 607.7 . 608 1505 C34H46N505F 623.8 624
1506 C33H47N405F 598.7 599
1507 C32H44N405FC1 619.2 619
1508 C32H43N405F3 620.7 621
1509 C34H44N505F 621.7 622
1510 C32H45N405F 584.7 585
1511 C30H43N4O5FS 590.8 593
1512 C34H47N505 605.8 606
1513 C32H45N405F 584.7 585
1514 C33H48N405 580.8 581
1515 C32H44N405 564.7 565
1516 C32H44N405 564.7 565
1517 C32H44N405 564.7 565
1518 C32H45N405F 584.7 585
1519 C29H40N5O5F 557.7 558
1520 C31H42N605 578.7 579
1521 C33H48N406 596.8 597
1522 C30H44N4O5S 572.8 573
1523 C32H42N506F 61 1.7 612
1524 C31H40N4O5F4 624.7 625
1525 C33H42N505F3 645.7 646
1526 C31 H39N405F 566.7 567
1527 C32H45N406C1 617.2 617
1528 C32H44N405F2 602.7 603 1529 C33H47N405F 598.7 599
1530 C32H44N405F2 602.7 603
1531 C33H47N406F 614.7 615
1532 C34H47N505 605.8 606
1533 C30H39N4O6F 570.7 571
1534 C32H41N506 591.7 592
1535 C31H45N504 551.7 552
1551 C31H40N4O5 548.7 549
1552 C31H40N4O5 548.7 549
1553 C32H42N405 562.7 563
1554 C31H40N4O5 548.7 549
1555 C31H41FN405 568.7 569
1556 C31H42N405 550.7 551
1558 C30H37N4O4F 536.6 537
1559 C33H46N404 562.7 563
1560 C33H46N405 578.7 579
1565 C30H39N4O6F 570.7 571
1566 C32H41N506 591.7 592
1601 C31H50N4O5 558.8 559
1602 C31H50N4O5 558.8 559
1603 C31H50N4O5 558.8 559
1604 C30H48N4O5 544.7 545
1605 C30H46N4O5 542.7 543
1606 C32H50N4O7 602.8 603 1607 C32H50N4O7 602.8 603
1608 C31H45N407F 604.7 605
1609 C32H50N4O7 602.8 603
1610 C32H50N4O7 602.8 603
1611 C32H50N4O8 618.8 619
1612 C29H46N407S 594.8 595
1613 C31H47N407C1 623.2 623
1614 C31H46N407F2 624.7 625
1615 C32H50N4O7 602.8 603
1616 C32H47N507 613.7 614
1617 C33H49N507 627.8 628
1618 C30H47N5O7 589.7 590
1619 C30H47N4O5F 562.7 563
1620 C32H49N505 583.8 584
1621 C30H47N4O5C1 579.2 579
1622 C30H46N4O5F2 580.7 581
1623 C32H47N505 581.7 582
1624 C30H47N4O5F 562.7 563
1625 C31H50N4O6 574.8 575
1626 C28H46N405S 550.8 551
1627 C31H50N4O5 558.8 559
1628 C31H50N4O5 558.8 559
1630 C29H45N405F 548.7 549
1631 C31H47N505 569.7 570 1632 C33H51N505 597.8 598
1633 C31H49N405F 576.7 577
1634 C33H51N505 597.8 598
1635 C31H49N405F 576.7 577
1636 C30H48N4O6 560.7 561
1655 C30H48N4O6 560.7 561
1688 C31H40N4O5 548.7 549
1689 C31H41N405F 568.7 569
1690 C30H38N4O5F2 572.6 573
1691 C30H37N4O5F 552.6 553
1692 C32H39N505 573.7 574
1693 C32H38N505F 591.7 592
1694 C33H48N405 580.8 581
1695 C33H48N405 580.8 581
1696 C33H47N405F 598.7 599
1697 C35H49N505 619.8 620
1698 C35H49N505 619.8 620
1699 C31H43N405C1 587.1 587
1700 C31H39N405C1 583.1 583
1701 C32H42N405 562.7 563
1702 C30H39N4O5F 554.7 555
1703 C35H46N505F 635.8 636
1704 C31H39N405C1 583.1 583
1705 C34H47N405F 610.8 611 1706 C36H48N505F 649.8 650
1707 C36H44N505F 645.8 646
1708 C33H47N405F 598.7 599
1709 C34H42N505C1 636.2 636
1710 C33H43N405C1 61 1 .2 6Π
1711 C31H39N405F 566.7 567
1712 C30H38N4O5 534.6 535
1713 C34H41N505 599.7 600
1714 C30H47N4O5C1 579.2 579
1715 C31H49N405C1 593.2 593
1718 C36H45N505 627.8 628
1719 C35H46N505F 635.8 636
1720 C35H42N505F 631.7 632
1721 C34H46N405F2 628.7 629
1722 C32H45N405F 584.7 585
1723 C32H44N405F2 602.7 603
1724 C32H44N405F2 602.7 603
1725 C34H46N505F 623.8 624
1726 C34H42N505F 619.7 620
1727 C35H49N506 635.8 636
1728 C30H37N4O5C1 569.1 . 569
1729 C31H39N405C1 583.1 583
1730 C31H41N405C1 585.1 585
1731 C31H41N405CI 585.1 585 1732 C29H37N405C1 557.1 557
1733 C32H43N405C1 599.2 599
1735 C32H44N406 580.7 581
1736 C32H44N405 564.7 565
1737 C32H44N405 564.7 565
1738 C31H41N405C1 585.1 585
1739 C31H40N4O5FCI 603.1 603
1740 C31H40N4O5FC1 603.1 603
1741 C32H43N405C1 599.2 599
1742 C32H45N405C1 601.2 601
1743 C34H47N405F 610.8 611
1744 C34H47N405C1 627.2 627
1745 C33H43N505 589.7 590
1746 C33H45N405F 596.7 597
1747 C33H44N405F2 614.7 615
1751 C32H45N406F 600.7 601
1752 C35H48N505F 637.8 638
1753 C32H44N405FC1 619.2 619
1754 C34H43N505 601.7 602
1755 C34H42N505F 619.7 620
1756 C36H49N505 631 .8 632
1757 C31H44N504C1 586.2 586
1758 C3 H42N405FC1 605.1 605
1759 C32H41N405F 580.7 581 1760 C32H40N4O5F2 598.7 599
1761 C31H40N4O5C12 619.6 619
1762 C34H47N505 605.8 606
1763 C34H47N405F 610.8 611
1764 C36H50N5O5F 651.8 652
1768 C31H41N405C1 585.1 585
1769 C31H41N405F 568.7 569
1770 C33H42N505F 607.7 608
1771 C30H38N4O5F2 572.6 573
1772 C30H39N4O5F 554.7 555
1773 C33H40N5O5F 605.7 606
1774 C34H46N505F 623.8 624
1775 C32H38N505F 591.7 592
1776 C33H46N405 578.7 579
1777 C32H44N405 564.7 565
1778 C32H42N405 562.7 563
1779 C33H46N405 578.7 579
1780 C31H42N405 550.7 551
1781 C31H39N406C1 599.1 599
1782 C33H44N406 592.7 593
1784 C31H41N405C1 585.1 585
1785 C32H45N405C1 601.2 601
1786 C34H47N405C1 627.2 627
1787 C36H49N505 631.8 632 1789 C35H47N505 617.8 61 8
1790 C33H46N406 594.7 595
1791 C33H45N405F 596.7 597
1792 C33H45N405F 596.7 597
1794 C30H39N4O5C1 571 .1 57J
1795 C32H44N406 580.7 581
1796 C32H45N405F 584.7 585
1797 C35H48N405 604.8 605
1798 C33H46N405 578.7 579
1799 C31H40N4O5FC1 603.1 603
1800 C32H45N405C1 601.2 601
1801 C33H44N505F 609.7 610
1802 C34H47N505 605.8 606
1803 C34H45N505F2 641.7 642
1805 C33H47N405F 598.7 599
1806 C34H46N505C1 640.2■ 640
1808 C34H46N505F 623.8 624
1809 C33H40N5O5F 605.7 606
1810 C32H42N405 562.7 563
1811 C31 H41N405F 568.7 569
1812 C41H52N507FS 777.9 778
1813 C32H45N405C1 601.2 601
1814 C32H44N405FC1 619.2 619
1815 C36H48N505F 649.8 650 1824 C30H43N4O6F 574.7 575
1825 C33H46N405 578.7 579
1826 C33H46N405 578.7 579
1827 C33H42N505F 607.7 608
1829 C33H43N405C1 611.2 611
1830 C30H37N4O5C1 569.1 569
1831 C31H41N405C1 585.1 585
1832 C29H37N405C1 557.1 557
1834 C32H44N406 580.7 581
1835 C32H44N405 564.7 565
1836 C32H44N405 564.7 565
1837 C31H41N405C1 585.1 585
1838 C31H40N4O5C12 619.6 619
1839 C33H45N405F 596.7 597
1840 C32H46N405 566.7 567
1841 C32H42N406 578.7 579
1842 C33H43N406C1 627.2 627
1843 C34H45N505 603.8 604
1844 C34H45N505 603.8 604
1846 C33H45N405F3 634.7 635
1847 C31H45N505 567.7 568
1848 C32H44N405 564.7 565
1849 C32H44N405 564.7 565
1851 C36H48N506F 665.8 666 1852 C32H45N405F 584.7 585
1853 C33H44N505F 609.7 610
1854 C31H43N405F 570.7 571
1855 C31H42N405F2 588.7 589
1856 C32H42N405F4 638.7 639
1857 C34H46N505F 623.8 624
1858 C32H43N405C1 599.2 599
1859 C31H41N405CI 585.1 585
1860 C33H43N405F3 632.7 633
1861 C32H41N405F3 618.7 619
1862 C31H43N405F 570.7 571
1863 C33H44N505F 609.7 610
1864 C33H47N506 609.8 610
1866 C33H49N507S 659.8 660
1867 C33H44N405F4 652.7 653
1869 C33H45N405F 596.7 597
1870 C33H44N405F2 614.7 615
1871 C33H44N405FC1 631.2 631
1872 C32H42N405FC1 617.2 617
1875 C33H44N405FCI 631.2 631
1876 C31H37N405F 564.6 565
1878 C31H38N405 546.7 547
1879 C31H37N405F 564.6 565
1880 C34H43N505 601.7 602 1881 C33H44N405 576.7 577
1882 C32H44N405 564.7 565
1883 C32H43N405F 582.7 583
1884 C31H36N405F2 582.6 583
1885 C34H43N505F4 677.7 678
1888 C33H45N405F3 634.7 635
1889 C33H45N505 591.7 592
1890 C34H44N505F3 659.7 660
1891 C35H46N505F3 673.8 674
1892 C33H44N405F4 652.7 653
1893 C32H42N505F 595.7 596
1894 C34H44N605 616.8 617
1895 C34H45N505 603.8 604
1896 C35H46N605 630.8 631
1897 C33H44N505F 609.7 610
1898 C31H41N405F 568.7 569
1899 C31H42N405 550.7 551
1900 C33H43N505 589.7 590
1901 C33H44N405 576.7 577
1902 C35H45N505 615.8 616
1903 C32H43N405F 582.7 583
1904 C32H43N405C1 599.2 599
1905 C32H45N505 579.7 580
1906 C30H43N5O5 553.7 554 1907 C31H43N505 565.7 566
1909 C33H45N505 591.7 592
1911 C32H43N405F3 620.7 621
1912 C34H45N405F3 646.7 647
1913 C33H44N405F2 614.7 615
1914 C33H46N406 594.7 595
1916 C32H42N405F2 600.7 601
1918 C31H37N405F 564.6 565
1919 C31H36N405F2 582.6 583
1921 C33H42N405F4 650.7 651
1922 C34H46N605 618.8 619
1925 C32H42N405F4 638.7 639
1927 C34H47N506 621.8 622
1928 C32H46N406 582.7 583
1929 C30H37N4O5F 552.6 553
1930 C32H44N405 564.7 565
Notes
1. Molecular formulas and molecular weights are calculated automatically from the structure via ActivityBase software (ID Business Solutions, Ltd., Guildford, Surrey, UK).
2. M+H obtained from LC-MS analysis using standard methods.
3. All analyses conducted on material after preparative purification.
4. Biological Methods
The compounds of the present invention were evaluated for their ability to interact at the human ghrelin receptor utilizing a competitive radioligand binding assay, fluorescence assay, Aequorin functional assay or ΓΡ3 inverse agonist assay as described in the procedures be!ow. Such methods can be conducted, if so desired, in a high throughput manner to permit the simultaneous evaluation of many compounds.
Specific assay methods for the human (GHS-Rla), swine and rat GHS -receptors (U.S. Pat. No. 6,242,199, Intl. Pat. Appl. Nos. WO 97/21730 and 97/22004), as well as the canine GHS-receptor (U.S. Pat. No. 6,645,726), and their use in generally identifying agonists and antagonists thereof are known.
Functional ghrelin antagonists can be identified utilizing the methods described in WO 2005/1 14180, while inverse agonists of the receptor can be assayed using the methods of WO 2004/056869.
Appropriate methods for determining the functional activity of compounds of the present invention that interact at the human ghrelin receptor are also described in the Examples below.
The in vivo efficacy of compounds of the present invention can be illustrated, for example, using animal models of obesity such as those described in the literature. (WO 2004/056869; Nakazato, M.; Murakami, N.; Date, Y.; et al. Nature 2001, 409, 194-198; Murakami, N.; Hayashida, T.; uroiwa, T.; et al. J. Endocrinol 2002, 174, 283-288; Asakawa, A.; Inui, A.; Kaga, T.; et al. Gut 2003, 52, 947-952; Sun,Y.; Ahmed, S.; Smith, R.G. Mol. Cell Biol. 2003, 23, 7973-7981; Wortley, K.E.; Anderson, K.D.; Garcia, K.; et al. Proc. Natl Acad. Sci. USA 2004, 101, 8227-8232; Halem, H.A.; Taylor, J.E.; Dong, J.Z.; Shen, Y,; Datta, R.; Abizaid, A.; Diano, S.; Horvath, T.; Zizzari, P.; Btuet-Pajot, M.-T.; Epelbaum, J.; Culler, M.D. Eur. J. Endocrinol 2004, 151, S71-S75; Helmling, S.; Maasch, C; Eulberg, D.; et al. Proc. Natl. Acad. Sci USA 2004, 101, 13174-13179; Shearman, L.P.; Wang, S.P.; Helmling, S.; et al. Endocrinology 2006, 147, 1517- 1526; Reuter, T.Y. Drug Disc. Today: Dis. Models 2007, 4, 3-8; Shafrir, E.; Ziv, E. Am. J. Physiol. 2009, 296, E1450- E1452.) Similarly, numerous animal models are available for studying the effects of these compounds in diabetes. (Nandi, A. et al. Physiol Rev. 2004, 84, 623-647; Freude, S.; Schubert, M. Drug Disc. Today: Dis. Models 2007, 4, 9-16; Muniyappa, R.; Lee, S. Chen, H.; Quon, M.J. Am. J. Physiol. 2008, 294, E15-E26.)
Bl. Competitive Radioligand Binding Assay (Ghrelin Receptor)
The competitive binding assay at the human ghrelin receptor (GRLN, growth hormone secretagogue receptor, hGHS-Rla) was carried out analogously to assays described in the literature. (Bednarek MA et al. J. Med. Chem. 2000, 43, 4370-4376; Palucki, B.L. et al. Bioorg. Med. Chem.. Lett. 2002, 11, 1955-1957.) Materials
Membranes (GHS-R/HEK 293) were prepared from HEK-293 cells stably transfected with the human ghrelin receptor (hGHS-Rl a). These membranes were provided by PerkinElmer BioSignal (#RBHGHSM, lot#1887) and utilized at a quantity of 0.71 g/assay point.
1. [125T]-Ghrelin (PerkinElmer, #NEX-388); final concentration: 0.0070-0.0085 nM
2. Ghrelin (Bachem, #H-4864); final concentration: 1 μΜ
3. Multiscreen Harvest plates-GF/C (Miilipore, #MAHFC1H60)
4. Deep-well polypropylene titer plate (Beckman Coulter, #267006)
5. TopSeal-A (PerkinElmer, #6005185)
6. Bottom seal (Miilipore, #MATAH0P00)
7. MicroScint-0 (PerkinElmer, #6013611)
8. Binding Buffer: 25 mM Hepes (pH 7.4), .1 niM CaCl2, 5 mM MgCl2, 2.5 mM
EDTA, 0.4% BSA
Assay Volumes
Competition experiments were performed in a 300 μΐ filtration assay format.
1. 220 μΕ of membranes diluted in binding buffer
2. 40 lL of compound diluted in binding buffer
3. 40 of radioligand ([ 125I]-Ghrelin) diluted in binding buffer
Typical final test concentrations (N = 1) for compounds of the present invention:
10, 1, 0.5, 0.2, 0.1 , 0.05, 0.02, 0.01 , 0.005, 0.002, 0.001 μΜ.
Compound Handling
Compounds were provided frozen on dry ice at a stock concentration of 10 mM diluted in 100% DMSO and stored at -80°C until the day of testing. On the test day, compounds were allowed to thaw at rt overnight and then diluted in assay buffer according to the desired test concentrations. Under these conditions, the maximal final DMSO concentration in the assay was 0.1 %.
Assay Protocol
In deep- well plates, 220 \xL of diluted cell membranes (final concentration: 0.71. ίξΛνεΙΙ) were combined with 40 μΐ. of either binding buffer (total binding, N = 5), l μΜ ghrelin (non-specific binding, N = 3) or the appropriate concentration of test compound (N = 2 for each test concentration). The reaction was initiated by addition of 40 μΕ of [ i25I]- ghrelin (final cone. 0.0070 - 0.0085 nM) to each well. Plates were sealed with TopSeal-A, vortexed gently and incubated at rt for 30 min. The reaction was arrested by filtering samples through Multiscreen Harvest plates (pre-soaked in 0.5% polyethyleneimine) using a Tomtec Harvester, washed 9 times with 500 yiL of cold 50 mM Tris-HCl (pH 7.4, 4°C), and then plates were air-dried in a fumehood for 30 min. A bottom seal was applied to the plates prior to the addition of 25 \iL of MicroScint-0 to each well . Plates were than scaled with TopSeal- A and counted for 30 sec per well on a TopCount Microplate Scintillation and Luminescence Counter (PerkinElmcr) using a, count delay of 60 sec. Results were expressed as counts per minute (cpm).
Data were analyzed by GraphPad Prism (GraphPad Software, San Diego, CA) using a variable slope non-linear regression analysis. ; values were calculated using a d value of
0.01 nM for [ Tj-ghrelin (previously determined during membrane characterization).
Dmax values were calculated using the following formula:
Dmax = 1 - test concentration with maximal displacement - non-specific binding X 100
total binding - non-specific binding
where total and non-specific binding represent the cpm obtained in the absence or presence of 1 μΜ ghrelin, respectively.
Results for the examination of representative compounds of the present invention using this method are presented in the Examples.
B2. Fluorescence Functional Assay (Ghrelin Receptor)
Equipment
1 . ImageTrak Epi -Fluorescence system (Perkin-Elmer)
2. MultiDrop TiterTelc
3. C02 incubators: 5% C02, humidified, 37°C Materials
1. Hanks' BSS without phenol red (Life Technologies)
2. Hepes buffer
3. Probenecid (Sigma)
4. FLIPR Calcium-3 Assay Kit (Molecular Devices #R-8091)
5. Falcon cell culture 96- well black/clear bottom plates
6. 0.05% trypsin-EDTA 7. Cells: HEK293 cells expressing GHS-Rla receptor (Perkio-Elmer BioSignal) were grown in DMEM (Dulbecco's Modified Eagles Medium) with 10% FBS, 1% sodium pyruvate, 1% NEAA and 400 pg/mL geneticin
8. Ghrelin (reference agonist; Bachem, #FF4864)
9. [D-Lys3]-GHRP-6 (reference antagonist, Phoenix #031-22)
10. Assay buffer: HBSS - 20 niM Hepes containing 2.5 mM probenecid and 0.1% BSA (bovine serum albumin); pH 7.4
Compound Handling
Stock solutions of compounds (10 mM in 100% DMSO) were provided frozen on dry ice and stored at -80°C prior to use. From the stock solution, mother solutions were made at a concentration of 100 μΜ by 100-fold dilution in 26% DMSO. Assay plates were then prepared by appropriate dilution in assay buffer.
Typical Final Test Concentrations (N=10) for Test Compounds (agonist):
1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001 , 0.0003, 0.0001, 0.00003 μΜ.
Typical Final Test Concentrations (N=10) for Test Compounds (antagonist):
10, 3, 1, 0.3, 0.1 , 0.03, 0.01, 0.003, 0.001, 0.0003 μΜ.
Cell Preparation
Cells were maintained in culture as indicated above. The cells were harvested at a confluency of 70-90% the day before the experiment. Growth medium was removed and the cells rinsed briefly with PBS without Ca+2 and Mg+2. 0.05% Trypsin was added and the plates incubated at 37°C for 5 min to detach the cells. DMEM medium supplemented with 10% FBS was added to inactivate the trypsin and determine the cell concentration. The inoculum was adjusted to a final concentration of 200 cells/pL and dispensed at 200 pL per well into a 96-well block plate. The plates were incubated at 37°C overnight. The cellular confluence must be between 70-95% on the day of the experiment.
Assay Protocol
The plates were removed from the incubator and the media removed by inversion of the plates. Calcium-3 dye, 50 pL, was loaded and then incubated for 1 h at 37°C. The plate was again inverted and then 25 pL of assay buffer added. The plates were then transferred to the ImageTrak system for analysis. For agonist testing, after reading for ten (10) sec, 25 pL of 2x test compound or control was injected into the assay plate. Fluorescence was monitored for an additional 50 sec. A reading was taken every two (2) seconds for a total of 30 readings per assay point. For antagonist testing, after reading for ten (10) sec, 12.5 μί. of 3x test compound or control was injected into the assay plate and allowed to react for three (3) min. At that time, 4 iiM ghrelin (corresponds to EC80) was injected and fluorescence was monitored for an additional 60 sec. A reading was taken every two (2) seconds for a total of 125 readings per data point.
Analysis and Expression of Results
For agonists, values obtained for each assay point reflect Max-Min of fluorescencereadings where Max represents the maximal value of the 30 readings taken and Min represents the minimum value observed before injection of the compound from the first five readings. Concentration response curves were analyzed using GraphPad Prism (GraphPad Software, San Diego, CA) by non-linear regression analysis (sigmoidal dose-response). ECso values are calculated using GraphPad.
Emax values were calculated using the following formula:
Emax = counts at the concentration of compound with maximum response- Basal X 100
Ago(Emax) - Basal
where Basal and Ago(Emax) represent the average counts obtained in the absence or presence of 1 μΜ ghrelin, respectively.
For antagonists, values obtained for each assay point reflect Max-Min of fluorescence readings where Max represents the maximal value obtained after injection of ghrelin at EQ0 and Min represents the minimum value observed before injection of the compound from the first five readings. Concentration response curves were analyzed using GraphPad Prism (GraphPad Software, San Diego, CA) by non-linear regression analysis (sigmoidal dose- response). IC50 values are calculated using GraphPad.
Imax values were calculated using the following formula:
Imax = counts at concentration of compound with maximum response- Ago(ECg ) X 100
Basal - Ago(ECgo)
where Basal and Ago(EC8o) represent the average counts obtained in the absence or presence of 5 nM ghrelin at the second addition step, respectively.
B3. Aeqiiorin Functional Assay (GhreHn Receptor)
The functional activity of compounds of the invention found to bind to the GRLN (GHS-Rla) receptor can be determined using the method described below. (LePoul, E.; et al. J. Biomol. Screen. 2002, 7, 57-65; Bednarek, M.A.; et al. J. Med. Chem. 2000, 43, 4370-
4376; Palucki, B.L.; et al. Bioorg. Med. Chem. Lett. 2001, 77, 1955-1957.).
Materials
Membranes were prepared using AequoScreen™ (Perkin-Elmer, WaJtham, MA) cell lines expressing the human ghrelin receptor (cell line ES-410-A; receptor accession #60179). This cell line is constructed by transfection of the human ghrelin receptor into CHO-K1 cells co-expressing Gai 6 and the mitochondrially targeted Aequorin (Ref #ES-WT-A5).
1. Ghrelin (reference agonist; Bachem, #H-4864)
2. Assay buffer: DMEM (Dulbecco's Modified Eagles Medium) containing 0.1%
BSA (bovine serum albumin; pH 7.0.
3. Coelenterazine (Molecular Probes, Leiden, The Netherlands)
Typical final concentrations for test compounds, which are tested in duplicate:
0.1 , 0.3, 1 , 3, 10, 30, 100, 300, 1000, 3000 nM
Compound Handling
Stock solutions of compounds (10 mM in 100% DMSO) were typically provided frozen on dry ice and stored at -20°C prior to use. From the stock solution, mother solutions were made at a concentration of 1 mM by dilution to a final concentration of 30% DMSO. Assay plates were then prepared by appropriate dilution in DMEM medium containing 0.1% BSA. Under these conditions, the maximal final DMSO concentration in the assay was < 0.6%.
Ceil Preparation
AequoScreen™ cells were collected from culture plates with Ca2+ and Mg2+-free phosphate buffered saline (PBS) supplemented with 5 mM EDTA, pelleted for 2 minutes at 1000 X g, re-suspended in DMEM - Ham's F12 containing 0.1% BSA at. a density of 5 X l O6 cells/ml and incubated at room temperature for at least 4 h in the presence of 5 μΜ coelenterazine. After loading, cells were diluted with assay buffer to a concentration of 5 X 105 cells/ml.
Assay Protocol
For agonist testing, 50 μΐ of the cell suspension were mixed with 50 μΐ of the appropriate concentration of test compound or ghrelin (reference agonist) in 96-well plates (duplicate samples). Ghrelin (reference agonist) is tested at several concentrations concurrently with the test compounds in order to validate the experiment. The emission of light resulting from receptor activation in response to ghrelin or test compounds was recorded using the Hamamatsu Functional Drug Screening System 6000 reader (Hamamatsu Photonics K.K., Japan).
For antagonist testing, an approximate EC¾o concentration of ghrelin (i.e. 3.7 nM; 100 μί) was injected onto 100 μΕ of the cell suspension containing the test compounds (duplicate samples) after approximately 15 min incubation after the end of agonist testing and the consequent emission of light resulting from receptor activation was measured as described in the paragraph above. [D-Lys" ]-GHRP-6 was used a s a reference antagonist.
To standardize the emission of recorded light (determination of the " 100% signal") across plates and across different experiments, some of the wells contained 100 μΜ digitonin, a saturating concentration of ATP (20 μΜ) and a concentration of ghrelin equivalent to the EC50 obtained during test validation. Plates also contained the reference agonist and/or antagonist at a concentration equivalent to the ECgo obtained during the test validation.
Analysis and Expression of Results
Results are expressed as Relative Light Units (RLU). Concentration response curves were analyzed using GraphPad Prism (GraphPad Software, San Diego, CA) by non-linear regression analysis (sigmoidal dose-response) based on die equation E=Emax/(l +EC5o/C)n where E is the measured RLU value at a given agonist concentration (C), Eraax is the maximal response, EC50 is the concentration producing 50% stimulation and n is the slope index. For agonist testing, results for each concentration of test compound were expressed as percent activation relative to the signal induced by ghrelin at a concentration equal to the ECso (i.e. 3.7 nM). EC5o, Hill slope and %Emax values are reported.
For antagonist testing, results for each concentration of test compound were expressed as percent inhibition relative to the signal induced by ghrelin at a concentration equal to the ECgQ. Results for representative compounds of the invention are presented in the Examples. B4. Ghrelin Receptor Inverse Agonist Assay
The inverse agonist activity at the ghrelin receptor for compounds of the invention can be determined using the methods described in Intl. Pat. Appl. Publ. No. WO 2004/056869 and Hoist, B.; Cygankiewicz, A.; Halkjaer, T.; Ankersen, A. ; Schwartz, T.W. Mol. Endocrinol. 2003, 17, 2201-2210. As an alternative, a phosphatidyl inositol hydrolysis assay as reported in the literature (Jensen, A.A., et al. J. Biol. Chem. 2000, 275, 29547- 29555) can be utilized to assess the inverse agonist activity of compounds of the invention. In addition, the functional receptor assay termed Receptor Sepection and Amplification Technology (R-SAT), as described in U.S. Patent Nos. 5,707,798; 5,912,132; 5,955,281 and International Pat. Appl. Publ. No. WO 2007/079239, can be used to evaluate these compounds.
In addition, the following method can be utilized to assay for inverse agonist activity. (Thomsen, W.; et al. Curr. Opin. Biotechnol. 2005, 76, 655-665; Tozawa-Takahashi F; et al., 3 l th SBS Annual Conference. September 2005, Geneva; Trinquet, E.; Fink, M.; Bazin, H.; et al. Anal. Biochem. 2006, 358, 126-135; Bergsdorf, C; Kropp-Goerkis, C; Kaehler, l; Ketscher, L.; Boemer, U.; Parczyk, .; Bader, B. Assay Drug Dev. Technol. 2008, 6, 39-53.) Cell Stimulation:
1. Remove culture medium from the plate by inversion.
2. Add 70 μΐ of compound/well.
3. Incubate 30 min at 37°C.
4. Stop the reaction by adding 15 μΐ of lysis buffer/well.
5. Add 15 μ1 οΓ ά2/ννε11.
6. Add 15 μΐ of Anti-IPl cryptate/well.
7. Incubate lh at room temp on an orbital shaker at 100 RPM.
8. Read the fluorescence in a plate reader (Tecan GeniosPro or similar)
The above sequence was performed using using the HTRF IP-one kit (CisBio cat#62Pl APEC). For the simultaneous assay of multiple test compounds, 96-well plates can be utilized in this assay (white plate with flat-bottom well, Falcon #353296). These were seeded overnight with 100 000 of HEK-GHSR1 stable cells/well.
* Wells Al and A2 of each plate are used as negative control (wells without d2). Compounds are typically tested in replicate at the following concentrations:
0, 1 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 μΜ, 10 μΜ.
Compound dilution:
Compounds are stored at 10 mM in 100% DMSO.
lsl dilution 1/10 in 100% DMSO (1 mM final concentration).
2nd dilution 1/10 in H20 (0.1 mM final concentration).
Other dilutions are performed in a 96-well plate in stimulation buffer.
The results for representative compounds of the invention are provided in the Examples. B5. Plasma Protein Binding
The pharmacokinetic and pharmacodynamic properties of drugs are largely a function of the reversible binding of drugs to plasma or serum proteins such as albumin and ai-acid glycoprotein. In general, only unbound drug is available for diffusion or transport across cell membranes, and for interaction at the pharmacological target. On the other hand, drugs with low plasma protein binding generally have large volumes of distribution and rapid clearance since only unbound drug is available for glomerular filtration and, in some cases, hepatic clearance. Thus, the extent of plasma protein binding can influence efficacy, distribution and elimination. The ideal range for plasma protein binding is in the range of 87-98% for most drug products.
Protein binding studies were performed using human plasma. Briefly, 96-well microplates were used to incubate various concentrations of the test article for 60 min at 37°C. A concentration of 10 μΜ was a typical selection to be employed in this study. Bound and unbound fractions are separated by equilibrium dialysis, where the concentration remaining in the unbound fraction is quantified by LC-MS or LC-MS-MS analysis. Drugs with known plasma protein binding values such as quinine (-35%), warfarin (-98%) and naproxen (-99.7%) were used as reference controls.
Results for representative compounds of the invention are summarized in the Table 3.
Table 3. Human Plasma Protein Binding for
Representative Compounds of the Invention
Figure imgf000164_0001
B6. Assay for Cytochrome P450 Inhibition
Cytochrome P450 enzymes are implicated in the phase I metabolism of drugs. The majority of drug-drug interactions are metabolism-based and, moreover, these interactions typically involve inhibition of cytochrome P450s. Six CYP450 enzymes (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) appear to be commonly responsible for the metabolism of most drugs and the associated drug-drug interactions. Assays to determine the binding of compounds of the invention to the various metabolically important isoforms of cytochrome P450 metabolizing enzymes are commercially available, for example NoAb BioDiscoveries (Mississaugua, ON, Canada) and Absorption Systems (Exton, PA, USA). As well, a number of appropriate methods have been described or reviewed in the literature. (White, R.E. Ann. Rev. Phannacol. Toxicol. 2000, 40, 133-157; Li, A.P. Drug. Disc. Today 2001, 6, 357-366; Turpeinen, M.; Korhonen, L.E. Tolonen, A.; et al. Eur. J. Pharm. Sci. 2006, 29, 130-1.38.)
The key aspects of the experimental method were as follows:
1. Assay was performed on microsomes (Supersomes®, BD Gentest, Becton- Dickinson) prepared from insect cells expressing individual human CYP-450 subtypes, specifically:
- CYP subtypes: 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 , 3A4
- Two substrates are typically tested for CYP-3A4 as this enzyme exhibits complex inhibition kinetics
2. Assays monitored, via fluorescence detection, the formation of a fluorescent metabolite following incubation of the microsomes with a specific CYP substrate.
3. Compounds of the present invention were tested in duplicate samples at eight test concentrations using 3-fold serial dilutions (concentration range of 0.0457 to 100 μΜ).
4. For each CYP-450 enzyme, a specific inhibitor was tested in duplicate at eight concentrations as a positive control.
5. The concentration of the inhibitor or test compound that inhibited metabolite formation by 50% (IC50) was calculated by non-linear regression analysis of the % inhibition vs. log concentration (M) curve.
Results for representative compounds of the invention are summarized in Tables 4a and 4b below.
Table 4a. Cytochrome P450 Binding for
Representative Compounds of the Invention
Figure imgf000165_0001
1688 8.5 20.2
1777 6 Π..8
1778 7.7 21 .1
1780 6 35.7
1843 6.5 7.7
1848 8 14.1
1876 8.5 23.1
1878 11.6 45.3
1903 9 8
1918 16.3 8.1
1929 - 25.7
Nifedipine used as substrate (midazolam was also employed)
''Dextromethorphan used as substrate
No binding was obtained to the other CYP subtypes tested up to the highest concentration tested (300 μΜ).
Table 4b. Cytochrome P450 Binding for
Representative Compounds of the Invention
Figure imgf000166_0001
1429 0.7 > 20
1432 1.2 5.2
1433 2.6 3.1
1453 3.7 9.2
1479 1.5 > 20
1490 1.4 6.3
1501 1.5 > 20
1504 1.4 12.7
1515 1.1 > 8
1526 1.4 > 20
1601 2.6 > 5
1619 0.6 > 20
1693 2.2 -
1712 5.8 -
1720 1.6
1729 1.9 -
1730 1.6 -
1732 2.9 -
1919 11.5 - aMmidazo am used as substrate (nifedipine was also employed)
bDextromethorphan used as substrate
- indicates not tested with this subtype
B7. Determination of Caco-2 Permeability
The Caco-2 cell line, derived from a human colorectal carcinoma, has become an established in. vitro model for the prediction of drug absorption across the human intestine. (Sun, D.; Yu, L.X.; Hussain, M.A.; Wall, D.A.; Smith, .L.; Amidon, G.L. Curr. Opin. Drug Discov. Devel. 2004, 7, 75-85; Bergstrom, C.A. Basic Clin. Pharmacol. Toxicol. 2005, 96, 156-61; Balimane, P.V.; Han, Y.H.; Chong, S. AAPS J. 2006, 8, El-13; Shah, P.; Jogam, V.; Bagchi, T.; Misra, A. Biotechnol. Prog. 2006, 22, 186-198.) When cultured on semipermeable membranes, Caco-2 cells differentiate into a highly functionalized epithelial barrier with remarkable morphological and biochemical similarity to the small intestinal columnar epithelium. Fully differentiated cell monolayers can be used to assess the membrane transport properties of novel compounds. In addition, the apparent permeability coefficients (Papp) obtained from Caco-2 cell transport studies have been shown to reasonably correlate with human intestinal absorption.
Assays to determine the permeability of compounds of the invention utilizing Caco-2 cells are commercially available, for example NoAb BioDiscoveries (Mississaugua, ON, Canada) and Absorption Systems (Exton, PA, USA).
Alternatively, parallel artificial membrane permeability assays (PAMPA) can be utilized to assess intestinal permeability. (Avdeef, A. Expert Opi . Drug. Metab. Toxicol. 2005, 7, 325-342.)
Method
Permeability across the Caco-2 cell layer was determined by growing the cells on a membrane placed between two (donor and acceptor) chambers. Drug candidates are typically added to the apical (A) side of the cell layer and their appearance in the basolateral (B) side is measured over incubation time. Permeability in this direction represents intestinal absorption. Permeability may also be determined from the basolateral to the apical side of the Caco-2 cell. A higher apical to basolateral Pa p, compared to the basolateral to apical Papp, is indicative of carrier-mediated transport. P-gp mediated transport is suggested when a higher basolateral to apical Papp is observed relative to the apical to basolateral Papp.
Permeability (10 μΜ) for compounds of the invention in the apical to basolateral and basolateral to apical direction were tested in duplicate. Samples will be collected from the donor and acceptor chambers at the beginning (0 min) and following 60 min of incubation at 37°C and stored frozen at -70°C until bioanalysis. Samples for each test compound generated from the Caco-2 permeability assay were further analyzed by LC -MS-MS. The permeability ot H]-mannitol and [Ή] -propranolol were determined in parallel as controls.
The permeability coefficient (Papp) of each compound and radiolabeled standard was determined using the following equation:
PaPP = dQ x l/Ci x l/A
dT
where dQ/dT represents the permeability rate, Cj denotes the initial concentration in the donor compartment, and A represents the surface area of the filter. Cj is determined from the mean concentration of duplicate samples taken prior to addition to the donor compartment. Permeability rates were calculated by plotting the cumulative amount of compound measured in the acceptor compartment over time and determining the slope of the line by linear regression analysis. The duplicate and mean apical to basolateral and basolateral to apical Papp's were reported for each compound and standard.
To further ascertain the involvement of Pgp, use of an inhibitor of Pgp, for example cyclosporine A, can be utilized in this evaluation and the results with and without inhibitor compared. Results for representative compounds of the invention arc summarized in Table 5.
Table 5. Caco-2 Permeability of Representative Compounds of the Invention
Figure imgf000169_0001
a Average of three experiments b Cyclosporin A
B8. Metabolic Stability in Human Liver Microsomes
The liver is the primary site for phase I (oxidation) and phase 11 (glucuronidation) enzymatic activity responsible for xenobiotic metabolism. Human liver microsomes are used as in vitro screen of metabolic activity for candidate drugs. Similar studies can be run with microsomes from other species, such as those used for in vivo studies, to determine any significant species differences in the stability profile. The aim of this study was to measure the broad-spectrum metabolic stability of representative compounds of the invention.
The key aspects of the experimental design are summarized below: • Human liver microsomes (mixed pool of 15 male and female donors) were purchased from In Vitro Technologies (Baltimore, MD).
- Microsomes characterized for phase I (Cyp2A6( 2D6, 2E1 , 1 A2, 2C19, 3A4, 4A) and phase Π (glucuronidation) enzymatic activity.
• Assays are performed using a final concentration of 0.8 mg/mL of microsomes in 100 mM potassium phosphate buffer (1.5 raM NADPH, 8 mM MgCl2, pH 7.4, 37°C).
• Compounds are tested in duplicate samples at a single concentration of 5 μΜ (0,05% DMSO).
• Test articles are incubated with the microsomes at 37°C. Samples are collected at 0, 1 5 and 30 min.
• Test compounds and propranolol (positive control) samples are analyzed in comparison to an internal standard by LC/MS/MS.
• Metabolic half-life is determined by non-linear regression analysis of the metabolic degradation curve obtained by the %compound remaining at time = 0, 15 and 30 min.
Results obtained for representative compounds of the invention are presented in Table 6.
Table 6. Metabolic Stability of Representative Compounds of the Invention in Human Liver Microsomes
Figure imgf000170_0001
1412 35.4
1418 32.2
1432 25.1
1451 10.4
1458 9.8
1473 14.2
1479 15.7
1482 34.6
1486 8.7
1492 14.6
1501 23.6
1503 20.9
1505 51.5
1506 7.5
1512 24.7
1515 54.5
1526 13.6
1528 35.5
1529 13.8
1565 7.8
1619 69.3
1630 38.7
1688 41.4
1690 21.8
1691 53.7
1692 121
1693 83.8
1699 85.2
1700 32.8
1701 40.4
1702 14.1
1703 44.8 1704 33.5
1707 27.3
1712 58.2
1713 48.8
1718 43.6
1719 23.4
1720 23.2
1723 64.3
1725 66.5
1726 41.5
1729 54.8
1730 61.9
1732 52.2
1737 83.9
1738 53.2
1739 26.1
1740 28.3
1742 157.4
1745 117.0
1746 38.6
1751 109.6
1752 14.3
1754 43.7
1755 47.8
1758 90.4
1759 40.6
1760 34.8
1761 77.0
1762 73.4
1763 15.6
1777 39.6
1778 58.1 1780 25.3
1843 . 33.7
1848 60.7
1876 30.9
1878 34.7
1903 47.9
1918 14.3
B9. Pharmacokinetic Analysis
The pharmacokinetic (PK) behavior of compounds of the invention and their pharmaceutical compositions can be ascertained by methods well known to those skilled in the art and can be used to investigate the pharmacokinetic parameters (elimination half-life, total plasma clearance, etc.) for intravenous, subcutaneous and oral administration of these substances. (Wilkinson, G. R. "Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination" in Goodman & Oilman's The Pharmacological Basis of Therapeutics, Tenth Edition, Hardman, J.G.; Limbird, L.E., Eds., McGraw Hill, Columbus, OH, 2001, Chapter 1.) See also U.S. Patent Nos. 7,476,653; 7,491,695; Intl. Pat. Appl. WO 2008/033328 and U.S. Patent Appl. Publ. 2008/0194672. As an example, compound 1505 has the PK profile below.
Figure imgf000173_0001
The determination of PK parameters for additional representative compounds of the invention is presented in the Examples.
B10. Ex-vivo Potency Evaluation on the Rat Stomach Fundus
This method is employed to provide an additional evaluation of the potency of compounds of the invention as ghrelin antagonists by treatment of rat stomach fundus strips in an organ bath ex vivo in the presence or absence of electrical field stimulation (EFS). Ghrelin peptide is used to simulate the activity of the tissue and then the ability of varying concentrations of the test compound investigated.
Method
Fundus strips (approximately 0.4 x 1 cm) were cut from the stomach of adult male Wis tar rats parallel to the circular muscle fibers. They were placed between two platinum ring electrodes, 1 cm apart (Radnoti, ADInstruments, USA) in 10 ml tissue baths containing Krebs solution bubbled with 5 % C02 in <¾ and maintained at 37 °C. Tissues were suspended under 1.5 g resting tension. Changes of tension were measured isometrically with force transducers and recorded with a PowerLab 8/30 data acquisition system (ADInstruments, USA). Tissues were allowed to equilibrate for 60 min during which time bath solutions were changed every 35 min.
EFS was achieved by applying 0.5 ms pulses, 5 Hz frequency, at a maximally effective voltage of 70 V. EFS was applied for 30 sec at 3 min intervals for a 30 min initial period. This initial period was separated by a 5 min interval with wash out of the bath solution. Then, a second period of stimulation was started. After obtaining consistent EFS- evoked contractions (after three or four 30 sec stimulations), the effects of ghrelin as a positive control, ghrelin with test compounds at various concentrations (for example 0.01-10 μΜ), L-NAME (300 μΜ, as control) or their respective vehicles, applied non-cumulatively, on responses to EFS were studied over a 30 min period. Responses to the agents were measured and expressed as % of the mean of three or four pre-drug responses to EFS . All compounds were dissolved at 1 niM in distilled water or MeOH, as stock solutions.
Results
IC50 values for the inhibition of ghrelin-induced contractility by representative compounds of the invention are presented in Table 7.
Table 7. Inhibition of Rat Fundus Contractility by
Representative Compounds of the Invention
Figure imgf000175_0001
Bll. Effects of 14-Day Administration of Representative Compounds of the Invention on Glucose Homeostasis and Metabolism in Wistar Rats
Objective
The objective of the study was to determine the effects of representative compounds of the invention on body weight, food and water consumption, glucose homeostasis and tolerance as well as serum lipids, plasma insulin and selected metabolic parameters in the liver, adipose tissue and skeletal muscle in male Wistar rats, when administered subcutaneously or orally for 14 d.
Test Protocol
On experimental day -7 animals were stratified according to body weight into an appropriate number of groups of 6 animals each (main study animals). Test compounds were administered as solutions either subcutaneously or orally. The dose volume was 2 or 3 mL/kg. Timing of dosing was done to ensure maximal exposure during the dark phase, particularly at the beginning of the dark phase when feeding is more intense.
Figure imgf000176_0001
Vehicle (Group 1) as well as two of the test compounds (Group 2 and Group 5) were administered once daily 1 h prior to the end of the light phase (5:00 P.M.) while other test compounds (Group 3 and Group 4) were administered twice daily at 10:00 A.M. and 5:00 P.M. Other dose levels and concentrations can be investigated similarly.
In-life Observations
For the study animals, the data collected from study Days -7 to 16 are reported. Body weights were recorded for all animals daily starting on Day -7 prior to initiation of dosing, at the time of group assignment and throughout the study period as weli as terminally prior to necropsy. Food and water intake was measured every 3 days at 8:00 A.M. starting on Day 1 prior to initiation of dosing and throughout the treatment period. From all animals of Groups 1-5 (main study animals), blood was collected by a cardiac puncture on experimental Day 16 at 08:00 AM for the determination of plasma concentrations of glucose, as well as serum concentration of free fatty acids, triacylglycerol, and total cholesterol. One drop of blood (~ 20 ΐ^) was used for plasma glucose on Accu- Chek Aviva glucometers (Roche Diagnostics, Indianapolis, IN). For the other parameters, one (1) mL blood was collected in pre-cooled serum separation clotting activator tubes (Sarstedt). The blood was centrifuged at 2500 rpm (4°C, 10 min), serum transferred into non- coated tubes and stored at - 80°C until analysis.
Blood Sampling for Oral Glucose Tolerance Test (OGTT)
The oral glucose tolerance test was carried out in all animals of Groups 1 -5 around 8:00 A.M. The test was performed on half of the animals from each group on experimental day 3 and on the other half of the animals from each group on experimental day 4. The same procedure was repeated on experimental days 14 and 15. Animals were subjected to an overnight fast (food removed the day before at 5:00 PM). Blood samples of approximately 250 pL each for plasma glucose and insulin measurements were collected into EDTA coated tubes ( 2-EDTA microtainer tubes, Becton Dickinson) from a tail vein, at 0, 15, 30, 60, and 120 min on experimental days 3, 4, 13 and 14, after oral administration of 1.5 g/kg glucose (dextrose, Sigma Aldrich, 450 mg/ml dosing solution). The glucose solution was administered by oral gavage via a stainless steel feeding needle (18 X 2", Popper @ Sons, cat. # 20068-642, VWR). While glucose concentrations were determined from a drop of blood of this sample (Accu-Chek Aviva glucometers, Roche Diagnostics), the remainder was centrifuged at 4000 rpm for 10 min. at 4°C, and the resulting plasma transferred into non- coated tubes and stored at -80°C for insulin determination.
Analytical Methods
Plasma insulin was measured in duplicate for each data point and animal with an HTRF insulin detection kit (Cat. No. 621NSPEB, CisBio, USA). Plasma glucose was measured using ACCU-CHEK Aviva glucometers (Roche Diagnostics). Serum cholesterol and triglycerides was measured using standard enzyme assay kits (TGs: cat. # 1 1488872216, Roche Diagnostics; Choi: cat. # 11489232216, Roche Diagnostics). The measurements will be performed on a Hitachi 912 analyzer. Serum free fatty acids (FFA) was measured in duplicates using a commercially available colorimetric enzyme assay kit (HR series NEFA- HR (2) kit, WAKO Chemicals). Data Evaluation and Statistics
All data was entered into Excel 2003 spreadsheets and subsequently subjected to re!evant statistical analyses (GraphPad Prism, GraphPad Software, San Diego, CA). Results are presented as mean ± SD (standard deviation) unless otherwise stated. Statistical evaluation of the data is carried out using one-way analysis of variance (ANOVA) with appropriate post-hoc analysis between control and treatment groups in cases where statistical significance was established.
B12. Suppression of Feeding Response
As another approach to determining the in vivo activity of compounds of the invention, suppression of the feeding response in fasted rats can be performed as described in the literature (Sartor, O.; et al. Endocrinology 1985, 117, 1441-1447).
B13. Effects of Acute Administration of Representative Compounds of the Invention on Glucose Homeostasis and Metabolism in Male Zucker Fatty Rats
Objective
The objective of this study is to determine the acute effects of test compounds on body weight change, food and water consumption and glucose homeostasis in male Zucker fatty rats 24 h post-dose and after 3 days of subcutaneous administration. The same parameters are evaluated 24 h post-dose and after 3 days of administration of lest compound by the intraperitoneal route. The male Zucker fatty rat has been selected as an insulin resistance and genetically defined obesity model which is sensitive to the effect of different insulin sensitizers in acute as well as in chronic settings.
Animals
Rats were individually housed in rodent cages with soft wood bedding on the bottom and equipped with water bottles. All individual cages were clearly labeled with a cage card indicating study number, group, animal number and dose level. Each animal was uniquely identified by an animal number. The animal number was designated the day the animals arrived at the animal facility. The animal room environment was controlled (targeted ranges: temperature 22 ± 2°C; relative humidity 50 ± 10%; light/dark cycle: 12 hours light, 12 hours dark, lights on from 06:00 AM to 06:00 PM). A regular rodent diet (Charles River 5075 rodent chow, Purina Mills, Canada) was provided to the animals ad libitum, after food weighing. Municipal tap water was provided to the animals ad libitum via water bottles. Fresh tap water was provided after water bottle weighing. An acclimation period of approximately 4 days for all groups was allowed between the receipt of animals and the start of treatment to accustom the rats to the laboratory environment. On experimental day -3, animals were stratified according to body weight into an appropriate number of groups of 4 animals each.
Test Protocol
Test compounds were administered, as solutions, subcutaneously or intraperitoneally at the targeted doses indicated below. The dose volume was 3 mL/kg. Groups 2, 3 and 5 were dosed once daily around 7:00 a.m., while groups 1 , 4, 6 and 7 were dosed twice daily (b.i.d) at around 7:00 a.m. and 4:00 p.m. On Day 1 on half of the animals (Subset A) and on Day 2 on the other half (Subset B), an OGTT was performed 2 hrs post-dosing (around 9:00 a.m.). The OGTT was repeated the same way on Days 3 and 4.
Figure imgf000179_0001
Other dose levels and concentrations can be investigated similarly. For the study animals, tire data collected from study Days -3 to 4 were reported. Body weights were recorded for all animals on Day -3 prior to initiation of dosing, at the time of group assignment and daily throughout the study period (Day 1 -4). 24 h food and water intake was measured (around 12:00 p.m.) on Day 2 and 4 (Subset A) and Day 3 and 5 (Subset B). On Day 1, animals from groups 3, 4 and 7 were sampled for blood (~ 100 μΐ) 15 min, 30 min, 3 hr and 2 hrs post-dosing (just before the OGTT) for PK analysis. Blood was centrifuged at 4000 rpm for 10 min. at 4°C, and the resulting plasma transferred into non- coated tubes and stored at -80°C until analysis. On Day 3 , only a 2 hrs post-dosing (just before the OGTT) blood sample was taken for PK analysis.
An oral glucose tolerance test was carried out in animals of all groups on Day 1 and 2 (half of the animals) as well as on day 3 and 4 (other half of the animals). This was done 2 hrs post-dosing. Animals were subjected to an overnight fast (food removed the day before at 5:00 PM). To this effect blood samples of approximately 20 pL each for plasma glucose and 230 μΤ for plasma insulin measurements were collected into EDTA coated tubes (K2-EDTA microtainer tubes, Becton Dickinson) from a tail vein, at 0 (pre-glucose), 15, 30, 60, and 120 min on experimental day 3 and 4 (blood sampling for glucose only on Day 1 and 2, no insulin) after oral administration of 1.5 g kg glucose (dextrose, Sigma Alclrich, 450 mg/ml dosing solution). The glucose solution was administered by oral gavage via a stainless steel feeding needle ( 1 8 X 2", Popper @ Sons, cat. # 20068-642, VWR). While glucose concentrations will be determined from a drop of blood (Accu-Chek Aviva glucometers, Roche Diagnostics), the remainder will be centrifuged at 4000 rpm for 10 min. at 4°C, and the resulting plasma transferred into non-coated tubes and stored at -80°C for insulin determination. Plasma insulin was measured in duplicate for each data point and animal with an HTRF insulin detection kit (62INSPEB, CisBio, USA). Plasma glucose will be measured using ACCU-CHEK Aviva glucometers (Roche Diagnostics).
Data Evaluation and Statistics
All data was entered into Excel 2003 spreadsheets and subsequently subjected to relevant statistical analyses (GraphPad Prism, GraphPad Software, San Diego, CA). Results are presented as mean ± SD (standard deviation) unless otherwise stated. Statistical evaluation of the data was carried out using one-way analysis of variance (ANOVA) with appropriate post-hoc analysis between control and treatment groups in cases where statistical significance is established. B14. Effects of Subchronic Administration of Representative Compounds of the Invention in Male Zucker Fatty Rats
Objective
The objective of this study is to determine the subchronic effects of test compounds on body weight change, food and water consumption, as well as glucose homeostasis and insulin levels in male Zucker fatty rats up to 7 days upon oral administration. The male Zucker fatty rat was selected as an. insulin resistance and genetically defined obesity model which is sensitive to the effect of different insulin sensitizers in acute as well as in chronic settings.
Animals
Rats were individually housed in rodent cages with soft wood bedding on the bottom and equipped with water bottles. All individual cages were clearly labeled with a cage card indicating study number, group, animal number and dose level. Each animal was uniquely identified by an animal number. The animal number was designated the day the animals arrived at the animal facility. The animal room environment was controlled (targeted ranges: temperature 22 ± 2°C; relative humidity 50 ± 10%; light/dark cycle: 12 hours light, 12 hours dark, lights on from 06:00 AM to 06:00 PM). A regular rodent diet (Charles River 5075 rodent chow, Purina Mills, Canada) was provided to the animals ad libitum, after food weighing. Municipal tap water was provided to the animals ad libitum via water bottles. Fresh tap water was provided after water bottle weighing.
An acclimation period of approximately 7 days for all groups was allowed between the receipt of animals and the start of treatment to accustom the rats to the laboratory environment. On experimental day -7, animals were stratified according to body weight into an appropriate number of groups of 4 or 8 animals each.
Test Protocol
Test compound was administered, as a solution, orally, at the doses indicated. The dose volume was 5 mL/kg/day. Groups were dosed once daily around 8:00 a.m. On Day 3, on half of the animals (Subset A) and on Day 4 on the other half (Subset B), an OGTT was performed 2 hrs post-dosing (around 10:00 a.m.). The OGTT was repeated the same way on Days 7 (Subset A) and 8 (Subset B). Group Test Article Dose Total daily Dose Dosage No of No. (mg/kg) dosage Concentration Volume Animals
(mg/kg) (mg/mL) (mL/kg/day)
1 Vehicle control 0 0 0 5 8
(Fatty) (P-o.)
2 Test cmpd (10 10 10 2 5 8
(Fatty) mg kg, p.o.)
3 Test cmpd (30 30 30 6 5 8
(Fatty) mg/kg, p.o.)
4 Vehicle treated 0 0 0 5 4
(Lean) (p.o.)
Other dose levels and concentrations can be investigated similarly.
For the study animals, the data collected from study Days -7 to 8 are reported. Body weights were recorded for all animals on Day -7 prior to initiation of dosing, at the time of group assignment and daily throughout the study period (Day 1-8). Food and water intake was measured daily throughout the study period (Day 1-8). On Day 1 (Subset A), Day 2 (Subset B), Day 3 (Subset A), Day 4 (Subset B), Day 7 (Subset A) and Day 8 (Subset B), animals from Groups 2 and 3 were sampled for blood into EDTA coated tubes (K2-EDTA microtainer tubes, Becton Dickinson) from a tail vein (~ 100 μΐ) 2 hrs post-dose for PK analysis. Blood was centrifuged at 4000 rpm for 10 min. at 4°C, and the resulting plasma transferred into non-coated tubes and stored at -80°C until analysis.
An oral glucose tolerance test (OGTT) was carried out in animals of all groups on Day 3 (half of the animals) as well as on day 4 (other half of the animals). This was done 2 hrs post-dose. Animals were subjected to an overnight fast (food removed the day before at 5:00 PM). Blood samples of approximately 20 pL each for plasma glucose and 230 pL for plasma insulin measurements were collected into EDTA coated tubes (K2-EDTA microtainer tubes, Becton Dickinson) from a tail vein, at 0 (pre-glucose), 15, 30, 60, and 120 min after oral administration of 1.5 g kg glucose (dextrose, Sigma Aldrich, 450 mg/mL dosing solution). The glucose solution was administered by oral gavage via a stainless steel feeding needle (18 X 2", Popper @ Sons, cat. # 20068-642, VWR). While glucose concentrations were determined from a 20 pL drop of blood (Accu-Chek Aviva glucometers, Roche Diagnostics), the remaining 230 pL was centrifuged at 4000 rpm for 10 min. at 4°C, and the resulting plasma transferred into non-coated tubes and stored at -80°C for insulin determination. These procedures were performed on Day 7 (Subset A) and 8 (Subset B). It is worth noting that, in order to minimize blood volume withdrawal from the animals, blood samples for insulin measurement were taken only at time 0 (pre-glucosc) on Day 3 and 4 and additionally at times 15, 30, 60 and 120 min. on Day 7 and 8, as stated above.
From all animals, blood was collected by a cardiac puncture on experimental Day 7 (Subset A) and 8 (Subset B) for the determination of serum concentration of free fatty acids, triglycerides, and total cholesterol. This was performed right after the OGTT. For this, 1 mL of blood was collected in pre-cooled serum separation clotting activator tubes (Sarstedt). The blood was centrifuged at 2500 rpm (4°C, 10 min), serum transferred into non-coated tubes and stored at - 80°C until analysis. Serum samples (250 each) for triglycerides, total cholesterol and free fatty acids were analyzed using appropriate methods.
Plasma insulin was measured in duplicate for each data point and animal with an HTRF insulin detection kit (62TNSPEB, CisBio, USA), Plasma glucose was measured using ACCU-CHEK Aviva glucometers (Roche Diagnostics). Serum cholesterol and triglycerides was measured using standard enzyme assay kits (TGs: cat. # 1 1488872216, Roche Diagnostics; Choi: cat. # 1 1489232216, Roche Diagnostics). The measurements were performed on a Hitachi 912 analyzer. Serum free fatty acids (FFA) were measured in duplicate using a commercially available colori metric enzyme assay kit (HR series NEFA- HR (2) kit, WAKO Chemicals). Absorbance was obtained using a GENios Pro automated plate reader (Tecan).
Data Evaluation and Statistics
All data was entered into Excel 2003 spread sheets and subsequently subjected to relevant statistical analyses (GraphPad Prism, GraphPad Software, San Diego, CA). Results are presented as mean ± SD (standard deviation) unless otherwise stated. Statistical evaluation of the data was carried out using one-way analysis of variance (ANOVA) with appropriate post-hoc analysis between control and treatment groups in cases where statistical significance was established. B15. Effects of Subchronic Administration of Compounds of the Invention in Male ob/ob Mice
Objective
The objective of this study is to determine the subchronic effects of test compounds on body weight change, food and water consumption, as well as glucose homeostasis and insulin levels in male ob/ob mice upon oral administration for up to 7 days. The male ob/ob mouse was selected as a type 2 diabetes (T2DM) and genetically defined obesity model which is sensitive to the effect of different insulin sensitizers in acute as well as in chronic settings. More precisely, this model displays a deletion in the leptin gene.
A similar study in this model was conducted to determine the acute and subchronic effects of test compounds on body weight change, food and water consumption, glucose homeostasis, insulin and glucagon levels, as well as lipid profile and brain penetration upon oral administration to the male ob/ob mice for up to 28 days.
Animals
Mice were individually housed in rodent cages with soft wood bedding on the bottom and equipped with water bottles. All cages were clearly labeled with a cage card indicating study number, group, animal number and dose level. Each animal was uniquely identified by an animal number marked on their tail with indelible ink. The animal number was designated the day the animals arrive at the animal facility. The animal room environment was controlled (targeted ranges: temperature 22 ± 2°C; relative humidity 50 ± 10%; light/dark cycle: 12 hours light, 12 hours dark, lights on from 06:00 AM to 06:00 PM). A regular rodent diet (Charles River 5075 rodent chow, Purina Mills, Canada) was provided to the animals ad libitum. Municipal tap water was provided to the animals ad libitum via water bottles. Fresh tap water was provided after water bottle weighing. An acclimation period of approximately 7 days for all groups was allowed between the receipt of animals and the start of treatment to accustom the rats to the laboratory environment. On experimental Day -7, animals were stratified according to body weight and glycemia into an appropriate number of groups of 5 or 10 animals and two groups of 5 animals.
Test Protocol (7 day study)
Test compounds were administered, as a solution, orally, at the doses indicated. The dose volume will be 5 mLAg/day. Groups were dosed once daily around 4:00 p.m. As positive controls, rosiglitazone (Avandia®), an approved anti-diabetic drug of the thiazolidinediones family (ppar gamma agonist) which has been specifically reported to normalize glycemia in the ob/ob mouse model (Liu et ai, J. Med. Chem.., 46: 2093-2103, 2003) was used. The CB 1 receptor antagonist rimonabant (Accomplia®) was reported to reduce body weight and food intake in different models of Type 2 diabetes and obesity and was also employed (Rasmussen and Huskinson Behavioral Pharmacol. 2008, 19, 735-742,; Bobo, G.; et al. Hepathology 2007, 46, 122-329; Di Marzo; et al„ Nature 2001, 410, 822- 825).
Figure imgf000185_0001
Other dose levels and concentrations can be investigated similarly.
For the study animals, the data collected from study Day -7 to Day 8 were reported. Body weights were recorded for all animals on Day -7 prior to initiation of dosing, at the time of group assignment and daily throughout the study period (Day 1 -8). Food and water intake was measured 4 hrs post-dosing, 2 hrs after the beginning of the dark cycle (around 8:00 p.m.) on Day 1 and 7 (Subset A) as well as on Day 2 and 8 (Subset B) and then daily in 24h intervals from Day 3 through Day 8. On Day 1 (Subset A) and Day 2 (Subset B), blood was sampled from 3 animals/group from Groups 2 through 4 into EDTA coated tubes (K2-EDTA microtainer tubes, Becton Dickinson) from a tail vein (~ 100 p L) 4 hrs post-dose for PK analysis. Blood was centrifuged at 4000 rpm for 10 min. at 4°C, and the resulting plasma transferred into non-coated tubes and stored at -80°C until analysis. The same procedures were repeated on Day 7 (Subset A) and Day 8 (Subset B) 24 hrs post-dose. From all animals, a terminal blood sample was collected (approximately 5 mL total) by cardiac puncture on experimental Day 7 (Subset A) and 8 (Subset B) for the determination of plasma concentrations of glucose and insulin and serum concentrations of free fatty acids, triglycerides and total cholesterol. Blood samples for plasma insulin measurements (250 pL) were collected into EDTA coated tubes (K2-EDTA microtainer tubes, Becton Dickinson). Blood was centrifuged at 4000 rpm for 10 min. at 4°C, and the resulting plasma transferred into non-coated tubes and stored at -80°C until analysis. Additionally, 1 mL of blood was collected in pre-cooled serum separation clotting activator tubes (Sarstedt). The blood was centrifuged at 2500 rpm (4°C, 10 min), serum transfciTed into non-coated tubes and stored at -80°C until analysis. Serum samples (250 pL each) for triglycerides, total cholesterol and free fatty acids were analyzed using appropriate methods.
Animals from Groups 1-4 had their brain removed immediately after the terminal bleed for test compound brain concentration measurement. Brains were kept on ice and put at -80°C until analysis.
Plasma insulin was measured in duplicate for each data point and animal with an HTRF insulin detection kit (62INSPEB, CisBio, USA). Plasma glucose (20 pL blood sample) was measured using ACCU-CHEK Aviva glucometers (Roche Diagnostics). Serum cholesterol and triglycerides were measured using standard enzyme assay kits (TGs: cat. # 11488872216, Roche Diagnostics; Choi: cat. # 1 1489232236, Roche Diagnostics) on a Hitachi 912 analyzer. Serum free fatty acids (FFA) were measured in duplicate using a commercially available colorimetric enzyme assay kit (HR series NEFA-HR (2) kit, WAKO Chemicals). Absorbance was read on a GENios Pro automated plate reader (Tecan).
Test Protocol ( 15 day study) .
Test compounds were administered, as a solution, orally, at the doses indicated. The dose volume was 5 mL kg/day. Groups 1-4 (Subset A) were especially dosed at 9:00 a.m. on Day 1 , Day 7, Day 14 and Day 15. Otherwise, these groups were dosed once daily around 3:00 p.m. from Day 2 through Day 6 and from day 8 through 13. Groups 5-8 (Subset B) were dosed once daily around 3 :00 p.m. from Day 1 through Day 14 and men at 9:00 a.m. on Day
15.
Figure imgf000187_0001
Other dose levels and concentrations can be investigated similarl y.
For the study animals, the data collected from study Day -7 to Day 1 5 were reported. Body weights were recorded for all animals on Day -7 prior to initiation of dosing, at the time of group assignment and daily throughout the study period (Day 1 - 15). Fasting glucose levels from Groups 1-4 (subset A) were monitored on day 1, 7 and 14. Non-fasting glucose levels from Groups 5-8 (Subset B) were monitored on Day 1 , 7 and 14. Food and water intake were measured acutely 20 min, 1 hr, 2 hr and 4 hr post-dose in one subset of animals (Groups 1-4, Subset A) on Day 1 as well as on Day 7 and daily in 24 h intervals from Day 1 through Day 14 in Subset B animals (Groups 5-8). On Day 14, in all animals from Groups 1 -4 (Subset A) an oral glucose tolerance test OGTT) was performed. For this, the animals were fasted overnight. Blood samples for plasma glucose concentrations were taken at 0 (pre-glucose), 15, 30, 60 and 120 min after oral administration of 1.5 g/lcg glucose (dextrose, Sigma Aldrich, 450 mg/ml dosing solution). The glucose solution was administered by oral gavage via a stainless steel feeding needle (18 X 2", Popper @ Sons, cat. # 20068-642, VWR). Glucose concentrations were determined from a 20 drop of blood and measurements performed on an Accu-Chek Aviva glucometer (Roche Diagnostics).
On Day 15, blood was sampled from all animals of Groups 2 and 3 (Subset A) into EDTA coated tubes (K2-EDTA microtainer tubes, Becton Dickinson) from a tail vein (~ 100 μΐ) 0, 15 min, 30 min, 1 hr, 2 hr, and 4 hr post-dose for PK analysis (n=2 mice/treatment group/time point). Blood was centrifuged at 4000 rpm for 10 min at 4°C, and the resulting plasma transferred into non-coated tubes and stored at -80°C until analysis. From all animals of Groups 5-8 (Subset B), a terminal blood sample was collected (approximately 1 mL total) by cardiac puncture on experimental Day 1 5 for the determination of plasma concentrations of insulin, glucagon, free fatty acids, triglycerides, total cholesterol, LDL, HDL as well as HDL/total cholesterol ratio. Blood samples were collected into EDTA coated tubes (K2- EDTA microtainer tubes, Becton Dickinson). Blood was centrifuged at 4000 rpm for 10 min at 4°C, and the resulting plasma transferred into non-coated tubes and stored at -80°C until analysis.
On Day 15, animals from Groups 1-3 (Subset A) as well as from Groups 6 and 7 (Subset B) had their brain removed 30 min, 1 hr, 2 hr or 4 hr post-dose for test compound brain concentration measurement (n=3 mice/treatment group/time point). Brains were kept on ice and frozen at -80°C until analysis.
Plasma insulin and glucagon were measured for each data point and animal with an HTRF insulin detection kit (62INSPEB, CisBio, USA). Plasma glucose (20 μ Ε blood sample) will be measured using an ACCU-CHEK Aviva glucometer (Roche Diagnostics). For clinical chemistry determinations, 35 of plasma was analysed on a Cholestech LDX analyzer (ManthaMed, ississauga, ON, Canada) for triglycerides, HDL cholesterol, non-HDL cholesterol, LDL cholesterol, total cholesterol (TC) and TC/HDL ratio. Serum free fatty acids (FFA) were measured in duplicate using a commercially available colorimetric enzyme assay kit (HR series NEFA-HR (2) kit, WAKO Chemicals). Absorbance was read on a GENios Pro automated plate reader (Tecan).
Test Protocol (28 day study)
Test compounds were administered, as a solution, orally, at the doses indicated. The dose volume was 5 mL/kg/day. Groups 1-4 (Subset A) were especially dosed at 9:00 a.m. on Day 1, Day 7, Day 14, Day 21 and Day 28. Odierwise, these groups were dosed once daily around 3:00 p.m. from Day 2 through Day 6, from day 8 through 13, from Day 15 through Day 20 and from Day 22 through 28. Groups 5-8 (Subset B) were dosed once daily around 3:00 p.m. from Day 1 through Day 27 and then at 9:00 a.m. on Day 28.
Figure imgf000189_0001
p.o.)
8 (Lean) Vehicle 0 0 0 5 6 control (p.o.)
Other dose levels and concentrations can be investigated similarly.
For the study animals, the data collected from study Day -7 to Day 28 were reported. Body weights were recorded for all animals on Day -7 prior to initiation of dosing, at the time of group assignment and daily throughout the study period (Day 1-28). Fasting (16 hr fast) glucose levels from Groups 1-4 (subset A) were monitored on day 1, 7, 14, 21 and 28. Non- fasting glucose levels from Groups 5-8 (Subset B) were monitored on Day 1, 7, 14, 21 and 28. Food and water intake were measured acutely 20 min, 1 hr, 2 hr and 4 hr post-dose in one subset of animals (Groups 1-4, Subset A) on Day 1, Day 7 as well as on Day 21 and daily in 24 h intervals from Day 1 through Day 28 in Subset B animals (Groups 5-8). On Day 1 and Day 14, in all animals from Groups 1-4 (Subset A) an oral glucose tolerance test OGTT) was performed. For this, the animals were fasted overnight. Blood samples for plasma glucose concentrations were taken at 0 (pre-glucose), 15, 30, 60 and 120 min after oral administration of 1.5 g/kg glucose (dextrose, Sigma Aldrich, 450 mg/mL dosing solution). The glucose solution was administered by oral gavage via a stainless steel feeding needle (18 X 2", Popper @ Sons, cat. # 20068-642, VWR). Glucose concentrations were determined from a 20 μL· drop of blood and measurements performed on an Accu-Chek Aviva glucometer (Roche Diagnostics).
On Day 28/29, blood was sampled from all animals of Groups 2 and 3 (Subset A) into EDTA coated tubes (K2-EDTA microtainer tubes, Becton Dickinson) from a tail vein (~ 100 μΐ) 0, 15 min, 30 min, 1 hr, 2 hr, and 4 hr post-dose for PK analysis (n=2 mice/treatment group/time point). Blood was centrifuged at 4000 rpm for 10 min at 4°C, and the resulting plasma transferred into non-coated tubes and stored at -80°C until analysis. A terminal blood sample was collected (approximately 1 mL total) from Groups 2 and 3 (Subset A) and Groups 5-8 (Subset B) by cardiac puncture on experimental Day 28/29 for the determination of plasma concentrations of insulin, glucagon, acylated and unacylated ghrelin, growth hormone, GLP- 1, IGF-1 , free fatty acids, triglycerides and total cholesterol. Blood samples were collected into EDTA coated tubes (K2-EDTA microtainer tubes, Becton Dickinson). Blood was centrifuged at 4000 rpm for 10 min at 4°C, and the resulting plasma transferred into non- coated tubes and stored at -80°C until analysis. On Day 28/29 , animals from Groups 1-3 (Subset A) as well as from Groups 6 and 7 (Subset B) had their brains removed 30 min, 1 hr, 2 hrs or 4 hrs post-dose for test compound brain concentration measurement (n 3 mice/treatment group/time point). Brains were kept on ice and frozen at -80°C until analysis.
On Day 28/29, all animals from Groups 1-4 (Subset A) as well as from Groups 5-8 (Subset B) had their liver removed after the terminal bleed for determination of free fatty acids, triglycerides and total cholesterol levels. Livers were kept on ice and frozen at -80°C until analysis.
Plasma insulin and glucagon were measured for each data point and animal with an HTRF insulin detection kit (62INSPEB, CisBio, USA). Plasma glucose (20 p L blood sample) will be measured using an ACCU-CHEK Aviva glucometer (Roche Diagnostics). Plasma acylated and unacylated ghrelin as well as growth hormone were measured using enzyme immunoassay kits (A05117, A05118 and A05104, respectively, from Alpco Diagnostics, USA). Plasma IGF- 1 and GLP-1 were measured using IGF- 1 (mouse, rat) ELISA and GLP- 1 (ac-tive 7-36) ELISA kits from Alpco Diagnostics (USA). For cl inical chemistry determinations, 35 pL of plasma was analysed on a Cholestech LDX analyzer (ManthaMed, Mississauga, ON, Canada) for triglycerides and serum cholesterol. Serum free fatty acids (FFA) were measured in duplicate using a commercially available colorimetric enzyme assay kit (HR series NEFA-HR (2) kit, WAKO Chemicals). Absorbance was read on a GENios Pro automated plate reader (Tecan). Liver free fatty scids, triglycerides and total cholesterol levels were measured using commercially available colorimetric enzyme assay kits (free fatty acid quantification kit K612- 100, triglyceride quantification kit K622- 100 and cholesterol/cholesteryl ester quantitation kit K603-100, Biovision, Mountain View, CA, USA).
Data Evaluation and Statistics
All data was entered into Excel 2003 or 2007 spreadsheets and subsequently subjected to relevant statistical analyses (GraphPad Prism or GraphPad Instat, GraphPad Software, San Diego, CA). Results are presented as mean ± SD (standard deviation) unless otherwise stated. Statistical evaluation of the data is carried out using one-way analysis of variance (ANOVA) with appropriate post-hoc analysis between control and treatment groups in cases where statistical significance was established. B16. hERG Channel Inhibition
The product of the hERG (human ether-a-go-go) gene is an ion channel responsible for the IKr repolarizing current, where alterations to this current have been shown to elongate the cardiac action potential and promote the appearance of early after-depolarizations. Direct interactions of compounds with the hERG channel account for the majority of known cases of cardiotoxicity.
Method
The key aspects of the experimental method are as follows:
• hERG gene stably expressed in HEK293 cells
• Borosilicate microelectrodes are used to record whote cell IKr currents over a predetermined pulse protocol
• Control currents are recorded in the absence of inhibitor (E-4031 , positive control) or test compound.
• Compounds are tested at 1 and 10 μΜ:
• The compound is allowed to perfuse the cells for 5 min.
• Three currents are then recorded by applying the same pulse protocol as in control conditions.
• A single concentration (0.5 μΜ) of a positive control (for example, E-4031, known inhibitor of ΙκΓ) is also tested
Results
Compounds 1712, 1848 and 1929 showed no significant effect on hERG channel function in comparison to vehicle (0.1 % DMSO) controls up to 100 μ Μ.
5. Pharmaceutical Compositions
The macrocyclic compounds of the present invention or pharmacologically acceptable salts thereof according to the invention may be formulated into pharmaceutical compositions of various dosage forms. To prepare the pharmaceutical compositions of the invention, one or more compounds, including optical isomers, enantiomers, diastercomers, racemates or stereochemical mixtures thereof, or pharmaceutically acceptable salts thereof as the active ingredient is intimately mixed with appropriate carriers and additives according to techniques known to those skilled in the art of pharmaceutical formulations.
A pharmaceutically acceptable salt refers to a salt form of the compounds of the present invention in order to permit their use or formulation as pharmaceuticals and which retains the biological effectiveness of the free acids and bases of the specified compound and that is not biologically or otherwise undesirable. Examples of such salts are described in Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wermuth, C.G. and Stahl, P.H. (eds.), Wiley-Verlag Helvetica Acta, Zurich, 2002 [IS B N 3-906390-26-8]. Examples of such salts include alkali metal salts and addition salts of free acids and bases. Examples of pharmaceutically acceptable salts, without limitation, include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-l ,4-dioates, hexyne-l ,6-dioates, bcnzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycollates, tartrates, melhanesulfonates, ethane sulfonates, propanesulfonates, toluenesulfonates, naphthalene- 1 -sulfonates, naphthalene-2-suIfonates, and mandelates.
If an inventive compound is a base, a desired salt may be prepared by any suitable method known to those skilled in the art, including treatment of the free base with an inorganic acid, such as, without limitation, hydrochloric acid, hydrobromic acid, hydroiodic, carbonic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, or with an organic acid, including, without limitation, formic acid, acetic acid, propionic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, stearic acid, ascorbic acid, glycolic acid, salicylic acid, pyranosidyl acid, such as glucuronic acid or galacturonic acid, aipha-hydroxy acid, such as citric acid or tartaric acid, amino acid, such as aspartic acid or glutamic acid, aromatic acid, such as benzoic acid or cinnamic acid, sulfonic acid, such as p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, cycloliexylaminosulfonic acid or the like.
If an inventive compound is an acid, a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like. Illustrative examples of suitable salts include organic salts derived from amino acids such as glycine, lysine and arginine; ammonia; primary, secondary, and tertiary amines such as ethylenediamine, Ν,Ν'-dibenzylethylenediamine, diethanolamine, choline, and procaine, and cyclic amines, such as piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
The carriers and additives used for such pharmaceutical compositions can take a variety of forms depending on the anticipated mode of administration. Thus, compositions for oral administration may be, for example, solid preparations such as tablets, sugar-coated tablets, hard capsules, soft capsules, granules, powders and the like, with suitable carriers and additives being starches, sugars, binders, diluents, granulating agents, lubricants, disintegrating agents and the like. Because of their ease of use and higher patient compliance, tablets and capsules represent the most advantageous oral dosage forms for many medical conditions.
Similarly, compositions for liquid preparations include solutions, emulsions, dispersions, suspensions, syrups, elixirs, and the like with suitable carriers and additives being water, alcohols, oils, glycols, preservatives, flavoring agents, coloring agents, suspending agents, and the like. Typical preparations for parenteral administration comprise the active ingredient with a carrier such as sterile water or parenter'ally acceptable oil including polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil, with other additives for aiding solubility or preservation may also be included. In the case of a solution, it can be !yophilized to a powder and then reconstituted immediately prior to use. For dispersions and suspensions, appropriate carriers and additives include aqueous gums, celluloses, silicates or oils.
The pharmaceutical, compositions according to embodiments of the present invention include those suitable for oral, rectal, topical, inhalation (e.g., via an aerosol) buccal (e.g., sub-lingual), vaginal, topical (i.e., both skin and mucosal surfaces, including airway surfaces), transdermal administration and parenteral (e.g., subcutaneous, intramuscular, intradermal , intraarticular, intrapleural, intraperitoneal, intrathecal, intracerebral, mtracranially, intraarterial, or intravenous), although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular active agent which is being used.
Compositions for injection will include the active ingredient together with suitable carriers including propylene glycol-alcohol-water, isotonic water, sterile water for injection (USP), emulPhor™-alcohol-water, cremophor-EL™ or other suitable carriers known to those skilled in the art. These carriers may be used alone or in combination with other conventional solubilizing agents such as ethanol, propylene glycol, or other agents known to those skilled in the art.
Where the macrocyclic compounds of the present invention are to be applied in the form of solutions or injections, the compounds may be used by dissolving or suspending in any conventional diluent. The diluents may include, for example, physiological saline, Ringer's solution, an aqueous glucose solution, an aqueous dextrose solution, an alcohol, a fatty acid ester, glycerol, a glycol, an oil derived from plant or animal sources, a paraffin and the like. These preparations may be prepared according to any conventional method known to those skilled in the art.
Compositions for nasal administration may be formulated as aerosols, drops, powders and gels. Aerosol formulations typically comprise a solution or fine suspension of the active ingredient in a physiologically acceptable aqueous or non-aqueous solvent. Such formulations are typically presented in single or multidose quantities in a sterile form in a sealed container. The sealed container can be a cartridge or refill for use with an atomizing device. Alternatively, the sealed container may be a unitary dispensing device such as a single use nasal inhaler, pump atomizer or an aerosol dispenser fitted with a metering valve set to deliver a therapeutically effective amount, which is intended for disposal once the contents have been completely used. When the dosage form comprises an aerosol dispenser, it will contain a propellant such as a compressed gas, air as an example, or an organic propellanl including a fluorochlorohydrocarbon or fluorohydrocarbon.
Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth or gelatin and glycerin.
Compositions for rectal administration include suppositories containing a conventional suppository base such as cocoa butter.
Compositions suitable for transdermal administration include ointments, gels and patches.
Other compositions known to those skilled in the art can also be applied for percutaneous or subcutaneous administration, such as plasters.
Further, in preparing such pharmaceutical compositions comprising the active ingredient or ingredients in admixture with components necessary for the formulation of the compositions, other conventional pharmacologically acceptable additives may be incorporated, for example, excipients, stabilizers, antiseptics, wetting agents, emulsifying agents, lubricants, sweetening agents, coloring agents, flavoring agents, isotonicity agents, buffering agents, antioxidants and the like. As the additives, there may be mentioned, for example, starch, sucrose, fructose, lactose, glucose, dextrose, mannitol, sorbitol, precipitated calcium carbonate, crystalline cellulose, carboxymethylcellulose, dextrin, gelatin, acacia, EDTA, magnesium stearate, talc, hydroxypropylmethytcellulose, sodium metabisulfite, and the like.
In some embodiments, the composition is provided in a unit dosage form such as a tablet or capsule.
In further embodiments, the present invention provides kits including one or more containers comprising pharmaceutical dosage units comprising an effective amount of one or more compounds of the present invention.
The present invention further provides prodrugs comprising the compounds described herein. The term "prodrug" is intended to mean a compound that is converted under physiological conditions or by solvoiysis or metabolically to a specified compound that is pharmaceutically active. The "prodrug" can be a compound of the present invention that has been chemically derivatized such that, (i) it retains some, all or none of the bioactivity of its parent drug compound, and (ii) it is metabolized in a subject to yield the parent drug compound. The prodrug of the present invention may also be a "partial prodiug" in that the compound has been chemically derivatized such that, (i) it retains some, all or none of the bioactivity of its parent drug compound, and (ii) it is metabolized in a subject to yield a biologically active derivative of the compound. Known techniques for derivatizing compounds to provide prodrugs can be employed. Such methods may utilize formation of a hydrolyzable coupling to the compound.
The present invention further provides that the compounds of the present invention may be administered in combination with a therapeutic agent used to prevent and/or treat metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders. Exemplary agents include analgesics including opioid analgesics, anesthetics, antifungals, antibiotics, antiinflammatories, including nonsteroidal anti-inflammatory agents, anthelmintics, antiemetics, antihistamines, antihypertensives, antipsychotics, ant iarthri tics, antitussives, antivirals, cardioactive drugs, cathartics, chemotherapeutic agents such as DNA-interactive agents, antimetabolites, tubulin-interactive agents, hormonal agents, and agents such as asparaginase or hydroxyurea, corticoids (steroids), antidepressants, depressants, diuretics, hypnotics, minerals, nutritional supplements, parasympathomimetics, hormones such as corticotrophin releasing hormone, adrenocorticotropin, growth hormone releasing hormone, growth hormone, thyrptropin-releasing hormone and thyroid stimulating hormone, sedatives, sulfonamides, stimulants, sympathomimetics, tranquilizers, vasoconstrictors, vasodilators, vitamins and xanthine derivatives.
Other therapeutic agents that can be used in combination with the compounds of the present invention include a GLP- 1 agonist, a DPP-IV inhibitor, an amylin agonist, a PPAR-a agonist, a PPAR-γ agonist, a PPAR-α/γ dual agonist, a GDIR or GPR 1 19 agonist, a PTP- 1 B inhibitor, a peptide YY agonist, an 1 Ι β-hydroxysteroid dehydrogenase ( l l p-HSD)- l inhibitor, a sodium-dependent renal glucose transporter type 2 (SGLT-2) inhibitor, a glucagon antagonist, a glucokinase activator, an α-glucosidase inhibitor, a glucocorticoid antagonist, a glycogen synthase kinase 3β (GSK ^) inhibitor, a glycogen phosphorylase inhibitor, an AMP- activated protein kinase (AMPK) activator, a fructose- 1 ,6-biphosphatase inhibitor, a sulfonyl urea receptor antagonist, a retinoid X receptor activator, a 5-HTja agonist, a 5-HT2c agonist, a 5-HT6 antagonist, a cannabioid antagonist or inverse agonist, a melanin concentrating hormone- 1 (MCH-1) antagonist, a melanocortin-4 (MC4) agonist, a leptin agonist, a retinoic acid receptor agonist, a stearoyl-CoA desaturase- 1 (SCD- 1 ) inhibitor, a neuropeptide Y Y2 receptor agonist, a neuropeptide Y Y4 receptor agonist, a neuropeptide Y Y5 receptor antagonist, a neuronal nicotinic receptor θ4β2 agonist a diacylglycerol acyltransferase 1 (DGAT- 1) inhibitor, a thyroid receptor agonist, a lipase inhibitor, a fatty acid synthase inhibitor, a glycerol-3-phosphate acyltransferase inhibitor, a CPT- 1 stimulant, an a i A- adrenergic receptor agonist, an a2A-adrenergic receptor agonist, a β.ν adrenergic receptor agonist, a histamine H3 receptor antagonist, a cholecystokinin A receptor agonist and a GABA-A agonist.
Subjects suitable to be treated according to the present invention include, but are not limited to, avian and mammalian subjects, and are preferably mammalian. Mammals of the present invention include, but are not limited to, canines, felines, bovines, caprines, equines, ovines, porcines, rodents (e.g. rats and mice), lagomorphs, primates, humans, and tire like, and mammals in utero. Any mammalian subject in need of being treated according to the present invention is suitable. Human subjects are preferred. Human subjects of both genders and at any stage of development {i.e. , neonate, infant, juvenile, adolescent, adult) can be treated according to the present invention.
Illustrative avians according to the present invention include chickens, ducks, turkeys, geese, quail, pheasant, ratites (e.g. , ostrich) and domesticated birds (e.g. , parrots and canaries), and birds in ovo. The present invention is primarily concerned with the treatment of human subjects, but the invention can also be earned out on animal subjects, particularly mammalian subjects such as mice, rats, dogs, cats, livestock and horses for veterinary purposes, and for drug screening and drug development purposes.
In therapeutic use for treatment of conditions in mammals (i.e. humans or animals) for which an antagonist or inverse agonist of the ghrelin receptor is effective, the compounds of the present invention or an appropriate pharmaceutical composition thereof may be administered in an effective amount. Since the activity of the compounds and the degree of the therapeutic effect vary, the actual dosage administered will be determined based upon generally recognized factors such as age, condition of the subject, route of delivery and body weight of the subject. The dosage will be from about 0.1 to about 100 mg/kg, administered orally 1 -4 times per day. In addition, compounds may be administered by injection at approximately 0.01 - 20 mg/kg per dose, with administration 1 -4 times per day. Treatment could continue for weeks, months or longer. Determination of optimal dosages for a particular situation is within the capabilities of those skilled in the art.
6. Methods of Use
The compounds of the present invention can be used for the prevention and treatment of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, addictive disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hypeiproliferative disorders, central nervous system disorders, inflammatory disorders and combinations thereof where the disorder may be the result of multiple underlying maladies.
Metabolic and/or endocrine disorders include, but are not limited to, obesity, diabetes, in particular, type II diabetes, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and steatosis. Obesity and obesity- associated disorders include, but are not limited to, retinopathy, hyperphasia and disorders involving regulation of food intake and appetite control in addition to obesity being characterized as a metabolic and/or endocrine disorder. Appetite or eating disorders include, but are not limited to, Prader-Willi syndrome and hyperphagia. Addictive disorders include, but are not limited to, alcohol dependence or abuse, illegal drug dependence or abuse, prescription drug dependence or abuse and chemical dependence or abuse (non-limiting examples include alcoholism, narcotic addiction, stimulant addiction, depressant addiction and nicotine addiction). Cardiovascular disorders include, but are not limited to, hypertension and dyslipidemia. Gastrointestinal disorders include, but are not limited to, irritable bowel syndrome, dyspepsia, opioid-induced bowel dysfunction and gastroparesis. Hyperproliferative disorders include, but are not limited to, tumors, cancers, and neoplastic tissue, which further include disorders such as breast cancers, osteosarcomas, angiosarcomas, fibrosarcomas and other sarcomas, ieukemias, lymphomas, sinus tumors, ovarian, uretal, bladder, prostate and other genitourinary cancers, colon, esophageal and stomach cancers and other gastrointestinal cancers, lung cancers, myelomas, pancreatic cancers, liver cancers, kidney cancers, endocrine cancers, skin cancers, and brain or central and peripheral nervous (CNS) system tumors, malignant or benign, including gliomas and neuroblastomas. Central nervous system disorders include, but are not limited to, seizures, seizure disorders, epilepsy, status epilepticus, migraine headache, cortical spreading depression, headache, intracranial hypertension, central nervous system edema, neuropsychiatric disorders, neurotoxicity, head trauma, stroke, ischemia, hypoxia, anxiety, depression, Alzheimer's Disease, obesity, Parkinson's Disease, smoking cessation, additive disorders such as alcohol addiction, addiction to narcotics (such as cocaine addiction, heroin addiction, opiate addiction, etc.), anxiety and neuroprotection (e.g. reducing damage following stroke, reducing damage from neurodegenerative diseases like Alzheimer's, protecting against toxicity damage from ethanol. Inflammatory disorders include, but are not limited to, general inflammation, arthritis, for example, rheumatoid arthritis and osteoarthritis, and inflammatory bowel disease. The compounds of the present invention can further be used to prevent and/or treat cirrhosis and chronic liver disease. As used herein, "treatment" is not necessarily meant to imply cure or complete abolition of the disorder or symptoms associated therewith.
The compounds of the present invention can further be utilized for the preparation of a medicament for the treatment of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, obesity and obesity-associated disorders, appetite or eating disorders, cardiovascular disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
Further embodiments of the present invention will now be described with reference to the following examples. It should be appreciated that these examples are for the purposes of illustrating embodiments of the present invention, and do not limit the scope of the invention. Example 1
Amino Acid Building Blocks
Example AA1. Standard Procedure for the Synthesis of H-(3Me)Cpg-OH
O
CH2l2i Et2Zn ~7 Jones Reagent
OH ^ ^ nu ^ \-- ΠΗ
DCM -20°C -> rt acetone, 0°C
AA1-A 0/n AAl-B 10 min AA1-C
51% {2 steps)
Figure imgf000200_0001
BuLi. THF,
>78°C (20 min) ->
2 h), 68%
Figure imgf000200_0002
Step AAl-1: Cyclopropanation. To a solution of 3-methyl-3-buten-l-ol (AA1-A, 3,52 mL, 34.8 mmol, 1.0 eq) in DCM (350 mL) at -20°C under an argon atmosphere, was carefully added neat diethylzinc (17.9 mL, 174 mmol, 5.0 eq) and diiodomethane (28.1 mL, 348 mmol, 10.0 eq) and the temperature quickly raised to 0°C. (CAUTION: Temperature control is very important. Diiodomethane (mp: 5-8°C) and diethylzinc (mp: -28°C) can freeze and stop agitation suddenly with a risk of explosion upon melting). The reaction was warmed slowly to room temperature and stirred overnight. To the mixture was added saturated NH4C1 (aq) and the aqueous phase extracted with Et20 (3x). The combined organic phase was washed with saturated aq. NaHC03 (2x), brine (lx), dried over MgS04, filtered, then the filtrate concentrated by a rotary evaporator under low temperature and pressure due to the low boiling point of the product to afford 2-(l-methylcyclopropyl)ethanol (AA1 -B, 12.4 g, >100%, orange liquid), which was used without further purification in the next step.
Step AA1-2. Oxidation. A solution of AA1-B (34.8 mmol, 1.0 eq) in acetone (350 mL) was cooled at 0°C. Jones reagent was added until the solution remained orange in color and stirred for an additional 10 min at 0°C. Water was added and the resulting aqueous phase extracted with Et20 (3x). Then the combined organic phase was extracted with 1M sodium carbonate (3x). The combined aqueous phase was washed with Et20 (3x), then acidified to pH=2 with 6N HC1 at 0°C and extracted with Et20 (3x). The combined organic phase was washed with water (lx), brine (lx), dried over MgSC>4, filtered, then the filtrate concentrated in vacuo to yield 2-(l -methylcyclopropyl)acetic acid (AA1-C, 2.03 g, 51 % for 2 steps) as a colorless liquid with an obnoxious odor.
Step AA1-3. Chiral auxiliary anchoring. To AAl-C (2.03 g, 17.8 mmol, 1.0 eq) in THF
(200 mL) at -78°C, was added Et3N (2.98 mL, 21.4 mmol, 1.2 eq) and PivCl (2.41 mL, 19.6 mmol, 1.1 eq) to form a mixed anhydride. This mixture was stirred 15 min at -78°C and 45 min at 0°C, then cooled down to -78°C. Separately, to the chiral auxiliary (AA1-D, 2.61 g, 16.0 mmol, 0.9 eq) in THF (80 mL) at -78°C, was added 1 .6 M n-BuLi in hexanes (10 mL, 16.0 mmol, 0.9 eq) and this mixture stirred 20 min at -78°C. Then, via cannula, the anhydride solution was added to the mixture containing the chiral auxiliary at -78°C and the reaction stirred 2 h at room temperature, then saturated NH4C1 (aq) added. The aqueous phase was extracted with EtOAc (3x). The combined organic phase was washed with brine (lx), dried over MgS04, filtered, then the filtrate concentrated in vacuo. The residue was purified by flash column chromatography (gradient, 1:4 to 2:3, Et20:hexanes) to provide AAi -E (3.15 g, 68%, white solid).
Step AA1-4. HaSogenation. To AAI-E (3.15 g, 12.2 mmol, 1.0 eq) in DCM (94 mL) at
-78°C, was added DTPEA (2.55 mL, 19.6 mmol, 1 .2 eq) and Bu2BOTf (3.44 mL, 12.8 mmol, 1.05 eq). The reaction was stirred 10 min at -78°C, then cannulatecl into a . suspension of NBS (2.39 g, 13.4 mmol, 1.1 eq) in DCM (42 mL) at -78°C. The resulting mixture was stirred 2 h at -78°C and 2 hours at 0°C. To this was added 1 M sodium thiosulfate and stirred for 10 min. The aqueous phase was extracted with DCM (3x). The combined organic phase was washed with brine (xl ), dried over MgS04, filtered, then the filtrate concentrated in vacuo. The residue was immediately (to limit potential decomposition in the crude state) purified by flash column chromatography (100% DCM) to afford AA1-F (667 mg, 17%, white solid).
Step AA1-5. Azide formation. To AALF (667 mg, 1.97 mmol, 1.0 eq) in DMSO (20 mL) at room temperature, was added NaN3 (642 mg, 9.87 mmol, 5.0 eq). The reaction was stirred 1 h at room temperature, then water added. The aqueous phase was extracted with Et20 (3x). The combined organic phase was extracted with brine (lx), dried over MgS04, filtered, then the filtrate concentrated in vacuo to yield AA1 -G (552 mg, 93%) as a white solid.
Step AA1-6. Auxiliary cleavage. To AA1 -G ( 1.45 g, 4.83 mmol, 1.0 eq) in THF/H20 (3: 1, 100 mL) at room temperature, was added LiOH (608 mg, 14.5 mmol, 3.0 eq) and H202 (30%, 1.38 rnL, 24.2 mmol, 5.0 eq). The reaction was stirred at room temperature for 2 h, then the THF evaporated and H20 added. The aqueous solution was washed with DCM (3x), then acidified to pH=2 with 3N HCl. The acidic aqueous phase was extracted with Et20 (3x). The combined organic phase was washed with 1 M Na2S203 (3x), dried over MgSOd, filtered, then concentrated in vacuo to afford AA1-H (830 mg, 100%) as a colorless oil).
Step AA1-7. Azide reduction. To AA1-H (830 mg, 5.35 mmol, 1 .0 eq) in THF/H20 (2: 1, 105 mL) at room temperature, was added 50% wet 10% Pd/C (250 mg, 20% w/w). Hydrogen gas was bubbled directly into this solution for 30 min, then stirred overnight under a hydrogen atmosphere. If reaction was incomplete as indicated by TLC, the catalyst was removed by filtration, a fresh amount of catalyst was added and treated with hydrogen gas in a Parr apparatus for 1 h at 20 psi. When the reaction was completed, it was filtered through a Celite® pad and carefully rinsed with THF/H20, then the filtrate evaporated in vacuo to remove THF. (Note that the product sometimes precipitates during the hydrogenation.) The resulting aqueous phase was washed with DCM (3x), then concentrated in vacuo (or alternatively lyophilized) to afford H-(3Me)Cpg-OH (355 mg, 51 %) as a grayish solid.
Example AA2. Standard Procedure for the Synthesis of H-anti-(3H,4Me)Cpg-OH
AA2
Figure imgf000202_0001
BuLi, THF,
-78°C (20 min) ->
RT (2 h), 73%
NaN3, DMSO
RT, 1 h, 96%
Figure imgf000202_0002
AA2-C AA2-H H-anti-(3H,4Me)C|)g-OH
Step AA2-1: Cyclopropanation. To a solution of (Z)-pent-3-en-l-ol (AA2-A, 3.34 g, 38.9 mmol, 1.0 eq) in DCM (390 mL) at -20°C, was carefully added neat diethylzinc (20.0 mL, 194 mmol, 5.0 eq) and diiodomethane (31.4 mL, 398 mmol, 10.0 eq) and temperature quickly raised to 0°C. (CAUTION: Temperature control is very important. Diiodomethane (mp: 5- 8°C) and diethylzinc (mp: -28°C) can freeze and stop agitation suddenly with a risk of explosion upon melting). The reaction was warmed slowly to room temperature and stirred overnight. Saturated NH4C1 (aq) was added and the aqueous phase extracted with Et20 (3x). The combined organic phase was washed with saturated aq. NaHC03 (2x), brine(lx), dried over MgS04, filtered, then concentrated by rotary evaporator under low temperature and pressure due to the low boiling point of the product to afford 2-(2-methylc.yclopropyl)ethanoi (AA2-B, 29.5 g, >100%, dark liquid), which was used as obtained in the next step.
Step AA2-2. Oxidation. A solution of AA2-B (38.9 rnmol, 1.0 eq) in acetone (390 mL) was cooled to 0°C. Jones reagent was added until the solution remained orange in color, then stirred for an additional 10 min at 0°C. Water was added and the aqueous phase extracted with Et20 (3x). The combined organic phase was extracted with 1M sodium carbonate 1M (3x). Then, the resulting combined aqueous phase was washed with Et20 (3x), acidified to pH=2 with 6N HC1 at 0°C and extracted with Et20 (3x). The combined organic phase was washed with water (lx), brine (lx), dried over MgS0 , filtered, then the filtrate concentrated in vacuo to provide 2-(l.-methylcyclopropyl)acetic acid (AA2-C, 1 .7 g, 38% for 2 steps) as a colorless liquid with an unpleasant odor.
Step AA2-3. Chiral auxiliary anchoring. To the chiral auxiliary (AA2-D, 2.19 g, 13.4 rnmol, 0.9 eq) in THF (75 mL) at -78°C, was added 1.6 M n-BuLi in hexanes (8.4 mL, 13.4 rnmol, 0.9 eq) and the solution stirred 20 min at -78°C. To AA2-C (1.7 g, 14.9 rnmol, 1.0 eq) in THF (166 mL) at -78°C, was added Et3N (2.5 mL, 17.9 rnmol, 1.2 eq) and PivCl (2.02 mL, 16.4 rnmol, 1.1 eq) in order to form a mixed anhydride and the reaction stirred 15 min at - 78°C and 45 min at 0°C, then cooled down to -78°C. The anhydride solution was added via cannula to the auxiliary mixture at -78°C, then stirred 2 h at room temperature. Saturated NH4CI (aq) was added and the aqueous phase extracted with EtOAc (3x). The combined organic phase was washed with brine (lx), dried over MgS04, filtered, then the filtrate concentrated in vacuo. The residue was purified by flash column chromatography (gradient, 1:4 to 2:3, Et20 hexanes) to yield AA2-E (2.8 g, 73%) as a colorless oil.
Step AA2-4. Halogenation. To AA2 E (2.8 g, 10.8 rnmol, 1.0 eq) in DC (83 mL) at -78°C, was added DIPEA (2.25 mL, 13.0 rnmol, 1.2 eq) and Bu2BOTf (3.05 mL, 1 1.4 rnmol, 1.05 eq), then the mixture stirred 10 min at -78°C. This solution was transferred via cannula to a suspension of NBS (2.11 g, 11.9 mmol, 1.1 eq) in DCM (37 mL) at -78°C, then stirred 2 h at - 78°C and 2 h at 0°C. 1M Sodium fhiosulfate was added and the mixture stirred for 10 min. The resulting aqueous phase was washed with DCM (3x). The combined organic phase was washed with brine (lx), dried over MgS04, filtered, then the filtrate concentrated in vacuo. The residue was purified immediately to avoid composition in the crude state by flash column chromatography (100% DCM) to afford AA2 F (2.98 g, 82%) as an orange oil.
Step AA2-5. Azide formation. To AA2-F (2.98 g, 8.82 mmol, 1.0 eq) in DMSO (88 mL) at room temperature, was added NaN3 (2.87 g, 44.1 mmoi, 5.0 eq). The mixture was stirred 1 h at room temperature, then water added. The aqueous phase was washed with Et20 (3x). The combined organic phase was washed with brine (I x), dried over MgSC^, filtered, then the filtrate concentrated in vacuo to yield AA2-G (2.54 g, 96%) as an orange oil.
Step AA2-6. Chiral auxiliary cleavage. To AA2-G (2.54 g, 8.47 mmol, 1.0 eq) in THF/H20 (3: 1, 180 mL) at room temperature, was added LiOH (1.07 g, 25.4 mmol, 3.0 eq) and 30% H202 (2,42 mL, 42,4 mmol, 5.0 eq), then the reaction stirred at room temperature for 2 h. The THF was evaporated from the reaction mixture in vacuo, then H20 added. The aqueous phase was washed with DCM (3x), acidified to pH~2 with 3N HC1. The acidic aqueous phase was washed with Et20 (3x). The combined organic phase was washed with 1 M Na2S203 (3x), dried over MgSC>4, filtered, then the filtrate concentrated in vacuo to provide AA2-H (1.05 g, 80%) as a colorless oil.
Step AA2-7. Azide reduction. To AA2-H (1.05 g, 6.77 mmol, 1.0 eq) in THF/H20 (2: 1, 135 mL) at room temperature, was added 50% wet 10% Pd/C 1 (300 mg, 20% w/w). Hydrogen gas was bubbled directly into this solution for 30 min and stirred overnight under a hydrogen atmosphere. If reaction is incomplete as indicated by TLC, the catalyst was removed by filtration, a fresh amount of catalyst was added and the reaction treated with hydrogen gas in a Parr apparatus for 1. h at 20 psi. When the reaction was completed, it was filtered through a Celite® pad and carefully rinsed with THF/H20, then concentrated in vacuo to remove the THF. (Note that the product sometimes precipitates during the hydrogenation.) The resulting aqueous phase was washed with DCM (3x), then concentrated in vacuo (or alternatively lyophilized) to give H-anti-(3H,4Me)Cpg-OH (794 mg, 91%) as a beige solid.
Example AA3. Standard Procedure for the Synthesis of H-syn-(3H,4Me)Cpg-OH
Figure imgf000204_0001
AA3-A O/N AA3-B O/N, 89 (2 steps) AA3-C
Figure imgf000204_0002
BuLi, THF,
-78°C (20 min) ->
RT 2 h), 69%
Figure imgf000204_0003
AA3-F AA3-G H-syn-(3H,4IVIe)Cpg-OH Step AA3-1: Cyclopropanation. To a solution of (E)-pent-3-en-l -ol (AA3-A, 4.77 mL, 38.9 mmol, 1.0 eq) in DCM (390 mL) at -20°C, was carefully added neat diethylzinc (20.0 mL, 194 mmol, 5.0 eq) and diiodomethane (31.4 mL, 398 mmol, 10.0 eq) and temperature quickly raised to 0°C. (CAUTION: Temperature control is very important. Diiodomethane (mp: 5- 8°C) and diethylzinc (mp: -28°C) can freeze and slop agitation suddenly with a risk of explosion upon melting). The reaction was warmed slowly to room temperature and stirred overnight. Saturated NH4C3 (aq) was added and the aqueous phase extracted with Et20 (3x). The combined organic phase was washed with saturated aq. NaHC03 (2x), brine(lx), dried over MgS04, filtered, then concentrated by rotary evaporator under low temperature (bath T < 15 °C) and pressure due to the low boiling point of the product to afford methyl-2-(2- methylcyclopropyl)acetate (AA3-B, 19 g, >100%, dark liquid), which was used as obtained in the next step.
Step AA3-2. Ester hydrolysis. To AA3-B (38.9 mmol, 1.0 eq) in THF/H20 (1:1, 200 mL) was added LiOH (8.17 g, 194.5 mmol, 5.0 eq) and the reaction stirred overnight. The THF was evaporated in vacuo and the remaining aqueous phase washed with Εί20 (3x). The aqueous phase was acidified to pH 2 with 3 N HC1, then extracted with Ε120 (3x). The combined organic phase was washed with brine (lx), dried with MgS04, filter, then the filtrate concentrated under reduced pressure to afford 2-(2-methylcyclopropyl)acetic acid (AA3-C, 3.96 g, 89% for 2 steps) as an orange liquid with an unpleasant odor.
Step AA3-3. Chiral auxiliary anchoring. To the chiral auxiliary (AA2-D, 5.09 g, 31.2 mmol, 0.9 eq) in THF (173 mL) at -78°C, was added 1 .6 M n-BuLi in hexanes (19.5 mL, 31.2 mmol, 0.9 eq) and the solution stirred 20 min at -78°C. To AA3-C (3.96 g, 34.7 mmol, 1.0 eq) in THF (386 mL) at -78°C, was added Et3N (5.8 mL, 41.6 mmol, 1.2 eq) and PivCl (4.71 mL, 38.2 mmol, 1.1 eq) in order to form a mixed anhydride and the reaction stirred 15 min at -78°C and 45 min at 0°C, then cooled back to -78°C. The anhydride solution was added via cannula to the auxiliary mixture at -78aC, then stirred 2 h at room temperature. Saturated NH4CI (aq) was added and the aqueous phase extracted with EtOAc (3x). The combined organic phase was washed with brine (lx), dried over M0SO4, filtered, then the filtrate concentrated in vacuo. The residue was purified by flash column chromatography (gradient, 1:4 to 2:3, Et20 hexanes) to yield AA3-D (6.18 g, 69%) as a white, solid.
Step AA3-4. Halogenation. To AA3-D (6.18 g, 23.9 mmol, 1.0 eq) in DCM (184 mL) at -78°C, was added DIPEA (4.99 mL, 28.7 mmol, 1.2 eq) and Bu2BOTf (6.73 mL, 25.1 mmol, 1.05 eq), then the mixture stirred 10 min at -78°C. This solution was transferred via cannula to a suspension of NBS (4.68 g, 26.3 mmol, LI eq) in DCM (82 mL) at -78°C, then stirred 2 h at -78°C and 2 h at 0°C. 1M Sodium thiosulfate was added and the mixture stirred for 10 min. The resulting aqueous phase was washed with DCM (3x). The combined organic phase was washed with brine (lx), dried over MgS0 , filtered, then the filtrate concentrated in vacuo. The residue was purified immediately to avoid composition in the crude state by flash column chromatography (100% DCM) to afford AA3-E (5.41 g, 67%) as a yellow oil.
Step AA3-5. Azide formation. To AA3-E (2.70 g, 7.99 mmol, 1.0 eq) in DMSO (80 mL) at room temperature, was added NaN3 (2.60 g, 40.0 mmol, 5.0 eq). The mixture was stirred 1. h at room temperature, then water added. The aqueous phase was washed with Et20 (3x). The combined organic phase was washed with brine (l ), dried over MgSC¼, filtered, then the filtrate concentrated in vacuo to yield AA3-F (2.53 g, 100%,) as a white solid.
Step AA3-6. Chiral auxiliary cleavage. To AA3 F (2.53 g, 8.43 mmol, 1.0 eq) in THF/H20 (3: 1, 168 mL) at room temperature, was added LiOH (1.06 g, 25.3 mmol, 3.0 eq) and 30% H2O2 (2.66 mL, 42.1 mmol, 5.0 eq), then the reaction stirred at room temperature for 2 h. The THF was evaporated from the reaction mixture in vacuo, then H20 added. The aqueous phase was washed with DCM (3x), acidified to pH=2 with 3N HQ. The acidic aqueous phase was washed with Et20 (3x). The combined organic phase was washed with 1 M Na2S203 (3x), dried over MgS04, filtered, then the filtrate concentrated in vacuo to provide AA3-G (1.15 g, 80%) as an orange oil.
Step AA3-7. Azide reduction. To AA3-G (1.15 g, 7.42 mmol, 1.0 eq) in THF/H20 (2: 1, 18 mL) at room temperature, was added 50% wet 10% Pd/C 1 (230 mg, 20% w/w). Hydrogen gas was bubbled directly into this solution for 30 min and then stirred overnight under a hydrogen atmosphere. If reaction is incomplete as indicated by TLC, the catalyst was removed by filtration, a fresh amount of catalyst was added and the reaction treated with hydrogen gas in a Parr apparatus for 1 h at 20 psi. When the reaction was completed, it was filtered through a Celite® pad and carefully rinsed with THF/H20, then concentrated in vacuo to remove the THF. (Note that the product sometimes precipitates during the hydro genation.) The resulting aqueous phase was washed with DCM (3x), then concentrated in vacuo (or alternatively lyophilized) to give H-syn-(3H,4Me)Cpg-OH (472 mg, 49%) as a brown solid. Example AA4. Standard Procedure for the Synthesis of H- -(S)Me
Figure imgf000207_0001
1 ) Cs2C03 (20% water)
2) BnBr, DMF
Figure imgf000207_0002
This synthesis was based on the reaction methodology described by Evans for the synthesis of chiral amino acids (Evans, D. A.; Ellman, J. A.; Dorow, R. L. Tetrahedron Lett. 1987, 28,
1123-1126). An asymmetric auxiliary was added to chiral acid AA4-A (1.83 g) using standard methodology to give AA4-B (2.9 g, 85%). Asymmetric bromination to provide
AA4-C (2.6 g, 72%, plus 10-15%' unreacted AA4-B) was followed by azide SN2 displacement to afford AA4-D (2.3 g, 100%). Cleavage of the auxiliary provided AA4-E, then formation of the benzyl ester gave AA4-F. Reaction with triphenylphosphine to form the iminophosphorane, then hydrolysis with water converted the azide to an amine and gave 500 mg (28%, 3 steps) of the protected amino acid, H- -(S)Me-Phe-OBn.
Example AA5. Standard Procedure for the Synthesis of o-Tyr Lactone (AA5-3)
Figure imgf000207_0003
AA5-1 AA5-2 AA5-3
41 %
To a solution of Boc-(D.L)oTyr~OH (AA5-1, 2.76 g, 9.82 mmol, 1.0 eq) in DCM (49 mL) was added DIPEA (3.4 mL, 19.6 mmol, 2.0 eq) followed by Ac20 (1.02 mL, 10.8 mmol, 1.1 eq). The mixture was stirred for 3 h at RT. Solvent was evaporated in vacuo and the residue dissolved in EtOAc. This organic phase was washed with citrate buffer (1 M, pH 3.5, 3x), brine (lx), dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography [gradient, EtOAc/Hex (1: 1) to 100% EtOAc] to give lactone AA5-3 as a white solid ( 1.06 g, 41%) In addition, 1.06 g of a fraction containing a mixture of AA5-1 and acetylated o-tyrosine (AA5-2) was obtained.
Example 2
Synthesis of Tethers
A. Standard Procedure for the Synthesis of Tether T59
Figure imgf000208_0001
59-4 Boc-T59b(THP)
Step T59-1 : To a solution of Boc-T8 (32.3 g, 110.2 mmol, 1.0 eq) in THF (500 mL) were added imidazole (15.0 g, 220.4 mmol, 2.0 eq) and TBDMSCI (21.6 g, 143.3 mmol, 1.3 eq) and the mixture stirred 2 h with monitoring by TLC. The solution was then treated with saturated aqueous NH4CI and the aqueous phase extracted with EtOAc. The combined organic phase was dried over MgS04, filtered and the filtrate concentrated under reduced pressure. The resulting residue was filtered through a silica gel pad (10% EtOAc/90% hexanes) to give 59-1 as a colorless oil (100%).
TLC: Rf = 0.60 (30% EtOAc/70% hexanes; detection: UV, Mo/Ce).
Step T59-2: To a solution of 59-1 (20.1 g, 49.3 mmol, 1.0 eq) in a mixture of H20:t-BuOH (1 : 1, 500 mL) were added AD-mix β (60 g) and methanesulfonamide (4.7 g, 49.3 mmol, 1.0 eq) and the resulting orange mixture stirred at 4°C for 36-48 h during which time the color changes to yellow. Once TLC indicated the reaction was complete, sodium sulfite (75 g, 12.0 eq) was added and the mixture stirred at room temperature 1 h. The mixture was extracted with EtOAc, then the combined organic phase extracted with water and brine. The organic phase was dried over MgS04, filtered and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (50% EtOAc/50% hexanes) to give 59-2 as a yellow oil (96%).
TLC: Rf = 0.41 (50% EtOAc/50% hexanes; detection: UV, Mn04).
Step T59-3: To a solution of 59-2 (20.9 g, 47.4 mmol, 1.0 eq) in DCM (300 mL) at 0°C were added pyridine (15 mL) and DMAP (293 mg, 2.4 mmol, 0.05 eq). Triphosgene (1.4.1 g, 47.4 mmol, 1.0 eq) in DCM (50 mL) was then slowly added to this mixture. The reaction was stirred at 0°C for 45 min at which time TLC indicated the reaction was completed. The solution was treated with saturated aqueous NH4CI and the organic phase separated. The aqueous phase was extracted with Et20 and the combined organic phase extracted with saturated aqueous NH4CI. The organic phase was dried over MgS04, filtered and the filtrate concentrated under reduced pressure. The resulting residue was filtered through a silica gel pad (30% EtO Ac/70% hexanes) to give 59-3 as a yellow oil (91%).
TLC: Rf = 0.56 (50% EtOAc/50 % hexanes; detection: UV, Mo/Ce).
Step T59-4: To a solution of 59-3 (20.2 g, 43.3 mmol, 1.0 eq) in a mixture of 95% EtOH:acetone (3: 1, 400 mL) was added Raney Ni (50% in water, 51 mL, 433 mmol, 10.0 eq). Hydrogen was bubbled into this solution for 6 h with monitoring by TLC. When the reaction was completed, N2 was bubbled through the mixture to remove excess hydrogen, then the mixture filtered though a Celite pad and rinsed with EtOAc. Concentration of the filtrate under reduced pressure gave 59-4 as a colorless oil sufficiently pure to be used for the next step.
TLC: Rf = 0.29 (30% EtOAc/70 % hexanes; detection: UV, Mo/Ce).
Step T59-5: To a solution of the alcohol 59-4 (17.0 g, 40.0 mmol, 1.0 eq) in CH2C12 (250 mL) were added DHP (4.4 mL, 48.0 mmol, 1.2 eq) and PTSA (380 mg, 2.0 mmol, 0.05 eq). The mixture was stirred at room temperature for 1 h. Upon completion as indicated by TLC (30% EtO Ac/70 % hexanes; detection: UV, Mo/Ce; Rf = 0.51 ), the solution was treated with saturated aqueous NaHC0 , then the aqueous phase extracted with CH2CI2. The combined organic phase was dried over MgS04, filtered and the filtrate concentrated under reduced pressure. The residue was dissolved in THF (250 mL) and a 1M solution of TBAF in THF (80.0 mL, 80.0 mmol, 2.0 eq) added. The mixture was stirred at it for 1 h. When TLC indicated the reaction was complete, the mixture was treated with brine the layers separated, and the aqueous phase extracted with EtOAc. The combined organic phase was dried over MgS04, filtered and the filtrate concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (50% EtOAc/50% hexanes) to give BooT59b(THP) as a yellow oil (76%, 3 steps).
TLC: Rf = 0.12 (30% EtOAc/70% hexanes; detection: UV, Mo/Ce);
nC NMR (CDCI3, ppm): δ 19.5, 25.5, 25.6, 28,6, 30.8, 31.1, 33.5, 44.5, 61.5, 62.6,
69.9, 75.0, 96.7, 3 1 1.0, 120.9, 121.0, 328.1 , 131.8, 356.9.
To obtain Boc-T59a and its THP-protected derivative, the same procedure as above was followed, but utilizing AD-mix a, with the yields for the sequence being comparable. Other suitable protecting groups in place of THP can be introduced in the last step as well.
B. Standard Procedure for the Synthesis of Tether T104b
1 ) TEMPO, NaOCI,
Figure imgf000210_0001
Step T 104-1. To a solution of ethyl (lR,2S)-cis-2-hydroxy-cyclohexanoate 104-1 (obtained from Julich, now Codexis, product no. 15.60, 50 g, 290 mmol) in THF (500 mL) was added imidazole (29.6 g, 435 mmol) and TBDMSC1 (49.8 g, 331 mmol). The reaction was stirred at RT for 72 h and then quenched with saturated NH4CI (aq). The mixture was extracted with Et20 (3x). The organic phases were combined, dried over MgSC , filtered, and the filtrate concentrated under reduced pressure to yield the intermediate protected ester (104-2, 93 g), which was used directly in the next step.
Step T 104-2. 104-2 (215 g, 0.75 mol) obtained from the previous step was dissolved in DCM (2 L) and the solution cooled to -30°C. To this solution was added DIBAL-H (1 M solution in DCM, 2250 mL, 2.25 mol) over a period of 1.5 h. The reaction mixture was stirred 1 h at 0UC and then poured into an aqueous solution of Rochelle salts (2 M, 4 L) at 0°C. This mixture was vigorously stirred overnight at RT, then extracted with DCM (3x). The combined organic phase was washed with brine, dried over MgS04l filtered, and the filtrate concentrated under reduced pressure to give 155 g of 304-3 (85%).
Step T 104-3. To a solution of 104-3 (196 g, 0.8 mol) in CH2C12 (2 L) at 0°C was added TEMPO ( 12.5 g, 80 mmol) followed by an aqueous solution of KHC03 (1.6 M, 862 g) and an aqueous solution of KBr (2.7 M, 196 g). The mixture was vigorously stirred and an 11 % NaOCl aqueous solution (573 mL, 1 .04 mol, 1.3 eq) added over 45 min. When the addition was completed, the mixture was stirred for an additional 15 min at 0°C, then quenched with an aqueous solution of 1 M Na2S203 (1 L). The mixture was extracted and the aqueous phase washed with CH2Q2 (2 x 500mL). The combined organic phase was dried over MgSC¼, filtered, and the filtrate concentrated under reduced pressure to afford the intermediate aldehyde (104-4, 190 g), which was used in the next step without further purification.
Step T 104-4. 104-4 ( 1 16 g, 480 mmol) and ethyl triphenylphosphoranylidene carbonate (250 g, 720 mmol) were dissolved in benzene (2 L) and the reaction heated to reflux overnight. The mixture was cooled to RT and evaporated to 50% volume. Hexanes was added, the mixture stirred for 15 min with precipitation of the Ph P=0 byproduct, then filtered through a pad of silica gel and rinsed with 10% EtOAc/hexanes. The filtrate was concentrated to dryness under reduced pressure to provide 104-5 ( 125 g, 50%).
Step T104-5. To 104-5 (200 g, 640 mmol) dissolved in EtOAc (3 L) was added 10% Pd/C (50% wet, 68 g) and H2 bubbled into the mixture for 16 h. The mixture was filtered through a pad of Celite and the filter cake rinsed with EtOAc (1 L). The combined filtrate and washings were concentrated under reduced pressure, then the residue (104-6, 180 g) dissolved in Et20. The solution was cooled to 0°C, L1AIH4 (16.3 g, 430 mmol) added portion- wise, and the mixture stirred for 1 h at 0°C. The reaction was quenched by slowly adding water (17 mL), followed by 15% NaOH aqueous solution ( 1 7 mL), and finally water (51 mL). This mixture was stirred 1 h at 0°C, then filtered. The filtrate was concentrated in vacuo to give the intermediate alcohol (104-7, 152.6 g). This alcohol was dissolved in THE (3 L) and triphenylphosphine (220.6 g, 841 mmol), phthalimide ( 123.7 g, 841 mmol) and DIAD (154.5 mL, 785 mmol) added. The mixture was stirred 5 h at RT, then the solvent evaporated under reduced pressure. The residue was dissolved in MTBE, stirred for 1 h at RT during which the Ph3P~0 byproduct precipitated, then filtered. The filtrate was evaporated under- reduced pressure and the residue purified by flash chromatography (gradient, 5% Et20/hexanes to 20% Et20/hexanes) to give 104-8 (194 g, 75%).
Step T 104-6. 104-8 (194 g, 483 mmol) was dissolved in a solution of 1 % HCi/MeOH (3 L). This solution was stirred at RT overnight, then quenched with water (1.5 L). The mixture was extracted with DCM (2 x 1.5 L) and the combined organic fractions dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was passed through a pad of silica gel and rinsed with 10% Et20/hexanes to remove the silanol byproduct, then with Et20 until no additional compound was eluting as evidenced by TLC. The solvents were removed under reduced pressure to yield 104-9 (138.5 g, 98%) as a white solid.
Step T 104-7. To a solution of 104-9 (135 g, 470 mmol) in MeOH (3 L) was added hydrazine (88 mL, 1.41 mol). This mixture was stirred at RT for 64 h, then filtered and the filter cake rinsed with EtOH (500 mL). The filtrate and washings were combined and evaporated under reduced pressure. The residue was dissolved in EtOH (1 L), filtered again, and the filter rinsed with EtOH (250 mL). The filtrate and washings were combined and evaporated to dryness under reduced pressure. The residue was redissolved with EtOH (1 L) and again evaporated to dryness in vacuo. The residue was then dissolved in DCM, filtered and the filter rinsed with DCM. The combined filtrate and washings were evaporated to dryness under reduced pressure to give the intermediate amino alcohol 104-10, which was dissolved in a 1: 1 mixture of THF/water (3 L). To this mixture were added Na2C03 (150 g, 1.41 mol) followed by (Boc)20 (153.8 g, 705 mmol). The reaction was stirred overnight at RT and quenched with water. The mixture was extracted with Et20 (3x). The combined organic phase was washed with brine, dried over MgS04, filtered, and the filtrate concentrated to dryness under reduced pressure. The resulting residue was purified by flash chromatography (gradient, 15%Et20/Hexanes to 50% Et20/Hexanes) to provide 104-11 (73 g, 60%) as an oil. Step T104-8. To a solution of 104-11 (13.8 g, 53.7 mmol) in ethyl vinyl ether (500 mL) was added mercuric acetate (5.13 g, 16.1 mmol) and the solution heated at reflux for 24 h. Another 0.3 eq of mercuric acetate was then added and the solution again heated at reflux for another 24 h. The solution was cooled to RT, quenched with an aqueous saturated solution of Na2C0 and extracted with Et20 (3x). The combined organic phases were washed with brine, dried over MgS04) filtered, and tire filtrate concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (10% EtiO/hexanc containing 2% Et3N) to yield 104-12 as a colorless oil (8.6 g, 94%).
Step T104-9. To a solution of 104-12 (13.2 g, 46.6 mmol) in THF (400 mL) at 0l'C was slowly, over a period of 15 min, added a 1 M solution of BHvTHF (69.9 mL, 69.9 mmol). The mixture was stiiTed 1 h at 0°C, then 2 h at RT. The solution was cooled to 0°C and a 5 N solution of NaOH (90 mL) added, followed by a 30% aqueous solution of H202 (200 mL). The mixture was stiiTed 15 min at 0°C, then 2 h at RT. The solution was extracted with EtoO (3x). The combined organic phase was washed with brine, dried over MgSC»4, filtered, and the filtrate concentrated to dryness under reduced pressure. The resulting residue was purified . by flash chromatography (30% EtOAc/he anes) to afford Boc-T104b (11.4 g, 81%).
HPLC/MS: Gradient A4, tR = 7.05 min, [M+H 302.
The enantiomeric tether Boc-T104a can be accessed similarly using ethyl (l S,2R)-cis-2- hydroxy-cyclohexanoate 104-13.
Figure imgf000213_0001
104-13 Boc-T104a
C. Alternative Procedure for the Synthesis of Tether T104b
SAMP (1.0 eq)
C6H6/reflux
Figure imgf000214_0001
104-14 104-15 104-16
CuCI2 aq.
THF/4.5
Figure imgf000214_0002
104-20 Boc-T104b ^n alternative synthetic route to T104b involves as a key step the asymmetric alkylation of cyclohexanone derivatized with (5)-l-arnino-2-methoxymethylpyiTolidine (SAMP) hydrazone as the chiral auxiliary (Enders, D. Alkylation of Chiral Hydrazones. In Asymmetric Synthesis; Morrison, J.D., Ed.; Academic Press: Orlando, FL, 1984; Vol. 3, pp 275-339.) and 104-C as the electrophile. 104-16 thus obtained was subjected sequentially to hydrazone cleavage and L-Selectride reduction to give the alcohol 104-18. O-Alkylation with bromoacetic acid, borane reduction, then hydrogenolysis of the benzyl protecting group gave Boc-T104b.
Figure imgf000214_0003
SAMP RAMP
A similar sequence, but using (R)-l-amino-2-methoxymethylpyrrolidine (RAMP) hydrazone as the chiral auxiliary, was utilized to provide Boc-T104a in comparable yields.
Figure imgf000215_0001
D. Standard Procedure for the Synthesis of Tether T134
Figure imgf000215_0002
134-4
62%
H2 (400psi), Pd/C
EtOH abs, rt, 72 h
Figure imgf000215_0003
134-5 BOC-T 34a
Step T134-1. To a solution of (R)-(-)-2-amino-l-butanol (134-0, 50 g, 561 mmol, 1.0 eq) in THF/water (1:1, 2.8 L) were added (Boc)20 (129 g, 589 mmol, 1.05 eq) and Na2C03 (71.3g, 673mmol, 1.2 eq) and the solution stirred overnight. THF was removed in vacuo and the aqueous phase was extracted with ether (3 x 500 mL). The combined organic phase was washed with 1M citrate buffer (200 mL) and brine (200 mL), dried with MgS04, filtered and concentrated under vacuum. The crude was purified on silica gel (dry pack, 50% EtOAc/Hexanes) to give 134-1 (104.9 g, 554 mmol, 99%) as a colorless oil.
Step T 134-2: To a solution of 134-1 (93.8 g, 496 mmol, 1.0 eq) in CH2C12 (1.24 L) at 0°C was added TEMPO (7.75 g, 49.6 mmol, 0.1 eq), followed by a 2.75M aqueous solution of KBr (130 g) and a 1.6M solution of KHC03 (570 g). NaOCl (11.5%/water, 420 mL, 645 mmol, 1.3 eq) was then added dropwise over ~ 30 min with vigorous stirring. The reaction was stirred 10 min at 0°C, then a 1M solution of Na2S20;¾ (aq, 400 mL) added to quench excess of oxidant. The mixture was stirred 5 min at 0°C and warmed to it over 90 min. The phases were separated and the aqueous phase extracted with CH2CI2 (2 x 1 L). The combined organic phase was washed with water (1 L) and brine (500 mL), dried with MgS04, filtered, then the filtrate concentrated under vacuum to give 134-2 (95 g, 508 mmol,. >100%) as an orange oil, which was used without further purification for the next step.
Step T134-3: To a solution of tosyl azide (117.3 g, 595 mmol, 1.2 cq, Org. Synth. Coll. Vol. 5, p.179 (1973); Vol. 48, p36 (1968)) in MeCN (7.4 L) at 0°C was added K2C03 (206 g, 1.4 9mol, 3 eq), followed by 134- A (98.8 g, 595 mmol, 1.2 eq). The reaction was warmed to rt and stirred for 3 h. The crude 134-2 from the previous step in MeOH (1.5L) was then added and the reaction stirred overnight. The solvents were evaporated in vacuo and water (1.5 L) and Et20 (1 L) added to the residue. The phases were separated and the aqueous phase extracted with Et20 (2 x 1 L). The combined organic phase was washed with water (200 mL) and brine (200 mL), dried with MgS04, filtered, then the filtrate concentrated under vacuum. The residue was triturated with pentane (5 x 500 mL), then the solvent from the triturations concentrated under vacuum. The resulting residue was purified by flash chromatography (gradient, 5-10% EtOAc/hexanes) to give 134-3 (33.7 g, 1 84 mmol, 37% for 2 steps).
Step T 134-4: Into a solution of 134-3 (20.2 g, 110 mmol, 1.7 eq) and bromo-alcohol 134-B (22.6 g, 64.8 mmol, 1.0 eq) in MeCN (325 mL) was bubbled argon for 20 min. Recrystaliized Cul (248 mg, 1.30 mmol, 0.02 eq), PdCl2(PhCN)2 (744 mg, 1.94 mmol, 0.03 eq), t- BU3PHBF4 (1.22 g, 4.21 mmol, 0.065 eq) and Pr2NH (16 mL, 110 mmol, 1.7 eq) were then added. The reaction was stirred under an argon atmosphere for 40 h at rt. The reaction was filtered through a silica gel pad and the pad rinsed with EtOAc. The volatiles were removed in vacuo and the residue purified by flash chromatography (gradient, 5-10-20% EtOAc/hexanes) to afford 134-4 (18.3 g, 40.5 mmol, 62%) as a mixture of starting bromide, alkyne and other unknown impurities.
Step T134-5: To alkyne 134-4 (18.2 g, 40.5 mmol, 1.0 eq) in absolute EtOH (300 mL) was added 10% Pd/C (50% wet, 4.29 g, 0.02 eq). The mixture was placed in a Parr reactor under a pressure of 400 psi of hydrogen for 72 h. The reaction can be monitored by HPLC. The mixture was filtered through a Celite® pad then concentrated under vacuum. The residue was dissolved in THF and 1M TBAF inTHF (48 mL, 48 mmol) added. The reaction was stirred 2 h at rt then solvent evaporated in vacuo. The resulting residue was purified by flash chromatography (gradient, 10-15-20-30-40-50% acetone/he ancs) to give a mixture of the fully (134-5) and partially reduced products (7.8 g, 22.9 mmol, 57%). This mixture was then dissolved in absolute EtOH (1 15 mL) and 10% Pd/C (50% wet, 2 g, 0.04 eq) added. The reaction was stirred overnight under H2 (400 psi) in a Pan- reactor. The solution was filtered through a Celite pad and the filtrate evaporated under vacuum. The residue was purified by flash chromatography (gradient, 10-20% acetone/hexanes) to give T134 (5.51 g, 15.1 mmol). Note that 2-(3-fluorophenoxy)ethanol was often present as an impurity in this product. To remove ti is material, the impure product was dissolved in HCl/MeOH ( 10% w/w) and agitated 24 h, then the volatiles removed in vacuo. The residue was dissolved in water (100 mL), then washed with MTBE (4 x 25 mL) until TLC confirmed removal of the 2-(3- fiuorophenoxy)ethanol impurity. THF (100 mL) was added followed by a2C03 to adjust the pH to 10. Excess Boc20 was added and the solution stirred overnight. The THF was evaporated under vacuum and the aqueous phase extracted with MTBE (3 x 100 mL). The combined organic phase was dried with MgSC>4, filtered, then the filtrate concentrated under vacuum to obtain a residue that was purified by flash chromatography (gradient, 20-40% acetone/hexanes) to give clean Boc-T134a (3.87 g, 11.3 mmol, 28%, 2 steps) as an oil.
HPLC/MS: Gradient A4, tR = 7.39 min, M+ 341 ;
Ή NMR (DMSO, 300 MHz): δ 7.13-7.06 (m ,1H), 6.82 (dd, 1 H, ./ = 2.5, 11.5Hz), 6.68- 6.56 (m, 2H), 4.83 (t, 1H, / = 5.5Hz), 3.98 (t, 2H, J = 5.1Hz), 3.72 (dd, 2H, J = 5.5, 10.3Hz), 3.32-3.20 (ra, 1H), 2.60-2.40 (m, 2H), 1.66- 1.22 (m, 4H), 1.39 (s, 9H), 0.79 (t, 3H, y = 7.4Hz)..
The enantiomeric tether T135b is constructed starting from the enantiomer of 134-0.
E. Standard Procedure for the Synthesis of Tether T135
Figure imgf000217_0001
Figure imgf000217_0002
BOC-T135 Step T135-1. To a solution of 2-bromo5-fluorophenol (135-0, 15.0 g, 78.5 mmol, 1.0 eq) and 135- A (30.2 g, 126.4 mmol, 1.6 eq) in DMF (Drisolv, 225 mL) are added potassium carbonate (13.0 g, 93.5 mmol, 1.2 eq), potassium iodide (2.5 g, 15.1 mmol, 0.19 eq). The solution was heated to 55°C and stirred overnight under nitrogen. The solvent was concentrated to dryness under reduced pressure, then the residual oil was diluted with water (200 mL) and extracted with Et20 (3 x 150mL). The organic phases are combined and washed with 1 M citrate buffer (2x), brine (Ix), dried with magnesium sulfate, filtered, and the filtrate evaporated under vacuum. The crude product was purified by flash chromatography (10% EtOAc/pentane) to give 135-1 as a yellowish solid. (20.0 g, 73%)
TLC: Rf = 0.68 (25% EtOAc Hex; detection: UV, CMA).
Step T135-2. To a solution of 135- 1 (17.0 g, 48.7 mmol, 1.0 eq) in MeOH (Drisolv, 162 mL) was added HC1 (12.1 M, 25 μΕ, 0.486 mmol, 1 mol%) and the reaction stirred 2.5 h at rt. H20 was then added and the aqueous layer washed with Et20 (2 x 300 mL). The organic layers were combined, washed with saturated aqueous NH4CI (300 mL), brine (300 mL), dried over MgS04, filtered, and the filtrate concentrated under reduced pressure to leave an orange oil. Purification by flash chromatography (40% EtO Ac/Hex) afforded 10.7 g (94%) of 135-2 as a colorless oil.
TLC: Rf = 0.57 (30% EtO Ac/Hex; detection: UV, KMn04);
Ή NMR (300 MHz, CDCI3): δ 7.48 (dd, J = 6.3, 8.7 Hz, 1H), 6.58-6.68 (m, 2H), 4.12
(m, 2H), 4.01 (m, 2H), 2.17 (br, 1H).
Step Tl.35-3. In a flame dried flask, MeCN (26 mL) was introduced and degassed with multiple argon/vacuum cycles for 30 min. Then, Pd(OAc)2 (143 mg, 0.640 mmol, 0.05 eq), P(i tol)3 (388 mg, 1.27 mmol, 0.10 eq), diBoc-allylamine (135-B, see procedure following, 3.6 g, 14.0 mmol, 1.1 eq), Et3N (3.6 mL, 25.5 mmol, 2 eq) and alcohol 135-2 (3.0 g, 12.8 mmol, 1.0 eq) were added. The solution was stirred at rt, quickly degassed, then heated to reflux at 1 10°C for 20 h under an argon atmosphere. The reaction mixture was allowed to cool to rt, quenched with H20 (20 mL), and the layers separated. The aqueous layer was washed with Et20 (2 x 60 mL). The organic layers were combined, washed with saturated aqueous NH4C1 (70 mL), brine (70 mL), dried over MgS04, filtered, and the filtrate concentrated under vacuum to give the crude product. Purification by flash chromatography (gradient, 30% to 40% Et20/Hex) afforded 4.25 g (81 ) of 135-3 as a pale yellow solid.
TLC: Rf = 0.39 (30% Et20/Hex; detection: UV, KM1 O4);
HPLC/MS: Gradient A4, tR = 8.55 min, [M+NaJ+ 434; Ή NMR (300 MHz, CDC13): δ 7.35 (dd, J= 6.9, 8.7 Hz, I H), 6.79 (d, J = 15.9 Hz, 1 H), 6.56-6.68 (m, 2H), 6.17 (dt, J = undetermined, 15.9 Hz, 1 H), 4.31 (dd, J = 1.2, 6.3 Hz, 2H), 4.05-4.09 (m, 2H), 3.94-3.98 (m, 2H), 2.26 (br m, 1 H), 1.51 (s, 1 H). Step T135-4. To a solution of 135-3 (4.25 g, 10.3 mmol, 1 ,0 eq) in DCM (Dnsolv, 52 mL) under nitrogen, TFA ( 1 .15 mL, 15.5 mmol, 2.0 eq) was added and the solution stirred at rt for 1.75 h with TLC monitoring. Additional TFA (0.5 or 1 eq) was added if reaction was incomplete. The solvent was evaporated under reduced pressure, and the resulting oil purified by flash chromatography with preadsorption on silica (gradient, 40% to 50% Et20/hex aires) to yield 2.2 g (70%) of Boc-T135 as a white solid.
TLC: Rr = 0.46 (40% Et20/Hex; detection: UV, KMn04);
HPLC/MS : Gradient A4, tR = 6.63 min, [M+Na 334;
!H NMR (300 MHz, CDC13): 5 7.15-7.087 (m, 1 H), 6.74-6.52 (m, 4H), 4.74 (s (br), 1H), 4.13-4.09 (m, 2H), 4.00-3.97 (m, 2H), 3.92 (t (br), J = 5 Hz, 2H), 1.93 (s (br), 1H), 1.46 (s, 9H).
F. Standard Procedure for the Synthesis of Reagent 135-B
, ΝΗρ (Boc)20, Et3N ^ MHBoc (Boc)20, DMAP
DCM, 0°C CH3CN, 60°C, O/N
1 35"B 97% «5-Β2 80 o /o 135-B
T135-5. (Boc)20 ( 1 12 g, 0.531 mol) was added by portions over 2 h to a solution of allylamine (30 g, 0.526 mol) and triethylamine (95 mL, 0.684 mol) in DCM (900 mL) at 0°C, then the solution stirred O/N. The reaction mixture was washed successively with citrate buffer (pH 3.5, 3x), NaHC03 (2x) and brine (2x), dried over anhydrous MgS04, filtered, and the filtrate evaporated under vacuum to give 80.5 g (97%) of 135-B 1.
TLC: Rf: 0.35 (30/70 EtOAc Hex; detection: UV, KMn04).
Step T 135-6. To a solution of 135-B 1 (80.5 g, 0.513 mol) in CH3CN (1.8 L) were added (Boc)20 (134.2 g, 0.615 mol) and DMAP (4.39 g, 0.036 mol). The mixture was heated O/N at. 60°C. The solvent was removed and the crude compound was purified by dry pack (10% EtOAc/Hex) to provide 135-B as a white solid (105 g, 80%).
TLC: Rr: 0.27 (30/70 EtOAc/Hex; detection: UV, Kmn04);
Ή NMR (300 MHz, CDC13): δ 5.78-5.90 (1H, m); 5.09-5.20 (2H, m); 4.17 (2H, dt, J=5.5 and 1.5 Hz); 1.5 (9H,s). G. Standard Procedure for the Synthesis of Tether T136
Figure imgf000220_0001
Pd(OAc)2i P(o-tol)3
80% Et3N, MeCN, 1 10°C
^/ " N B0C2
(135-B)
Figure imgf000220_0002
Boc-T136 136-2
Step 136- 1. To a solution of 2-bromo-4-fluorophenol ( 136-0, 30.0 g, 158 mmol, 1 .0 eq) and protected bromoethanol (136-A, 41.4 g, 173.8 mmol, 1.1 eq) in DMF (Drisolv, 320 mL) were added potassium carbonate (28.0 g, 205.4 mmol, 1.3 eq), potassium iodide (5.24 g, 31.6 mmol, 0.2 eq) at rt. The solution was heated to 55°C and stirred overnight under nitrogen. The mixture was allowed to cool to rt and H20 (400 mL) added. The resulting solution was washed with Et20 (3 x 300 mL). The combined organic layer was washed successively with H20 (2 x 300 mL), saturated aq. NH4C1 (300 mL), brine (300 mL), dried over MgS04, filtered, and the filtrate evaporated to dryness under vacuum. The crude product thus obtained was used without further purification for the next step, but could be purified by flash chromatography (10% Et20/Hex) to give the alkylated phenol as a colorless solid (79 mmol scale, 27.3 g, 99%).
TLC: Rf = 0.69 (10% Et20/Hex; detection: UV, CM A).
Step 136-2. To a solution of crude product from Step 136-1 (55.1 g, 158 mmol, 1.0 eq) in THF (320 mL) was added TBAF (1 M solution in THF, 237 mL, 237 mmol, 1.5 eq). The reaction was stirred overnight at rt, then H20 (300 mL) added and the layers separated. The aqueous phase was washed with EtOAc (2 x 300 mL). The combined organic layer was washed with saturated aq. NH4C1 (300 mL), brine (300 mL), dried over MgS04, filtered, and the filtrate concentrated to dryness under reduced pressure. The crude product was purified by flash chromatography (40% EtO Ac/Hex) to afford 26.0 g (70%, 2 steps) of 136-1 as a pale orange solid (in other batches, 136-1 was obtained as a colorless solid).
TLC: Rf = 0.34 (40% EtOAc/Hex; detection: UV, KMnQ4). Step 136-3. To a flame-dried flask, MeCN (130 mL) was introduced and degassed with multiple argon-vacuum cycles for 30 min. Then, Pd(OAc)2 (715 mg, 3.19 mmol, 0.05 eq), P(o-tol)3 (1.94 g, 6.38 mmol, 0.10 eq), diBoc-allylamine (135-B, 18.0 g, 70.2 mmol, 1.1 eq), Et3N (18 mL, 127 mmol, 2 eq) and 136-1 (15.0 g, 63.8 mmol, 1.0 eq) were added. The solution was stirred at rt and quickly degassed, then heated at 1 10°C for 20 h under argon. The reaction mixture was allowed to cool to rt, quenched with H20 (300 mL), the layers separated, and the aqueous layer washed with Εί20 (2 x 90 mL). The combined organic layers was washed with saturated aq. NH4CI (100 mL), brine (100 mL), dried over MgSC>4, filtered, and the filtrate concentrated to dryness under vacuum to give the crude product which was used with no further purification for the next step, but could be purified by flash chromatography (gradient, 30% to 40% Et20/Hex) to yield 1 1.6 g (80%, 35 mmol scale) of 136-2 as a pale yellow solid.
TLC: Rf = 0.37 (30% EtOAc/Hex; detection: UV, Mn04).
Step 136-4. To a solution of crude 136-2 (26.2 g, 63.8 mmol, 1.0 eq) in DCM (Drisolv, 320 mL) under nitrogen, TFA (9.5 mL, 127.6 mL, 2.0 eq) was added. The solution was stirred at rt for 1.75 h with TLC monitoring. Upon completion, the solvent was evaporated under reduced pressure, and the resulting oil purified by flash chromatography with preadsorption on silica (40% Et207Hex) to afford 10.2 g (51% for 2 steps) of Boc-T136. In a separate experiment, 6.1 g (70%, 28.2 mmol scale) of Boc-T136 was obtained as a pale yellow solid.
TLC: Rf = 0.29 (40% Et20/Hex; detection: UV, KMnOit);
HPLC/MS: Gradient A4, tR = 6.62 min, [M+Na]+ 334;
lH NMR (300 MHz, CDCI3): δ 7.08 (dd, / = 3, 9 Hz, 1H), 6.89-6.76 (m, 3H), 6.17 (dt, J = 6, 16 Hz, 1H), 4.81 (s (br), 1H), 4.06-4.02 (m, 2H), 3.96-3.93 (m, 2H), 3.88 (m (br), 2H), 2.71 (s (br), 1H), 1.45 (s, 9H).
H. Standard Procedure for the Synthesis of Tether T137
Figure imgf000222_0001
1. Br'^/0TBS (136-A)
70% K2C03, l, DMF, 55°C
2. TBAF, THF, 25°C
Figure imgf000222_0002
Boc-7137 137-4 137-3
Step T137-1. To a solution of n-BuLi (1.6 M in hexane, 82.0 mL, 130.8 mmol, 1.1 eq) in THF (dry, freshly distilled from Na-benzophenone ketyl, 450 mL) was added a solution of 3- fluoroanisole (137-0, 15.0 g, 118.9 mmol, 1.0 eq) in THF (dry, 45 mL) dropwise at -78°C under N2 (over -25 min). The solution was stirred at -78°C for 30 min. A solution of I2 (36.1 g, 142.7 mmol. 1.2 eq) in THF (dry, 100 mL) was then added dropwise at -78 °C (addition time: 30 min, the addition funnel was rinsed with THF at the end of the addition). The solution was allowed to warm to -60°C and stirred 45 min with TLC monitoring of the reaction progress. When reaction was complete, H20 (100 mL) was added carefully at -60°C, followed by Na2S03 (10% w/v; 100 mL), and the mixture stirred for 5 min. The aqueous phase was washed with hexane (3x). The combined organic phase was washed with NaHS03 (10% w/v; 2x), H20 (2x), dried over anhydrous MgSC^, filtered, and the filtrate concentrated under reduced pressure to afford a yellow residue. Purification by flash chromatography (10% EtOAc/Hex) gave 25.3 g (84%) of 137-1 as a colorless oil. The crude product could also be used directly for the next step of the sequence.
TLC: Rf =0.34 (5% EtOAc Hex; detection: UV, Mo/Ce);
HPLC/MS: Gradient A4, tR = 6.64 min, M+ 252.
Step T137-2. To a solution of 137-1 (25.0 g, 99.2 mmol, 1.0 eq) in DCM (Drisolv, 100 mL) was added a solution of BBr3 in DCM (1.0 M, 248 mL, 248 mmol, 2.5 eq) dropwise at -30°C under N2 (over -30 min). The solution was stirred at -30°C for 3 h, then allowed to warm to rt overnight. The mixture was cooled to 0°C and MeOH carefully added dropwise (gas generation), followed by addition of H20. The cooling bath was removed and the mixture stirred for 10 min at room temperature. The aqueous layer was separated and washed with DCM. The organic layers were combined, washed with brine (300 mL), dried over anhydrous MgS04, filtered, and the filtrate concentrated under reduced pressure to give a black residue. Purification by flash chromatography (20% EtO Ac/Hex) affords 21.5 g (91%) of 137-2 as a brown oil. The crude oil could also be used directly for the next step of the sequence.
TLC: Rf = 0.35 (20% EtO Ac/Hex; detection: UV, KMn04);
HPLC: Gradient B4, tR = 7.02 min.
Step T137 3. To a solution of 137-2 (18.8 g, 79.07 mmol, 1.0 eq) and protected bromoethanol (136-A, 20.8 g, 87.0 mmol, 1.1 eq) in DMF (Drisolv, 320 mL) were added potassium carbonate (14.2 g, 102.8 mmol, 1.3 eq), potassium iodide (2.62 g, 15.8 mmol, 0.2 eq) at it. The solution was heated to 55°C. and stirred overnight under N2. The mixture was allowed to cool to rt and H20 (500 mL) added. The layers were separated and the aqueous layer washed with Et20 (3 x 300 mL). The organic layers were combined, washed with H20 (2 x 300mL), saturated aq. NH4C1 (300 mL), brine (300 mL), dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The crude oil thus obtained was used with no further purification for the next step.
Step T 137-4. To a solution of the crude oil from step T.137-3 (31.0 g, 79.07 mmol, 1.0 eq) in MeOH (263 mL) was added HC1 (12.1 M, 65 μί, 0.79 mmol, 0.01 eq). The reaction was stirred 2.5 h at rt, then H20 added and the layers separated. The aqueous layer was washed with Et20 (2 x 300 mL). The organic layers were combined, washed with saturated aq. NH4C1 (300 mL), brine (300 mL), dried over MgS04, filtered, and the filtrate concentrated under reduced pressure to give an orange oil. Purification by flash chromatography (40% EtO Ac/Hex) afforded 26.0 g (70%, 2 steps) of 137-3 as a white solid.
TLC: Rf = 0.38 (50% MTBE/Hex; detection: UV, CAM).
Step T 137-5. Into a flame dried flask, MeCN (92 mL) was introduced and degassed with multiple argon-vacuum cycles for 30 min. Then, Pd(OAc)2 (516 mg, 2.30 mmol, 0.05 eq), P(o-tol)3 (1.40 g, 4.61 mmol, 0.10 eq), diBoc-allylamine (135-B, 13.0 g, 50.7 mmol, 1.1 eq), Et3N (13.0 mL, 92.18 mmol, 2 eq) and alcohol 137-3 (13.0 g, 46.1 mmol, 1.0 eq) were added. The solution was stirred at rt and quickly degassed, then heated to 110 °C for 20 h under argon. The reaction mixture was allowed to cool to rt, quenched with H20 (150 mL) and the layers separated. The aqueous layer was washed with Et20 (2 x 90 mL). The organic layers were combined, washed with saturated aq. NH4CI (100 mL), brine (100 mL), dried over MgS04, filtered, and the filtrate concentrated under vacuum to give crude 137-4 which was used without further purification for the next step, but could be purified by flash chromatography (gradient, 30% to 40% Et20/Hex).
TLC: R|- = 0.35 (30% Et20/Hex; detection: UV, KMn04); HPLC : Gradient A4 , tR = 8.54 min.
Step T137-6. To a solution of crude 137-4 (7.0 g, 17.0 mmol, 1 .0 eq) in DCM (Drisoiv, 90 mL) under nitrogen, TFA (1.90 mL, 127.6 mL, 2.0 eq) was added and the solution stirred at it for 1.75 h with TLC monitoring. More TFA (0.5 eq) could be added if reaction was not complete. When complete, the solvent was evaporated under reduced pressure, and the resulting oil purified by flash chromatography with pre-adsoiption on silica (gradient, 40% to 50% Et20/Hex) to afford 3.71 g (70%) of Boc-T137 as a white solid after trituration with hexanes.
TLC: Rr = 0.30 (40% Et20/Hex; detection: UV, KMn04);
HPLC/MS: Gradient A4, tR - 6.71 min, [M+Naf 334;
Ή NMR (300 MHz, CDCI3): δ 7.15-7.087 (m, 1H), 6.74-6.52 (m, 4H), 4.74 (s (br), 1H), 4.13-4.09 (m, 2H), 4.00-3.97 (m, 2H), 3.92 (t (br), J - 5 Hz, 2H), 1.93 (s (br), 1H), 1.46 (s, 9H).
I. Standard Procedure for the Synthesis of Tether T138
Figure imgf000224_0001
Boc-T138
Step T138-1. To a solution of 2,3-difluoro-6-bromophenol (138-0, 25 g, 120 mmol, 1.0 eq) and 135-A (48.6 g, 239 mmol, 1.7 eq) in dry DMF (535 mL) were added potassium carbonate (19.8 g, 144 mmol, 1.2 eq) and potassium iodide (4.0 g, 24 mmol, 0.2 eq). The solution was heated to 55°C and stirred overnight under nitrogen. The solvent was removed under reduced pressure until dryness, then the residual oil diluted with water and extracted with diethyl ether (3x). The organic phase were combined and washed with citrate buffer (2x) and with brine (lx). The organic phase was dried over anhydrous MgS04, filtered, and the filtrate concentrated under vacuum to give 138-1 as a brown solid (32 g), which was used without further purification for the next step.
TLC: R,: 0.83 (30%/70% EtO Ac/Hex); detection: UV, Mn04);
HPLC/MS: Gradient A4, tR = 13.87 min, [M+H+2]+ 369.
Step T138-2. To a solution of 138-1 (30.2 g, 120 mmol, 1.0 eq) in THF (600 mL), TBAF (1.0 M solution in THF, 240 mL, 240 mmol, 2.0 eq) was added. The reaction was stirred for 1 h at RT. The mixture was diluted with diethyl ether, washed with saturated aqueous ammonium chloride solution (l ) and brine (lx). The organic phase was dried over anhydrous MgS04, filtered, and the filtrate concentrated under vacuum. The residue was purified by flash chromatography (25% EtO Ac/Hex) to provide 138-2 as a colorless oil (27.2 g, 90%, 2 steps).
TLC: Rf: 0.27 (30%/70% EtOAc/Hex); detection: UV, KMnC¼);
HPLC: Gradient A4, tR = 5.73 min.
Step T138-3. A solution of 138-2 (10.63 g, 40.0 mmol, 1.0 eq) in acetonitrile (84 mL) was degassed using the following cycle: vacuum, nitrogen, vacuum, nitrogen. To this were added palladium acetate (472 mg, 0.05 eq) and P(o-tol)3 (1.38 g, 0.1 eq). The mixture was degassed once again, then triethylamine (11.8 mL, 79 mmol, 2.0 eq) and 135-B (11.8 g, 43 mmol, 1.1 eq) added. The solution was stirred at 110°C O/N. Water was then added and the aqueous phase extracted with ethyl acetate (4x). The combined organic phase was washed with water and brine, dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue thus obtained was purified by flash chromatography (30% EtOAc/Hex) to yield 138-3 as a golden syrup (12.4 g, 73%).
TLC: Re: 0.28 (40%/60% EtOAc/Hex); detection: UV, KMn04);
HPLC/MS: Gradient A4, tR = 9.06 min, [M+Naf 452.
Step T138-4. To a solution of 138-3 (11.53 g, 27.0 mmol, 1.0 eq) in DCM (135mL) under nitrogen was added TFA (3.0 mL, 40 mmol, 1.5 eq). The reaction was stirred at RT until completion and then the solvent evaporated to dryness under reduced pressure. The residue was purified by flash chromatography (30% EtOAc/Hex) to give Boc-T ! 38 as a yellow solid.
TLC: Rf: 0.25 (40%/60% EtOAc/Hex); detection: UV, M11O4);
HPLC/MS: Gradient A4, tR = 6.83 min, [M]+ 329, [2M+H]+ 559;
Ή NMR (CTX¾): δ 7.2 (1H, dd, J=11.2 and 8.9Hz); 6.77 to 6.66 (2H, m); 6.13 (1H, dt, J=15.9, 6.2Hz); 4.71 (1H, bs); 4.06 to 4.01 (2H, m); 4.01 to 3.93 (2H, m); 3.92 to
3.85 (2H, m); 2.21(lh, bs); 1.46 (9H, s). J. Standard Procedure for the Synthesis of Tether T139
Figure imgf000226_0001
Cul, PdCi2(PhCN}2,
iBu3PHBF4 , NHBoc DIPA, dioxane, 139-B
rt, O/N, Ar
Figure imgf000226_0002
Step T139-1: To a solution of bromide 139-0 (25 g, 120 mmol, 1 ,0 eq) and protected bromoethanol 139- A (48,6 g, 239 mmol, 1.7 eq) in dry DMF (535 mL) were added potassium carbonate (19.8 g, 144 mmol, 1.2 eq) and potassium iodide (4.0 g, 24 mmol, 0.2 eq). The solution was heated to 55°C, then stirred overnight under nitrogen. The solvent was removed under reduced pressure, then the residual oil diluted with water and extracted with Et20 (3x). The organic phases were combined and washed with citrate buffer (2x) and brine (lx). The organic phase was dried over anhydrous MgS04, filtered, then the filtrate concentrated under vacuum. The crude product 139-1 (32 g) was thus obtained as a brown solid and used without further purification for the next step.
TLC: Rf: 0.83 (30/70 EtO Ac/Hex; detection: UV, KMn04);
HPLC/MS: Gradient A4, tR = 13.87 min, [M+2f 368,
Step T139-2: To a solution of 139-1 (30.2 g, 120 mmol, 1.0 eq) in THF (600 mL), TBAF (1.0 M solution in THF, 240 mL, 240 mmol, 2.0 eq) was added. The reaction was stirred for 1 h at room temperature. The mixture was then diluted with Et20, washed with saturated aqueous ammonium chloride solution (2x) and brine (lx). The organic phase was dried over anhydrous MgS04, filtered, then the filtrate concentrated under vacuum. The crude residue was purified by flash chromatography (25% EtOAc/Hex) to give the alcohol 139-2 as a colorless oil (27.2 g, 90% 2 steps).
TLC: Rf: 0.27 (30/70 EtO Ac/Hex; detection: UV, KMn0 ).
Step T139-3: Into a solution of alcohol 139-2 (10 g, 40 mmol, 1.0 eq), Boc-propargylamine 139-B (10.4 g, 68 mmol, 1.7 eq) in dioxane (ACS grade, 40 mL) was bubbled argon for 15- 20 min. Then, tBu3PHBF4 (454 mg, 0.03 eq), recrystallized copper (I) iodide (150 mg, 0.02 eq), dichlorobis(benzonitrile) palladium (II) (150 mg, 0.02 eq) and diisopropylamine (9.5 mL, 67 mmol, 1.7 eq) were added and the reaction mixture stirred at it overnight under argon. The solution was diluted with EtOAc, filtered through a silica gel pad and washed with ethyl acetate until no more material was eluting. The filtrate was concentrated under reduced pressure, then the crude residue purified by flash chromatography (30% EtOAc/Hex to give the alkyne 139-3 as a golden syrup (8.3 g, 70%).
TLC: Rf: 0.28 (30/70 EtOAc/Hex; detection: UV, KMn04);
HPLC/MS : Gradient A4, tR = 6.71 min, M+ 327.
Step T 139-4: To a solution of alkyne 139-3 (8.3 g, 25 mmol, 1.0 eq) in 95% ethanol (241 mL) under nitrogen was added palladium on carbon (5.7 g, 50% water) and then hydrogen bubbled into the mixture overnight. When the reaction was complete as indicated by Ή NMR, nitrogen was bubbled through the mixture for 10 min to remove excess hydrogen. The solvent was filtered through a Celite pad and washed with ethyl acetate until no further material was eluting. The filtrate was concentrated under reduced pressure. The resulting crude residue was purified by flash chromatography (30% EtOAc/Hex) to give Boc-T139 as a yellowish oil (7.65 g, 90%).
TLC: Rf: 0.13 (25/75 EtOAc/Hex; detection: UV, ninhydrin);
HPLC/MS: Gradient A4, tR = 6.91 min, M+ 331 ;
Ή NMR (300 MHz, CDC13): δ 6.85-7.0 (m, ] H,), 6.6-6.7 (m, 1H,), 4.9-5.0 (m, Ϊ Η), 3.95-4.1 (m, 4H), 3.15-3.2 (m, 2H), 2.9-3.0 (m, 1 H), 2.55-2.65 (m, 2H), 1.75-1.95 (m, 2H), 1.45 (s, 9H).
K. Standard Procedure for the Synthesis of Tether T140
Figure imgf000227_0001
Step T 140-1 . To a solution of bromide 140-0 (25 g, 120 mmol, 1.0 eq) and protected bromoethanol 140-A (48.6 g, 239 mmol, 1.7 eq) in dry DMF (535mL) were added potassium carbonate (19.8 g, 144 mmol, 1.2 eq) and potassium iodide (4.0 g, 24 mmol, 0.2 eq). The solution was heated to 55°C and stirred overnight under nitrogen. The solvent was removed under reduced pressure until dryness, then the residual oil diluted with water and extracted with Et20 (3x). The organic phases were combined, washed with 1M citrate buffer (2x) and brine (lx), dried over anhydrous MgS04, filtered, then the filtrate concentrated under vacuum. The crude product 140-1 (32 g) thus obtained was a brown solid and used without further purification for the riext step.
TLC: Rf: 0.83 (30/70 EtO Ac/Hex; detection: UV, KM11O4);
HPLC/MS: Gradient A4, tR = 13.87 min, [M+2J+ 368.
Step T 140-2. To a solution of crude protected alcohol 140-1 (30.2 g, 120 mmol, 1.0 eq) in THF (600 mL) was added TBAF (1.0 M solution in THF, 240 mL, 240 mmol, 2.0eq). The reaction was stirred for 1 h at rt. The reaction mixture was diluted with Et20, washed with saturated ammonium chloride solution (2x) and brine (lx). The organic phase was dried over anhydrous MgS04, filtered, then the filtrate concentrated under vacuum. The crude residue was purified by flash chromatography (25% EtOAc/Hex) to give the alcohol 140-2 as a colorless oil (27.2 g, 90% for 2 steps).
TLC: Rf: 0.27 (30/70 EtO Ac/Hex; detection: UV, Mn04).
Step Tl 40-3. To a solution of alcohol 140-2 (9.5 g, 38 mmol, 1.0 eq) and 140-B (10.82 g, 64 mmol, 1.7 eq) in dioxane (ACS grade, 38 mL) was bubbled argon for 15-20 min. Then, tBu PFIBF4 (707 mg, 0.07 eq), recrystaliized copper (I) iodide (143 mg, 0.02 eq), dichlorobis(benzonitrile) palladium (II) (431 mg, 0.03 eq) and diisopropy!aminc (9.5 mL, 67 mmol, 1.7 eq) were added and the reaction mixture was stirred at rt overnight under argon. The solution was diluted with EtOAc, filtered through a silica gel pad and washed with ethyl acetate until no more material was eluting. The solvent was removed under reduced pressure, then the crude product purified by flash chromatography (30% EtOAc/Hex) to give the alkyne 140-3 as a golden syrup. (6.5 g, 54%).
TLC: Rf: 0.28 (30/70 EtOAc/Hex; detection: UV, KMn04);
HPLC/MS: Gradient A4, tR = 7.01 min, M+ 341.
Step T 140-4. To a solution of alkyne 140-3 (6.2 g, 18 mmol, 1.0 eq) in 95% ethanol (171 mL) under nitrogen was added palladium on carbon (4.04 g, 50% water), then hydrogen gas bubbled into it overnight. When the reaction was complete as indicated by Ή NMR, nitrogen was bubbled through the reaction for 10 min to remove the excess hydrogen. The solvent was filtered through a Celite pad and washed with ethyl acetate until no more material was eluting. The filtrate was concentrated under reduced pressure and the crude product purified by flash chromatography (30% EtOAc/Hex) to give Boc-T140a as a yellowish oil (4.63 g, 75%).
TLC: Rf: 0.13 (25/75 EtO Ac/Hex; detection UV, ninhydrin);
HPLC/MS: Gradient A4, tR = 7.81 min, M+ 345;
Ή NMR (300 MHz, DMSO): δ 6.8-7.0 (m, 1H,), 6.0-6.7 (m, 1H,), 4.5-4.65 (m, 1H), 3.85-4.1 (m, 4H), 3.55-3.75 (m, 1H), 3.2-3.35 (m, 1H), 2.6-2.7 (m, 1 H), 2.4-2.6 (m, 1H), 1.8-2.0 (m, 1 H) 1.45 (s, 9H), 1.15 (d, 3H, J=6.6Hz).
Use of 140-C, the enantiomer of 140-B, in the same sequence can be used to provide the enantiomeric tether Boc-T140b.
Figure imgf000229_0001
Boc-T140b
L. Standard Procedure for the Synthesis of Tether T141
Figure imgf000229_0002
Step T141-l. To a solution of the nitrile 141-1 (6.0 g, 18.7 mmol, 1.0 eq) in THF (93.5 mL) was added a solution of 10 M B¾-DMS (2.8 mL, 28.1 mmol, 1.5 eq) and the resulting mixture stirred at reflux overnight. Progress of the reaction was monitored by TLC (20% EtOAc/Hex; detection: UV, ninhydrin; the product amine was at the baseline). Once completed, the solution was cooled to 0°C and MeOH added slow!y to quench the excess BH3. The mixture was stirred 1 h at rt, then Et3N (3.9 mL, 28. 1 mmol, 1.5 eq) and (Boc)20 (5.1 g, 22.4 mmol, 1.2 eq) added. The resulting mixture was stirred at rt 3 d with monitoring of the reaction by TLC (20% EtO Ac/Hex; detection: UV, ninhydrin; Rf = 0.15). A saturated aqueous solution of NH4CI was then added slowly and the layers separated. The aqueous phase was extracted with EtOAc and Che combined organic phase was dried over MgS04, filtered and the filtrate concentrated in vacuo. The residue was purified by flash chromatography (gradient, 20% to 40% EtOAc/Hex) to give 141-2 as yellow oil (4.8 g, 53%).
HPLC/MS: Gradient A4, tR = 1 1.86 min, [M+H 426.
Step T141-2. To a solution of 141-2 (1.7 g, 4.00 mmol, 1 .0 eq) in DCM (20 mL) were added H20 (81 pL, 4.50 mmol, 1.125 eq) and Dess-Martin periodinane (2.1 g, 5.0 mmol, 1.25 eq). The resulting mixture was stirred at rt 25 min. Progress of the reaction was monitored by TLC (15% EtOAc/Hex; detection: UV, Mo/Ce; Rf = 0.48.) An aqueous sodium thiosulfate solution (10%, 25 mL) was added slowly. The aqueous phase was separated and the organic phase washed with aqueous sodium thiosulfate (10%, 2 x 25 mL)., dried over MgSC>4, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (gradient, 5% to 15% EtOAc/Hex) to provide 141-3 as colorless oil (1.4 g, 82%).
HPLC/MS: Gradient A4, tR = 12.38 min, [M+NaJ+ 446.
Step T141 -3. To a solution of 141-3 (1.4 g, 3.30 mmol, 1.0 eq) in DCM (26 mL) were added trimethyl orthoformate ( 1.1 mL, 9.90 mmol, 3 eq), ethylene glycol (1.8 mL, 33.0 mmol, 10 eq) and APTS (62 mg. 0.33 mmol, 0.1 eq). The resulting mixture was stirred at rt for 20 h. Progress of the reaction was monitored by TLC (40% EtOAc/Hex; detection: UV, Mo/Ce; Rf = 0.14.) and HPLC. A saturated aqueous solution of NaHCO^ (30 mL) was added and the resulting aqueous phase extracted with DCM (3 x 30 mL). The combined organic phase was dried over MgS04, filtered, and the filtrate concentrated in vacuo. The residue was purified by flash chromatography (gradient, 40% to 60% EtOAc/ Hex) to give the Boc-T141 as a colorless oil (1.1 g, 92%).
HPLC/MS: Gradient A4, tR = 6.45 min, M+ 353;
1H MR (CDCI3, ppm): δ 7.42 (dd, J = 7.61, 1.76 Hz, 1H), 7.27 (dt, J - 7.79, 7.76, 1.80 Hz, 1H), 7.00-6.85 (m, 2H), 4.97 (br, 1H), 4.20-3.65 (m, 9 H), 3.17 (dd, J = 12.04, 5.98 Hz, 2H), 2.34 (t, J = 6.43, 6.43 Hz, 2H), 1.42 (s, 9 H). M. Standard Procedure for the Synthesis of Tether T142
Figure imgf000231_0001
Step 142-1. To a solution of 142-1 (4.2 g, 9.9 mmol, 1.0 eq) in DCM (49.5 mL) was added H20 (200 LiL, 1 1.1 mmol 1.13 eq) and Dess-Martin periodinane (6.28 g, 14.8 mmol, 1.5 eq). The reaction was stirred 2 h at rt. A second portion of Dess-Martin periodinane was added (1.05 g, 2,5 mmol, 0,25 eq) was added and the reaction was stirred an additional 2 h. The resulting white precipitate was removed by filtration and rinsed with DCM. The filtrate and rinses were combined and washed with an aqueous solution of 10% sodium thiosulfate, dried over MgS04, filtered, and the filtrate concentrated to dryness in vacuo. The residue was purified by flash chromatography (gradient, 10% to 15% to 20% EtOAc/Hex) to obtain 142-2 as a white solid (3.4 g, 82.8%).
HPLC/MS : Gradient A4, tR = 12.17 min, [M+Naf 446.
Step 142-2. To a solution of 142-2 (3.46 g, 8.2 mmol, 1.0 eq), trimethylorthoformate (2.7 mL, 24.5 mmol, 3.0 eq) and ethylene glycol (4.8 mL, 81.8 mmol, 10,0 eq) in DCM (41 mL) was added PTSA (154 mg, 0.81 mmol, 0.1 eq) and the reaction stirred for 4 h at rt. An aqueous solution of NaHC03 (satd.) was added and the organic phase separated. The aqueous phase was extracted with DCM (2x) and the combined organic phase dried over MgS04, filtered, and the filtrate removed in vacuo. The residue was purified by flash chromatography (gradient, 40%, 50%,60% 75% EtOAc/Hex) to provide Boc-T142 as a white solid (2.18 g, 75.6%).
HPLC MS: Gradient A4, tR = 6.39 min, [M+H]+ 354;
Ή NMR (CDC13, ppm): δ 7.29-7.17 (2H, m), 6.93-6.84 (2H, m), 5,00 (1H, bs), 4.15- 4.08 (3H, bm), 3.98-3.85 (5H, m), 3.64 (1H, bs), 3.28 (1 H, bd), 3,10 (2H, m), 1.45 (9H, s). N. Standard Procedure for the Synthesis of Tether T143
Figure imgf000232_0001
Figure imgf000232_0002
Step T143-1. NaH (60% in mineral oil, 2,32 g, 58 mmol, 1.0 eq) was added portion-wise to a well-stirred solution of 2-hydroxyphenethyl alcohol (143-0, Aldrich, 8.0 g, 58 mmol, 1.0 eq) in DMF (200 mL) at 0°C under a nitrogen atmosphere. Stirring was continued for 10 min at 0°C, then the bromoalkane (143-A, 20.8 g. 87 mmol, 1.5 eq) added, followed by Kl (1.9 g, 11.6 mmol, 0.2 eq), and the reaction stirred overnight allowing it to warm gradually to rt. HPLC can be used to monitor disappearance of the alcohol starting material. The solution was concentrated in vacuo (vacuum pump, bath T ca. 50°C), then EtOAc (300 mL) added. The organic phase was washed with saturated aqueous NaHCO¾ (2 x 100 mL), water (1 x 100 mL), brine (1 x 100 mL), then dried (MgS04), filtered and the filtrate concentrated under reduced pressure. The resulting liquid residue was purified by flash chromatography (20% EtOAc/Hex) to yield 10.2 g (59%) of 143-1 as a slightly yellow liquid. This reaction was also performed from 863 μί of alcohol to afford 1.70 g of product (83%). The alkylation was also performed with K2C03 as a base and heating at 70 °C to give 143-B 1 in 57% yield.
TLC: Rf = 0.29 (20% EtOAc/Hex; detection: UV, KMn04);
HPLC/MS: Gradient A4, tR = 9.50 min, [M+Hf 297.
Step T143-2. Tosyl chloride (7.61 g, 39.9 mmol, 1.05 eq) was added portion-wise to a stirred solution of 143-1 (11.3 g, 38.0 mmol, 1.0 eq), DMAP (464 mg, 3.8 mmol, 0.1 eq) and triethylamine (5.81 mL, 41.8 mmol, 1.1 eq) in dichloromethane (127 mL) at 0°C under a nitrogen atmosphere. Stirring was continued for 2 h at 0°C (during which some salts precipitated), then 1 h at rt. When TLC monitoring indicated that all 143-1 was exhausted, 100 mL of dichloromethane were added and the solution washed with saturated aqueous NaHC03 (2 x 100 mL), water (1 x 100 mL), brine (1 x 100 mL), then dried (MgS04), filtered and the filtrate concentrated under reduced pressure. The liquid residue was purified by flash chromatography (20% EtO Ac/Hex) to afford 14.6 g (85%) of 143-2 as a yellow syrup. This reaction was also performed from 100 mg of alcohol to provide 138 mg of product (91%).
TLC: Rf = 0.35 (20% EtO Ac/Hex; detection: UV, KMn04);
Ή-NMR (CDC13, 300 MHz): δ 0.06 (6H, s), 0.89 (9H, s), 2.42 (3H, s), 2.97 (3H, t, J
= 7.0), 3.85-3.95 (4H, stack), 4.12 (2H, t, J = 7.0), 6.75-6.87 (2H, m), 7.04-7.09 (1H, m), 7.14-7.25 (3H, m), 7.63-7.69 (2H, m).
Step T143-3. 143-B (see synthesis following, 6.82 g, 46.7 mmol, 1.44 eq) was added in one portion to a solution of 143-2 (14.6 g, 32.4 mmol, 1.0 eq), KI (13.5 g, 81 mmol, 2.5 eq) and diisopropylethylamine (8.46 mL, 48.6 mmol, 1.5 eq) in DMF (65 mL). The resulting suspension was stirred in an Ace Tube (Ace Glass, Inc., 150 mL capacity) at rt for 30 min under vacuum to degas DMF. The screw cap (Teflon coating) was replaced and the reaction heated to 100°C overnight with stirring (upon heating, the suspension becomes a solution), after which HPLC indicated disappearance of the tosylate. The solution was cooled (some salts precipitated at rt) and saturated aqueous NaHC03 added (300 mL). This was extracted with EtOAc (3 x 100 mL) and the combined organic layer washed with brine (50 mL), dried (MgS04), filtered and the filtrate concentrated in vacuo (vacuum pump to remove residual DMF). Purification by flash chromatography (20% EtOAc/Hex) afforded 2.70 g (20%) of 143-3 as a yellow oil. This reaction was also performed from 138 mg of 143-2 to give 89 mg of product (68%),
TLC: Rf = 0.35 (20% EtOAc/Hex; detection: UV, KMn04);
FIPLC/MS: Gradient A4, tR = 8.09, 11.05 min (possible rotamers), [M+H]+ 425;
1H NMR (CDC13, 300 MHz): δ 0.10 (6H, s), 0.91 (9H, s), 1.46 (9H, s), 2.17 (2H, s),
2.60 (2H, s), 2.85 (3H, s), 3.98-4.05 (4H, stack), 5.60-5.75 (1H, br s), 6.80-6.90 (2H, m), 7.13-7.19 (2H, m).
Step T143-4. TBAF (1M in THF, 7.0 mL, 7.0 mmol, 1.1 eq) was added dropwisc to a stirred solution of 143-3 (2.70 g, 6.36 mmol, 1.0 eq) in THF (32 mL) at 0°C. Stirring was continued for 2 h at 0°C at which time TLC indicated no remaining starting material. The solution was concentrated in vacuo (bath T, rt) and the resulting yellow oil purified by flash chromatography (gradient, 10%, 50%, 70% EtOAc/Hex) to yield 143-4 as a slightly yellow oil that solidifies upon refrigeration (1.72 g, 87%). This reaction was also performed from 89 mg of 143-3 to afford 61 mg of product (94%).
TLC: Rf = 0.10 (20% EtOAc/Hex; detection: UV, KMn04);
HPLC/MS: Gradient A4, tR = 5.72 min, [M+H]+ 31 1 ; Ή-NMR (CDCi3, 300 MHz): δ 1.47 (9H, s), 2.63 (3H, br s), 2.80-2.95 (4H, stack), 3.09-3.25 (1H, br s), 3.95-4.03 (2H, br s), 4.64-4.10 (2H, m), 5.75-5.79 (1H, br s), 6.81-6.92 (2H, m), 7.12-7.21 (2H, m).
O. Standard Procedure for the Synthesis of Reagent 143-B
Boc20
H2N~NH2 x H20 H2
isopropanoi
143-B1 0 °C
Figure imgf000234_0001
NaBH3CN (2.0 eq)
eOH/AcOH (9: 1 )
Figure imgf000234_0002
Step T143-5. Polyhydrated hydrazine (143-Bl, Aldrich, contains an unknown amount of water; 47 g, approximately 734 mmol, 1.0 eq) was stirred in isopropanoi (188 mL) at 0°C for 15 min. Boc20 (80 g, 367 mmol, 0.5 eq) in isopropanoi (94 mL) was then added dropwise to the first solution at 0°C. The solution turned cloudy upon addition of this second solution and gas evolution was observed. This was stirred 20 min at 0°C, then concentrated in vacuo (bath T, 45°C); the solution became clear upon heating. Dichloromethane (200 mL) was added to the residue and the solution dried over MgS04, filtered, and the filtrate concentrated in vacuo to provide 46.7 g of 143-B2 as a colorless syrup that solidified upon storage in the refrigerator. This was typically pure enough (TLC, Ή N R) to use in the next step. Flash chromatography (MeOH dichloro methane) could also be performed to provide highly pure samples.
Ή-NMR (CDCI3, 300 MHz): δ 1.41 (9H, s), 3.69 (2H, br s), 5.80 (1H, br s).
Step T143-6. Benzaldehyde (35.7 mL, 353 mmol, 1.0 eq) was added dropwise to a stirred suspension of 143-B2 (46.7 g, 353 mmol, 1.0 eq) and powdered 4 A molecular sieves (Aldrich-activated, used as received, 9.3 g, 20% by weight) in dichloromethane (1 L) using a round-bottom flask fitted with a rubber septum. The reaction was monitored by Ή NMR of removed aliquots and after 5 h showed completion. The sieves were removed by filtration and the filtrate concentrated in vacuo, with the product precipitating during evaporation, to afford 143-B3 as a white solid (78.1 g, quantitative) that was sufficiently pure to be used as such in the next reaction.
TLC: Rt■ = 0.70 (5% MeOH/CH2Cl2; detection: Mn04, UV). Step T 143-7, Sodium cyanoborohydride (44.4 g, 706 mmol, 2.0 eq) was added portion-wise to a stirred solution of 143-B3 (78.1 g, 353 mmol, 1.0 eq) in MeOH/AcOH (9/1 , 1 L) at rt. The cloudy solution clears slowly upon addition of 143-B3 and was accompanied by H2 evolution. The reaction was stirred overnight at rt (TLC and Ή NMR showed completion). This was concentrated to dryness in vacuo (with at least one co- evaporation with toluene to remove AcOH) and the residue dissolved in saturated aqueous NaHC03 (900 mL). The aqueous layer was extracted with CH2C12 (3 x 300 mL) and the combined extracts were dried (MgS0 ), filtered, and the filtrate concentrated in vacuo to give 143-B4 as a colorless syrup (60.4 g, 76%) that was sufficiently pure by TLC and NMR to be used as such in the next step.
TLC: Rf = 0.45 (2% MeOH/CH2Cl2; detection: KMn04, UV);
1H-NMR (CDC13, 300 MHz): S 1.42 (9H, s), 3.98 (2H, s), 6.01 (1H, br s), 7.24-7.41 (5H, stack).
Step T143-8. Paraformaldehyde (27 g, 270 mmol, 2,0 eq), sodium cyanoborohydride (21 g, 337 mmol, 2.5 eq) and AcOH (7.73 mL, 135 mmol, 1 .0 eq) were successively added to a stirred solution of 143-B4 (30 g, 135 mmol, 1 .0 eq) in MeOH (450 mL) in a round-bottom flask fitted with a rubber septum at rt. The reaction was stirred overnight at rt at which time Ή NMR of a removed aliquot showed a complete reaction (it was difficult to follow by TLC). This was concentrated in vacuo (bath T ca. 30 °C) to give a white gum that was dissolved in saturated aqueous NaHC03 (1 L). The aqueous layer was extracted with CH2CI2 (3 x 500 mL), dried (MgS04), filtered, and the filtrate concentrated under reduced pressure to afford 12.1 g (38%) of 143-B5 as a white solid which was shown by NMR and TLC to be sufficiently pure to be used as such.
TLC: Rf = 0.35 (2% MeOH/CH2Cl2; detection: KMn04, UV);
Ή NMR (CDCI3, 300 MHz): δ 1.40 (9H, s), 2.61 (3H, s), 3.92 (2H, br s), 4.02 (1H, br s), 5.42 ( 1H, br s), 7.26-7.40 (5H, stack).
Step T143-9. Argon was bubbled thru a solution of 143-B5 ( 12.1 g, 51 .3 mmol, 1.0 eq) in absolute ethanol (256 mL) at rt for 30 min. 10% Pd/C (2.72 g, 2.56 mmol, 0.05 eq) was then added carefully to the stirred solution and hydrogen bubbled through the mixture for 30 min. After this, a balloon of ¾ was fitted over the rubber septum-sealed round-bottom flask and the reaction stirred overnight at rt. Filtration through a pad of Celite, washing with 10% MeOH in CH2CI2, followed by concentration of the filtrate in vacuo afforded 143-B (7.49 g, 91%) as a colorless oil that solidified upon standing. 1 H NMR and TLC showed that this material was pure enough to be used as obtained.
TLC: R| = 0.60 (2% MeOH/CH2Cl2; detection: KMn0 , UV); Ή-NMR (CDCI3, 300 MHz): δ 1.41 (9H, s), 2.61 (3H, s), 6.01 ( l H, b ).
P. Standard Procedure for the Synthesis of Tether T144
Figure imgf000236_0001
59-4 Boc-T144b
Step T 144- 1. To a solution of 59-4 (synthesized as described in the standard procedure for T59, 4.0 g, 9.4 mmol, 1.0 eq) in Mel (37.6 mL) was added Ag20 (21.8 g, 94 mmol, 10 eq) and the reaction stirred 2 d at rt. The solids were removed by filtration and rinsed with Mel. To the filtrate was added a second portion of Ag20 (21.8 g, 94 mmol, 10 eq) and the reaction stirred an additional 2 d. Monitoring of the reaction was done by TLC (3/7, EtOAc/Hex). The solution was filtered and the residue rinsed with DCM The filtrate was concentrated in vacuo and the crude residue purified by flash chromatography (gradient, 20% to25% EtOAc/Hex) to give the protected methyl ether intermediate (2.2 g, 53.3%). In addition, some starting material was recovered (1.6 g).
HPLC/MS: Gradient A4, tR = 13.54 min, [M+H]+ 440.
Step T 144-2. To a solution of the protected methyl ether intermediate (2.2 g, 5.0 mmol, 1.0 eq) in THF (20 mL) was added a solution 1.0 M TBAF in THF (7.5 mL,7.5 mmol, 1.5 eq) and the reaction stirred 1.5 h at rt. Brine was added and the aqueous phase extracted with MTBE (3x). The combined organic phase was dried over MgSC , filtered and the filtrate concentrated to dryness in vacuo. The residue was purified by flash chromatography (gradient, 1/1 to 3/2 EtOAc/Hex) to provide Boc-T144b (1.6 g, 100%).
HPLC/MS: Gradient A4, tR = 6.43 min, [M+Hf 326;
Ή NMR (CDC13, pp ): δ 7.22-7.16 (2H, m), 6.93-6.83 (2H, m), 5.05 (1H, bs), 4.16- 4.07 (3H, m), 4.00-3.98 (2H, m), 3.59 (1 H, bs), 3.33 (3H, s), 3.06-2.9 (1H, m), 2.90- 2.79 (2H, m), 1.44 (9H, s).
The enantiomeric tether, Boc-T144a, can be accessed from the enantiomeric precursor 59-5.
As previously indicated, this compound is in turn synthesized as described for 59-4, but using
AD-mix a.
Figure imgf000237_0001
59-5 Boc-T1 4a
Q. Standard Procedure for the Synthesis of Tether T145
Figure imgf000237_0002
1 ) Bn2NH*HCI
(CH20)x, AcOH, 60°C, 5 h
2} LAH, THF, -78°C, 2 h
3) Hz , 0% Pd/C, 95%ESOH/AcOH (9: 1)
RT, 3 d
Figure imgf000237_0003
Step T145-1. To a solution of 7-hydiOxyindanone (145-0, 2.0 g, 13.5 mmol, l.Oeq) and benzyl 2-bromoethyl ether (145-A, 3.16 mL, 20.3 mmol, 1.5 eq) in DMF (Drisolv, 50 mL) were added potassium carbonate (2.33 g, 16.9 mmol, 1.25 eq) and potassium iodide (448 mg, 2.70 mmol, 0.20 eq). The solution was heated to 55°C and stirred overnight under nitrogen. The reaction was diluted with water (200 mL) and the mixture extracted with ethyl acetate (3 x 50 mL). The organic phases were combined, dried with magnesium sulfate, filtered, and the filtrate evaporated to dryness under reduced pressure. The residue was purified by flash chromatography (30% EtOAc/Hex) to give 145-1 (3.08, 81%) as a white solid.
Step T145-2. Dibenzylamine (2.6 mL, 13.6 mmoi, 1.25 eq) was dissolved in methanol (30 mL), then hydrochloric acid (4 M in dioxane, 5 mL, 20 mmol, 16 eq) added. The mixture was concentrated under reduced pressure to give dibenzylamine hydrochloride. This material was dissolved in acetic acid (40 mL), 145-1 (3.08 g, 10.9 mmol, 1.0 eq) and paraformaldehyde (425 mg, 14.2 mmol, 1.3 eq) added, and the mixture stirred at 60°C for 5 h. The reaction was concentrated under reduced pressure, then DCM (50 mL) added and the mixture treated with a saturated aqueous solution of sodium bicarbonate until a pH of 9 was attained. The aqueous layer was discarded and the organic layer dried over magnesium sulfate, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (10% MTBE/toluene) to give 145-2 as a yellowish oil. Although this material contained dibenzylamine, it was suitable for use in the next step.
HPLC MS: Special conditions, tR = 5.63 min, [M+H]+ 492.
Step T145-3. 145-2 (4.47 g, 9.10 mmol, 1.0 eq) was dissolved in THF (75 mL), cooled to - 78°C, then treated with LAH (0.175 g, 4.55 mmol, 0.5 eq) for 2 h. At that time, a 20% aqueous solution of potassium hydroxide (50 mL) was added and the mixture extracted with ethyl acetate (3x). The combined organic phase was dried over magnesium sulfate, filtered, and the filtrate concentrated under reduced pressure to give 145-3. Since the product and the starting material are not distinguishable by TLC or HPLC analysis, MS analysis must be checked for completion of the reaction.
HPLC/MS: Special conditions, tR = 5.70 min, [M+H]+ 494.
Step T145-4. 145-3 (3.78 g) from the previous step was dissolved in a mixture of 95% ethanol and acetic acid (100 mL, 9: 1). Palladium on charcoal (3.78 g, 10% w/w, 50% wet) and the mixture submitted to 1 atmosphere of hydrogen gas (atmospheric pressure). After 3 d, the mixture was filtered through Celite and the filter cake washed with acetic acid and 95% ethanol. The solvent was removed under reduced pressure with low heat (bath T < 40°C) to obtain 145-4.
HPLC/MS: Special conditions, tR = 2.34 min, [M+H]+ 224.
Step T 1.45-5. 145-4 as obtained from the previous step was dissolved in DCM (80 mL), palladium on charcoal (500 mg, 10% w/w, 50% wet) and p-toluene sulfonic acid (2.9 g, 15.34 mmol, 2 eq) added and the mixture submitted to 1 atmosphere of hydrogen gas (atmospheric pressure). After 2 h, the mixture was filtered through Celite and the filter cake washed with a mixture of THF and water (200 mL, 1: 1). Sodium carbonate (4.3 g, 40.1 mmol, 5.3 eq) was added and the organic solvents were removed under reduced pressure to leave an aqueous solution of the amino acid 145-5. Disappearance of the starting material was determined by HPLC analysis.
HPLC/MS: Special conditions, tR = 2.95 min, LM+H]+ 208.
Step T145-6. To the aqueous solution of 145-4 were added THF (100 mL) and Boc20 (2.5 g, 11.5 mmol, 1.5 eq). The mixture was stirred for 3 h, then diluted with a saturated aqueous ammonium chloride solution (400 mL), The aqueous phase was extracted with ethyl acetate (3 x 100 mL). The combined organic layer washed with brine (50 mL), dried over magnesium sulfate, filtered, and the filtrate concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (40% EtOAc/hexanes) to give Boc-T145 as a colorless oil (1.03 g, 34% overall yield for 5 steps) along with the corresponding acetate of the tether alcohol (145-6, 600 mg, 17% overall yield for 5 steps).
HPLC/MS : Special conditions, tR = 5.57 min, [M+H]+ 308.
Ή NMR (CDC13) 300 MHz): δ 7.11 (t, 1H, J = 8.0 Hz, CH aryl), 6.83 (d, 1 H, J = 7.0 Hz, CH aryl), 6.66 (d, 1H, d = 8.0 Hz, CH aryl), 4.67 (bs, 1 H, NHBoc), 4.12-4.08 (m, 2H, CH20), 3.98-3.93 (m, 2H, CH20), 3.23-3.18 (m, 1 H, CHNHBoc), 3.11-2.99 (m, 2H, arylCH2), 2.75-2.58 (m, 3H, CH2CHCH2), 1.45 (s, 9 H, C(CH3)3)
R. Standard Procedure for the Synthesis of Tether T146
Figure imgf000239_0001
146-4 Boc-T146b(THP)
Step T146-1: To a solution of Boc-T135 (3.5 g, 11.0 mmol, 1.0 eq) in THF (50 mL) were added imidazole (1.5 g, 22.0 mmol, 2.0 eq) and TBDMSCl (2.21 g, 15.0 mmol, 1.3 eq) and the mixture stirred 2 h with monitoring by TLC. The solution was then treated with saturated aqueous NH4C1 and the aqueous phase extracted with EtOAc (2x). The combined organic phase was dried over MgS04, filtered and the filtrate concentrated under reduced pressure. The resulting residue was filtered through a silica gel pad (10% EtOAc/90% hexanes) to give 146-1 as a white solid (100%). TLC: Rf = 0.60 (30% EtOAc/70% hexanes; detection: UV, Mo/Ce)
HPLC MS: Gradient A4, tR = 13.51 min, [M]+ 425
Step T 146-2: To a solution of 146-1 (4.46 g, 10.5 mmol, 1.0 eq) in a mixture of H20:t-BuOH (1: 1, 104 mL) were added AD-mix β (12.8 g) and methanesulfonamide (998 mg, 10.5 mmol, 1.0 eq) and the resulting orange mixture stirred at 4°C for 36-48 h during which time the color changes to yellow. Once TLC indicated the reaction was complete, sodium sulfite (15 g, 12.0 eq) was added and the mixture stirred at room temperature 1 h. The mixture was extracted with EtOAc (3x), then the combined organic phase extracted with water and brine. The organic phase was dried over MgSC>4, filtered and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (50% EtOAc/50% hexanes) to give 146-2 as a yellow oil (96%).
TLC: Rr = 0.41 (50% EtOAc/50% hexanes; detection: UV, KMn0 )
HPLC/MS: Gradient A4, tR = 10.63 min, [MJ+ 459, [M+Na|+ 482
Step T 146-3: To a solution of 146-2 (4.5 g, 9.79 mmol, 1.0 eq) in DCM (62 mL) at 0°C were added pyridine (3.1 mL) and DMAP (60 mg, 0.49 mmol, 0.05 eq). Triphosgene (2.9 g, 9.79 mmol, 1.0 eq) in DCM (10 mL) was then slowly added to this mixture. The reaction was stirred at 0°C for 45 min at which time TLC indicated the reaction was completed. The solution was treated with saturated aqueous NH4C1 and the organic phase separated. The aqueous phase was extracted with Et20 (2x) and the combined organic phase extracted with saturated aqueous NH4C!. The organic phase was dried over MgS04> filtered and the filtrate concentrated under reduced pressure. The resulting residue was filtered through a silica gel pad (30% EtOAc/70% hexanes) to give 146-3 as a yellow oil (91%).
TLC: Rr = 0.56 (50% EtOAc/50% hexanes; detection: UV, Mo/Ce)
HPLC/MS: Gradient A4, tR = 11.96 min, [M]+ 485
Step T 146-4: To a solution of 146-3 (2.49 g, 4.9 mmol, 1 .0 eq) in a mixture of 95% EtOH:acetone (3:1, 60 mL) was added Raney Ni (50% in water, 16 mL, 49 mmol, 10.0 eq). The reaction was stirred under 500 psi of hydrogen in a Parr hydrogenator for one week. At that time, N2 was bubbled through the mixture to remove excess hydrogen, then the mixture filtered though a Celite pad and rinsed with EtOAc. Concentration of the filtrate under reduced pressure and flash chromatography (20% EtOAc/80% Hex) of the residue provided 146-4 as a colorless oil (1.1 g, 56%).
TLC: Rf = 0.29 (30% EtOAc/70% hexanes; detection: UV, Mo/Ce)
HPLC/MS: Gradient A4, tR = 12.35 min, [M+H]+ 444 Step T146-5: To a solution of the alcohol 146-4 (1.1 g, 2.48 mmol, 1.0 eq) in CH2C12 (16 mL) were added DHP (272 μΤ, 2.97 mmol, 1.2 eq) and PTSA (24 mg, 0.124 mmol, 0.05 eq). The mixture was stirred at room temperature for 1 h with TLC monitoring (30% EtOAc/70% hexanes; detection: UV, Mo/Ce; Rf = 0.51). Additional DHP (2 x 0.3 eq) was added to force the reaction to completion. At that time, the solution was treated with saturated aqueous NaHC03, then the aqueous phase extracted with CH2CI2. The combined organic phase was dried over MgS04, filtered and the filtrate concentrated under reduced pressure. The crude residue was purified by flash chromatography (20% EtO Ac/80% Hex) to give 1.2 g of the intermediate diprotected diol.
The residue was dissolved in THF (16 mL) and a 1 M solution of TBAF in THF (4.96 mL, 4.96 mmol, 2.0 eq) added. The mixture was stirred at rt for 1 h. When TLC indicated the reaction was complete, the mixture was treated with brine, the layers separated, and the aqueous phase extracted with EtOAc. The combined organic phase was dried over MgS04, filtered and the filtrate concentrated to dryness under reduced pressure.' The residue was purified by flash chromatography (50% EtO Ac/50% hexanes) to give Boc-T146b(THP) as a yellow oil (76%, 3 steps).
TLC: Rf = 0.12 (30% EtOAc/70% hexanes; detection: UV, Mo/Ce)
HPLC/MS: Gradient A4, tR = 7.49 min, [M]+ 413, [M+Na]+ 436
To obtain Boc-T146a and its THP-protected derivative, the same procedure as above can be followed, but utilizing AD-mix a. Other suitable protecting groups in place of THP can be introduced in the last step as well.
S. Standard Procedure for the Synthesis of Tether T147
Figure imgf000242_0001
147-0 147-1 147-2
Figure imgf000242_0002
147-3 147-4 147-5
Figure imgf000242_0003
Step T147-1, Dihydropyran (13.4 mL, 146 mmol, 1.5 cq) was added dropwise at 0°C to 2- bromoethanol (10.3 mL, 146 mmol, 1.5 eq). The mixture was stirred 30 min at 0°C and then 2 h at rt. Salicylaidehyde (147-0, 10.2 mL, 97.0 mmol, 1.0 eq) was added to this mixture, followed by potassium carbonate (14.6 g, 106 mmol, 1.1 eq), potassium iodide (3.15 g, 19 mmol, 0.2 eq) and dry DMF (50 mL). The reaction was stirred at 70°C overnight. The solution was cooled to rt and diluted with ethyl ether (200 mL). The inorganic salts were removed by filtration and the filtrate diluted with hexanes (200 mL). The organic layer was washed with water (3x), then concentrated to dryness under reduced pressure. Compound 147-1 thus obtained was reduced directly in the next step without further purification.
TLC: Rr = 0.18 (MTBE/Hexanes, 1/4; detection: UV, vanillin)
HPLC/MS: Gradient A4, tR = 6.27 min, [MJ+ 250, [M+Naf 273
Step T147-2. Crude compound 147-1 was dissolved in THF (200 mL) and water (200 mL) and cooled at 0°C. To this mixture, sodium borohydride (3.67 g, 97 mmol) was added and the reaction followed by TLC (20% EtOAc/Hexanes). When no more 147-1 was present, water (400 mL) was added and the mixture extracted with ethyl acetate (3 x 100 mL). The combined organic layer was washed with brine, dried over magnesium sulfate, filtered, and the filtrate concentrated under reduced pressure. The material obtained was purified by flash chromatography (40% EtOAc/Hexanes) to obtain 147-2 as a colorless oil (19.7 g, 81 % over two steps). TLC: Rr = 0.08 (20% EtOAc/Hexanes; detection: UV, vanillin)
HPLC/MS: Gradient A4, tR = 5.79 min, [M]+ 252, [M+Na]+ 275
Step T 147-3. 147-2 (17.9 g, 71 mmol, 1.0 eq) and carbon tetrabromide (23.6 g, 71 mmol, 1.0 eq) were dissolved in DCM (500 mL) and the solution cooled to -45°C using an ethylene glycol/water/dry ice bath. Triphenylphosphine (18.6 g, 71 mmol, 1.0 eq) was added to this portion-wise, waiting for all the triphenylphophine to dissolve before each subsequent addition. The mixture was stirred 45 min and concentrated under reduced pressure. The residue was purified by flash chromatography (MTBE/DCM, 1/1.9) to provide 147-3 as a yellowish oil (21.9 g, 98%).
TLC: Rf = 0.68 (MTBE/DCM, 1/9; detection: UV, vanillin)
HPLC/MS: Gradient. A4, tR = 7.51 min, [M+H]+ 315, [M+Na]+ 337, 339
Step T147-4. Triphenylphosphine (13.0 g, 49.4 mmol, 1.0 eq) was added to a solution of 147- 3 (15.6 g, 49.4 mmol, 1.0 eq) in toluene (300 mL). The mixture was refluxed for 4 h, then cooled to rt. The precipitated solid was removed by filtration through a fine fritted glass filter and the solid obtained dried under vacuum (oil pump) for 1 h. The phosphonium salt 147-4 was obtained as a white solid (1.8.7 g, 77%). Note that the THP moiety was removed in this process as evidenced by both Ή NMR in CDC13 and HPLC. This had to be replaced before the next transformation as described in the next step.
HPLC/MS: Gradient A4, tR = 5.72 min, LMJ+ 413
Step T147-5. APTS (8 mg, 0.02 mmol, 0.001 eq) was added to a solution of 147-4 (18.6 g, 37.6 mmol, 1.0 eq) and DHP (17.2 mL, 188 mmol, 5.0 eq) in DCM (200 mL). The mixture was stirred 1 h at rt, then the solvent removed under reduce pressure. The residue was placed under vacuum (oil pump) to obtain a foam. Dry THF (Drisolv, new bottle, 400 mL) was added and the suspension stirred at rt. BuLi (1.6 in hexanes, 25.1 mL, 37.6 mmol, 1.0 eq) was added and the mixture stirred for 30 min. Ethyl trlfluoropyruvate (5.00 mL, 37.6 mmol, 1.0 eq) was then added and the reaction stirred for 10 min. The mixture was poured into water (1.4 L) and extracted with MTBE (4 x 200 mL). The combined organic layer was dried over magnesium sulfate, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (30% EtOac/Hexanes) to yield 147-5 as a colorless oil (7,47 g, 51%).
TLC: Rf = 0.53 (40% EtOAc/Hexanes; detection: UV, vanillin)
HPLC: Gradient A4, tR = 6.58 min (note that some cleavage of the THP protecting group was observed) Step T147-6. Ester 147-5 (7.47 g, 19.3 mmol, 1.0 eqj was dissolved in DCM (Drisolv, 200 mL) and the solution cooled to -45°C using an ethylene glycol/water/dry ice bath. DIBAL-H (1 M in DCM, 58 mL, 58 mmol, 3,0 eq) was added to the solution. The reaction was monitored by TLC (30% MTBE/Hexanes) and the temperature of the reaction allowed to increase slowly until completion of the reaction was observed. Potassium hydroxide (20% w/v aqueous, 300 mL) was added and the mixture extracted with DCM (3 x 100 mL). The combined organic layer was dried over magnesium sulfate, filtered, and the filtrate concentrated under reduced pressure. The crude product was purified by flash chromatography (MTBE/hexanes, 3/7) to give 147-6 as a colorless oil (4.33 g, 65%).
TLC: Rr = 0.1 1 (MTBE/Hexanes, 1/4; detection: UV, vanillin)
HPLC/MS: Gradient A4, tR = 7.01 min, [M 346, [M+Naf 369
Step T147-7. Lithium chloride (583 mg, 13.8 mmol, 1.1 eq) was dissolved in dry DMF (30 mL) at it, then 147-6 (4.33 g, 12.5 mmol, 1.0 eq) and 2,4,6-collidine (1.91 mL, 14.4 mmol, 1.15 eq) were added and the mixture cooled to 0°C. Methanesulfonyl chloride (freshly distilled improves the yield, 1.12 mL, 14.4 mmol, 1.15 eq) was added and the mixture warmed to rt and stirred for 2 h. Sodium azide (4.07 g, 62.6 mmol, 5.0 eq) was added and the mixture stirred overnight. The reaction was diluted with water (400 mL) and extracted with MTBE (3x). The combined organic layer was washed with saturated sodium bicarbonate, water and brine, dried over magnesium sulfate, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (30%MTBE/hexanes). 147-7 was obtained as a colorless oil (2.70 g, 58%).
TLC: Rf = 0.34 (MTBE/Hexanes, 3/7; detection: UV, vanillin)
HPLC/MS: Gradient A4, tR = 10.22 min, [M-N2f 343
Step T147-8. The azide 147-7 (834 mg, 2.25 mmol, 1.0 eq) was dissolved in methanol (25 mL). Concentrated HC1 (0.25 mL) was added and the reaction monitored by TLC (30% MTBE hexanes). When the reaction was complete by TLC, the reaction was concentrated under reduced pressure, then dried under vacuum (oil pump). The deprotected material (635 mg, 98%) was dissolved in ethyl acetate (10 mL), then Boc20 (725 mg, 3.32 mmol, 1.5 eq) and Pd/C ( 10% w/w, 50% wet, 65 mg) added and the mixture hydrogenated under 50 psi of hydrogen for 24 h. The reaction was filtered through Celite, washed with ethyl acetate, and the combined filtrate and washings concentrated under reduced pressure. The residue was purified by flash chromatography (40% EtOAc hexanes). Boc-T147 was obtained as colorless oil (668 mg, 83%).
TLC: Rf = 0.41 (MTBE/Hexanes, 2/3; detection: UV, ninhydrin) HPLC/MS: Gradient A4, tR = 7.16 min, [M+Naf 386
Ή NMR (300 MHz, DMSO-d6): δ 7.21-7.17 (m, 2 H, Ar), 6.90-6.80 (m, 3H, Ar + NHBoc), 4.82 (t, 1H, J = 5.4 Hz, OH), 4.00 (t, 2H, ./ = 5.1 Hz, ArOCH2), 3.73 (q, 2H, J = 5.4 Hz, CH2OH), 3.22-3.00 (m, 2H, CEbNHBoc), 2.85-2.62 (m, 3H, CH2Ar + CHCF3), 1.35 (s, 9H, C(CH3)3).
T. Standard Procedure for the Synthesis of Tether T148 NH2 87%
Figure imgf000245_0001
Step T 148-1: To a solution of Boc-T156a (2.57 g, 8.36 mmol, 1.0 eq) in THF (42 mL) were added imidazole (1.14 g, 16.7 mmol, 2.0 eq) and TBDMSC1 (1.64 g, 10.9 mmol, 1.3 eq) and the mixture stirred 2 h with monitoring by TLC. The- solution was then treated with saturated aqueous NH4CI and the aqueous phase extracted with EtOAc (3x). The combined organic phase was dried over MgS04, filtered and the filtrate concentrated under reduced pressure. The resulting residue was purified by flash chromatography (15% EtO Ac/85% hexanes) to give 148-1 as a colorless oil (100%).
TLC: Rf = 0.54 (25% EtO Ac/75% hexanes; detection: UV, vanillin)
HPLC/MS: Gradient A4, tR = 13.72 min, [M]+ 421, [M+Na]+ 444
Step T148-2: To a solution of 148-1 (2.80 g, 6.60 mmol, 1.0 eq) in a mixture of H20:t-BuOH (1 : 1, 66 mL) were added AD-mix β (8.1 g) and methanesulfonamide (632 mg, 6.60 mmol, 1.0 eq) and the resulting orange mixture stirred at 4°C for 4 d. Once TLC indicated the reaction was complete, sodium sulfite (15.8 g, 125.4 mmol, 19.0 eq) was added and the mixture stirred at room temperature 1 h. Water was added and the mixture extracted with EtOAc (3x), then the combined organic phase extracted with water and brine. The organic phase was dried over MgS04, filtered and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (gradient, 30% to 50% EtOAc/hexanes) to give 148-2 as a colorless oil (2.60 g, 87%).
TLC: Rf = 0.32 (30% EtOAc/70% hexanes; detection: UV, vanillin)
HPLC/MS: Gradient A4, tR = 11.25 min, [M+H]+ 456
Step T148-3: To a solution of 148-2 (2.6 g, 5.7 mmol, 1.0 eq) in DCM (30 mL) at 0°C were added pyridine (2.0 mL) and DMAP (35 mg, 0.29 mmol, 0.05 eq). Triphosgene (1.7 g, 5.7 mmol, 1.0 eq) in DCM (5 mL) was then slowly added to this mixture. The reaction was stirred at 0°C for 1 h at which time TLC indicated the reaction was completed. The solution was treated with saturated aqueous NH4CI and the organic phase separated. The aqueous phase was extracted with DCM (3x). The combined organic phase was dried over MgS04, filtered and the filtrate concentrated under reduced pressure. The resulting residue was filtered through a silica gel pad (30% EtOAc/70% hexanes) to give 148-3 as a yellow oil (2.7 g, 100%).
TLC: Rf = 0.53 (30% EtOAc/70% hexanes; detection: UV, vanillin)
HPLC MS: Gradient A4, tR = 12.00 min, [M]+ 481
Step T148-4: To a solution of 148-3 (3.1 g, 6.4 mmol, 1.0 eq) in a mixture of 95% EtOH:acetone (3: 1, 80 mL) was added Raney Ni (50% in water, 7.5 mL, 64.0 mmol, 30.0 eq). Hydrogen was bubbled into the solution for 2 d. At that time, N2 was bubbled through the mixture to remove excess hydrogen, then the mixture filtered though a Celite pad and rinsed with EtOAc. Concentration of the filtrate under reduced pressure and flash chromatography (gradient 20% to 25% EtOAc/Hex) of the residue provided 148-4 as a colorless oil (1.4 g, 50%).
TLC: Rf = 0.44 (30% EtOAc/70% hexanes; detection: UV, vanillin)
HPLC/MS : Gradient A4, tR = 12.69 min, [M+H]+ 440
Step T148-5: To a solution of the alcohol 148-4 (1.4 g, 3.2 mmol, 1 .0 eq) in CH2C12 (30 mL) were added DHP (0.35 mL, 3.8 mmol, 1.2 eq) and PTSA (30 mg, 0.16 mmol, 0.05 eq). The mixture was stirred at room temperature for 2 h with TLC monitoring (30% EtOAc/70% hexanes; detection: UV, vanillin; Rf = 0.54). At that time, the solution was treated with saturated aqueous NaHC03, then the aqueous phase extracted with CH2C12 (3x). The combined organic phase was dried over MgS0 , filtered and the filtrate concentrated under reduced pressure. The residue was sufficiently pure to continue on to the next step.
The residue was dissolved in THF (30 mL) and a 1 M solution of TBAF in THF (4.8 mL, 4.8 mmol, 2.0 eq) added. The mixture was stirred at it for 1 h. When TLC indicated the reaction was complete, the mixture was treated with brine, the layers separated, and the aqueous phase extracted with EtOAc (3x). The combined organic phase was dried over MgS04, filtered and the filtrate concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (gradient, 30% to 50% EtO Ac/he anes) to give Boc-T148c(THP) as a yellow oil (73%, 2 steps).
TLC: Rf = 0.16 (30% EtOAc/70% hexanes; detection: UV, vanillin)
HPLC/MS: Gradient A4, tR = 8.11 min, \M}+ 409, [M+Na]+ 432
To obtain Boc-T148a and its THP-protected derivative, the same procedure as described above can be followed, but utilizing AD-mix a. Other suitable protecting groups in place of THP can be introduced in the last step as well. Similarly, starting from T156b, and using the same procedures as above utilizing AD-mix-β and AD-mix-a, provide the diastereomeric tethers Boc-T148d and Boc-T148b, respectively. Appropriate protection of the hydroxyl moiety for these tethers, including THP, can be done using standard techniques.
II. Standard Procedure for the Synthesis of Tether T149
1 ) TEMPO, NaOCi,
Figure imgf000248_0001
149-5
Figure imgf000248_0002
Boc-T149b was synthesized using an almost identical procedure to that already described for the corresponding cyclohexyl derivative, Boc-T104b. However, the starting chiral β- hydroxyester, T149-1, was accessed through asymmetric reduction of the β-ketoester, 149-0, using Baker's yeast as described below.
Step 149-1. (Adapted from the procedure in Crisp, G.T.; Meyer, A.G. Tetrahedron 1995, 57, 5831-5845.) MgS04 (2 g), H2P04 (8 g) CaC03 (30 g) and dextrose (304 g) were added to water (2 L) at 36°C. Baker's yeast (24 g) was added and the mixture stirred using a mechanical stirrer due to the thickness of the solution at 36°C for 45 min. The β-keto-ester 149-0 (20.3 g, 130 mmol) was slowly added over approximately 5 min to the mixture and the reaction stirred 72 h at 36°C. The mixture was filtered trough a Celite pad which was rinsed with water (2 x 300 mL). The combined filtrate and washings were extracted with Et20 (5 x 500mL) and the combined organic phase washed with brine, dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by vacuum fractional distillation (b.p 40°C, oil pump) to give 149-1 as a colorless oil (13.3 g, 65%). Compound 149-1 is also commercially available (Julich, now Codexis, product no. 31.60).
HPLC/MS: Gradient A4, tR = 4.11 min, [M+H]+ 159.
V. Standard Procedure for the Synthesis of Tethers T150a and T150b
Figure imgf000249_0001
.OTBDMS 1 ) 1 % HCI/MeOH
toluene ΟΗ
RT, 1 h H,
H
140X CCI3 ,NHBoc
2} 5 N NaOH, EtOH 5% Rh/alumina {sealed tube) OX -> RT, 4 h RT, O/N
18 h O 3} (Boc)20, THF/H2 ( 100%
66% 150-4 RT, O/N 50-5
64%
Figure imgf000249_0002
Step T 150-1. To a solution of (£)-bromopropene (15 g, 124 mmol) in THF/Et20 (1 : 1 , 150 mL) was added a 1.7 M solution of f-BuLi in hexanes (146 mL, 248 mmol) at -100°C under N2. The reaction was then stirred at -78°C for 1 h. The reaction was returned to -100°C and a solution of 104-4 (15 g, 62 mmol) in THF/Et20 (1 :1 , 100 mL) added over a period of 30 min. After the addition, the reaction was stirred 1 h at -78°C, then quenched with a saturated solution of NaHC<¾ (aq). The mixture was extracted with Et20 (3x). The combined organic phase was washed with brine, dried over Na2S0 , filtered, and the filtrate concentrated under reduced pressure. The crude product was purified by flash chromatography (5% Et20/hexanes) to give a 1.2:1 mixture of diastereoisomers with different configurations at the free hydroxyl carbon atom, 6.95 g for the (R)-isomer, 150-1 , and 8.37 g for the (S)-isomer, 150-2 (87% total yield).
Step T 150-2. A suspension of KH (30% in mineral oil, 560 mg, 4.2 mmol) in hexanes (1 mL) was added to a solution of 150-1 (6.0 g, 21.1 mmol) in THF (18 mL) at 0°C. The mixture was stirred 10 min at RT, then added via cannula to a solution of trichloroacetonitrile (3.2 mL, 31.6 mmol) in THF (18 mL) at 0°C. The reaction was stirred 1 h at 0°C , then quenched with saturated solution of NaHC03 (aq). The mixture was extracted with Et20 (3x), the combined organic phase was dried over Na2S04, filtered, and the filtrate concentrated under reduced pressure. Purification of the residue by flash chromatography (5% Et20/hexanes + 1% Et N) provided 150-3 (6.42 g, 71%) containing some minor impurities.
Step T 150-3. A solution of 150-3 (6.4 g, 15 mmol) in toluene (1 0 mL) was heated at 140°C in a sealed tube for 18 h. The reaction was stopped, evaporated under reduced pressure, and the residue purified by flash chromatography (5% Et20/hexane) to yield the 150-4 as a colorless oil (4.2 g, 66%).
Step T 150-4. 150-4 (4.2 g, 9.8 mmol) was dissolved in a 1% HC1 in MeOH solution (100 mL). The reaction was stirred 1 h at RT, then evaporated to dryness in vacuo. The residue was dissolved in EtOH (100 mL) and a .5 N aqueous solution of NaOH (100 mL) was added at 0°C. The mixture was stirred 4 h at RT, then the EtOH evaporated under reduced pressure. To the residual aqueous phase, THF (100 mL) was added followed by (Boc)20 (5.36 g, 24.6 mmol). The biphasic mixture was stirred overnight at RT, then diluted with water and extracted with Et20 (3x). The combined organic phase was washed with brine, dried over MgS04! filtered, and the filtrate concentrated under reduced pressure. The purification of the residue thus obtained was done by flash chromatography (gradient., 5% EtOAc/hexanes to 30% EtOAc/hexanes) to afford 150-5 as a colorless oil (1.69 g, 64%).
Step T150-5. To a solution of 150-5 (1.30 g, 4.8 mmol) in EtOH (50 mL) was added 5% Rh/alumina (490 mg). Hydrogen was bubbled through the reaction for 5 min, then the reaction stirred overnight under a hydrogen atmosphere, The reaction was filtered through a Celite pad, which was rinsed with Et20, and the combined filtrate and rinses evaporated to dryness under reduced pressure to give 150-6 (1.3 g, 100%).
Step T150-6. To a solution of 150-6 (1.3 g, 4,8 mmol) in ethyl vinyl ether (50 mL) was added mercuric acetate (460 mg, 1.44 mmol) and the solution heated at reflux for 24 h. At that time, another 0.3 eq of mercuric acetate was added and the solution heated at reflux for an additional 24 h. The solution was then cooled to RT, quenched with an aqueous saturated solution of Na2C03, and extracted with Et20 (3x). The combined organic phase was washed with brine, dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (5% Et20/hexanes with 2% Et3N) to yield 150-7 as a colorless oil (1.38 g, 97%).
Step T150-7. To a solution of 150-7 (1.35 g, 4.5 mmol) in THF (45 mL) was slowly added, over a period of 15 min at 0°C, a 1 M solution of BH3-TFIF (6.9 mL, 6.9 mmol). The mixture was stirred 1 h at 0°C, then 2 h at RT. The solution was then cooled to 0°C and a 5 N solution of NaOH (10 mL) added, followed by a 30% aqueous solution of H202 (20 mL). The reaction was stirred 15 min at 0°C, then 2 h at RT. The mixture was extracted with Et20 (3x). The combined organic phase was washed with brine, dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (20% EtOAc/hexanes) to afford Boc-T150a (1.27 g, 90%)
The other diastereomeric tether, Boc-T150b, was accessed using an identical sequence starting from 150-2.
NHBoc
Figure imgf000251_0001
150-9 Boc-T150b
W. Standard Procedure for the Synthesis of Tether T151
Figure imgf000251_0002
Figure imgf000251_0003
Step T151-1. To the iodophenol derivative 151-0 (5.10 g, 19.3 mmol, 1.0 eq) in dichloro methane (80 mL), was added i-butylchlorodimethylsilane (3.19 g, 21.3 mmol, 1.1 eq) and, last, imidazole (1.45 g, 21.3 mmol, 1.1 eq). The milky solution was stirred at RT for 2.5 h. A saturated aqueous ammonium chloride solution (100 mL) was added and the mixture vigorously stirred for 5 min. The phases were allowed to separate and the aqueous phase extracted with dichloromethane (2x). The organic phases were combined, washed with brine, dried over Na2S04, filtered, and the filtrate concentrated under reduced pressure. The resulting yellow liquid was purified on a short silica gel column (gradient, 4% to 10% EtOAc:Hexanes) to obtain 151-1 as a colorless liquid (7.25 g, 99%).
TLC: Rf = 0.40 (15% EtOAc:He anes; detection: KMnO«
Step T151-2. 151-1 (541 mg, 1.43 mmol, 1.0 eq), 151-A (see synthesis following, 403 mg, 1.79 mmol, 1 .25 eq), tri(o-tolyl)phosphine (44 mg, 0.143 mmol, 0.1 eq) and palladium diacetate (16 mg, 0.072 mmol, 0.05 eq) were dissolved/suspended in anhydrous acetonitrile (10 mL) under dry nitrogen. Triethylamine (402 pL, 2.864 mmol, 2.0 eq) was then added. The resulting pale yellow mixture was heated at reflux. The mixture quickly darkened and became black after 3 h of heating. After 23 h, heating was stopped, the mixture cooled to RT, and the solvent evaporated to dryness under reduced pressure. The residue was dissolved in 10% EtOAc:Hexanes (8-10 mL) and filtered through a short silica pad with washing with an additional 40 mL of 10% EtOAc:Hexanes. After evaporation of the combined filtrate and washings under reduced pressure, the resulting yellow oil was further purified by flash chromatography (5% EtOAc:Hexanes) to provide 151-2 as a bright yellow oil (627 mg). The Ή NMR and LC-MS analyses indicated that there was some 151 -A in this material, which was used in the next step without further purification.
TLC: Rf = 0.25 (5% EtOAc:Hexanes; detection: vanillin, CAM, KMn04).
Step T151-3. 151-2 (627 mg, 1.32 mmol, 1.0 eq) was dissolved in TITF (13.2 mL). A 1 M solution of tetra-jV-butylammonium fluoride in THF (1.58 mL, 1.58 mmol, 1.2 eq) was added dropwise over a period of 1 min. The solution immediately turned a deep yellow. The reaction was stirred at RT for 2 h, after which TLC (30% EtOAc:Hcxanes)indicated a clean conversion. The mixture was quenched with saturated aqueous NaCl solution (25 mL) and stirred vigorously for 5 min. The phases were allowed to separate and the aqueous phase extracted with ethyl acetate (2x). The organic phases were combined, washed with brine, dried over Na2S04, filtered, and the filtrate concentrated under reduced pressure. The resulting yellow oil was purified by flash chromatography (30% EtOAc:Hexanes). Only the most pure fractions were collected, as a slightly more polar impurity was hard to separate from the desired product. Boc-T151a was isolated as white crystals, 300 mg (58% over two steps).
TLC: Rf = 0.30 (30% EtOAc:Hexanes; detection: CAM);
HPLC/MS: Gradient A4, tR = 7.00 min, [M+Na]+ 384;
Chiral HPLC analysis: 88% ee; Ή NMR (CDCI3): δ 7.40 (dd, 1H, Jj = 7.6, J2 = 1.6), 7.25 (td, 1H,J, = 8.8, J2 = 1.6), 7.08 (d, 1H, J = 16.0), 6.95 (t, 1H, / = 7.0), 6.87 (d, 1H, J = 8.2), 6.16 (dd, l H, J} = 16.0, J2 = 6.5), 5.17 (bs, 1H). 4.97 (bs, 1H), 4.11 (t, 2H, J = 5.0),' 3.99 (t, 2H, ./ = 5.0), 2.48 (bs, 1 H), 1.47 (s, 9H).
The enantiomeric tether with the (S)-configuration, Boc-T151b is accessed by the same procedure, but starting from the enantiomeric amino acid, 151 -B.
Y. Standard Procedure for the Synthesis of Reagent 151-A
Cr o-
Figure imgf000253_0001
Step T151-A. (5)-(-)-2-Methyl-2-propanesulfinamide 151-Al (1.84 g, 15.2 mmol, 1 .1 eq) was mixed with trifluoroacetaldhyde ethyl hemiacetal (151-A2, 1.99 g, 13.8 mmol, 1.0 eq). Titanium tetraethoxide (4,3 mL, 20.7 mmol, 1.5 eq), was added to form a clear, thick solution which was heated at 70°C with a reflux condenser under nitrogen for 3 d. By then, the solution had gradually become yellow. The reaction mixture was allowed to cool to RT, diluted with 100 mL of ethyl acetate, then poured into 100 mL of saturated aqueous NaCl solution under vigorous stirring. The biphasic mixture was filtered through Cetite and the filter cake rinsed with ethyl acetate. The phases were allowed to separate and the aqueous phase extracted with ethyl acetate (lx). The organic phases were combined, washed with brine, dried over Na2SC>4, filtered, and the filtrate concentrated under reduced pressure to leave a yellow oil. TLC (50% EtOAc : Hexanes) revealed that the two product diastereomers each had a significantly different Rf (0.2 vs. 0.4). Flash chromatography (gradient, 40% to 60% EtO Ac: Hexanes) afforded 151-A3a as white powder (1.84 g, 54%) and 151-A3b as white crystals (830 mg, 24%). Both compounds appeared pure by Ή NMR spectroscopy and TLC. 351 -A3a, TLC: Rf = 0.15 (50% EtOAc:Hexanes; detection: vanillin (blue green antispots);
351-A3b, TLC: Rf = 0.35 (50% EtOAc:Hexanes; detection: vanillin (blue green antispots).
Step T151-B. 151-A3a (830 mg, 3.36 mmol, 1.0 eq) was dissolved in dich!oromethane (26 mL) under nitrogen and the solution cooled to -60°C. A 1.0 M solution of vinylmagnesium bromide in THF (8.4 mL, 8.4 mmol, 2.5 eq) was added dropwise over a period of 10 min, after which the reaction was left to stir at -60°C for an additional 45 min. The temperature was gradually allowed to rise to -20°C over a period of 75 min. At that time, approximately 50 mL of an aqueous solution saturated in NH4C1 were added to the mixture and it was stirred vigorously for 15 min while allowing to warm to RT. The phases were separated and the aqueous phase extracted with dichloromethane (3x). The organic phases were combined, washed with brine, dried over a2S04, filtered, and the filtrate concentrated under reduced pressure. The resulting yellow oil was purified by flash chromatography (50% EtOAc:Hexanes). 151-A4a was obtained as a pale yellow oil, 715 mg (93%). The ratio of diastereomers observed by l9F NMR was 19: 1.
TLC: Rf = 0.30 (50% EtOAc:Hexanes; detection: KMn04).
151-A3b was transformed into 151-A4a using the exact same procedure except for the temperature used for addition of the vinylmagnesium bromide (-40°C instead of -60°C).
Step T151-C. 151-A4a (715 mg, 3.119 mmol, 1.0 eq) was dissolved in methanol (1 .5 mL). A 4 M solution of hydrogen chloride in 1 ,4-dioxane (1.5 mL, 6.24 mmol, 2.0 eq) was added dropwise over a period of 1 min. The solution was allowed to stir at RT for 75 minutes, after which TLC indicated a complete reaction. The solvents were evaporated under reduced pressure to yield a sticky oil. About 400 pL of methanol were added to dissolve the oil, then 15-20 mL of cold ether was added with stirring, which precipitated the hydrochloride salt. This solid was filtered under vacuum and rinsed with 5-10 mL cold ether. 151-A5a was obtained as a white powder, 361 mg (72%).
TLC: Rf = baseline (50% EtOAc:Hexanes; detection: KM11O4).
Step T151-D. 151-A5a (361 mg, 2.24 mmol, 1.0 eq) was dissolved in THF (7 mL) and water (7 mL). Sodium carbonate (321 mg, 3.02 mmol, 1.1 eq) and di-r-butyl-dicarbonate (660 mg, 3.02 mmol, 1.1 eq) were successively added to the biphasic mixture. The resulting solution was stirred overnight at RT. Distilled water' (~30 mL) was added to the mixture. The phases were allowed to separate and the aqueous phase extracted with EtOAc (3x). The organic phases were combined, washed with brine, dried over Na2S04, filtered, and the filtrate concentrated under reduced pressure. The resulting yellowish oil was purified by flash chromatography (30% EtOAc:Hexanes) to provide 151-A as white needles, 403 mg (80%).
TLC: Rf = 0.55 (30% EtOAc:Hexanes; detection: KMn04).
Ή NMR (CDCI3): δ 5.89-5.82 (m, 1H), 5.50-5.40 (m, 2H), 4.83 (br s, 2H), 1.46 (s, 9H).
The enantiomeric amino acid, 151 -B, is accessed by the same procedure, but starting from the enantiomeric (R)-(-)-2-methyl-2-prppanesulfinaraide, 151 B l . This is in turn used to prepare the enantiomeric tether, T151b.
Figure imgf000255_0001
Z. Standard Procedure for the Synthesis of Tethers T152 and T157
Figure imgf000255_0002
1 ) Raney-Ni, H2
NH3-EtOH, RT, ON
85%
2) Boc20, THF-H20 "
0°C -> RT, ON
Figure imgf000255_0003
BOC-T157 152-4
Step T 152-1. To a solution of 7 -hydroxy- indanone (152-0, 4.15 g, 28 mmol, 1.0 eq, Minuti, L. et. al. Tetrahedron Asy tn. 2003, 14, 481-487) in DMF (dry, 85 mL) was added I 56-A (synthesis described after that for T156, 10 g, 42 mmol, 1.5 eq), K2C03 (4.84 g, 35 mmol, 1.25 eq) and KI (0.93 g, 5.6 mmol, 0.2 eq). The mixture was stirred at 55°C (oil bath) overnight (-16 h) under N2. The reaction was monitored by TLC (Hexane/EtOAc, 4/1; detection: UV, MnC ). The mixture was cooled to rt, Η20 (200 raL) added, the layers separated, then the aqueous layer extracted with EtOAc (3 x 250 mL). The combined organic phase was washed with brine (100 mL), dried over anhydrous Na2S04, filtered then the filtrate concentrated under reduced pressure and dried under vacuum (oil pump). The residue was purified by flash chromatography (He anes/EtOAc, 5/1) to afford 8.6 g (100%) of 152-1 as a colorless oil.
1H NMR (CDC13, 300 MHz): δ 7.47 (m, 1H), 6.99 (d, J = 7.6, 1 H), 6.84 (d, ./ = 8.2, 1H), 4.19 (t, J = 5.8, 2 H), 4.04 (t, / = 5.6, 2 H), 3.06 (t, J = 5.6, 2 H), 2.64 (m, 2 H), 0.89 (s, 9 H), 0.10 (s, 6 H)
Step T152-2. NaH (1.18 g, 60 wt% in oil, 29.4 mmol, 1.5 eq) was washed with pentane (15 mL), the pentane removed by syringe, and THF (dry, freshly distilled from Na-benzophenone ketyl, 60 mL) added. Diethyl methylcyanophosphonate (3.7 mL, 23.5 mmol, 1.2 eq) was carefully (due to hydrogen gas evolution) added dropwise to the suspension by syringe at 0°C under N2. The mixture was stirred at RT for 1.0 h, cooled to 0°C, then a solution of 156- 1 (6.0 g, 19.6 mmol, 1.0 eq) in THF (dry, 20 mL) added dropwise. The mixture was allowed to warm to rt, then stirred overnight with TLC monitoring. The solution was concentrated under reduced pressure to give a black residue which was dissolved in H20 (50 mL) and saturated aq. NaHC03 (50 mL). This aqueous solution was extracted with EtOAc (3 x 150 mL). The combined organic phase was washed with brine (50 mL), dried over anhydrous Na2S04, filtered, and the filtrate concentrated under reduced pressure and dried under vacuum (oil pump) to give a black liquid which was purified by flash chromatography (hexancs/EtOAc, 6/1) to afford 5.7 g (88%) of 152-2 as a white solid. From TLC and ! H NMR analysis, it appeared that a single geometric isomer was isolated.
Ή NMR (CDCI3, 300 MHz): δ 7.29 (t, J = 7.9, 1 H), 6.92 (d, J = 7.6, 3 H), 6.75 (d, J = 8.2, 1 H), 6.28, 6.27 (s, 1 H), 4.15 (t, J = 5.0, 2 H), 4.00 (t, J = 5.2, 2 H), 3.08 (s, 2 H), 3.07 (s, 2 H), 0.91 (s, 9 H), 0.10 (s, 6 H).
Step T152-3. To a solution of NH3 in EtOH (2.0 M, 100 mL) was added 152-2 (5.7 g, 17.3 mmol, 1.0 eq) and Raney 2800 Ni (5.7 g, slurry in H20; 100 wt%). The mixture was stirred under H2 (70 psi) at RT overnight (-20 h). The mixture was passed through a pad of Celite, then washed with MeOH:Et3N (5: 1, 240 mL). The combined solution was concentrated under reduced pressure and dried under vacuum (oil pump) to give 5.77 g of a yellow oil which was submitted for the subsequent step without further purification. LC-MS indicated that double bond partly remained, ratio could not be easily determined due to the overlap of signals. Extension of the hydrogenation time or conduct under higher hydrogen pressure would be expected to give 1.52-3 almost exclusively.
Step T152-4. The yellow oil was dissolved in THF/H20 (1/1 , 120 mL) and Na2C03 (2.75 g, 26 mmol, 1.5 eq) was added. The mixture was cooled to 0°C and Boc20 (4.54 g, 20.8 mmol, 1.2 eq) added in one portion. The reaction was stirred at 0°C for 30 min, then RT overnight with TLC monitoring of reaction progress. The layers were separated. The aqueous phase was extracted with ether (3 x 120 mL). The combined organic phase was washed with brine (80 mL), dried over anhydrous Na2S04, filtered, then the filtrate concentrated under reduced pressure and dried under vacuum (oil pump). The resulting residue was purified by flash chromatography (gradient, Hexanes/EtOAc, 20/1 to 15/1) to afford 2.42 g of 152-3, 1.39 g of 152-4 and 2.6 g of mixture of 152-3 and 152-4 as colorless oils [85% overall yield (152- 3+152-4) for two steps].
152-3
Ή NMR (CDC13, 300 MHz): S 7.10 (t, J = 7.9, 1 H), 6.82 (d, J = 7.3, 1 H), 6.66 (d, J = 7.9, 1 H), 4.85 (s, br, 1 H), 4.00 (m, 4 H), 3.50 (m, 5 H), 2.21 (m, 1 H), 1.87 (m, 2 H), 1.65 (m, 1 H), 1.44 (s, 9 H), 0.91 (s, 9 H), 0.09 (s, 6 H)
MS: 336 (M++l-Boc)
152-4
MS: 334 (M++LBoc)
Step T 152-5. To a solution of 152-3 (2.42 g, 5.55 mmol, 1.0 eq) in THF (2.0 mL) was added a solution of TBAF (1.0 M in THF, 20 mL, 3.6 eq). The color of the solution changed to green-black immediately. The reaction solution was stin'ed at RT for 30 min with monitoring by TLC (Hexane/EtOAc, 2/1; detection: UV, CMA). Upon completion, the solution was passed through a pad of silica gel and eluted with EtOAc (100 mL). The combined organic solution was concentrated under reduced pressure and dried under vacuum (oil pump). The residue was purified by flash chromatography on (gradient, hexanes/EtOAc, 5/1 to 3/1 to 2/1) to yield 1.4 g (78%) of Boc-T152 as a colorless sticky oil.
Ή NMR (CDCI3, 300 MHz): δ 7.11 (t, J = 7.9, 1 H), 6.84 (d, J = 7.6, 1 H), 6.66 (d, J = 8.2, 1 H), 4.98 (s, br, 1 H), 4.08 (m, 4 H), 3.35 (m, 1 H), 3.18 (m, 2 H), 3.00 (m, 1 H), 2.80 (m, 1 H), 2.23 (m, 1H), 1.99 (m, 1 H), 1.78 (m, 2 H), 1.45 (s, 9H).
I3C NMR (CDC , 75 MHz): δ 155.38, 145.90, 134.24, 127.98, 1 17.36, 108.86, 79.34, 69.38, 61.39, 39.90, 39.57, 33.99, 31.74, 31.48, 28.43
MS: 222 (M++l -Boc)
in a similar manner to that described above, Boc-T157 was obtained from 152-4. Ή NMR (CDCI3, 300 MHz): δ 7.13 (t, J = 7,9, 1 H), 6.88 (d, J = 7.3, 1 H), 6.70 (d, / = 8.2, 1 H), 6.47 (s, 1 H), 4.66 (s, br, 1 H), 4.17 (m, 2 H), 4.02 (m, 2 H), 3.88 (t, J = 6.7, 2 H), 2.99 (m, 2 H), 2.78 (m, 2 H), 2.23 (s, br, 1 H), 1.46 (s, 9 H)
MS: 264 (M++2H+-f-Bu)
AA. Standard Procedure for the Synthesis of Tether T153
Figure imgf000258_0001
DP PA, Et3N
47%
i-BuOH, Δ, 24 b
Figure imgf000258_0002
Step T153-L As described in the literature (Uchikawa, O. et. al. J. Med. Chem. 2002, 45, 4212-4221 ; Uchikawa, O. et. al. J. Med. Chem. 2002, 45, 4222-4239), NaH (3.4 g, 60 wt% in oil, 85 mmol, 1.5 eq) was washed with pentane (25 mL), the pentane removed by syringe, and THF (dry, freshly distilled from Na-benzophenone ketyl, 300 mL) then added. To this suspension, trimeUiylphosphonoacetate (11 mL, 68.1 mmol, 1.20 eq) was carefully (due to hydrogen evolution) added dropwise (-30 min) by syringe at 0°C under N2. The mixture was stirred at RT for 1.0 h, cooled to 0°C, then 8-methoxy-2-tetralone (153-0, 9.0 g, 51 mmol, 1.0 eq) added in one portion. The mixture was allowed to warm to rt, then stirred overnight. Progress of the reaction was monitored by TLC (hexanes/EtOAc, 4/1; detection: UV, KMnO^. The brown solution was concentrated in vacuo to give a black residue. This residue was dissolved in H20 (150 mL) and EtOAc (200 mL). The layers were separated and the aqueous phase extracted with EtOAc (3 x 250 mL). The combined organic phase was washed with brine (150 mL), dried over anhydrous Na2S04, filtered, then the filtrate concentrated under reduced pressure and dried under vacuum (oil pump). The resulting black residue was purified by flash chromatography (hexanes/EtOAc, 5/1) to afford 1.08 g of 153-1 A and 10.52 g of 153-1B (total yield 98%) as colorless oils. The structures of 153-lA and 153-1B were deduced from the NMR s ectral data.
Figure imgf000259_0001
153-1 A 1 53-1 B
153-lA
Ή NMR (CDC13, 300 MHz): δ 7.13 (t, J = 7.9, 1 H), 6.77 (d, J = 7.6, .1 H), 6.72 (d, J = 8.2, 1 H), 5.89 (qu, J - 1.5, 1 H), 3.83, (s, 3 H), 3.71. (s, 3 H), 3.52 (s, 2 H), 3.12 (m, 2 H), 2.86 (t, J = 7.0, 2 H);
13C NMR (CDCI3, 75 MHz): δ 167.05, 160.13, 156.46, 138.62, 126.53, 123.38, 120.22, 114.07, 107.61, 55.29, 50.85, 33.17, 29.87, 27.52.
153 IB:
Ή NMR (CDCI3, 300 MHz): δ 7.08 (t, J = 7.9, 1 H), 6.73 (d, = 6.5, 1 H), 6.71 (d, J = 7.9, 1 H), 3.82 (s, 3 H), 3.70 (s, 3 H), 3.25 (s, 2 H), 2.82 (t, J = 7.9, 2 H), 2.32 (t, J = 7.9, 2 H);
13C NMR (CDCI3, 75 MHz): δ 171.80, 154.53, 135.99, 132.74, 127.28, 122.81 ,
120.04, 1 39.90, 108.67, 55.44, 51.83, 42.96, 28.24, 26.74.
Step Tl 53-2. To a solution of 153- IB (6.0 g, 25.8 mmol) in 95% EtOH (120 niL) was added Pt02 (600 mg, 10 wt%). The mixture was stirred under a H2 filled balloon at RT overnight (-16 h). The solution was passed through a pad of Celite, eluted with EtOAc, and the resulting organic solution concentrated under reduced pressure and dried under vacuum (oil pump) to afford 6.05 g (100%) of 153-2 as a colorless oil. Similarly, treatment of 153-lA also afforded 153-2, which was verified by 1H NMR and LC-MS co- injection.
Ή NMR (CDCI3, 300 MHz): δ 7.08 (t, J = 7.9, 1 H), 6.71 (d, J = 7.3, 1 H), 6.65, J =
7.9, 1 H), 3.81 (s, 3 H), 3.71 (s, 3 H), 2.94 (m, 1 H), 2.82 (m, 2 H), 2.41 (m, 2 H), 2.20
(m, 2 H), 1.93 (m, 1 H), 1.46 (m, 1 H);
MS: 235 M+H]+.
Step T153-3. 152-2 (7.02 g, 30 mmol, 1.0 eq) was dissolved in DCM (dry, 150 mL). The solution was cooled to -30°C (dichloroethane-dry ice bath), then a solution of BBr3 in DCM (1.0 M, 75 mL, 2.5 eq) added dropwise. After addition, the black solution was stirred at - 30°C for 40 min, then 0°C for 3.0 h, always under N2, with monitoring by TLC (hexanes/EtOAc, 4/1 ; detection: UV, KMn<¾). When complete, MeOH (dry, 20 mL) was added dropwise (but not slowly) to the mixture with vigorous stirring and maintaining low temperature, followed by the addition of H20 (150 mL). The mixture was kept at 0°C for 2-3 min. The layers were separated, and the aqueous phase extracted with DCM (3 x 150 mL). The combined organic phase was dried over anhydrous Na2S04, filtered, then the filtrate concentrated under reduced pressure and dried under vacuum (oil pump) to give a black residue which was purified by flash chromatography (He anes/EtOAc, 5/1) to afford 5.01 g (76%) of 153-3 as a pale yellow solid.
Ή NMR (CDC13, 300 ΜΗζ):δ 6.98 (t, J = 7.9, 1 H), 6.68 (d, J = 7.6, 1 H), 6.60 (dd, J = 7.9, 0.9, 1 H), 3.72 (s, 3 H), 2.92(m, 1 H), 2.82 (m, 2 H), 2.43 (m, 2 H), 2.24 (m, 2 H), 1.93 (m, 1H), 1 .44 (m, 1 H);
i 3C NMR (CDCI3, 75 MHz): δ 173.50, 153.43, 138.01 , 126.15, 122.40, 121 .1 1 , 111.86, 51.63, 41.03, 31 .09, 29.14, 28.97, 28.72.
Step T153-4. To a solution of 153-3 (5.0 g, 22.7 mmol, 1.0 eq), benzyloxyethanol ( 153-A, 4.4 mL, 30.6 mmol, 1.35 eq) and triphenylphosphine (8.0 g, 30.6 mmol, 1.35 eq) in THF (dry, 120 mL) was added DIAD (6.0 mL, 30.6 mmol, 1 .35 eq) dropwise using a syringe at 0°C under N2. The solution was stirred at 0°C for 30 min, then allowed to warm to RT and stirred overnight. The solution was concentrated under reduced pressure and dried under vacuum (oil pump) to give a pale yellow oil which was purified by flash chromatography (hexanes/EtOAc, 5/1) to obtain 5.98 g (75%) of 153-4 as a colorless oil.
Ή NMR (CDCI3, 300 MHz): δ 7.31 (m, 5 H), 7.06 (t, J = 7.9, 1 H), 6.71 (d, / = 7.6, 1 H), 6.64 (d, J = 7.9, 1 H), 4.65 (s, 2 H), 4.14 (m, 2 H), 3.85 (m, 2 H), 3.68 (s, 3 H), 3.00 (m, 1 H), 2.82 (m, 2 H), 2.40 (m, 2 H), 2.24 (m, 2H), 1.93 (m, 1 H), 1 .42 (m, 1 H).
Step T153-5. To a solution of 153-4 (4.98 g, 14 mmol, 1.0 eq) in THF (35 mL) was added a solution of LiOH H20 (2.9 g, 70 mmol, 5.0 eq) in H20 (35 mL) at 0°C. The mixture was stirred at 0°C for 30 min, then allowed to warm to room temperature and stirred for 24 h. THF was removed in vacuo, then an aqueous solution of HC1 (20 wt%) was added dropwise to adjust the pH to 1.0. The acidified solution was extracted with EtOAc (3 x 80 mL). The combined organic phase was dried over anhydrous Na2S04, filtered, then the filtrate concentrated under reduced pressure and dried under vacuum (oil pump). The resulting residue was dissolved in toluene (2 x 25 mL), concentrated again under reduced pressure and dried under vacuum (oil pump) to provide 4.8 g ( 100%) of 153-5 as a white solid. Ή NMR (CDCI3, 300 MHz): δ 7.32 (m, 5 H), 7.01 (t, J = 7.9, 1 H), 6.67 (m, 2 H), 4.62 (s, 2 H), 4.11 (m, 2 H), 3.83 (m, 2 H), 3.01 (m, 1 H), 2.79 (m, 2 H), 2.36 (m, 2 H), 2.13 (m, 2 H), 1.95 (m, 1 H), 1.40 (m, 1 H);
13C NMR (CDCI3, 75 MHz): δ 177.57, 158.72, 140.51 , 139.55, 130.28, 129.66, 129.54, 127.94, 126.84, 123.20, 1 10.16, 75.07, 70.75, 69.64, 42.95, 33.42, 31.52, 31.00, 30.84.
Step T153-6. To a solution of 153-5 (4.76 g, 14 mmol, 1 .0 eq) in i-BuOH (freshly distilled from Na under nitrogen, 85 mL) was added triethylamine (freshly distlled from CaH2, 2.2 mL, 15.4 mmol, 1.1 eq) and diphenylphosphoryl azide (DPPA, 3.33 mL, 15.4 mmol, 1 .1 eq) under N2. The solution was refluxed for 24 h under N?. After returning to rt, the solution was concentrated under reduced pressure and dried under vacuum (oil pump) to give a pale yellow solid. This yellow solid was dissolved in DCM (400 mL), washed successively with a solution of NaOH (1.0 M, 2 x 80 mL), H20 (80 mL) and brine (80 mL), dried over anhydrous Na2S04, filtered, then the filtrate concentrated under reduced pressure and dried under vacuum (oil pump) to give a pale yellow solid which was purified by flash chromatography (Hexanes/EtOAc, 5/1) to afford 2.7 g (47%) of 153-6 as a white solid. In addition, 1.39 g of 153-7, the t-butyl ester of 153-5, as a colorless oil, and 1.19 g of 153-8, of undetermined structure, was isolated from the chromatography.
153-6
]H NMR (CDCI3, 300 MHz): δ 7.3 1 (m, 5 H), 7.05 (t, J = 1.9, 1 H), 6.71 (d, 7 = 7.6, 1 H), 6.64 (d, / = 7.9, 1 H), 4.62 (s, 2 H), 4.13 (m, 2 H), 3.84 (L, J = 5.0, 2 H), 2.99 (m,
1 H), 2.82 (m, 2 H), 2.27 (m, 4 H), 1.93 (m, 1 H), 1.46 (s, 9 H), 1 .43 (m, 1 H);
i C NMR (CDCI3, 75 MHz): δ 172.30, 156.49, 138.20, 137.86, 128.40, 127.65, 125.84, 125.22, 121.28, 107.91 , 80.13, 73.35, 68.71 , 67.51 , 42.66, 31.37, 29.46, 29.13, 28.65, 28.14;
MS: 419 [M+Na]+.
153-7
!H NMR (CDCI3, 300 MHz): δ 7.33 (m, 5 H), 7.05 (t, J = 7.9, 1 H), 6.71 (d, J = 7.6, 1 H), 6.64 (d, J = 8.2, 1. H), 4.65 (s, 2 H), 4.15 (dt, J = 2.0, 4.7, 2 H), 3.85 (t, J = 5.0, 2 H), 3.16 (m, 2 H), 2.95 (dd, = 16.7, 5.0, 1 H), 2.81 (m, 2 H), 2.19 (m, 1 H), 1.90 (m,
2 H), 1.45 (s, 9 H), 3 .37 (m, 1 H);
i 3C NMR (CDCI3, 75 MHz): δ 156.52, 138.16, 138.06, 128.42, 127.66, 125.89, 124.93, 121.29, 107.99, 73.29, 68.59, 67.49, 46.28, 34.82, 29.06, 28.42, 27.41 , 26.60; MS: 312 [M+H-Bocf. 153-8
Ή NMR (CDCI3, 300 ΜΗζ):δ 7.31 (m, 5 H), 7.06 (t, ./ = 7.6, 1 H), 6.71 (d, J = 7.0, 1 H), 6.65 (d, J = 7.9, 1 H), 4.65 (s, 2 H), 4.15 (m, 2 H), 3.85 (t, J = 5.3, 2 H), 3.27 (m, 2 H), 2.94 (m, 1 H), 2.81 (m, 2 H), 2.22 (m, 1 H), 1.90 (m, 2 H), 1.30 (m, 2 H);
MS: 381 [M+H]+.
Step T153-7. To a solution of 153-6 (2.7 g, 6.56 mmol) in 95% EtOH/EtOAc/DCM (4/2/1, 70 mL) was added Pd-C (Degussa, -54% H20, 675 mg, 25 wt%). The mixture was shaken under ¾ (Parr, 60 psi) at RT for 4.0 h with the reaction monitored by TLC (hexanes/EtOAc, 2/1 ; detection: UV, CMA). The mixture was passed through a pad of Celite to remove the catalyst and eluted with EtOAc. The combined organic phase was concentrated under reduced pressure and dried under vacuum (oil pump) to give a pale yellow solid which was purified by flash chromatography (gradient, Hexanes/EtOAc, 1 /1, then DCM EtOAc, 1/1) to afford 2.1 1 g (100%) of Boc-T153 as a white solid.
1H NMR (CDCI3, 300 MHz): δ 7.06 (t, J = 7.9, 1 H), 6.73 (d, J = 7.6, 1 H), 6.65 (d, J = 7.9, 1 H), 4.73 (s, 1 H), 4.08 (m, 2 H), 3.97 (m, 2 H), 3.20 (t, J = 6.1, 2 H), 2.92 (dd, 7 = 16.7, 4.4, 1 H), 2.79 (m, 2 H), 2.20 (m, 2 H), 1.89 (m, 2 H), 1.46 (s, 9 H), 1.36 (m, 1 H);
13C NMR (CDCI3, 75 MHz): δ 156.23, 138.18, 125.98, 124,84, 121.53, 108.03, 79.18, 69.16, 61.59, 46.21, 34.92, 29.03, 28.40, 27.31 , 26.56;
MS: 222 [M+H-Boc]+.
BB. Standard Procedure for the Synthesis of Tether T154
Figure imgf000262_0001
BOC-T1 54
Step T154-1. To a solution of 2-iodoaniiine (154-0, 13.1 g, 60.0 mmol, 1.0 eq) in THF (70 mL) at 0°C was added a solution of NaHMDS (3 M in THF, 132 mL, 132 mmol, 2.2 eq) and the resulting mixture stirred at RT for 25 min. Boc20 (14.5 g, 66.0 mmol, 1.1 eq) was added and the mixture stirred at RT for 2.5 h. 0.5 M HC1 was added and the aqueous phase extracted with EtOAc. The combined organic phase was dried over MgS04, filtered, and the filtrate concentrated to dryness under reduced pressure. The resulting residue was purified by flash chromatography (7% EtOAc, 93% hexanes) to give 154-1 (19.0 g, 100%).
Step 154-2. To a solution of 154-1 (12.6 g, 39.6 mmol, 1.0 eq) in DMF (150 mL) were added NaH (60% in oil, 2.1 g, 53.5 mmol, 1.35 eq), KI (32.9 g, 198 mmol, 5.0 eq) and 135-A (12.8 g, 53.5 mmol, 1.35 eq), and the resulting mixture stirred at 80°C overnight. The mixture was allowed to cool to RT and water added. The aqueous phase was extracted with MTBE and the combined organic phase was extracted with brine. The organic phase was dried over MgS04, filtered, and the filtrate concentrated to dryness under reduced pressure to give 154-2 as a white solid (18 g, 95%).
Step T 154-3. To a solution of 154-2 (17.3 g, 36.0 mmol, 1.0 eq) in DMF (100 mL) were added 135-B (13.9 g, 54.0 mmol, 1.5 eq), P(o-Tol)3 (1.1 g, 3.6 mmol, 0.1 eq), K2C0 (9.9 g, 72.0 mmol, 2.0 eq) and Bu4NBr (1.16 g, 3.6 mmol, 0.1 eq), and the resulting mixture degassed with Ar. Pd(OAc)2 (0.8 g, 3.6 mmol, 0.1 eq) was added and the mixture again degassed with Ar. The resulting mixture was stirred at 90"C for 20 h. Water was added and the aqueous phase extracted with ether. The combined organic phase was extracted with brine, dried over MgS04, filtered, and the filtrate concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (1 1 % EtOAc, 89% hexanes) to give the compound 154-3 (13.0 g, 60%) plus some recovered starting material (7.8 g).
Step Tl 54-4. To a solution of 154-3 (11.9 g, 19.6 mmol, 1.0 eq) in THE (60 mL) was added a solution of TBAF ( 1 M in THF, 39.2 mL, 39.2 mmol, 2.0 eq) and the resulting mixture stirred at RT overnight. Water was added and the aqueous phase extracted with EtOAc. The combined organic phase was extracted with brine, dried over MgS04, filtered, and the filtrate concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (40% EtOAc, 60% hexanes) to give 154-4 as a solid (9.2 g, 95%).
HPLC/MS: Gradient A4, tR = 9.81 min, [M]+ 492, [M+Naf 515
Step T 154-5. To a solution of 154-4 (3.3 g, 6.7 mmol, 1.0 eq) in 95% EtOH (20 mL) was added 5% Pd/C (300 mg). Hydrogen was bubbled through the mixture, which was then stirred under a hydrogen atmosphere overnight. Nitrogen was bubbled through the mixture to remove excess hydrogen, then the mixture filtered through a Celite pad and the filter rinsed with EtOAc. The combined filtrate was concentrated under reduced pressure to give 154-5 in quantitative yield. HPLC/MS: Gradient A4, tR = 10.41 min, [My 494, [M+Naf 517
Step T 154-6. To synthesize Boc-T154, one of the Boc groups is selectively removed from 154-5 using the procedure as described for T135 (Step 135-4), T136 (Step 136-4) and T137 (137-6) by treatment of 154-5 with TFA in DCM at RT with monitoring by TLC to ensure no loss of the other Boc groups.
CC. Standard Procedure for the Synthesis of Tether T156
^^^OH TBSCI, imidazole
Br
DMF, rt, o/n
Figure imgf000264_0001
2 steps 156-2
156-0
Pd(OAc)2 P(o-tol)3
NHBoc DMP, H20 NHBoc !VlePPhaBr, ¾-BuOK t NHBoc
Et3N
,OH CH2Cl2 rt, 1 h ^° THF, -78°C->rt, O/N "--^ MeCN
156-B1 156-B2 156-B3 reflux, 2 h
Figure imgf000264_0002
Boc-T156a
Step T 156-1. To a solution of 2-bromoethanol (50 g, 400 mmol, 1 eq) and imidazole (54.5 g, 800 mmol, 2 eq) in THF (1600 mL) was added TBDMSCi (63.3 g, 420 mmol, 1.05 eq) and the solution reaction became milky. After overnight agitation, Et O was added (1600 mL) and the mixture washed with a saturated aqueous solution of NH4CI (2 x 250 mL) and brine (250 mL). The organic phase was dried with MgS04, filtered, and the filtrate evaporated under reduced pressure to give 156-A (97 g, 405 mmol, >100%) as an oil. When imidazole was seen remaining in this material, it can be removed by dissolution in Et20, washing with 1 M citrate buffer, then evaporation of the organic under reduced pressure. Alternatively, 156- A was available commercially (Aldrich cat. no. 428426).
Step T156-2. A solution of 2-iodophenol (156-0, 7.66 g, 34.8 mmol, 1.0 eq) in DMF (115 mL) was degassed under high vacuum for 10 min. Nitrogen was introduced into the flask and 156- A (10 g, 41.8 mmol, 1.2 eq), KI (1.16 g, 6.96 mmol, 0.2 eq) and K2C03 (6.01 g, 43.5 mmol, 1.25 eq) were added. The mixture was stirred at 55°C overnight under nitrogen. Solvent was removed under vacuum (oil pump), water (150 mL) added and the aqueous phase extracted with Et20 (3 x 150 mL). The combined organic phase was washed with 1 M Na2C03 (50 mL) and brine (200 mL), dried with MgS04, filtered, and the filtrate concentrated under reduced pressure to give 156-1 which was sufficiently pure to be used directly for the next step.
Step T 156-3. To a solution of 156- 1 (from previous reaction) in THF (350 mL) was added TBAF (1 M solution in THF, 63 mL, 63 mmol, 1 .5 eq). The reaction was stirred for 2 h. Et20 (600 mL) was added and the organic phase washed with a saturated solution of aq, NH4CI (2 x 100 mL) and brine (100 mL), dried with MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (40% EtOAc/hexanes) to afford 9.1 g (99%, 2 steps) of 156-2.
Step T156-4. A solution of 156-2 (4.55 g, 17.2 mmol, 1.0 eq) and 156-B3 (3.24 g, 18.9 mmol, 1.1 eq) in MeCN (110 mL) was degassed with argon for 45 min. To the degassed solution was added Et3N (4.8 mL, 34.4 mmol, 2.0 eq), P(o-tol)3 (524 mg, 1.72 mmol, 0.1 eq) and Pd(OAc)2 (193 mg, 0.86 mmol, 0.05 eq). The reaction was heated to reflux with agitation for 2 h under argon. After cooling to rt, the solvent was removed in vacuo and the residue dissolved in CH2C12 ( 100 mL) and water (100 mL). The phases were separated and the aqueous phase extracted with CH2C12 (2 x 100 mL). The organic phase was dried with MgSC>4, filtered, and the filtrate evaporated under reduced pressure. The residue was purified using flash chromatography (30% EtOAc/hexanes) to give Boc-T156a (2.98 g, 9.7 mmol, 56%) as a brown solid. Note that without N-protection, this compound exhibits some instability.
HPLC/MS : Gradient A4, tR = 6.77 min, [M+Naf 330
The enantiomeric tether, Boc-T156b, is accessed by the same procedure, but starting from the enantiomeric amino alcohol (R)-(-)-2-amino-l -propanoi, 156-C l .
Figure imgf000265_0001
DD. Standard Procedure for the Synthesis of Reagent 156-B3
DMP, H2Q NHBoc MePPh3Br, t-BuQK ¾ NHBoc
Figure imgf000266_0001
CH2CI2, rt, 1 h THF, ~78°C->rt, O/N
156-B1 156-B2 156-B3
Step T156-5. To a solution of 156-B 1 (7.01 g, 40 mmol, 1.0 eq) in CH2C12 (180 mL) was added DMP (23.8 g, 56 mmol, 1.4 eq). CH2C12 (containing 0.1 % H20 , 820 mL, 45 mmol, 1.125 eq) was then added over 30 min. The solvent was evaporated to dryness in vacuo and the residue dissolved in ether (500 mL) and a mixture of an saturated aqueous solution of NaHC<¾ and a solution of 10% Na2S203 (1 : 1 ) (400 mL). This mixture was agitated for 1 h, the phases separated, and the organic phase washed with water ( 100 mL) and brine (500 mL). The organic phase was dried with MgSO^, filtered, and the filtrate evaporated under reduced pressure to provide 156-B2 (6.2 g) that was used directly for next step.
Step T156 6. To a solution of MePPh3Br (31.4 g, 88 mmol, 2.2 eq) in THF (250 mL) was added t-BuOK (8.98 g, 80 mmol, 2.0 eq). The solution was agitated 90 min, cooled to -78°C and 156-B2 in THF (150 mL) added by cannula. The ice bath was removed and the reaction agitated at RT overnight. A saturated aq. solution of NH4CI ( 100 mL) was added to dissolve the precipitated salts, the mixture agitated 5 min, and the phases separated. The aqueous phase was extracted with ether (2 x 200 mL). The combined organic phase was washed with brine (50 mL), dried with MgS04, filtered, and the filtrate evaporated under reduced pressure to obtain a residue that was purified by flash chi matography (10% EtO Ac/hex anes) to yield 156-B3 (70%, 2 steps) as a white solid.
The enantiomeric aminoalkene, Boc-156C-3, is accessed by the same procedure, but starting from the enantiomeric amino alcohol (R)-(-)-2-amino-l -propanol, 156-C l .
EE. Standard Procedure for the Synthesis of Tether T158
Figure imgf000267_0001
BOC-T 58
Step T158-1. To a solution of 2-bromobenzaldehyde ( 158-0, 9.6 g, 51.9 mmol, 1.0 eq) in C¾CN (300 mL) were added 135-B (14.7 g, 57.1 mmol, 1.1 eq), (o tol)3P (1.6 g, 5.2 mmol, 0.1 eq), Pd(OAc)2 (584 mg, 2.6 mmol, 0.05 eq) and Et3N (14.6 mL, 103.8 mmol, 2.0 eq). The resulting mixture was stirred at reflux overnight. The mixture was cooled to RT and the solvent evaporated under reduced pressure. Water was added and the aqueous phase extracted with CH2CI2. The organic phase was extracted with brine (2x). The combined organic phase was dried over gS04, filtered, and the filtrate concentrated to dryness under reduced pressure. The residue was purified by flash chromatography (15% EtOAc, 85% hexanes) to afford the 158-1 as a yellow oily semi-solid (17.5 g, 94%).
TLC: Rr = 0.49 (30% EtOAc, 70% hexanes; detection: UV, Mo/Ce).
Step T158-2. To a solution of 158-1 (9.3 g, 25.8 mmol, 1.0 eq.) in EtOH (200 mL) was added a suspension of Raney/Ni in water (3 mL) and hydrogen was bubbled into the heterogeneous mixture. The reaction was stirred under a hydrogen atmosphere for 7 h. Nitrogen was then bubbled through the reaction solution to remove excess hydrogen and the mixture filtered through a silica gel pad. The silica was rinsed with 50%EtO Ac/Hex and the combined filtrate and washings evaporated under reduced pressure. 158-2 was obtained as a yellow oil (8.8 g, 94%).
TLC: Rf = 0.29 (30% EtOAc, 70% hexanes; detection: UV, Mo/Ce).
Step T158-3. To a solution of 158-2 (8.8 g, 24.1 mmol, 1.0 eq.) in CH2C12 (200 mL) was added Dess-Martin periodinane (14.3 g, 33.7 mmol, 1.4 eq). The resulting mixture was stirred at RT for 1.5 h. Aqueous saturated NaHC03 solution was added and the aqueous phase extracted with CH2CI2. The combined organic phase was dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The resulting residue was purified by flash chromatography (20% EtOAc, 80% hexanes) to provide 158-3 as a white solid (6.8 g, 77%).
TLC: Rf = 0.43 (30% EtOAc, 70% hexanes; detection: UV, Mo/Ce).
Step T158-4. To a suspension of NaH (60% in oil, 1.12 g, 28.1 mmol, 1.5 eq) at 0°C in THF (150 mL) was slowly added the phosphonate (4.1 niL, 28.1 mmol, 1.5 eq). Caution, hydrogen was generated from this reaction. The mixture was stirred 15 min, then 158-3 (6.8 g, 18.7 mmol, 1 .0 eq) in THF (50 mL) added. The resulting mixture was stirred at RT for 2 h. Aqueous saturated NH4CI solution was added and the aqueous phase extracted with EtOAc. The combined organic phase was dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (20% EtOAc, 80% hexanes) to yield 158-4 as a pale yellow oil (7.3 g, 94%).
TLC: Rr = 0.42 (20% EtOAc, 80% hexanes; detection: UV, Mo/Ce).
Step T158-5. To a solution of 158-4 (7.3 g, 17.4 mmol, 1.0 eq.) in CH2C12 (200 mL) was added TFA (1.9 mL, 26.1 mmol, 1.5 eq). The resulting mixture was stirred at RT for 4 h. Aqueous saturated NaHC03 solution was added and the aqueous phase extracted with CH2CI2. The combined organic phase was dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (30% EtOAc, 70% hexanes) to give 158-5 as a pale yellow oil (5.4 g, 96%).
TLC: Rf = 0.40 (30% EtOAc, 70% hexanes; detection: UV, Mo/Ce).
Step ΊΊ58-6. To a solution of a solution of 158-5 (5.4 g, 16.9 mmol, 1.0 eq) at -78°C in CH2CI2 (100 mL) was added DIBAL (1 M in CH2C12, 42.3 mL, 42.3 mmol, 2.5 eq). The resulting mixture was stirred at -78°C for 30 min, then at 0°C for 1 h. If the reaction was not complete as indicated by TLC, 1 eq additional of DIBAL was added. A I M solution of Rochelle salts was added and the mixture stin'ed 1 h. The aqueous phase was extracted with CH2C12 until TLC indicated no additional material was being extracted. The combined organic phase was dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (60% EtOAc, 40% hexanes) to provide Boc-T158 as a colorless oil (4.6 g, 94%).
TLC: Rf = 0.17 (50% EtOAc, 50% hexanes; detection: UV, Mo/Ce);
HPLC/MS: Gradient A4, tR = 6.83 min, [M]+ 291, [M+Naf 314. FF. Standard Procedure for the Synthesis of Tether T159
Figure imgf000269_0001
'""'^ Boc-T-159
Step T159- 1 . To a solution of 2-bromophenol (159-0, 45 g, 260 mmol, 1.0 eq) in acetone (1.3 L) was added anhydrous potassium carbonate (71.9 g, 520 mmol, 2.0 eq) and allyl bromide (34.6 g, 24.2 mL, 286 mmol, 1.1 eq). The suspension was stirred at reflux under argon for 6 h. The reaction was cooled to RT, then the solvent removed under vacuum, cold water (500 mL) added and the aqueous phase extracted with ether (3 x 500 mL). The combined organic phase was washed with water (200 mL) and brine ( 100 mL), dried with magnesium sulfate, filtered, and the filtrate concentrated under vacuum to give 159- 1 as an oil (55.6 g, 213 mmol, 100%) that was used in the next step without further purification.
TLC: Rf = 0.32 (25% CH2Cl2/hexanes).
Step T 159-2. A solution of 159- 1 (51.0 g, 239 mmol, 1.0 equiv) in N,N-diethylaniiine (36 mL, 1 : 1 v/v) was stirred at reflux for 4 h. The reaction could be followed by Ή NMR. The solution was allowed to cool to RT and dilute HCl added (300 mL). The aqueous phase was extracted with ether (3 x 300 mL). The combined organic phase was dried with magnesium sulfate, filtered, and the filtrate concentrated under vacuum. The residue was dissolved in ether (500 mL) and extracted with 1 N NaOH (4 x 250 mL). The aqueous phase was acidified to pH 2-3 with 6 N HCl, then extracted with ether (3 x 250 mL). The combined organic phase was dried with magnesium sulfate, filtered, and the filtrate concentrated under vacuum to provide 159-2 as an oil (46 g), contaminated with some diethylaniline, that was used as obtained in the next step.
Step T159-3. To a solution of 159-2 (46 g) in CHC13 (2.4 L) was added m-CPBA (80.5 g, 359 mmol, 1.5 eq) and TFA (1.8 mL, 24 mmol, 0.1 eq). The reaction was stirred at reflux overnight. TFA (1.8 mL) was added and reaction stirred for 3 h. Another portion of TFA (14.4 mL) was added and reaction stirred an additional 3 h. The reaction was cooled to RT, then washed with a saturated solution of sodium bicarbonate (2 x 500 mL) and brine (500 mL). The organic phase was dried with magnesium sulfate, filtered, and the filtrate concentrated under vacuum to give an orange solid that was purified by flash chromatography (gradient, 20% - 30% - 40% EtOAc/hexanes). Two product-containing fractions were obtained. The first (20 g) was repurified by flash chromatography with the same conditions as above to afford 12.0 g (52.4 mmol, 21.9%, 2 steps) of 159-3. The second (14.9 g, 65.0 mmol, 27.2%, 2 steps) contained pure 159-3.
Step T 159-4. To a solution of 159-3 (2.67 g, 11.6 mmol, 1.0 eq), 135-B (3.29 g, 12.8 mmol, 1.1 eq) and Et N (3.2 mL, 23.2 mmol, 2.0 eq) in MeCN (preferably degassed, 72.5 mL) was added P(o-tol)3 (706 mg, 2.32 mmol, 0.2 eq) and Pd(OAc)2 (260 mg, 1.16 mmol, 0.1 eq). The mixture was stirred at reflux overnight under argon. The solution was concentrated under vacuum, water (250 mL) and CH2CI2 (250 mL) added and the phases separated. The aqueous phase was extracted with CH2CI2 (2 x 250 mL). The combined organic phase was dried with magnesium sulfate, filtered, and the filtrate concentrated under vacuum to give an oil which was purified by flash chromatography (30% EtOAc/hexanes) to afford 5 g (>100%) of a 2: 1. mixture of the product (159-4) and starting material (159-3).
Step T159-5. To a solution of 159-4 (5 g, 12.3 mmol) in CH2C12 (60 mL) was added TFA (1.1 mL, 15 mmol, 1.22 eq) The mixture was stirred at RT for 3 h. Ether (250 mL) was then added and the organic phase washed with a saturated solution of sodium bicarbonate (50 mL) and brine (50 mL). The organic phase was dried with magnesium sulfate, filtered, and the filtrate concentrated under vacuum to give a yellow residue which was purified by flash chromatography (gradient, 30% - 40% - 50% EtOAc/hexanes) to afford 1.69 g (48%, 2 steps) of Boc-T159 as a yellow oil.
TLC: Rr = 0.35 (50% EtOAc hexanes)
GG. Standard Procedure for the Synthesis of Tether T160
Figure imgf000271_0001
160-0 70°C, 4 h 160-1
Figure imgf000271_0002
BOC-T160
Step T160-1. To a solution of 2-hydroxybenzaldehyde (160-0, 1.2 g, 4.8 mmol, 1.0 eq) in DMF (20 mL) were added potassium carbonate (1.5 g, 10.8 mmol, 1.1 eq), potassium iodide (332 mg, 2.0 mmol, 0.2 eq) and 136-A (4.2 mL, 19.6 mmol, 2.0 eq). The resulting mixture was stirred at 70°C for 4 h. The solution was cooled to RT and brine added. The aqueous phase was extracted with ether and the combined organic phase was extracted with brine (2x). The organic phase was dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (15% EtOAc, 85% hexanes) to give 160-1 (3.0 g, > 100%, contains trace of 136-A as detected by Ή NMR).
TLC: Rf = 0.55 (20% EtOAc, 80% hexanes; detection: UV, Mo/Ce).
Step T 160-2. To a solution of phosphonate 160-A (3.6 g, 15.0 mmol, 1.5 eq, Alagappan Thenappan and Donald J. Burton J. Org. Chem 1990, 4639) at -78°C in THF (150 mL) was added a solution of n-BuLi (2 M in pentane, 7.5 mL, 15.0 mmol, 1.5 eq). The resulting mixture was maintained at -78°C for 10 min, then 160-1 (2.8 g, 10.0 mmol, 1.0 eq) in THF (50 mL) added and the resulting mixture stirred at -78°C for 45 min. Saturated aqueous NH4C1 was added and the aqueous phase extracted with EtOAc. The combined organic phase was dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (10% EtOAc, 90% hexanes) to provide 160-2 (3.9 g, 105%, contains a trace of 136-A as detected by Ή NMR).
TLC: Rf = 0.58 (20% EtOAc, 80% hexanes; detection: UV, Mo/Ce).
Step T 160-3. To a solution of ester 160-2 (3.7 g, 10.0 mmol, 1.0 eq) at -78°C in CH2C12 (100 mL) was added a solution of DIBAL (1 M in CH2C12, 25.0 mL, 25.0 mmol, 2.5 eq, amount critical as loss of TBDMS protection was observed with greater excess of DIBAL). The resulting mixture was stirred at -78°C for 30 min, then at 0°C for 1 h. Acetone and Na2SO4T0 H20 were added and the resulting mixture stirred at RT for 2 h. The precipitate was filtered and rinsed with EtOAc and CH2C12. The solvents were evaporated under reduced pressure and the residue purified by flash chromatography (30% EtOAc, 70% hexanes) to yield 160-3 (2.8 g, 85%, 3 steps).
TLC: Rf = 0.46 (30% EtOAc, 70% hexanes; detection: UV, Mo/Ce).
Step T160-4. To a solution of 160-3 (2.6 g, 8.0 mmol, 1.0 eq) at 0°C in CH2C12 (50 mL) were added Et3N (5.6 mL, 40.0 mmol, 5.0 eq) and MsCl (1.2 mL, 16.0 mmol, 2.0 eq). The resulting mixture was stirred at 0°C for 1 h. Water was added and the aqueous phase extracted with CH C12. The combined organic phase was dried over MgS0 , filtered, and the filtrate concentrated under reduced pressure to give the crude mesylate 160-4 (contains trace of Ms CI) that was used as obtained this for the next step.
TLC: Rf = 0.24 (20% EtOAc, 80% hexanes; detection: UV, Mo/Ce).
Step T 160-5. To a solution of 160-4 (3.2 g, 8.0 mmol, 1 .0 eq) in DMF (30 mL) was added NaN3 (2.6 g, 40.0 mmol, 5.0 eq). The resulting mixture was stirred at RT for 2 h. Water was added and the aqueous phase extracted with ether. The combined organic phase was extracted with brine and the organic phase dried over MgS04, filtered, and the filtrate concentrated under reduced pressure to give the crude azide 160-5 (1.9 g, 68%, 2 steps) that was sufficiently pure to be used as obtained for the next step.
TLC: Rr = 0.68 (20% EtOAc, 80% hexanes; detection: UV, Mo/Ce).
Step T160-6. To a solution of 160-5 (1.9 g, 5.4 mmol, 1.0 eq) in THF (50 mL) were added PPh (2.1 g, 8.1 mmol, 1.5 eq) and water (5 mL). The resulting mixture was heated at 50°C overnight. (TLC: Rf = baseline (20% EtOAc, 80% hexanes; detection: UV, Mo/Ce). The solution was cooled to RT, then water (50 mL), Na2C03 (572 mg, 5.4 mmol, 1.0 eq) and (Boc)20 (1.2 g, 5.4 mmol, 1.0 eq) added. The resulting mixture was stirred at RT for 2 h. (TLC: Rf = 0.36 (20% EtOAc, 80% hexanes; detection: UV, Mo/Ce). Water was added and the aqueous phase extracted with EtOAc. The combined organic phase was dried over MgS04, filtered, and the filtrate concentrated to dryness under reduced pressure. To the residue in THF (30 mL) was added a solution of TBAF (1 M in THF, 8.1 mL, 8.1 mmol, 1.5 eq). The resulting mixture was stirred at RT for 1 h. Water was added and the aqueous phase extracted with EtOAc. The combined organic phase was dried over MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (60% EtOAc, 40% hexanes) to give Boc-T160 (1.3 g, 76%, 3 steps).
TLC: Rf = 0.10 (20% EtOAc, 80% hexanes; detection: UV, Mo/Ce);
HPLC/MS : Gradient A4, tR = 6.51 min, [Mf 31 1 , [M+Na]+ 334.
HH. Standard Procedure for the Synthesis of Tethers T161 and T177
Η2Ν ^0Η Na2CQ3, (Boc)sO BocH N ^ DMP, H;Q BocHN^^ CBr,, PPI¾ BocHN .^ ..Br
THF/waler 1 CH,<¾, RT. 1 h ) Zn. DCM I £f
RT, ON ^ 75% ^ 0X -> RT ^
94% 161 -1 161 -2 24 161 -3
46%
BocHN^ ^- v Ί (161 -A) [f " "^ "OH H2 (400 psi), 10% PcJ/C ^ ^
THF -78°C Cu!, Et3N 95% BOH. 24 h ^ NHBoc 1 h PdCyPPhj), , ΝΗΒοο 80%
¾¾ . J.. . CH3CN, RT, O N
1 b1 " 92%
Boc-T16 a
161 -5
(Boc-T177a)
Step T161-1. To a solution of 134-0 [(R)-(-)-2-amino-l-butanol, 5 g, 56 mmol, 1.0 eq] in THF/water (1/1) were added (Boc)20 (12.9 g, 59 mmol, 1.05 eq) and sodium carbonate (7.12 g, 67 mmol, 1.2 eq). The solution was stirred at RT overnight. The solvent was removed under reduced pressure, the residue dissolved in ether and a citrate buffer solution added. The aqueous phase was extracted with ether (3x). The combined organic phase was dried with MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by passing through a pad of silica gel (50% EtOAc/Hex) to afford 10 g (94%) of 161-1 as a colored oil.
Step T161-2. (Based on the procedure in Meyer, S.D. and S.L. Schreiber J. Org. Chem 1994, 59, 7549-7552.) To a solution of 161-1 (7.55 g, 40 mmol, 1.0 eq) in DCM (230 mL) was added Dess-Martin periodinane .(DMP, 24 g, 56 mmol, 1.4 eq). H20 (1.5 mL, 1.4 eq) was added with a dropping funnel to this solution over 0.5 h with vigorous stirring. After 0.5 h, Et20 was added, the solution filtered, and the filtrate concentrated under reduced pressure. The residue was dissolved in Et20 and the solution washed successively with saturated NaHCO3/10% sodium thiosuifate (1:1), water and brine. Extra wash with bicarbonate- thiosuifate are sometimes needed to remove the acetic acid formed by the DMP reagent. The combined aqueous phase was back extracted with Et20 (Ix) and the combined organic phase was dried with MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified through a pad of silica gel (20% EtOAc/Hex) to give 5.4 g (75%) of 161-2 as a white solid that was gently azeotroped with toluene (3x, bath temp = 30°C, oil pump) and was used immediately in the next step.
TLC: Rf = 0.3 (hexanes/EtOAc, ¼; detection: KMnUj, UV).
Step T161-3. To Zn powder [activated by the following sequence: wash successively with 0.5 N HC1 (3x), H20 (3x), MeOH (3 ), Et20 (3x) and dried under vacuum (oil pump), 3.8 g, 53 mmol, 2.0 eqj and CBr4 (19.2 g, 53 mmol, 2.0 eq) in DCM (173 mL) at 0°C was added PPh3 (15.2 g, 58 mmol, 2.0 eq) in three portions over 5 min,. with an exothermic reaction observed. The solution was stirred at RT for 24 h The solution turned from yellow to a pink suspension. Freshly prepared aldehyde 161-2 (5.0 g, 26 mmol, 1.0 eq) was added in DCM (30 mL). The solution turns to a dark violet over the next 24 h. The solution was concentrated under reduced pressure, then purified by flash chromatography (hexanes/EtOAc, 10/1) to provide 161-3 (4.3 g, 46%) as a white solid.
TLC: Rr = 0.67 (EtOAc/Hexanes, 3/7; detection: Mn04).
Step T161-4. To a solution of 161-3 (2.0 g, 5.83 mmol, 1.0 eq) in THF (distilled from Na- benzophenone ketyl, 95mL) at -78°C was added dropwise a freshly titrated solution of n- BuLi in hexanes (1.8 M, 10.5 mL, 17.5 mmol, 3.0 eq). The solution was stirred at -78°C for 1.0 h. A solution of 0.01 N NaOH (100 mL) was added and the mixture wanned to RT. The aqueous phase was extracted with Et20 (2 x 120 mL). The combined organic phase was washed with brine (2 x 300mL), dried over MgS04, filtered, and concentrated under reduced pressure, then purified by flash chromatography (hexanes/EtOAc, 4/1) to give 880 mg (88%) of 161-4 as a white solid.
TLC: Rf = 0.57 (Et20/Hexanes, 2/3; detection: KMn04).
Step T161-5. To a solution of 161-4 (880 mg , 4.81 mmol, 1.0 eq) and 161-A (see procedure for Cbz-T33a, 1.65 g, 6.25 mmol, 1.3 eq) in CH3CN (38 mL) was bubbled argon for 20 min. Et3N (freshly distilled from Ca¾, 2.4 mL, 224 mmol, 3.6 eq) was added and argon was bubbled for 10 min. Recrystallized Cul (28 mg, 0.144 mmol, 0.03 eq) and PdCl2(PPh3)2 (102 mg, 0.144 mmol, 0.03 eq) were then added to the solution. The reaction was stirred under an argon atmosphere overnight at RT. The volatiles were removed under reduced pressure and the residue purified by flash chromatography (DCM/EtOAc, 4/1 ) to afford 1.4 g (92%) of 161-5 as an orange solid. Note that care must be taken to remove all unreacted 161-A as it can prove very difficult to separate later.
TLC: Rf = 0.13 (Et20/Hexanes, 1/4: detection: KMn04).
Step T161 -6. To 161-5 (1.4 g, 4.39 mmol, 1.0 eq) was added 10% Pd/C (210 mg, 15% by weight) and 95% EtOH (128 mL). The mixture was placed in a Parr hydrogenator under a pressure of 400 psi of hydrogen for 24 h. The reaction was filtered through a Celite pad, then the filtrate concentrated under reduced pressure to yield 1.12 g (80%) of Boc-T16i as a colorless oil. Similarly, 29.7 g of Boc-T161a was synthesized using this procedure in 16% overall yield from 50.0 g of 134-0.
1H NMR (CDC13, 300 MHz): δ 7.18-7.10 (m ,2H), 6.90-6.82 (m ,2H), 4.58-4.46 (m,
2H), 4.2-3.8 (m, 4H), 3.5 (m, 1H), 2.85-2.7 (m, 1 H), 2.65-4.45 (m, 1H), 1.8-1.2 (m,
4H), 1.44 (s, 9H), 0.8 (t, 3H, J = 7 Hz);.
HPLC/MS (Gradient A4): tR: 7.3 min, [MJ+ 323.
The enantiomeric tethers, Boc-T161b and Boc-T177b, are accessed by the same procedure, but starting from the amino alcohol (S)-(-)-2-amino- l-butanol, 161 -6, enantiomeric to 134-0.
Figure imgf000275_0001
II. Standard Procedure for the Synthesis of Tether T162
Figure imgf000275_0002
162-2
Pd{dba)z (0.03 eq), PPh3 (0.1 eq),
NHBoc TBAF (3 eq)
(162-A) THF, 60°C, O/N
72%
Figure imgf000275_0003
Boc-T162a 162.3
Step T162-1. To a solution of /-butylamine (43.6 g, 62.9 mL, 600 mmol, 3.0 eq) in dry toluene (170 mL) was added Br2 (35.1 g, 11.3 mL, 220 mmol, 1.1 eq) dropwise at -30°C (-10 min) under N2. The mixture was cooled to -78°C, and a solution of 2-fluorophenol (162-0, 22,5 g, 200 mmol, 1.0 eq) in DCM (110 mL) was added dropwise under N2 (-30 min). The mixture was warmed to RT gradually and stirred overnight. The reaction was diluted with diethyl ether and the organic phase washed with 1.0 M HCl (2x) and brine (lx). The organic phase was dried over anhydrous MgS04, filtered, and the filtrate evaporated under reduced pressure. The residue was purified by flash chromatography (10% EtO Ac/Hex) to give the 162- 1 as a brown solid (26 g, 68%).
TLC: Rf: 0.45 (EtO Ac/Hex, 25/75; detection: UV, KMn04).
Step T162-2. To a solution of 162-1 (26.0 g, 136 mmol, 1.0 eq) and 136- A (52.1 g, 218 mmol, 1.6 eq) in dry DMF (500 mL) are added potassium carbonate (22.6 g, 163.2 mmol, 1.2 eq) and potassium iodide (4,5 g, 27.2 mmol, 0.2 eq). The solution was heated and stirred at 55"C overnight under nitrogen. The mixture was diluted with water (500 mL) and diethyl ether (500 mL), and the aqueous phase extracted with Et20 (2 x 300mL). The organic phases are combined and washed with citrate buffer (400 mL) and brine (2 x 300 mL). The organic phase was dried over anhydrous MgS04, filtered, and the filtrate evaporated under reduced pressure. The yellowish oil residue was purified by flash chromatography (5% ethyl acetate/hexanes) to give 162-2 as a colorless oil (37.0 g, 78%).
TLC: Rf: 0.77 (EtO Ac/Hex, 25/75; detection: UV, KMn04).
Step T 162-3. A solution of 162-2 (1.05 g, 3.0 mmol, 1.0 eq), 162-A (1 .02 g, 6.0 mmol, 2.0 eq), PPh3 (79 mg, 0.3 mmol, 0.1 eq) and TBAF (1 M in THF, 9 mL, 9.0 mmol, 3.0 eq) in THF (10 mL) was degassed and refilled with argon twice. Pd2(dba)3 (137 mg, 0.15 mmol, 0.05 eq) was then added, the mixture degassed and refilled with argon, and the reaction stirred at 60"C overnight under argon. The solvents were evaporated under reduced pressure and the mixture diluted with EtOAc, filtered through a silica gel pad and washed with ethyl acetate until there was no more material eiuting as indicated by TLC. The solvent was removed under reduced pressure until dryness, then the residue purified by flash chromatography (40% EtOAc/Hex, repeated 2x) to yield 162-3 as an orange oil (700 mg, 72%).
TLC: Rf: 0.56 (EtOAc/DCM, 20/80; detection: UV, ninhydrin);
HPLC/MS (Gradient A4): tR: 6.66 min, [M]+ 323.
Step T 162-4. To a solution of 162-3 (700 mg, 2.2 mmol, 1 .Oeq) in 95% ethanol (30 mL) under nitrogen was added palladium on carbon (10% by weight, 50% water, 200 mg, 30% weight eq), then treated with hydrogen gas maintained at 60 psi for 4-6 h. The reaction was filtered through a Celite pad and washed with ethanol until no additional material was eiuting. The combined filtrate and washings was evaporated under reduced pressure until dryness. The residue was purified by flash chromatography (20% EtOAc/DCM) to give the Boc-T162a as a yellowish oil (690 mg, 97%).
TLC: Rf = 0.46 (20/80, EtOAc/DCM; detection: UV, ninhydrin);
HPLC/MS(Gradient A4): tR: 6.92 min, [M+H]+ 328; Ή NMR (CDCI3): δ 6.90 (m, 3H, Ar), 4.69 (br, 1H, NH), 4.15 (m, 2H), 3.93 (m, 2H), 3.67 (m, 1H), 3.07 (m, 1H, OH), 2.79 (m, 1H), 2.59 (m, 1 H), 1.82-1.59 (m, 2H), 1.43 (s, 9H), 1.14 (d, J = 6.5Hz, 3H).
The enantiomeric tether, Boc-T162b, is accessed by the same procedure, but starting from the enantiomeric amino alkyne, 162-B.
Figure imgf000277_0001
Boc-T162b
JJ. Standard Procedure for the Synthesis of Tether Ϊ163
Figure imgf000277_0002
163-0 55°C, O/N, H2 163-1
96%
Pd(Ci)2(Ph3P)2] Diisopropylamine
NHBoc Cul, Ph3P, 60°C, O/N
162-A 91 %
Figure imgf000277_0003
Boc-TI 63a
163-2
Step T163-1. To a solution of 2-bromo-4-fluorophenol (163-0, 14 g, 73 mmol, 1.0 eq) and protected 136-A (29.8 g, 125.0 mmol, 1.7 eq) in DMF (Dnsolv, 230 mL) are added potassium carbonate (12,7 g, 92 mmol, 1.25 eq) and potassium iodide (2.42 g, 14.8 mmol, 0.2 eq). The reaction was heated to 55°C and stirred overnight under nitrogen. The solvent was removed under reduced pressure until dryness, then the residual oil diluted with water (200 mL) and extracted with ether (3 x 150 mL). The organic phases are combined, washed with citrate buffer (2x), brine (Ix), dried with magnesium sulfate, filtered, and the filtrate evaporated to dryness under reduced pressure. The residue was purified by flash chromatography (10% EtO Ac/Hex) to give 163-1 as a yellowish solid (24.6 g, 96%).
TLC: Rf: 0.68 (EtOAc/Hex, 25/75; detection: UV, CMA); HPLC/MS (Gradient A4): tR: 13.93 min, [M+Hf 349, 351.
Step T163-2. To a solution of 163-1 (3.5 g, 10 mmol, 1.0 eq), 162-A (3.0 g, 17 mmol, 1.7 eq) and triphenylphosphine ( 161 mg, 0.06 eq) in diisopropylamine (ACS grade, 58 mL) was bubbled argon for 15-20 min. Then, recrystallized copper (1) iodide (39 mg, 0.02 eq) and dichlorobis(triphenyphosphine) palladium (Π) (210 mg, 0.03 eq) were added and the reaction mixture stirred at 60UC overnight under argon. The solution was filtered through a silica gel pad and washed with ethyl acetate until there was additional material e!uting. The solvent was removed under reduced pressure until dryness, then the residual oil purified by flash chromatography (10% EtOAc/Hex) to provide 163-2 as a yellowish oil (4.0 g, 91%).
TLC: Rf: 0.60 (EtOAc/Hex, 25/75; detection: UV, ninhydrin);
HPLC/MS (Gradient A4): tR: 13.65 min, [M]+ 437, [M+Na]+ 460.
Step T 163-3. To a solution of 163-2 (4.05 g 9.41 mmol, 1.0 eq) in 95% ethanol (241 mL) under nitrogen was added palladium on carbon (434 mg, 10%; by weight/50% water). (Note that more concentrated reaction conditions (> 0.04 ) led to some dimer formation.) The solution was stirred under 400 psi hydrogen gas overnight. When the reaction was complete, nitrogen was bubbled through the mixture for 10 min to remove the excess hydrogen. The solvent was filtered through a Celite pad and washed with ethyl acetate until there was no additional material eluting. The combined filtrate and washings were concentrated until dryness under reduced pressure. The resulting residue was purified by flash chromatography (gradient, 30% EtOAc Hex to 75% EtOAc/Hex) to yield Boc-T163a as a yellowish oil (2.8 g, 91%). The TBDMS group was removed during the hydrogenation.
TLC: Rf: 0.30 (EtOAc/Hex, 40/60; detection: UV, ninhydrin);
HPLC/MS (Gradient A4): tR: 7.00 min, [M+Na]+ 350;
1H NMR (CDC13): δ 6.84-6.75 (m, 3H), 4.6 (m, 1H), 4.01 (m, 2H), 4.0 (m, 4H), 3.65 (m, 1 H), 2.7 m, 1H), 2.55 (m, 1H), 1.85 (m, 1 H), 1.65(m, 1 H), 1.45(s, 6H), 1.15 (d , 7Hz, 3H).
The enantiomeric tether, Boc-T163b, is accessed by the same procedure, but starting from the enantiomeric amino alkyne, 162-B.
Figure imgf000278_0001
Boc-T163b KK. Standard Procedure for the Synthesis of Tether T164
Figure imgf000279_0001
Figure imgf000279_0002
, Ν Η·,
Figure imgf000279_0003
164-5
Figure imgf000279_0004
Step T 164-1. To a solution of rc-BuLi (36.1 mL, 1.6 M in hexanes, 57.8 mmo!, 1.1 eq) in THF (dry, distilled from Na-benzophenone ketyl, 200 mL) was added a solution of 3-fluoroanisole (164-0, 6.0 mL, 52.5 mmol, 1.0 eq) in THF (dry, 20 mL) dropwise at -78°C under N2 (-15 min). The reaction was stirred at -78 °C for 10 min, then a solution of h (16.0 g, 63 mmol. 1.2 eq) in THF (dry, 100 mL) was added dropwise at -60-78°C (-30 min). The mixture was allowed to warm to -60°C and stirred for 30 min. H20 (50 mL) was added carefully, followed by Na2S03 (10% w/v; 50 mL) and the solution stirred for 5 min. The layers were separated, the aqueous phase extracted with hexanes (3x). The combined organic phase was washed with Na2S03 (10% w/v; 2x) and H20 (2x), dried over anhydrous MgS04, filtered, and the filtrate concentrated under reduced pressure to leave a yellow residue, which was purified by flash chromatography (5% EtOAc/hexanes) to afford 9.3 g (70%) of 164-1 as a colorless oil.
TLC: Rf = 0.34 (5% EtOAc/95% hexanes; detection: UV, Mo/Ce).
Step T 164-2. To a solution of 164-1 (9.3 g, 36.9 mmol, 1.0 eq) in DCM (dry, 100 mL) was added a solution of BBr3 in DCM (1.0 M, 92.3 mL, 92.3 mmol, 2.5 eq) dropwise at -30°C under N2 (~30 min). The solution was allowed to warm to 0°C over 3 h, then stirred at 0°C for an additional 3 h. MeOH was added dropwise carefully (gas evolution), followed by the addition of H20. The cooling bath was removed and the mixture stirred for 10 min. The layers were separated and the aqueous phase extracted with DCM. The combined organic phase was dried over anhydrous MgS04, filtered, and the filtrate concentrated under reduced pressure to leave black residue, which was purified by flash chromatography (20% EtOAc/hexanes) to provide 7.5 g (86%) of 164-2 as a brown oil.
TLC: Rf = 0.09 (5% EtOAc/95% hexanes; detection: UV, Mo/Ce).
Step T164-3. To a solution of 164-2 (7.5 g, 31.5 mmol, 1.0 eq) and 136- A (11.3 g, 47.3 mmol, 1.5 eq) in DMF (dry, 100 mL) were added K2C03 (5.6 g, 41.0 mmol, 1.3 eq) and KI (1.0 g, 6,3 mmoi, 0.2 eq). The mixture was stirred at 55°C overnight. Water was added and the aqueous phase extracted with ether. The organic phase was washed with brine, dried with MgS04, filtered, and the filtrate concentrated under reduced pressure. The resulting residue was purified by flash chromatography (5% EtOAc/he anes) to give 13.7 g of a mixture of the expected product 164-3 and 136-A (15% by Ή NMR) that was used without further purification in the next step.
TLC: Rf = 0.57 (10% EtOAc/90% hexanes; detection: UV, Mo/Ce).
Step T 164-4. To a solution of 164-3 (12.8 g, 32.3 mmol, 1.0 eq) in THF (200 mL) was added a solution of TBAF (1 M in THF, 48.5 mL, 48.5 mmol, 1.5 eq) and the mixture stirred at RT for 30 min. Brine was added and the aqueous phase extracted with EtOAc. The combined organic phase was dried with MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (50%EtOAc, 50% hexanes) to yield 164-4 as a white solid (7.3 g, 80%, 2 steps).
TLC: Rf = 0.22 (50% EtOAc/50% hexanes; detection: UV, Mo/Ce).
Step T164-5. To a solution of 164-4 (7.3 g, 1.0 eq, 25.9 mmol) in THF (52 mL) was added 164-A malate salt (5.8 g, 28.5 mmol, 1.1 eq) and the mixture degassed with Ar for 30 min. Cul (recrystallized, 248 mg, 1.3 mmol, 0.05 eq), PdCl2(PPh )2 (912 mg, 1.3 mmol, 0.05 eq) and 2 M NH4OH in H20 (52.0 mL, 103.6 mmol, 4.0 eq) were added and the mixture again degassed with Ar for 30 min. The reaction was stirred at RT overnight with monitoring by HPLC. The THF was evaporated and the aqueous phase acidified to pH 2 with 2 N HCl with formation of a brown insoluble gum. The aqueous phase was filtered through a small pad of Celite and rinsed with 0.01 M HCl. The aqueous phase was adjusted to pH 13-14 with basified with 6 N NaOH and extracted with EtOAc. The combined organic phase was dried with MgS04, filtered, and the filtrate concentrated under reduced pressure to afford 165-5 as an orange solid (5.0 g, 86%). Step T164-6. To a solution of 164-5 (5.0 g, 22.4 mmol, 1.0 eq) in 95% EtOH (100 mL) was added wet 10% Pd/C (4.7 g, 2.24 mmol, 0.1 eq). The mixture was stirred in a Parr hydrogenator under 60 psi of ¾ for 5 h, with monitoring of the reaction by HPLC. Upon completion, nitrogen was bubbled through to remove excess hydrogen, then the mixture passed through a pad of Celite and rinsed with 95% EtOH. The combined filtrate and washings were concentrated under reduced pressure to provide 165-6 as an orange oil (5.0 g, 100%).
Step T164-7. To a solution of 165-6 (5.0 g, 22.0 mmol, 1.0 eq) in THF:H20 (1 : 1, 100 mL) were added Na2C03 (2.6 g, 24.2 mmol, 1.1 eq) and (Boc)20 (5.3 g, 24.2 mmol, 1.1 eq). The mixture was stirred at RT overnight, then water added. The aqueous phase was extracted with EtOAc and the combined organic phase was dried with MgS04, filtered, and the filtrate concentrated under reduced pressure. The residue was purified by flash chromatography (40%EtOAc, 60% hexanes) to give Boc-T164a as a pale yellow oil (6.4 g, 86%).
TLC: Rr = 0.47 (50% EtOAc/50% hexanes; detection: UV, Mo/Ce);
HPLC/MS (Gradient A4): tR: 7.16 min, fM+Naf 350;
!H NMR (300 MHz, CDC13): δ 7.10 (1H, q), 6.64 (2H, dd), 4.63 (1H broad), 413-392 (4H, m), 3.64 (1H, broad), 2.70 (2H, t), 1.80 and 1.59 (2H, 2 broad), 1.45 (9H, s), 1.15 (3H, d).
The enantiomeric tether, Boc-T164b, is accessed by the same procedure, but starting from the enantiomeric amino alkyne, 164-B.
Figure imgf000281_0001
LL. Standard Procedure for the S nthesis of Tether T165
Figure imgf000282_0001
165-0 165-A
TMSC! TBDMSCI, DIPEA
MeOH DCM
75% 80%
Figure imgf000282_0002
165-2
DiBAL-H
DCM
Figure imgf000282_0003
For T165a, the protected phenol 165-1 was coupled with the chiral alcohol 165-B derived from (S)-l,2-propanediol under Mitsunobu conditions to provide 165-2. Reduction of the ester to the alcohol was followed by step- wise standard transformations including conversion to the mesylate, azide displacement, reduction of the azide to the amine with triphenylphosphine, protection of the amine, and deprotection of the silyl ether to provide Boc-T1
Figure imgf000282_0004
TMSCI TBDMSCI, D!PEA
MeOH DCM
75% 80%
Figure imgf000282_0005
165-5
DiBAL-H
DCM
Figure imgf000282_0006
An identical sequence in equivalent yields is used to convert 165- 1 to Boc-T165b except that chiral alcohol 165-D derived from (R)-l,2-propanediol was employed in the Mitsunobu reaction (to form 165-5).
MM. Standard Procedure for the S nthesis of Tether T
Figure imgf000283_0001
BOC-T8 166-1
NaH, Mel
RT, 6 h
Figure imgf000283_0002
BOC-T166 166-2
The synthesis of tether T166 was realized starting from tether T8. Protection of the alcohol as its THP ether was followed by alkylation of the carbamate nitrogen with sodium hydride as base and methyl iodide as electrophile. Acidic cleavage of the THP ether was carried out at higher temperature, but left the Boc group intact, to provide Boc-T166.
NN. Standard Procedure for the Synthesis of Tether T167
Two alternative approaches to the synthesis of tether T167 are provided above. The first is by simple reduc
Figure imgf000283_0003
BOC-T166 Boc-T167
In addition, a similar sequence as described for Boc-T166 can be employed, but starting from tether T9.
Figure imgf000284_0001
Boc-T9 167-1
NaH, Mel
RT, 6 h
Figure imgf000284_0002
Boc-T167
OO. Standard Procedure for the Synthesis of Tether T168
, ΟΗ 1. TBDMSCI, imidazole
THF .,¾OTBDMS Ph-,P=CHCOOEt .OTBDMS
OEt 2. DIBAL-H, Et20,
T C6HBi reflux
-78°C
o O OEt
60%
104-1 68-1 168-2 O
Figure imgf000284_0003
168-3 168-4
Figure imgf000284_0004
Boc-T 68b
The synthesis of tether T168 was initiated from ethyl (lR,2S)-ci's-2-hydroxy-cyclohexanoate 104-1 (obtained from Julich, now Codexis). Protection of the alcohol as its t-butyldimethylsi!yl (TBDMS) ether was followed by controlled low temperature reduction of the ester to the corresponding aldehyde (168-1). Subsequent Wittig reaction gave the unsaturated ester 168-2. A series of transformations involving reduction of the double bond, lithium aluminum hydride reduction of the ester, and conversion of the alcohol to the corresponding phthalimido derivative via a Mitsunobu reaction produced intermediate compound 168-3 in very good yield, Deprotection of the TBDMS ether under acid conditions was followed by palladium catalyzed attachment of the allyl carbonate to afford 168-5. Cleavage of the phthalimido group with hydrazine and subsequent protection of the resulting amine as its Boc derivative provided 168-6. This intermediate was converted into Boc-T168 by ozonoloysis under reducing conditions. In addition, 168-6 could be transformed into the corresponding aldehyde, 168-7, by modification of the ozonolysis reducing conditions. 168-7 was useful in attachment of the tether by reductive amination.
O3, PPh3] CH2C!2
168-6
90% „NHBoc
168-7
PP. Standard Procedure for the Synthesis of Tether T169 l2 AgTFA
Figure imgf000285_0001
DIAD, THF eOH/THF {2:1 )
RT, 2 h 0°C->RT, 3 h CHCh RT
169-0 169-1 169-2
Figure imgf000285_0002
OTBDMS OTBDMS
H2i Pd/C BnO O Boc20, Na2C03 BnO.
EiOH, RT, 100 h NH2 THF/H20 NHBoc
RT, O/N
169-6 169-7
OH
TBAF BnO
THF, RT, 1 h NHBoc
Boc-T169a{Bn)
The free phenol of resorcinol monobenzoate (169-0) was protected as its benzyl ether using standard methods. Saponification of the ester gave 169-2, which was iodinated in the presence of silver trifluiOacetate to afford 169-3. Alkylation of the phenol with the protected bromide 169-A provided 169-4. In the key step, this was subjected to Pd(II) coupling with the chiral alkynyl amine 169-B yielding 169-5 possessing the entire framework of the tether. Subsequent sequential catalytic hydrogenation of the triple bond, Boc protection of the amine, and cleavage of the TBDMS ether were conducted with standard methods to leave Boc-T169a(Bn). Use of the enantiomeric amine of 169-B provided a route to the enantiomeric tether Boc-T169b(Bn).
Figure imgf000286_0001
QQ. Standard Procedure for the Synthesis of Tether T170
Figure imgf000286_0002
NBS, DCM -30°Ο, 30 min 65%
Figure imgf000286_0003
NHBoc
=— (170-B)
65% Cul, Pd{PhCN)2CI2
{f-Bu)3PBF4l HN(iPr)2,
Dioxane, 70°C, O/N
Figure imgf000286_0004
Starting from 30 g (0.14 mol) of resorcinol monobenzoate (169-0), the free phenol was protected as its benzyl ether utilizing standard methodology. Cleavage of the ester in base followed by bromination with NBS gave the 4-bromoderivative (170-4). Mitsunobu coupling with (S)-ethyl lactate (170- A) provided 170-5. The ester was reduced with lithium borohydride and the resulting bromoalcohol (170-6) subjected to Pd(II)-mediated coupling with Boc-propargylamine (170-B). The alkyne was reduced to 170-7, with concomitant cleavage of the benzyl ether, which protection then had to be restored under standard conditions to yield the protected tether derivative. Alternatively, 170-6 could be subjected to a different Pd(II)-mediated coupling reaction with Boc-allylamine (170-C) to provide the protected tether directly. Use of (R)-ethyl lactate (or other appropriate alkyl ester of (R)-lactic acid) in this procedure provides the corresponding protected enantiomeric tether Boc- T170b(Bn).
Figure imgf000287_0001
RR. Standard Procedure for the Synthesis of Tether T171
Figure imgf000287_0002
169-0 171 -1 171-2
Figure imgf000287_0003
Boc-T171a The synthesis of tether T171a proceeded as presented above starting from the monobenzoate of resorcinol (169-0). Protecting group manipulation followed by iodination gave 171-3. Alkylation with 171-A (equivalent to 134-0, see synthesis described with T 161 ) followed by Sonogashira coupling with 171-B gave intermediate 171-7. Reduction provided Boc-T171a, The enantiomeric tether T171b, is accessed using the same sequence, but using 171-C (equivalent to alkyne derived from 161-6, see synthesis described with T161), the enantiomeric reagent of 171 -B .
Figure imgf000288_0001
SS. Standard Procedure for the Synthesis of Tether T172
Figure imgf000288_0002
172-1 Boc-T172a
The synthesis of tether T172a proceeded starting from protected iodo-phenol 172-0 and a Pd(0)-mediated Sonagashira coupling with the protected amino alkyne, 172-A, to yield 172- 1. Reduction of the alkyne provided Boc-T172a.
The chiral reagent 172-A is accessed as illustrated originating from (R) 2-arnino-l-pentanol (172-2).
Figure imgf000288_0003
172-4
O O
,P(O e)2
NHBoc
N,
K2C03 MeOH
172-A RT,' 2 h
The enantiomeric tether, T172b, is constructed similarly, but using the reagent 172-B, which is synthesized as outlined for 172-A beginning from (S)-2-amino-l -pentanol. NHBoc
Figure imgf000289_0001
Boc-T172b
TT. Standard Procedure for the Synthesis of Tether T173 HBoc
Figure imgf000289_0002
173-1 Boc-T 3b
In a similar manner to that just described for T172, the preparation of tether T173b started from protected iodo-phenol 172-0 and a Pd(0)-mediated Sonagashira coupling with the protected amino alkyne, 173-A, to yield 173-1, followed by complete reduction of the alkyne yielded Boc-T173b. The 173-A reagent is accessed from the chiral amino alcohol, 173-0, as shown.
Figure imgf000289_0003
The enantiomeric tether Boc-T173a is constructed using the same process utilizing the reagent 173-B, which in turn can be synthesized from the enantiomeric amino alcohol 173-4 as described for 173-A. NH,
OH
173-4
173-B
Figure imgf000290_0001
Boc-T173a
UU. Standard Procedure for the Synthesis of Tethers T174 and T175
Figure imgf000290_0002
BOC-T175a
175-2
(Boc-T174a)
Tethers T174 and T175 are accessed from the same sequence starting from the alkylated phenol (175-0) prepared in a manner similar to the synthons already described, Deprotection followed by Sonogashira coupling with the chiral alkyne, 161-4, gave 175-2 in high yield, which is equivalent to Boc-T174a. Reduction of 175-2 then provided Boc-T175a also in excellent yield.
Figure imgf000291_0001
175-3
The enantiomeric tethers T174b and T175b are prepared employing an identical sequence using 175-3, the enantiomeric reagent to 161-4.
VV. Standard Procedure for the Synthesis of Tether TI76
^^ HBoc
(176-A)
Figure imgf000291_0002
In a straightforward manner, Sonogashira coupling of the alcohol 176-0 with Boc-protected propargylamine (176-A) yielded Boc-T176. 176-0 can be accessed from the corresponding pheno! by a two-step sequence involving alkylation with a protected 2-haloalcohol followed by deprotection.
WW. Standard Procedure for the Synthesis of Tethers T178 and T179
Figure imgf000291_0003
BH3.DMS {10 M)
Figure imgf000291_0004
Boc-T179a The tethers T178 and T179 both are generated from the single sequence illustrated above. Mitsunobu reaction of the halogenated phenol ( 179-0) with (S)-ethyl lactate gave 179-1. Hydrolysis to 179-2, followed by borane reduction provided the bromide 179-3, as the precursor to the Pd(0)-coupling reaction. Sonogashira of this intermediate using the chiral alkynylamine (179-A) gave 179-4, which is equivalent to Boc-T178a. Complete reduction of the triple bond then produced Boc-T179a.
An analogous method, but using the enantiomeric alkyne, 179-B, provides the protected tethers, Boc-T178b and Boc-T179b. Similar methods, but utilizing (R)-efhyi lactate or other appropriate (R)-lactate ester, are used to provide the diastereomeric tethers Boc-T178c, Boc- -T179c and Boc-T179d.
Figure imgf000292_0001
Boc-T178d
YY. Standard Procedure for the Synthesis of Tethers T180 and ΊΊ81
Figure imgf000293_0001
181-1
(Boc-T180a) HBoc
Figure imgf000293_0002
Boc-T181 a
Beginning from intermediate 1.79-3, tethers T180 and T181 are prepared by Sonogashira coupling with the protected alkynylamine 161-4 followed by reduction of the coupled product 181-1 (equivalent to Boc-Tl 80a) to provide Boc-T181a.
The diastereomeric tethers, Boc-Tl 80b and Boc-Tl 8 lb, are accessed by the same procedure, but using 175-3, the enantiomeric reagent to 161-4. Employing 179-6, the enantiomer of 179- 3, together with 161-4 or 175-3, can be used to synthesize Boc T180c and Boc-T181c or Boc-Tl 80d and Boc-Tl 8 Id, respectively.
Figure imgf000293_0003
Boc-Tl 80d ZZ. Standard Procedure for the Synthesis of Tethers T182 and TI83
Figure imgf000294_0001
Alkylation of the bromophenol 183-0 with (S)-ethyl lactate under Mitsunobu conditions is used to synthesize 183-1. Base hydrolysis followed by borane reduction gives the intermediate alcohol 183-3. Sonogashira coupling with the alkynylamine 161-4 yields 183-4, equivalent to Boc-T182a. Complete reduction of the triple bond then provides Boc-T183a. The diastereomeric tethers, Boc-T182b and Boc-T183b, are accessed by a similar procedure, but using 175-3, the enantiomeric reagent to 161-4. Employing 183-5, the enantiomer of 183 3, together with 161-4 or 175-3, can be used to synthesize Boc-T182c and Boc-T183c or Boc-T182d and Boc-T183d, respectively. 183-5 can be prepared from (R)-ethyl lactate or another suitable ester.
Figure imgf000295_0001
IJ93 AAA. Standard Procedure for the Synthesis of Tethers T184 and Tether T185
Figure imgf000296_0001
Boc-T185a
In a straightforward manner starting from intermediate 176-0, Sonogashira coupling with 161 -4 gives 185-1 (equivalent to Boc-T184a). Reduction of the alkyne then provides Boc- T185a.
The enantiomeric tethers, Boc-T184b and Boc-T185b, can be accessed by the same procedures, but using 175-3, the enantiomeric reagent to 161 -4.
Figure imgf000296_0002
BBB, Standard Procedure for the S nthesis of Tether T186
Figure imgf000296_0003
134-4 Boc-T186a
Deprotection of intermediate 134-4 under standard conditions is used to provide Boc-T186a. The enantiomer of 134-4 leads to the enantiomeric tether Boc-T186b. CCC. Standard Procedure for the Synthesis of Tether T187
Figure imgf000297_0001
100%
NHBoc (187-B)
Pd(PhCN)2CI2, dioxane Cul, P(Bu)3, 10% hexanes /-Pr2NH, 60°C, O/N
75%
Figure imgf000297_0002
Boc-T187 , 0 ' "
The dihalogenated phenol, 187-0, was alkylated with the protected bromo alcohol, 187-A, then subjected to Pd(0)-coupling conditions to prepare the intermediate 187-2 in very good yields, Deprotection utilizing standard methods gave Boc-T187.
DDD. Standard Procedure for the Synthesis of Tether T188
Br
Figure imgf000297_0003
NHBoc
Figure imgf000297_0004
Boc-T188a
The iodophenol, 188-1, was prepared through a diazotization-displacement sequence. Alkylation with the protected bromoalcohol 188-A, followed by hydrolytic removal of the silyl ether protecting group left 188-2. Sonogashira coupling with chiral alkynylamine 161-4 prepared Boc-T188a in modest yield. An alternative, one step sequence, was also effective for providing 188-2 directly from 188-0,
Figure imgf000298_0001
The enantiomeric tether, Boc-T188b, can be synthesized by the same procedure, but using
175-3, the enantiomeric reagent to 161-4.
EEE. Standard Procedure for the nthesis of Tether TI
Figure imgf000298_0002
188-2
A B-Alkyl Suzuki-Miyaura coupling of intermediate iodoalcohoi 188-2 with the alkene 189-1 was utilized to prepare the protected tether Boc-T189a. The reagent 189-1 was provided by partial reduction of the alkyne, 161-4.
^ NHBoc H2 ^\/NHBoc
; Lindlar's catalyst -
\ MeOH, RT
161 -4 80% 189_1
175-3, the enantiomer of 161-4, likewise can be used to provide 189-2. This, when subjected to the Pd(0)-conditions just described leads to the enantiomeric tether Boc-Tl 89b.
Figure imgf000298_0003
175-3 189-2 Boc-T189b
FFF. Standard Procedure for the Synthesis of Tether Ϊ190
Figure imgf000299_0001
.OH
HO" Base
Figure imgf000299_0002
Iodination of 190-0, followed by chlorination and displacement with the alkoxide from ethylene glycol, gives 190-3. B-Alkyl Suzuki -Miyaura coupling using protected allylamine
190-A leads to BOC-T190.
GGG. Standard Procedure for the Synthesis of Tether T191
Figure imgf000299_0003
Boc-T191 a
Modification of the alkene component in the process described for tether T190 is used to access tether T191. Substitution of the protected chiral unsaturated amine 189- 1 in the B-alkyl Suzuki-Miyaura reaction provides Boc-T 191 a. Analogously, 189-2, the enantiomer of 189- 1 , can be used to prepare the enantiomeric tether Boc-T ! 91 b. HHH. Standard Procedure for the Synthesis of Tether T192
Figure imgf000300_0001
192-0 192-1
Figure imgf000300_0002
The boronic acid, 192-1, is synthesized from the iodide, 192-0, by a multi-step process involving metal-halogen exchange, treatment with triisopropylborate and hydrolysis. Suzuki coupling with the chiral iodide gives 192-2, which is then deprotected to leave Boc-T192a. The enantiomer of 192-A can be employed to provide the enantiomeric tether, T192b.
III. Standard Procedure for the Synthesis of Tether Ϊ193
Figure imgf000301_0001
193-2
Figure imgf000301_0002
Boc-T 93a
Cyclopentenone (193-0) is reacted with the boronic acid 193-A in the presence of the chiral rhodium complex indicated to provide 193-1 in good optical purity (> 96% ee). Reductive amination, cleavage of the aromatic methyl ether and protection of the amine gives 193-4. Alkylation of the phenol with the protected synthon 193-B and deprotection of the silyl ether leads to Boc-T193a. Use of the S-BINAP ruthenium complex would produce 193-5, the enantiomeric cyclopentanone to 193-1, which in turn provides Boc-T193b.
Figure imgf000301_0003
193-5
Boc-T193b JJJ. Standard Procedure for the Synthesis of Tether T194
Figure imgf000302_0001
142-2 BOC-T194
Boc-T194 is synthesized from the ketone derivative 142-2, an intermediate in the construction of T142, by treatment with DAST, followed by treatment with TBAF to ensure complete deprotection of the TBDMS ether.
K K. Standard Procedure for the Synthesis of Tether T195
Figure imgf000303_0001
Figure imgf000303_0002
195-3 195-4
DIBAL-H, DCM
Figure imgf000303_0003
195-5 195-6
Figure imgf000303_0004
BOC-T195
Formation of the alkenyl triflate 195-1 from 195-0 is performed in a standard manner. Palladium-catalyzed carbonylation is followed by methyl ether deprotection to give 195-3. Mitsunobu reaction of the phenol with the mono-t-butyldimethylsilylether of ethylene glycol (195-B) yields 195-4. Reduction of the ester to the alcohol leads to 195-5, which is then converted into the diprotected amine 195-6 again using a Mitsunobu process. The synthesis of Boc-T195 is completed by deprotection of the silyl protecting group with fluoride. LLL. Standard Procedure for the Synthesis of Tether T197
Figure imgf000304_0001
1 ) Bn2NH*HCI
(CH20)x, AcOH, 60°C
2) NaBH4 MeOH
3) H2 Pd/'c, EtOH
Figure imgf000304_0002
Alkylation of 197-0 proceeds well to give the ketone, 197- 1 . Concomitant aminomethylaiion and reduction of the carbonyl occurs under the reducing conditions indicated to prepare 197- 2. Protection of the amine, dehydration and acetate hydrolysis results in Boc-T197.
MMM. Standard Procedure for the Synthesis of Tether T198
Figure imgf000304_0003
[C!atsenJ
198-0 198-1 198-2
O
PPh3i DIAD
HO.
OEt MTBE
(198-A) 0CC -> RT
Figure imgf000304_0004
198-5 0°C -> RT 198-4 198-3
Figure imgf000304_0005
198-6 Boc-T198a(Bn) This tether is constructed beginning with protection of 2-benzyloxyphenol ( 198-0) as an allyl ether followed by Claisen rearrangement to provide 1.98-2. Mitsunobu reaction with (S)-ethyl lactate (199-A) gave 198-3. Hydroboration of the double bond and subsequent oxidation yielded 198-4. Another Mitsunobu reaction, this time with di-t-butyiiminodicarboxylate gave 198-5. Reduction of the ester with lithium borohydride and base cleavage of one of the Boc groups succeeded in affording Boc-T198a(Bn). Use of (R)-ethyl lactate (or other appropriate alkyl ester of (R)-lactic acid) in this procedure provides the corresponding protected enantiomeric tether Boc-T198b(Bn).
NNN. Standard Procedure for the Synthesis of Tether TX99 Boc-(2RMe,50H)ol8r
Figure imgf000305_0001
In a manner analogous to that already described for T 170, this tether was constructed starting from commercially available 4-(benzyloxy)phenol (199-0). This was brominated to give the 2-bromo derivative (199-1), which was coupled to (S)-ethyl lactate (199-A) under Mitsunobu conditions to provide 199-2. The ester was reduced to the aicohol with DIBAL-H to afford 199-3. Suzuki coupling to the 9-BBN derivative of 170-A yielded the protected tether, Boc- T199a(Bn). Use of (R)-ethyl lactate (or other appropriate alkyl ester of (R)-lactic acid) in this procedure provides the corresponding protected enantiomeric tether Boc-T 199b(Bn).
Figure imgf000305_0002
OOO. Standard Procedure for the Synthesis of Tether T200
Figure imgf000306_0001
200-1
Figure imgf000306_0002
Similar to the process described for tether 192, halogen-metal exchange of the iodide 200-0, reaction with triisopropylborate and hydrolysis leads to the boronic acid, 200-1. Suzuki coupling with the chiral alkenyl iodide 192-A and silyl deprotection yields Boc-T200a. Alternatively, the tin reagent 192-B or its enantiomer can be employed in the route to this tether.
Figure imgf000306_0003
200-0
Boc-T200a
Use of 192-C, the enantiomer of 192-A, provides the enantiomeric tether, Boc-T200b.
Figure imgf000306_0004
PPP. Standard Procedure for the Synthesis of Tether T210
Figure imgf000307_0001
2 0-0 210-1 210-2
Figure imgf000307_0002
210-3
Successive transformations involving iodination of 3-trifluoromethylphenol .(210-0), alkylation of the phenol and deprotection of the silyl ether gave intermediate 210-2. Sonogashira coupling with the alkyne 134-3 followed by reduction of the triple bond provided protected tether Boc-T210a. The enantiomeric tether, Boc-T210b, can be synthesized by the same procedure, but using 175-3, the enantiomeric reagent to 161-4.
QQQ. Standard Procedure for the Synthesis of Tether T211
Figure imgf000307_0003
21 1 -7
Figure imgf000307_0004
Boc-T211 a
Diazotization of the aniline 21 1-1 and displacement with iodide gives 211-2. Conversion of the carboxyiic acid into the amide under standard methods followed by cleavage of the aromatic methyl ether provides 211-3. Alkylation of the freed phenol and deprotection of the silyl ether is used to prepare the precursor for the Pd(0)-coupling, which is performed in a manner similar to other such transformations already described. Reduction of the alkyne leads to 211-6, an intermediate which itself could be useful as a tether component. Dehydration of the amide to the nitrile, then removal of the resulting trifluoroacetyl groups yields the target tether, Boc-T21 1a. The enantiomeric tether, Boc-T211b, can be synthesized by the same procedure, but using 175-3, the enantiomeric reagent to 161-4.
RRR. Standard Procedure for the Synthesis of Tether T212
Figure imgf000308_0001
A generally high-yielding sequence starting from the amino acid 212-1 was used to prepare protected tether Boc-T212. Conversion of the amine to the iodide was accomplished through diazotization and treatment with iodide. Transformation of the acid to the amide using the intermediacy of the acyl chloride was followed by boron tribromide cleavage of the methyl ether. Alkylation of the phenol, hydrolytic removal of the silyl protecting group and Sonogashira coupling gave 212-5. Complete reduction of the triple bond then provided Boc- 212a. The enantiomeric tether, Boc-T212b, can be synthesized by the same procedure, but using 175-3, the enantiomeric reagent to 161-4.
SS. Standard Procedure for the Synthesis of Tether T213
Figure imgf000309_0001
213-5 Boc-T2 3a
Using the approach described previously, iodide 213-1 was accessed in fair yield from the corresponding aniline, 213-0, Alkylation, Sonogashira reaction and reduction provided 213-4. This intermediate, with orthogonal protection of the aromatic amine could be used as a tether component. In this instance, the amine was converted into the methanesulfonamide under standard conditions. Deprotection of the TBDMS moiety completed the synthesis of Boc- T213a. The enantiomeric tether, Boc-T188b, can be synthesized by the same procedure, but using 175-3, the enantiomeric reagent to 161-4.
TXT. Standard Procedure for the Synthesis of Tether T214
Figure imgf000310_0001
reflux -30°C->0°C THF/HjO (1 :1)
69% 3.5 h 66% (2 steps)
Figure imgf000310_0002
70%
214-5 Boc-T214a
Construction of this tether was initiated by Wittig reaction of the ketone 214-0. The resultmg unsaturated product was reduced, then the ester saponified lo provide 214-2. Single pot Curtius rearrangement with protection of the amine yielded 214-3. Cleavage of the methyl ether resulted also in loss of the Boc group, therefore requiring reinstallation under standard conditions. (S)-Ethyl lactate was employed in the Mitsunobu reaction of the phenol, which was followed by reduction of the ester to complete the synthesis of Boc-T214a. Use of (R)- ethyl lactate, or other simple ester, in the Mitsunobu for the above procedure accessed the enantiomeric tether Boc-T214b.
UUU. Standard Procedure for the Synthesis of Tether T215
215-0
Figure imgf000310_0003
2-Bromo-5-fluorophenol was alkylated utilizing the analogous procedure as already utilized for multiple other tethers. Pd(0)-catalyzed Sonogashira coupling using the racemic alkynyl amine 215-A (synthesized as described below) led in good yields to 215-1. The most efficient process to complete the synthesis was to deprotect the silyl group followed by reduction, which gave Boc-T215.
The key reagent 2] 5- A was prepared from the amino acid 215-0 as illustrated. Reduction of the acid to the alcohol and protection of the amine gave 215- 1 . Oxidation with Dess-Martin periodinane (DMP) provided the aldehyde, which was converted into the alkyne (215-A) in good yield for the overall process.
NH2 NHBoc NHBoc
1. NaBH4, 1 DMP, H20
F3C. „OH F3C.
2. Boc20, Et3N CH2CI2, 0°C -> rt
O
82% O/N
215-2
215-0 215-1
O 0
, P(OMe}2
NHBoc
N,
F .
2C03, MeOH-toiuene
0°->rt, 2 h
215-A 68% (2 steps)
VVV. Standard Procedure for the Synthesis of Tether T216
. NHBoc
Figure imgf000311_0001
216-2 Boc-T216a
The dihaiogenated pyridine 216-0 was subjected to displacement with the anion of ethylene glycol, followed by Sonogashira reaction using 161-4 as the alkyne partner and hydrogenation of the triple bond, to produce Boc-T216a. The enantiomeric tether, Boc- T216b, can be synthesized by the same procedure, but using 175-3, the enantiomeric reagent to 161 -4. WWW. Standard Procedure for the Synthesis of Tether T217
Figure imgf000312_0001
The requisite aniline 217-1 was prepared from 3-trifluoromethylanisole using the procedure described in the literature (Pews, R.G. J. Fluorine Chem. 1998, 87, 65-67). The amine to iodide transformation proceeded via the diazo compound using chemistry as has been described earlier. Nucleophilic removal of the methyl ether with cyanide freed the phenol for subsequent alkylation. Deprotection of the alcohol silyl group provided the coupling precursor 217-3. Following the Sonogashira reaction, reduction of the alkyne gave Boc- T217a. The enantiomeric tether, Boc-T21.7b, can be synthesized by the same procedure, but using 175-3, the enantiomeric reagent to 161-4,
XXX. Standard Procedure for the Synthesis of Tether T218
Figure imgf000312_0002
The mono-benzoate of 1,3-dihydroxybenzene, 218-0, was converted into the mono- benzylated derivative, 218-1, in high yield through a protection-deprotection sequence. Iodination in the presence of silver (I) was followed by alkylation and selective silyl ether removal led to 218-3. Coupling with the alkyne 161-4 under Sonogashira conditions was then followed by reduction to provide tether Boc-T218a in very good yield. The enantiomeric tether, Boc-T218b, can be synthesized utilizing the same procedure, but using 175-3, the enantiomeric reagent to 161-4.
YYY. Standard Procedure for the Synthesis of Tether T
Figure imgf000313_0001
89%
Boc-T219a
219-1
The same intermediate as described previously for T216 was employed to construct this tether as well. Sonogashira reaction of 216-1 with alkyne 164-A provided 219-1. Subsequent reduction of the triple bond and Boc-protection of the amine gave Boc-T219a. The enantiomeric tether, Boc-T219b, can be accessed by the same procedure, but starting from the enantiomeric amino alkyne, 164-B.
ZZZ. Standard Procedure for the Synthesis of Tether T220
Figure imgf000313_0002
Boc-T220a Protected tether T212a was utilized in the preparation of this tether as well. Dehydration of the amide to the nitrile by heating with trifluoroacetic anhydride provided 220-1. Removal of the trifluoroactey! groups on the amine and alcohol with mild basic hydrolysis led to Boc- T220a in essentially quantitative yield. The enantiomeric tether, Boc-T220b, can be synthesized by the same procedure, but using 175-3, the enantiomeric reagent to 161-4, in the preparation of the precursor amide, Boc-T212b.
Figure imgf000314_0001
Boc-T212b Boc-T220b
Example 3
Macrocyclic Compounds of the Invention
In the construction of macrocyclic compounds of the invention, the amino acids are referred to as AA| , AA2 and AA3 using the same numbering as is standard for peptide sequences, that is from the N- to the C-termrnus.
Example Ml. Standard Procedure for the Synthesis of Compound 1319.
The synthesis of compound 1319 is outlined in Figure 1.
Step Ml -1: Dipeptide formation. To a solution of Cbz-NMeThr-OH (Ml -A, 136 mmol, 1.0 eq) in TFTF/DCM (1:1, 1.15 L) was added H-(D)Phe-OtBu-HCl (Ml-B, 150 mmol, 1.1 eq) and HATU (143 mmol, 1.05 eq). The mixture was cooled to 0°C and DIPEA added. The reaction was stirred at RT for 2-3 d under nitrogen, concluding when HPLC analysis indicated complete disappearance of Ml -A. The mixture was then concentrated under reduced pressure to give a yellow oil. This residue was dissolved in DCM and purified by dry pack (50% EtOAc/Hexanes) to give 54 g (85%) of dipeptide Ml-C as a yellow solid.
Step Ml -2. Cbz deprotection. Ml-C (54 g, 115 mmol, 1.0 eq) was dissolved in 95% EtOH (1.6 L) under nitrogen. 10% Pd on C (50% wet) was added and ¾ (g) bubbled into the mixture overnight. The mixture was filtered through a Celite pad and the filtrate concentrated under reduced pressure to provide 38 g (100%) of Ml -D as a yellow oil.
Step Ml -3. Tosylate formation. To a solution of Boc-T8 (80 g, 0.273 mol, 1.0 eq), triethylamine (76 mL, 0.546 mol, 2.0 eq) and DMAP (6.72 g, 0.055 mol, 0.2 eq) in DCM (359 mL) under nitrogen at 0°C was added, in 30 mL portions (every 5 min until complete), a solution of tosyl chloride (54.6 g, 0.287 mol, 1.05 eq) in DCM (910 mL). The reaction was stirred overnight at RT with monitoring of the reaction by TLC. A saturated aqueous solution of ammonium chloride was added (1 L) and extracted with DCM (2 x 600mL). The organic phases were combined and washed with 0.1 N HC1 (3 x 600 mL) and brine (600 mL). The organic phase was dried with MgS04, filtered, and the filtrate concentrated under reduced pressure to provide 1 6 g of Ml-E as an orange oil that was used as obtained in the next step without any further purification.
TLC: Rr = 0.30 (25% EtOAc hexanes; detection: UV, Mo/Ce);
HPLC/MS : Gradient A4, tR = 8.22 min, [Mj+ 447.
Step Ml-4. AA1 Alkylation. A solution of Ml-E (122 g, 0.273 mol, 1.0 eq) in DMF (139 mL) was degassed under reduced pressure for 30 min. Potassium iodide (dried at 140°C under vacuum O/N, 1 13.4 g, 0.683 mol, 2.5 eq), potassium carbonate (113.4 g, 0.819 mol, 3.0 eq), H-Val-OMe (MLF, 68.7 g, 0.410 mol, 1.5 eq) and propionitnle (EtCN, 417 mL) were then added under a nitrogen atmosphere. The solution was heated at 100°C O/N with TLC monitoring. Water was added (2.2 L) and the mixture extracted with EtOAc (3 x 1 L). The organic phases were combined and washed successively with citrate buffer (2 x 1 L), a saturated aqueous solution of sodium bicarbonate (2 x 1 L) and brine (2 x 1 L). The organic phase was dried over MgS04, filtered, and the filtrate concentrated under reduced pressure to give a yellow oil. This residue was purified by dry pack (gradient, 15% to 25% EtOAc/Hex) to give 87 g (80%) of Ml-G as an orange oil.
TLC: Rf = 0.38 (40% EtOAc/hexanes; detection: UV, Mo/Ce).
Step Ml-5. Ester cleavage. To a solution of Ml-G (80.0 g, 190 mmol, 1.0 eq) in THF:MeOH (1 : 1 , 1200 mL) was added 4 M LiOH (674 mL) and the mixture agitated (mechanical stirring) overnight. Solvents were evaporated in vacuo to leave a yellow gel. Water was added and the heterogeneous mixture was cooled to 0°C. 3 M HQ was then added to obtain a pH = 3-4 and agitation (mechanic stirring) continued. Note that this pH range is important to avoid premature Boc deprotection. A white precipitate formed, which was collected by filtration, rinsed with water, then ether. The precipitate was dissolved in THF and concentrated under reduced pressure. The solid residue was azeotroped with toluene (2x) and THF (lx), then dried under vacuum (oil pump) until Ή NMR (DMSO-d6) indicated water remained in only a trace quantity. Ml-H (82.2 g, 100%) was thus obtained as a white solid.
Step Ml-6. Coupling. To a suspension of Ml -H (78.8 g, 184 mmol, 1.5 eq) and Ml -D (38.6 g, 115 mmol, 1.0 eq) in THF:CH2C12 (1: 1, 1.5 L) was added HATU (70 g, 184 mmol, 1.5 eq) and DIPEA (120 mL, 690 mmol, 6.0 eq ) slowly. Formation of a gel during this addition
31.3 made the mixture very difficult to stir. The heterogeneous mixture was agitated (mechanical stirring) overnight with TLC monitoring. The solvents were evaporated in vacuo and the residue dissolved in EtOAc. The organic solution was washed successively with citrate buffer (2x), NaHC<¾ sat. aq. (2x) and NaCl sat. aq. ( l ). The organic phase was dried over MgS04, filtered, then the filtrate concentrated under reduced pressure to leave a yellow oil. This residue was purified by dry pack (30% EtO Ac/Hex) to give 68.2 g (58%) of Ml-I as a beige foam.
TLC: Rf = 0.31 (60% EtOAc/hexanes; detection: UV, Mo/Ce).
Step Ml -7. Deprotection. Ml-I (74.8 g, 105 mmol, 1.0 eq) was stirred in a solution of 50% TFA, 3% TIPS/CH2CI2 (840 mL) 5 h. The solvents were evaporated in vacuo, toluene added and the mixture again evaporated in vacuo. The residue was dried under vacuum (oil pump) overnight to provide MLJ as a yellow-orange solid that was used without further purification in the ne t step.
Step Ml-8. Macrocycle formation. To a solution of Ml-J (105 mmol, 1.0 eq) in THF (10.5 L) were added DEPBT (47.1 g, 158.0 mmol, 1.3 eq) and DIPEA ( 1 10 mL, 630.0 mmol, 6.0 eq). The resulting mixture was agitated (mechanical stirring) overnight. The reaction can be monitored by HPLC. Upon completion, THF was evaporated in vacuo and 1 Na2C03 (aq) added. The aqueous phase was extracted with EtOAc (3x). Then, the combined organic phase was washed with 1 M Na2C03 (aq, lx) and NaCl sat. (aq, lx), dried over MgS04, filtered, and the filtrate concentrated under reduced pressure to leave an orange residue. This orange residue was purified by dry Pack (gradient, 3% to 5% MeOH), then the pro duct- containing fractions precipitated in CH3CN to give compound 1319, 8.2 g (50%, 2 steps).
Step Ml -9. HC1 salt formation. Approximately 1 g of 1319 was placed in a 40 mL vial and 10 mL of acetonitrile added. To the suspension was added 2 eq of 1 M HC1 (3.4 mL) and the resulting mixture diluted with water to obtain 20 mL of total solvent. A concentration of 50 mg/mL of solvents was obtained and the macrocycle was totally soluble. The solvents were frozen in liquid nitrogen for 15 min, then iyophilized for 3 d to obtain the HC1 salt of 1319. Using this method, 11.1 g of 1319ΉΟ was obtained. Example M2. Standard Procedure for the Synthesis of Compound 1346.
Figure imgf000317_0001
A slightly different, but still convergent, procedure than thai used for compound 1319 was employed for the construction of compound 1346. The tether, Boc-T158 was attached to AA[, Bts-lle-OMe, using a Mitsunobu reaction to give M2-1. Removal first of the Bts group, which both activated and protected the nitrogen of AAi, was effected using standard conditions with thiopropionic acid and base, to provide M2-2, then the ester cleaved with lithium hydroxide in THF/MeOH to prepare M2-3. The AA2-AA3 dipeptide, H-NMeThr- (D)Phe-Ot-Bu (M2-A), synthesized separately using standard methods, was attached to the AAi -tether component using HATU as coupling agent to afford a low yield of M2-4. The Boc and t-Bu protecting groups were simultaneously removed via the usual method to give the macrocyclization precursor, M2-5. Cyclization with DEPBT under dilute conditions (-10 nM) gave the product, 1346, in an overall yield of 7.2%, after Hash chromatographic purification. In addition, compounds M2-1 , M2-2 and M2-4 were purified with flash chromatography, while M2-3 and M2-5 were used crude.
Example M3. Standard Procedure for the Synthesis of Compound 1350.
Essentially the same procedure as that used for compound 1346 was employed for the construction of compound 1350 as presented in Figure 2. The tether, Boc-T8 was attached to AA] , Bts-Val-OMe (1.0 g), using a Mitsunobu reaction to give M3-1. (1.84, 100%). Removal first of the Bts group was performed using standard conditions with thiopropionic acid and base, to provide M3-2 (1.5 g, 100%), then the ester cleaved with lithium hydroxide (or trimethyltin hydroxide) in THF/MeOH to prepare M3-3 (78%). The AA2-AA3 dipeptide, H- NMeThr-(D)mTyr-OMe (M3-A), was synthesized separately from the protected amino acids M3-7 and M3-8 in 70% yield on a 2 g scale using standard methods as shown. M3-A was connected to the AA[ -tether component using HATU as coupling agent in DMF (or NMP) to afford a low yield of M3-4. First the methyl ester moiety and then the Boc group were removed via the usual methods to give the macrocyclization precursor, M3-6. Cyclization with DEPBT gave the product, 1350 (6.2 mg) after HPLC purification.
Example M4. Standard Procedure for the Synthesis of Compound 1351.
The same procedure as that used above for compound 1350 (Figure 2) was employed for the construction of compound 1351 (30.9 mg), but starting from Bts-Ile-OMe. Coupling to the M3-A dipeptide occurred in 55% yield.
Example M5. Standard Procedure for the Synthesis of Compound 1352.
The same procedure as that used above for compound .1350 (Figure 2) was employed for the construction of compound 1352 (5.0 mg), but starting from the tether T125a. Specific yields obtained through the sequence, starting from 1 g Bts-VaTOMe, were: AA[ -tether formation
(100%), Bts deprotection (89%), and ester cleavage (100%).
Example M6. Standard Procedure for the Synthesis of Compound 1 36.
As outlined in Figure 3, the same procedure as that used above for compound 1350 was employed for the construction of compound 1636 (0.2 mg), but starting from the tether T104.
In particular, the coupling yield of the AA] -tether component to the dipeptide M3-A was low
(8%).
Example M7. Standard Procedure for the Synthesis of Compound 1383.
A modified reaction procedure to that already described was employed for the construction of compound 1383 and is provided in Figure 4. M7-1 was synthesized from Bts-VaFOMe and Boc-T125a as previously described using a Mitsunobu reaction. The AA2-AA dipeptide, H- NMeThr-(D)Tyr(3-Cl)-OMe (M7-B), was synthesized separately from the protected amino acids Boc-NMeThr-OH and H-(D)Tyr(3-Cl)-OMe (M7-A) as shown in 80% yield after flash chromatography (gradient 80% to 95% EtO Ac/Hex). M7-B and M7-1 were connected using HATU as coupling agent in NMP to afford a 30% yield of M7-2 after flash chromatography (gradient 80% to 95% EtOAc/Hex). Next, the methyl ester moiety was cleaved using trimethyltin hydroxide and then the Boc group was removed with HC1 in EtOAc to give the macrocyclization precursor, M7-4. Cyclization with DEPBT gave the product, compound 1383 (25% yield, 4.7% overall) after flash chromatography (5% MeOH/EtOAc), then HPLC purification.
Example M8. Standard Procedure for the Synthesis of Compound 1390.
In Figure 5 is presented the modified reaction procedure to those already described, which was employed for the construction of compound 1390. The dipeptide M8-1 was synthesized from Boc-NMeThr-OH and AA4(Bn) using standard methods. Deprotection of the Boc group with 2, 1 M HC1 in EtOAc gave M8-2, which was coupled to M7-1 using HATU as coupling agent in DCM/THF to afford a 64% yield of M8-3. Next, the benzyl ester moiety was cleaved using hydrogenolysis, then the Boc group was removed with TFA to give the macro cyclizati on precursor, M8-4. Cyclization with DEPBT gave the product, compound 1390 (135 mg, 63% yield) after HPLC purification.
Example M9. Standard Procedure for the Synthesis of Compound 1401.
A different reaction procedure to those already described was employed for the incorporation of the o-Tyr amino acid into the macrocyclic framework as summarized in Figure 6. M9-1 was synthesized from Bts-Val-OMe and Boc-T I 25a as previously described using a Mitsunobu reaction. Deprotection of the Bts moiety from this material with 3-mercaptopropionic acid and base provided M9-2, then cleavage of the Boc group with 2.1 M HC1 in EtOAc gave M9-3. This was followed by reaction with the Boc-o-Tyr lactone (AA5-3) in the presence of DIPEA as base to afford M9-4. The Boc group of M9-4 was removed and Boc-NMeThr-OH coupled to the resulting deprotected intermediate using HATU to provide M9-5 in 85% yield. Next, the benzyl ester protection was removed by hydrogenolysis to afford M9-6. Deprotection of the Boc group from M9-6, then cyclization with HATU in the presence of DIPEA base gave the product, compound 1401 , after HPLC purification.
Example M10. Standard Procedure for the Synthesis of Compound 1300.
A modified reaction procedure to those already described was employed in order to incorporate the amino acid H-NMe-(p-OH)Val-OH as illustrated for the construction of compound 1300 (see WO 2006/137974) is provided in Figure 7. MlO-1 was synthesized from Bts-Ile-OMe and Boc-T8 as previously described using a Mitsunobu reaction in 94% yield after flash chromatography. Deprotection first of the Bts group, then of the methyl ester, were performed using standard methods to give M 10-3. The AA -AA3 dipeptide, Η-ΝΜε(β- OH)Val-(D)PheOMe (M10-E), was synthesized separately from the protected amino acids H- NMe(P-OTHP)Val-OBn (M10-A) and H-(D)Phe-OMe. Protecting group modifications to give Boc-NMe(P-OH)Val-OBn (M10-B) in 63% yield after flash chromatography. The benzyl ester protection was removed by hydrogenolysis to provide M10-C, which was connected to H-(D)Phe-OMe'HCl using HATU as coupling agent in NMP to afford a quantitative yield of M10-D after flash chromatography. M10-E was prepared from M10-D by standard cleavage of the Boc group. This derivative, M10-E, in turn, was coupled lo M10- 3 again using HATU in NMP with DIPEA as base, although in low yield (15%) of M10-4. Next, the methyl ester moiety was cleaved using trimethyltin hydroxide and then the Boc group was removed with TFA/TES to give the macrocyclization precursor, M 1.0-6. Cyclization with DEPBT in dilute conditions (0.01 M) gave the product, compound 1300 ( 7% yield), after flash chromatographic purification.
Example Mil. Standard Procedure for the Synthesis of Compound 1505.
A reaction procedure essentially the same as described in Example Ml was employed to access compound 1505 as outlined in Figure 8. The dipeptide component, Ml l-C, was constructed from the protected amino acid derivatives Cbz-NMeThr-OH (Mi l -A) and H-(D)Trp(Boc)-OtBu (Ml l-B). Ml l-A was obtained as its cyclohexylamine (CHA) salt and, therefore, had to be converted to the corresponding free base prior to use as is known to those skilled in the art. As an example, 33 g (140 mmol, 1.0 eq)) of M l 1 -A was prepared from 50 g of the CHA salt. To this was coupled 51 g (140 mmol, 1.0 eq) of Mll-B, followed by removal of the Cbz protection under standard hydrogenolysis conditions, to provide 75 g (126 mmol, 90%) of dipeptide Ml l-C. Separately, tether T134a was converted into the corresponding tosylate then reacted with H-Val-OMe as nucleophile in EtCN-DMF solvent to give Ml 1-1 in 85% yield. Deprotection of the methyl ester with LiOH proceeded in quantitative yield to provide Ml 1-2. This intermediate (105 mmol) was coupled to Ml l-C (75 g, 126 mmol, 1.2 eq) using HATU to afford Ml 1-3 in 70-80% yield. Simultaneous acidic cleavage of the Boc and tBu protecting groups gave the Macrocyclization precursor Ml.1-4 essentially quantitatively. Cyclization was effected using DEPBT DIPEA in THF at a dilute concentration of -10 nM. The macrocycle 1505 was thus obtained in 50% yield (23 g, 37 mmol) after purification.
Example 4
Biological Results
Representative compounds of the invention were evaluated using the methods detailed in Methods B l, for binding activity to the ghrelin receptor, Methods B2 and B3, for functional activity as an antagonist at the ghrelin receptor and Method B4, for functional activity as an inverse agonist at the ghrelin receptor. Results are shown in Tables 7, 8 and 9, respectively.
Table 7. Ghrelin Receptor Binding Activity for
Representative Compounds of the Invention
Figure imgf000321_0001
1337 B B
1338 B B
1339 C C
1340 B B
1341 C D
1342 A A
1343 A -
1344 B -
1345 B C
1346 C D
1347 C C
1348 C D
1349 B -
1453 - A
1503 A
1505 - A
1535 B -
1551 B C
1552 C C
1554 D D
1555 C -
1556 B C
1558 C c
1559 C c
1560 C D
1601 A -
1655 A A
1688 - A
1689 - B
1690 - A
1691 A
1692 - A 1693 - B
1694 - D
1695 - C
1696 - D
1697 - C
1698 B
1699 - B
1700 - A
1701 - A
1702 A
1703 - A
1704 - B
1705 - B
1706 - C
1707 - B
1708 - C
1709 - B
1710 - B
1711 - A
1712 - A
1713 - A
1714 - A
1715 - A
1718 - A
1719 - B
1720 - B
1721 - C
1722 - B
1723 - B
1724 - B
1725 - B
1726 - B 1727 D
1728 - B
1729 A
1730 - A
1731 C
1732 - B
1733 - C
1735 - B
1736 - B
1737 - A
1738 - A
1739 - A
1740 - A
1741 - D
1742 - B
1743 - B
1744 D
1745 - B
1746 A
1747 - B
1751 - A
1752 - B
1753 - B
1754 - A
1755 - A
1756 - B
1757 - B
1758 - A
1759 - A
1760 - A
1761 - B
1762 - B 1763 - A
1764 - D
1768 - B
1769 B
1770 - C
1771 A
1772 - A
1773 - B
1774 - B
1775 - A
1776 - A
1777 - A
1778 - B
1779 - B
1780 - B
1781 - D
1782 - D
1784 - C
1785 - C
1786 - C
1787 - C
1789 A
1790a - A
1790b - C
1791 A
1792a - A
1792b - C
1794 A
1795 - A
1796 - A
1797 - B
1798 - A 1799 - A
1800 B
1801 - A
1802 - A
1803 - A
1805 - B
1806 - B
1808 - A
1809 - A
1810 - A
1811 B
1812 - B
1813 - C
1814 - C
1815 - A
1824 - B
1825 - A
1826 - C
1827 - B
1840 - D
1841 - D
1842 - C
1843 - B
1843 - B
1844 - B
1846 - C
1847 - C
1848a - A
1848b B
1849 - B
1851 - D
1852 - D 1853 - B
1854 - C
1855 - B
1856 B
1857 - D
1858a A
1858b - B
1859 - B
1860a - A
1860b - B
1861a - B
1861b - C
1862 - D
1863 - D
1864 - D
1866 - D
1867 - B
1869 - B
1870 - B
1871 - B
1872 - A
1875 A
1876 - A
1878 - A
1879 - B
1880 - A
1883 - B
1884 - A
1885 - C
1888 - D
1889 - C
1891 - C 1892 - D
1893 D
1894 - D
1895 - C
1896 - c
1897 - c
1898 - c
1899 - B
1900a - B
1900b - D
1901 - C
1902a - B
1902b - B
1903a - B
1903b - C
1903c - C
1904 - A
1905a C
1905b - C
1906 - B
1907 - B
1912 - D
1913 - B
1916 - A
1918 A
1919 - A
1921 - C
1922a - A
1922b - B
1925 - D
1927 A
1928 - B
Figure imgf000329_0001
* Activity, both ¾ and IC50, expressed as follows: A = 1-1-0 nM, B = 10-100 nM, C = 100-500 nM; D > 500 nM
Table 8. Antagonist Activity of Representative
Compounds of the Invention
Figure imgf000329_0002
1375 B 1719 C
1376 C 1720 B
1378 C 1726 B
1380 B 1729 B
1381 B 1739 B
1383 B 1740 C
1384 C 1746 B
1387 B 1747 B
1390 C 1751 B
1391 A 1752 C
1392 A 1753 B
1393 B 1754 B
1394 ■ D 1755 B
1396 C 1763 B
1399 B 1773 B
1400 A 1774 B
1401 B 1775 C
1402 B 1776 B
1404 B 1777 B
1411 B 1778 B
1413 B 1780 B
1416 A 1789 B
1418 B 1790a C
1432 B 1799 C
1436 B 1801 B
1442 C 1803 B
1446 B 1804 B
1451 B 1805 C
1453 B 1806 C
1455 B 1808 B
1458 B 1809 B
1460 B 1810 B 1464 B 1812 C
1479 B 1843 A
1482 B 1848 A
1486 B 1876 A
1490 B 1878 A
1503 B 1903 A
1504 B 1918 B
1505 B 1929 B
1512 B
* Activity is expressed as follows: A < 1 nM; B = 1 - 10 nM, C = 10- 100 nM, D = 100-500 nM
Table 9. Inverse Agonist Activity of Representative Compounds of the Invention
Figure imgf000332_0001
1730 D
1732 D
1737 C
1738 B
1739 D
1740 D
1742 B
1743 D
1745 D
1746 C
1747 C
1751 D
1752 D
1753 C
1754 C
1755 C
1758 B
1759 C
1760 C
1761 C
1762 D
1763 D
1768 B
1769 D
1771 D
1772 D
1773 D
1774 C
1775 D
1776 C
1777 C
1778 D 1780 C
1789 D
1790a D
1791 C
1792a C
1794 B
1795 D
1796 B
1797 D
1798 D
1799 C
1801 B
1802 B
1803 B
1804 B
1805 D
1806 D
1808 B
1809 B
1810 B
1811 D
1812 C
1813 D
1814 D
1815 D
1824 D
1825 C
1827 D
1843 B
1847 B
1848a B
1848b D 1853 D
1854 D
1855 D
1858a C
1858b D
1859 C
1860a c
1862 D
1863 D
1867 D
1872 B
1875 C
1876 C
1878 B
1879 B
1884 B
1903a B
1904 B
1916 B
1918 C
1919 B
1922a C
1927 C
1928 c
1929 c
* Activity is expressed as follows: A =1 - 10 nM; B = 10-50 nM, C: 50- 100
nM, D: 100-500 nM
Example 5
A detailed analysis of the pharmacokinetic profile of representative compounds of the invention was conducted using the procedures outlined in Method B9. Results for both intravenous and oral administration are provided in Tables 10a and 10b.
Table 10a. Pharmacokinetic Parameters for Representative Compounds of the Invention Compound Compound Compound Compound
Compound
1777 1848 1929 1712
Intravenous
Dose mg/kg 2 2 2 2 tl/2 min 107 ± 4 108 ± 51 170 ± 62 138 ± 86
CI mL/min/kg 6 ± 2 17 ± 9 ■ 32 ± 4 62 ± 10
Vz mL/kg 882 ± 272 2554 ± 1467 7992 ± 3702 13237 ± 9572
369904 ± 155874 ±
AUCinf ng.min/mL 63809 ± 8606 32618 ± 5193
127112 1 15129
Oral
Dose mg/kg 8 8 8 8
Γ '-'max ng/mL 1075 ± 772 421 ± 16 628 ± 766 352 ± 297
15/30/15/15/15/
T * max min 30/30 15/15/30 15/15/15
15
190433 ± 66708 ± 107429 ±
AUCinf ng.min/mL 20174 ± 12692
1 14760 12061 130596
F % 13 ± 8 11 ± 2 42 ± 51 15 ± 10
Pharmacokinetic data on additional representative compounds of the invention are provided in Table 10b. A dose level of 2 mg/mL for intravenous administration and 8 mg/mL for oral administration were typically employed.
Table 10b. Pharmacokinetic Data for Representative Compounds of the Invention
Figure imgf000336_0001
1718 162 ±4 5 ± 1 17 ±6
1719 93 ± 11 44 ±3 nd
1720 70 ± 15 33 ± 12 nd
1726 171 ± 16 9±6 14 ±8
1746 107 ±4 12 ± 1 59 ±31
1751 46 ± 1 32 ±5 34 + 19
1754 106 ± 13 8 + J 39 ±44
1755 123 ±28 12 ± 13 7 + 4
1759 119 ± 101 14 ±2 nd
1773 70 ± 8 24 ± 11 2± 1
1775 74 ±27 18 ± 16 36 ±29
1776 105 ± 20 8±4 nd
1778 59 ±38 26 ± 18 nd
1789 52 ± 1 26 + 8 81 ±55
1803 103 ± 13 10 ± 1 nd
1847 70 ±42 19 + 16 10± 1
1876 159 ± 16 28 ±8 54 ± 19
1878 124 ±19 35 ± 1 nd
1903a 31 ± 13 17 + 9 nd
1904 65 ±25 34 ±4 nd
1918 114 ±53 14 ±7 d nd = not determined
Example 6
In vivo Evaluation in Animal Models of Metabolic Disease
A study of the effects of compound 1505 on metabolic parameters in the Zucker fatty rat, a standard model for the study of anti-obesity or anti-diabetes treatments, using Method B14 was performed. As shown in Figure 9, this compound at 30 mg/kg demonstrated significant reduction in net body weight over the course of the 7 day study period. Additionally, at this dose level, a significant decrease in the cumulative food consumption was also observed (Figure 10). On a daily basis, both the 10 mg/kg and 30 mg/kg doses exhibited significant reductions when compared to vehicle controls at the 2 day timepoint. The higher dose remained significant through the 6 day timepoint. In addition to the effect on weight, the OGTT results with compound 1505 (30 mg/kg) showed a decrease in blood glucose versus untreated controls at both day 3 and day 7. A lowering effect on insulin levels, as indicated by the area under the curve (AUC), was also obtained in this test. The insulin sensitivity index was higher, attaining significance at the higher dose.
Lastly, other metabolic parameters, including free fatty acids and total cholesterol, were also significantly reduced in both treatment groups. PK analysis demonstrated that sufficient plasma levels of compound 1505 were achieved confirming the efficacy of the molecule upon oral administration.
Example 7
In vivo Evaluation in A Further Aninia! Model of Metabolic Disease A study of the effects of compounds 1712 and 1848 on metabolic parameters in the ob/ob mouse, a standard model for the study of treatment of metabolic disorders, was conducted using Method B 15. As expected in the ob/ob mouse model, the animals were obese and showed aspects of the metabolic syndrome (e.g. hyperinuslinemia, glucose intolerance, dyslipidemia). (Leiter, E.H. FASEB J. 1989, 3, 2231-2241.) As shown in Figure 1 1 , acute cumulative food intake over a 2 hi" period, in fasted animals, was significantly reduced by treatment with compound 1712 compared to vehicle control animals.
In a separate 14 d study, a significant reduction in cumulative food intake (11.9%) at a dose of 75 mg/kg was observed for the compound 1848 treated animals compared to the vehicle control (Figure 12). In addition, a significant decrease was seen in blood glucose levels during an oral glucose tolerance test in the compound 1848 (75 mg/kg) treated mice compared to vehicle control suggesting improvement in glucose tolerance upon treatment. On other metabolic parameters, treatment with compound 1848 significantly reduced non-fasting glucose, insulin, glucagon, free fatty acids (FFAs), but not total cholesterol or triglycerides levels compared to vehicle control mice (Figure 13). These data indicate an improvement in insulin sensitivity in compound 3848-treated ob/ob mice.
The' foregoing is illustrative of the present invention and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

Claims

What is claimed is:
1. A compound of the formula (I):
Figure imgf000339_0001
(I)
pharmaceutically acceptable salt thereof, wherein:
T is selected from
Figure imgf000339_0002
and , wherein (NA) indicates the site of bonding of to NR4a of formula (I) and (NB) indicates the site of bonding to NR4c of formula (I);
Rj is selected from the group consisting of -(CH2)SCH3, -CH(CH3)(CH2)tCH3,
-(CH2)„CH(CH3)2, -C(CH3)3, -CH2-C(CH3)3, -CHR17OR, 8,
Figure imgf000339_0003
wherein s is 0, 1 , 2, 3 or 4; t is 1, 2 or 3 ; u is 0, 1 or 2; v is 1 , 2, 3 or 4; w is 1 , 2, 3 or 4; and Rn and R|2 are optionally present and, when present, are independently selected from the group consisting of C1 -C4 alkyl, hydroxyl and alkoxy; R|7 is hydrogen or methyl; and R | ¾ is selected from the group consisting of hydrogen, C | -C4 alkyl and acyl; R2a is selected from the group consisting of -CH3, -CH2CH3, -CH(CH3)2, -CF3, -CF2H and -CH2F;
2b is selected from the group consisting of -H and -CH ;
R3a is selected from the group consisting of hydrogen, C j-C4 alkyl, hydroxy! and alkoxy;
R3b is selected from the group consisting of hydrogen and C j -C4 alkyl;
R4a, R4 , R4c and R4ti are independently selected from the group consisting of hydrogen and C | -C4 alkyl;
R5, when Y [ is O or NR |6, is selected from the group consisting of hydrogen, C j -C4 alkyl and acyl; or, when Yj is C(=0), is selected from the group consisting of hydroxyl, alkoxy and amine;
R6 is selected from the group consisting of hydrogen, C1 -C4 alkyl, oxo and trifluoromethyl;
R7 is selected from the group consisting of hydrogen, C 1 -C4 alkyl, hydroxyl, alkoxy and trifluoromethyl; or R7 and X| together with the carbons to which they are bonded form a five or six-membered ring;
Rio is selected from the group consisting of hydrogen, C C4 alkyl, 1 , 1 , 1 - trifiuoroethyl, hydroxyl and alkoxy, with the provisos that when Lf, is CH, R io is also selected from trifluoromethyl and when L6 is N, R;Q is also selected from sulfonyl; or R io and Rga together fonn a five-or six-membered ring;
R26, 28 and R29 are independently selected from the group consisting of hydrogen, C1-C4 alkyl, hydroxyl, alkoxy and trifluoromethyl; or R2g and R2 together form a three- membered ring;
R27 is selected from the group consisting of hydrogen, C [-C4 alkyl, hydroxyl, alkoxy and trifluoromethyl; or R27 and X43 together with the carbons to which they are bonded form a five or six -membered ring
R30 is selected from the group consisting of hydrogen, C ! -C4 alkyl, hydroxyl, alkoxy and trifluoromethyl;
Ar is selected from the group consisting of:
Figure imgf000341_0001
and , wherein Mi, M2, M3, M4, M5, M6, M7, M and M| i are independently selected from the group consisting of O, S and NR[3, wherein R|3 is selected from the group consisting of hydrogen, C -C^ alkyl, formyl, acyl and sulfonyl; Mg, Mio and Mi2 are independently selected from the group consisting of N and CR14, wherein R|4 is selected from the group consisting of hydrogen and C[-C4 alkyl; X5, X6, X7, Xis> Xi9> X21, X22, 24, X25, X26, 27> 28, X29, X.-;o and X3] are independently selected from the group consisting of hydrogen, halogen, trifluoromethyl and C1-C4 alkyl; and Xs, X9,
X|0> lh X|2> X|3> X|4> Xl5> X]6> Xl7, X2 , X23> ;¾2, X33, } , X35> ^-36, X375 iS, ?95
X40, X41 and X42 are independently selected from the group consisting of hydrogen, hydroxyl, alkoxy, amino, halogen, cyano, trifluoromethyl and C1-C4 alkyl;
Li, L2, L3, L4 and are independently selected from the group consisting of CH and
N;
L5 is selected from the group consisting of CRi5R]5b, O and NR|5c, wherein Ri5a and Ri5b are independently selected from hydrogen, C1-C4 alkyl, hydroxyl and alkoxy; and Ri5c is selected from the group consisting of hydrogen, C1-C4 alkyl, acyl and sulfonyl;
L|o is selected from the group consisting of CR35aR35b, O and OC(=0)0, wherein R35a and R35h are independently selected from hydrogen, C1-C4 alkyl, hydroxyl and alkoxy;
Xi is selected from the group consisting of hydrogen, halogen, trifluoromethyl and C1-C4 alkyl; or Xi and R7 together form a five or six-member ed ring;
X2, X3 and X4 are independently selected from the group consisting of hydrogen, halogen, trifluoromethyl and C1-C4 alkyl; X43 and X44 are optionally present and, when present, are independently selected from the group consisting of C1-C4 alkyl, hydroxy!, alkoxy and trifluoromethyl; or X43 and R27 together form a five or six-membered ring; and
Y] is selected from the group consisting of C(=0), O and NRj6, wherein R|6 is selected from the group consisting of hydrogen, C 1-C4 alkyl, acyl and sulfonyl;
z is 0, 3 , 2 or 3; and
Z is selected from the group consisting of (Ar)-CHRKaCHR¾-(L6), (Ar)-CRgb=CR9b-(L<>) and -(Ar)-C≡C~ (L¾), wherein (Ar) indicates the site of bonding to the phenyl ring and (Lfi) the site of bonding to L6, Rsa and R¾ are independently selected from the group consisting of hydrogen, Cj-C4 alkyl, hydroxy!, alkoxy, oxo and trifluoromethyl; gb and R% are independently selected from the group consisting of hydrogen, C 1 -C4 alkyl, fiuoro, hydroxyl, alkoxy and trifluoromethyl; or RSa and R¾ together form a three-membered ring; or Rga and Rio together form a five- or six-membered ring; or Rga and X4 together form a five- or six-membered ring; or Rga and X4 together form a five- or six-membered ring; or R¾b and X4 together form a five- or six-membered ring; or R% and X4 together form a five- or six- membered ring.
The compound of formula (!) of claim 1, wherein
-CH(CH3)CH2CH3, -CH
Figure imgf000342_0001
R2a and R4i, are each -C¾;
R3a is hydrogen or -CH3;
R2b, R3b, R , R- C, R4d, R5. R6 and R7 are each hydrogen;
R9 is hydrogen or hydroxyl;
Rio is -CH3 or -CH2CH3;
Ar is
Figure imgf000343_0001
341
Figure imgf000344_0001
or ;
Lj , L2, L3, L4, L5 and L6 are each CH;
Xi is fiuoro and X2, X3 and X4 are hydrogen; or X2 is fiuoro and X [ , X3 and X4 are hydrogen; or X3 is fiuoro and Xi , X2 and X4 are hydrogen; or X4 is fiuoro and X i , X2 and X3 are hydrogen, or X2 and X3 are fiuoro and X] and X4 axe hydrogen;
Y is O; and
Z is CH2CH2 or C≡C;
or a pharmaceutically acceptable salt thereof.
3. The compound of formula (I) of claim 1 , wherein T is selected from the group consisting of:
Figure imgf000345_0001
Figure imgf000345_0002
Figure imgf000345_0003
Figure imgf000345_0004
T70
Figure imgf000345_0005
T125a(R) T125b (S)
Figure imgf000346_0001
T100 T104a (R,R) T105
T104b (S,S)
Figure imgf000346_0002
T106 T113a (R) T125a (R)
T113b (S) T125b (S)
Figure imgf000346_0003
T128a (2R,9R) T128c (2S,9R)
T128b (2R,9S) T128d (2S,9S)
Figure imgf000346_0004
T137 T138 T139
Figure imgf000346_0005
Figure imgf000347_0001
T143 T144a (R)
T144b (5)
Figure imgf000347_0002
T146a (R)
T147 T148a (8R,9R) T148c (8S,9R) T146b (S) T148b (8R.9S) T148d (8S.9S)
Figure imgf000347_0003
T1 9a(R,R} T150a (9R) T151
T149b{S,S) T150b (9S)
Figure imgf000347_0004
T152 T153 T154
Figure imgf000347_0005
T157
T156a (R)
Figure imgf000347_0006
Figure imgf000348_0001
Figure imgf000348_0002
T164a (R) T165a (R) T166
T164b (S) T165b (S)
Figure imgf000348_0003
T167 T168a (R,R) T169a (R)
T168b (S,S) T169b (S)
Figure imgf000348_0004
T173a (R) T174a (R) T175a (R)
T173b (S) T174b (S) T175b (S)
T178a (2R,9R) T178c (2S,9R)
Figure imgf000348_0005
T178b (2R,9S) T178d (2S,9S)
Figure imgf000349_0001
T179a (2R.9R) T179c (2S,9R) T180a (2R.9R) T180c (2S,9R) T181a {2R,9R) T181 c (2S,9R) T179b (2R.9S) T179d (2S,9S) T180b {2R,9S) T180d <2S,9S) T181 b (2R.9S) T181d <2S,9S)
T182a (2R,9R) T182c (2S,9R> T183a (2R.9R) T183c (2S,9R)
T182b (2R,9S) T182d (2S.9S) T183b (2R,9S) T183d (2S,9S)
Figure imgf000349_0002
T191a (R) T192a (R)
T191b {S) T192b (S) T193
Figure imgf000350_0001
Figure imgf000350_0002
Figure imgf000350_0003
T213a(R) T214a (R) T215 T213b (S) T214b (S)
Figure imgf000350_0004
T216a (R) T217a(R) T218a (R) T216b (S) T217b (S) T218b(S)
Figure imgf000350_0005
wherein (NA) indicates the site of bonding of to NR4a of formula (I), (NB) indicates the site of bonding to NR4c of formula (I) and Pg is a nitrogen protecting group.
4. The compound of claim 1 with the following structure:
Figure imgf000351_0001
Figure imgf000351_0002
Figure imgf000352_0001
Figure imgf000352_0002
Figure imgf000352_0003
Figure imgf000352_0004
Figure imgf000352_0005
5. A pharmaceutical composition comprising:
(a) a compound of claim 1 ; and
(b) a pharmaceutically acceptable carrier, excipient or diluent.
6. A pharmaceutical composition comprising:
(a) a compound of claim 4; and
(b) a pharmaceutically acceptable carrier, excipient or diluent.
7. A pharmaceutical composition comprising:
( ) a compound of claim 1 ;
(b) one or more additional therapeutic agents and
(c) a pharmaceutically acceptable carrier, excipient or diluent.
8. The pharmaceutical composition of claim 7, wherein the additional therapeutic agent is selected from the group consisting of a GLP- 1 agonist, a DPP-IV inhibitor, an amylin agonist, a PPAR-a agonist, a PPAR-γ agonist, a PPAR-α/γ dual agonist, a GDIR or GPR119 agonist, a PTP- 1B inhibitor, a peptide YY agonist, an Π β-hydroxysteroid dehydrogenase ( Ι ΐ β-HSD)- ! inhibitor, a sodium-dependent renal glucose transporter type 2 (SGLT-2) inhibitor, a glucagon antagonist, a glucokinase activator, an a-glucosidase inhibitor, a glucocorticoid antagonist, a glycogen synthase kinase 3β (ΰ8 -3β) inhibitor, a glycogen phosphorylase inhibitor, an AMP-activated protein kinase (AMPK) activator, a fructose- 1 ,6- biphosphatase inhibitor, a sulfonyl urea receptor antagonist, a retinoid X receptor activator, a 5-HT|a agonist, a 5-HT2c agonist, a 5-HT6 antagonist, a cannabioid antagonist or inverse agonist, a melanin concentrating hormone- 1 (MCH- 1) antagonist, a melanocortin-4 (MC4) agonist, a leptin agonist, a retinoic acid receptor agonist, a stearoyl-CoA desaturase-1 (SCD- 1) inhibitor, a neuropeptide Y Y2 receptor agonist, a neuropeptide Y Y4 receptor agonist, a neuropeptide Y Y5 receptor antagonist, a neuronal nicotinic receptor α4β2 agonist a diacyl glycerol acyltransferase 1 (DGAT-1) inhibitor, a thyroid receptor agonist, a lipase inhibitor, a fatty acid synthase inhibitor, a glycerol-3-phosphate acyltransferase inhibitor, a CPT- 1 stimulant, an (X| A-adrenergic receptor agonist, an α2Λ- drenergic receptor agonist, a β - adrenergic receptor agonist, a histamine H3 receptor antagonist, a cholccystokinin A receptor agonist and a GABA-A agonist.
9. The pharmaceutical composition of claim 8 wherein the GLP-1 agonist is selected from the group consisting of GLP-1, GLP-1 (7-36) amide, exenatide (exendin-4), liraglutide (NN221 1), gilatide, albiglutide (GSK-716155, albugon), taspoglutide, GLP1- I.N.T., GLP-1 DUROS, AC2592, AC2993 LAR, ADX4 (PAM), AR1-2255, ARL2651, BRX- 0585 (GLP-LTf), CJC-1 131, CJC 1134-PC (PC-DAC™:Exendin-4), CS-872, AVE-0010 (ZP-10), BIM-51.077 (R-1583), ΒΙΜ-5Π82, DA3071 , GTP-010, ITM-077, SUN E7001, ΤΉ- 0318, TH-0396, TTP-854, LY-335902 and LY-307161.
10. The pharmaceutical composition of claim 8 wherein the DPP-IV inhibitor is selected from the group consisting of sitagliptin, vidagliptm, saxagltptin (BMS-4771 18), alogliptin (SYR322), ABT-279, ALS-20426, ARI 2243, A 622, ASP8497, DA 1229, DB295, E3024, FE99901 1 , GRC-8200, KR-62436, KRP 104, MP-513, PHX1 149, PSN9301 , SK-0403, SYR619, TA-6666, TAK 100 and VMD-700.
11. The pharmaceutical composition of claim 8 wherein the amylin agonist is selected from the group consisting of amylin, pramlintide, MBP-0250 and PX811016.
12. The pharmaceutical composition of claim 8 wherein the PPAR- γ agonist is selected from the group consisting of pioglitazone, rivoglitazone, rosiglitazone and troglitazone.
13. The pharmaceutical composition of claim.8 wherein the agonist is a PPAR-α/γ dual agonist selected from the group consisting of ragaglitazar, tesaglitazar, muraglitazar, aleglitazar, cevoglitazar, R1439, PLX204 (PPM-204).
14. The pharmaceutical composition of claim 8 wherein the PTP- 1B inhibitor is selected from the group consisting of ISIS 113715 and KR61639.
15. The pharmaceutical composition of claim 8 wherein the 5-HT2c agonist is selected from the group consisting of lorcaserin, vabicaserin (SCA-136), ATHX-105, BVT933 (GW 876167), IK264, LY448100, MK-212, ORG- 12962, VR 1065, WAY- 163909 and YM348.
16. The pharmaceutical composition of claim 8 wherein the cannabioid antagonist or inverse agonist is selected from the group consisting of rimonabant, taranabant (MK- 0364), surinabant, AVE1625, AVN 342, CP-945,598, E-6776, GRC 10389, SLV-319, SR 147778, TM38837 and V24343.
17. The pharmaceutical composition of claim 8 wherein the peptide YY agonist is selected from the group consisting of peptide YY and peptide YY 3-36 (AC-162352).
18. The pharmaceutical composition of claim 8 wherein the lipase inhibitor is selected from the group consisting of orlistat and cetilistat.
19. The pharmaceutical composition of claim 8 wherein the a-glucosidase inhibitor is selected from the group consisting of acarbose, miglitol and voglibose.
20. The pharmaceutical composition of claim 8 wherein the SGLT-2 inhibitor is selected from the group consisting of dapagliflozin, remogliflozin, sergiiflozin, AVE2268, GSK189075.
21. The pharmaceutical composition of claim 8 wherein the Ι Ιβ-HSD-l inhibitor is selected from the group consisting of INCB13739, BVT.3498, BVT.2733, AMG 221 , PF- 915275.
22. The pharmaceutical composition of claim 8 wherein the glucokinase inhibitor is selected from the group consisting of R1440/GK3, RO-28-1675, PSN010 and ARRY-403,
23. The pharmaceutical composition of claim 8 wherein the additional therapeutic agent is selected from the group consisting of metformin, sibutrammc, phentermine, hetahistine, methamphetamine, benzphetamine, phendimetraziiie, diethylpropion, bupropion, topiramate, carbutamide, chlorpropamide, glibenclamide (glyburide), gliclazide, glimepiride, glipizide, gliquidone, mitiglinide, nateglinide, repaglinide, tolazamide, tolbutamide, and pharmaceutically acceptable salts thereof.
24. A kit comprising one or more containers comprising pharmaceutical dosage units further comprising an effective amount of one or more compounds of claim 1 or a pharmaceutically acceptable salt thereof, wherein the container is packaged with optional instructions for the use thereof.
25. A method of modulating GRLN (GHS-Rla) receptor activity in a mammal comprising administering to said mammal an effective GRLN (GHS-Rl a) receptor activity modulating amount of a compound of claim 1 ,
26. A method of treating a metabolic and/or endocrine disorder comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
27. The method of claim 26, wherein the metabolic and/or endocrine disorder is selected from the group consisting of obesity or an obesity-associated condition, diabetes, metabolic syndrome, non-alcoholic fatty acid liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and steatosis.
28. A method of treating an appetite or eating disorder comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
29. The method of claim 28, wherein the appetite or eating disorder is Prader- Willi syndrome or hyperphagia.
30. The method of claim 29, wherein the hyperphagia is diabetic hyperphagia.
31. A method of treating an addictive disorder comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
32. The method of claim 31, wherein the addictive disorder comprises alcohol dependence, drug dependence and/or chemical dependence.
33. A method of treating a cardiovascular disease comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
34. A method of treating a gastrointestinal disorder comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
35. A method of treating a genetic disorder comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
36. A method of treating a hyperproliferatlve disorder comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
37. A method of treating an inflammatory disorder comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
38. A method of treating a central nervous system (CNS) disorder comprising administering to a subject in need thereof an effective amount of a compound of claim i .
39. A macrocyclic compound selected from the group consisting of
Figure imgf000357_0001
and
or a pharmaceutically acceptable salt thereof.
PCT/US2010/054797 2009-10-30 2010-10-29 Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same WO2011053821A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN2010800600814A CN102812037A (en) 2009-10-30 2010-10-29 Macrocyclic Ghrelin Receptor Antagonists And Inverse Agonists And Methods Of Using The Same
JP2012537129A JP2013509434A (en) 2009-10-30 2010-10-29 Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of use thereof
CA2778990A CA2778990A1 (en) 2009-10-30 2010-10-29 Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
EP10774101A EP2493910A1 (en) 2009-10-30 2010-10-29 Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
AU2010313282A AU2010313282A1 (en) 2009-10-30 2010-10-29 Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25672709P 2009-10-30 2009-10-30
US61/256,727 2009-10-30

Publications (1)

Publication Number Publication Date
WO2011053821A1 true WO2011053821A1 (en) 2011-05-05

Family

ID=43264702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/054797 WO2011053821A1 (en) 2009-10-30 2010-10-29 Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same

Country Status (7)

Country Link
US (1) US20110105389A1 (en)
EP (1) EP2493910A1 (en)
JP (1) JP2013509434A (en)
CN (1) CN102812037A (en)
AU (1) AU2010313282A1 (en)
CA (1) CA2778990A1 (en)
WO (1) WO2011053821A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119800A1 (en) * 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US10030047B2 (en) 2015-10-27 2018-07-24 Hoffmann-La Roche Inc. Peptide macrocycles against acinetobacter baumannii
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
EP3432874B1 (en) * 2016-04-14 2021-01-13 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods and compositions for treatment of prader-willi syndrome
US11066443B2 (en) 2017-04-10 2021-07-20 Hoffmann-La Roche Inc. Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
EP1633774B1 (en) * 2003-06-18 2010-02-17 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
KR102112373B1 (en) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
DK3116887T3 (en) * 2014-03-13 2021-04-26 Univ Basel CARBOHYDRATE LIGANDER BINDING TO IGM ANTIBODIES TO MYELIN-ASSOCIATED GLYCOPROTEIN
WO2016021191A1 (en) * 2014-08-05 2016-02-11 Raqualia Pharma Inc. Serine derivatives as ghrelin receptor agonists
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2016077498A1 (en) 2014-11-12 2016-05-19 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017083882A1 (en) * 2015-11-11 2017-05-18 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs
WO2017083795A1 (en) * 2015-11-13 2017-05-18 Pietro Paolo Sanna Methods and compositions for treating alcohol use disorders
CN108129357B (en) * 2016-12-01 2021-12-21 上海医药工业研究院 Preparation method of anamorelin intermediate
CN107892710B (en) * 2017-10-10 2021-04-13 河北大学 Supported platinum complex oxidant easy to recycle and use and preparation method and application thereof
CN108727187B (en) * 2018-07-10 2020-04-24 淮安国瑞化工有限公司 Preparation method of (R) - (+) -2-p-hydroxyphenoxypropionic acid
CN109081793B (en) * 2018-09-28 2021-03-30 吉首大学 Sulfonamide urease inhibitor and preparation method and application thereof
KR20240031969A (en) * 2021-07-02 2024-03-08 포시 파마슈티컬스 컴퍼니 리미티드 Method for preparing sustained-release formulations for injection
CN115141125B (en) * 2022-07-22 2023-04-28 北京先通国际医药科技股份有限公司 Synthesis method and application of modified long-chain fatty acid type PET reagent precursor
CN116355512B (en) * 2022-12-19 2024-01-26 南昌航空大学 Method for preparing GO/Glu-Ce@HDTMS/PU super-hydrophobic anti-corrosion coating

Citations (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001492A1 (en) 1977-10-03 1979-04-18 Mobil Oil Corporation Certain oxazolines as load-carrying additives for gear oils
EP0080317A1 (en) 1981-11-20 1983-06-01 Hitachi, Ltd. Cassette loading device for cassette tape recorder
WO1997021730A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Growth hormone secretagogue receptor family
WO1997022004A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
US5707798A (en) 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
WO2001025257A2 (en) 1999-10-04 2001-04-12 Neokimia, Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
WO2001056592A1 (en) 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
WO2001087335A2 (en) 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
WO2002008250A2 (en) 2000-07-24 2002-01-31 Ardana Bioscience Limited Ghrelin antagonists
WO2002090387A1 (en) 2001-05-10 2002-11-14 Queensland University Of Technology Reproductive cancer diagnosis and therapy
WO2003004518A2 (en) 2001-07-06 2003-01-16 Ardana Bioscience Limited Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors
US6645726B1 (en) 1998-08-10 2003-11-11 Merck & Co., Inc. Canine growth hormone secretagogue receptor
WO2004004772A1 (en) 2002-07-05 2004-01-15 Chugai Seiyaku Kabushiki Kaisha Remedy for diabetes
WO2004009124A2 (en) 2002-07-19 2004-01-29 Cytos Biotechnology Ag Ghrelin-carrier conjugates
WO2004009616A2 (en) 2002-07-23 2004-01-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Ghrelin analogs
WO2004013274A2 (en) 2002-08-01 2004-02-12 Noxxon Pharma Ag Ghrelin binding nucleic acids
WO2004024183A1 (en) 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
WO2004056869A1 (en) 2002-12-20 2004-07-08 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2004084943A1 (en) 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2004111077A1 (en) 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
WO2005012332A1 (en) 2003-07-31 2005-02-10 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
WO2005012331A1 (en) 2003-07-31 2005-02-10 Tranzyme Pharma Spatially-defined macrocyclic compounds useful for drug discovery
WO2005030734A1 (en) 2003-09-26 2005-04-07 Abbott Laboratories Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (ghs-r) antagonists
WO2005035498A1 (en) 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. Use of nitrogenous bicyclic compound as feeding control agent
WO2005049828A1 (en) 2003-11-10 2005-06-02 Noxxon Pharma Ag Nucleic acids specifically binding bioactive ghrelin
WO2005048916A2 (en) 2003-11-20 2005-06-02 Biovitrum Ab Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders
WO2005068639A2 (en) 2004-01-20 2005-07-28 Cytos Biotechnology Ag Particle-induced ghrelin immune response
US20050171132A1 (en) 2003-09-26 2005-08-04 Zhili Xin Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
US20050187237A1 (en) 2003-11-04 2005-08-25 Distefano Peter Therapeutic compounds and uses thereof
WO2005097788A2 (en) 2004-04-02 2005-10-20 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof
WO2005114180A2 (en) 2004-05-14 2005-12-01 Novo Nordisk A/S Functional ghs-r antagonists
WO2006009674A1 (en) 2004-06-18 2006-01-26 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006009645A1 (en) 2004-06-18 2006-01-26 Tranzyme Pharma, Inc. Methods of using macrocyclic modulators of the ghrelin receptor
WO2006020930A2 (en) 2004-08-12 2006-02-23 Sapphire Therapeutics, Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
WO2006023608A2 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
WO2006046977A1 (en) 2004-10-26 2006-05-04 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and methods of using the same
WO2006052608A2 (en) 2004-11-01 2006-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2006137974A2 (en) 2005-06-13 2006-12-28 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
WO2007079239A2 (en) 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
WO2008008286A2 (en) 2006-07-12 2008-01-17 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
US20080051383A1 (en) 2006-07-06 2008-02-28 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
WO2008033328A2 (en) 2006-09-11 2008-03-20 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders
WO2008079705A2 (en) 2006-12-20 2008-07-03 Eli Lilly And Company Acyl-transferase
US20080194672A1 (en) 2007-02-09 2008-08-14 Tranzyme Pharma Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
WO2009020419A1 (en) 2007-05-14 2009-02-12 Suzanne L Dickson New treatment for chemical substance addiction
US20090275648A1 (en) * 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
WO2010039461A2 (en) 2008-10-03 2010-04-08 The Johns Hopkins University Methods for synthesis and uses of inhibitors of ghrelin o-acyltransferase as potential therapeutic agents for obesity and diabetes
US20100086955A1 (en) 2008-10-02 2010-04-08 University Of Texas, Board Of Regents Small Molecule Inhibitors of Ghrelin O-Acyltransferase
US20100196396A1 (en) 2009-02-04 2010-08-05 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
WO2010092289A1 (en) 2009-02-12 2010-08-19 Sanofi-Aventis 3-benzofuranyl-indol-2-one derivatives substituted at the 3 position, preparation thereof, and therapeutic use thereof
WO2010092288A1 (en) 2009-02-12 2010-08-19 Sanofi-Aventis Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1644335A4 (en) * 2003-07-11 2008-06-04 Bristol Myers Squibb Co Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US20070244048A1 (en) * 2006-03-20 2007-10-18 Marsh Donald J Neuromedin U receptor agonists and uses thereof

Patent Citations (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0001492A1 (en) 1977-10-03 1979-04-18 Mobil Oil Corporation Certain oxazolines as load-carrying additives for gear oils
EP0080317A1 (en) 1981-11-20 1983-06-01 Hitachi, Ltd. Cassette loading device for cassette tape recorder
US5707798A (en) 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
US5912132A (en) 1993-07-13 1999-06-15 Acadia Pharmaceuticals, Inc. Identification of ligands by selective amplification of cells transfected with receptors
US5955281A (en) 1993-07-13 1999-09-21 Acadia Pharmaceuticals, Inc. Identification of ligands by selective amplification of cells transfected with receptors
US6242199B1 (en) 1995-12-13 2001-06-05 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
WO1997021730A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Growth hormone secretagogue receptor family
WO1997022004A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
US6645726B1 (en) 1998-08-10 2003-11-11 Merck & Co., Inc. Canine growth hormone secretagogue receptor
WO2001025257A2 (en) 1999-10-04 2001-04-12 Neokimia, Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
WO2001056592A1 (en) 2000-02-01 2001-08-09 Novo Nordisk A/S Use of compounds for the regulation of food intake
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
WO2001087335A2 (en) 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
WO2002008250A2 (en) 2000-07-24 2002-01-31 Ardana Bioscience Limited Ghrelin antagonists
US20020187938A1 (en) 2000-07-24 2002-12-12 Romano Deghenghi Ghrelin antagonists
WO2002090387A1 (en) 2001-05-10 2002-11-14 Queensland University Of Technology Reproductive cancer diagnosis and therapy
WO2003004518A2 (en) 2001-07-06 2003-01-16 Ardana Bioscience Limited Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors
WO2004004772A1 (en) 2002-07-05 2004-01-15 Chugai Seiyaku Kabushiki Kaisha Remedy for diabetes
WO2004009124A2 (en) 2002-07-19 2004-01-29 Cytos Biotechnology Ag Ghrelin-carrier conjugates
WO2004009616A2 (en) 2002-07-23 2004-01-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Ghrelin analogs
WO2004013274A2 (en) 2002-08-01 2004-02-12 Noxxon Pharma Ag Ghrelin binding nucleic acids
WO2004024183A1 (en) 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
WO2004056869A1 (en) 2002-12-20 2004-07-08 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2004084943A1 (en) 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2004111077A1 (en) 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US20070021331A1 (en) 2003-06-18 2007-01-25 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US20060025566A1 (en) 2003-06-18 2006-02-02 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
WO2005012332A1 (en) 2003-07-31 2005-02-10 Tranzyme Pharma Spatially-defined macrocycles incorporating peptide bond surrogates
WO2005012331A1 (en) 2003-07-31 2005-02-10 Tranzyme Pharma Spatially-defined macrocyclic compounds useful for drug discovery
US7452862B2 (en) 2003-07-31 2008-11-18 Tranzyme Pharma, Inc. Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists
US20050171131A1 (en) 2003-09-26 2005-08-04 Christi Kosogof Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
US20050171132A1 (en) 2003-09-26 2005-08-04 Zhili Xin Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists
WO2005030734A1 (en) 2003-09-26 2005-04-07 Abbott Laboratories Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (ghs-r) antagonists
WO2005035498A1 (en) 2003-10-08 2005-04-21 Dainippon Sumitomo Pharma Co., Ltd. Use of nitrogenous bicyclic compound as feeding control agent
US20050187237A1 (en) 2003-11-04 2005-08-25 Distefano Peter Therapeutic compounds and uses thereof
WO2005049828A1 (en) 2003-11-10 2005-06-02 Noxxon Pharma Ag Nucleic acids specifically binding bioactive ghrelin
WO2005048916A2 (en) 2003-11-20 2005-06-02 Biovitrum Ab Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders
WO2005068639A2 (en) 2004-01-20 2005-07-28 Cytos Biotechnology Ag Particle-induced ghrelin immune response
WO2005097788A2 (en) 2004-04-02 2005-10-20 Elixir Pharmaceuticals, Inc. Sulfonamides and uses thereof
WO2005112903A2 (en) 2004-05-14 2005-12-01 Novo Nordisk A/S Use of ghrelin antagonists for improving cognition and memory
WO2005114180A2 (en) 2004-05-14 2005-12-01 Novo Nordisk A/S Functional ghs-r antagonists
WO2006009645A1 (en) 2004-06-18 2006-01-26 Tranzyme Pharma, Inc. Methods of using macrocyclic modulators of the ghrelin receptor
WO2006009674A1 (en) 2004-06-18 2006-01-26 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006020930A2 (en) 2004-08-12 2006-02-23 Sapphire Therapeutics, Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
WO2006023608A2 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
WO2006046977A1 (en) 2004-10-26 2006-05-04 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and methods of using the same
WO2006052608A2 (en) 2004-11-01 2006-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US20090275648A1 (en) * 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
WO2006137974A2 (en) 2005-06-13 2006-12-28 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
WO2007079239A2 (en) 2005-12-30 2007-07-12 Acadia Pharmaceuticals Inc. Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof
US20080051383A1 (en) 2006-07-06 2008-02-28 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
WO2008008286A2 (en) 2006-07-12 2008-01-17 Merck & Co., Inc. Substituted pyrazoles as ghrelin receptor antagonists
WO2008033328A2 (en) 2006-09-11 2008-03-20 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders
WO2008079705A2 (en) 2006-12-20 2008-07-03 Eli Lilly And Company Acyl-transferase
US20080194672A1 (en) 2007-02-09 2008-08-14 Tranzyme Pharma Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
WO2008130464A1 (en) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
WO2009020419A1 (en) 2007-05-14 2009-02-12 Suzanne L Dickson New treatment for chemical substance addiction
US20100086955A1 (en) 2008-10-02 2010-04-08 University Of Texas, Board Of Regents Small Molecule Inhibitors of Ghrelin O-Acyltransferase
WO2010039461A2 (en) 2008-10-03 2010-04-08 The Johns Hopkins University Methods for synthesis and uses of inhibitors of ghrelin o-acyltransferase as potential therapeutic agents for obesity and diabetes
US20100196396A1 (en) 2009-02-04 2010-08-05 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
WO2010092289A1 (en) 2009-02-12 2010-08-19 Sanofi-Aventis 3-benzofuranyl-indol-2-one derivatives substituted at the 3 position, preparation thereof, and therapeutic use thereof
WO2010092288A1 (en) 2009-02-12 2010-08-19 Sanofi-Aventis Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof

Non-Patent Citations (162)

* Cited by examiner, † Cited by third party
Title
"Biochemical Nomenclature and Related Documents, 2nd edition,", 1992, PORTLAND PRESS, pages: 39 - 67
"Biochemical Nomenclature and Related Documents, 2nd edition,", 1992, PORTLAND PRESS, pages: 68 - 69
ALI, R.; CUSI, K., ANN. MED., vol. 41, 2009, pages 265 - 278
AMINO ACIDS AND PEPTIDES, vol. 16, 1985, pages 387 - 410
ANGULO, P., NEW ENGL. J. MED., vol. 346, 2002, pages 1221 - 1231
ASAKAWA, A.; INUI, A.; KAGA, T. ET AL., GUT, vol. 52, 2003, pages 947 - 952
AVDEEF, A., EXPERT OPIN. DRUG. METAB. TOXICOL., vol. 1, 2005, pages 325 - 342
BACKES, B.J.; ELLMAN, J.A., CURR. OPIN. CHEM. BIOL., vol. 1, 1997, pages 86 - 93
BADAOUI, A.; DE SAEGER, C.; DUCHEMIN, J.; GIHOUSSE, D.; DE TIMARY, P.; STARKEL, P., EUR. J. CLIN. INVEST., vol. 38, 2008, pages 397 - 403
BAHEKAR,R.H.; JADAV, P.A.; PATEL, D.N.; PRAJAPATI, V.M.; GUPTA, A.A.; JAIN, M.R.; PATEL, P.R., TETRAHEDRON LETT., vol. 48, 2007, pages 5003 - 5005
BALIMANE, P.V.; HAN, Y.H.; CHONG, S., AAPS J., vol. 8, 2006, pages EL-13
BARTH, M.; RADEMANN, J., J. COMB. CHEM., vol. 6, 2004, pages 340 - 319
BEDNAREK MA ET AL., MED. CHEM., vol. 43, 2000, pages 4370 - 4376
BEDNAREK, M.A. ET AL., J. MED. CHEM., vol. 43, 2000, pages 4370 - 4376
BERGSDORF, C.; KROPP-GOERKIS, C.; KAEHIER, 1.; KETSCHER, L.; BOEMER, U.; PARCZYK, K.; BADER, B., ASSAY DRUG DEV. TECHNOL., vol. 6, 2008, pages 39 - 53
BERGSTROM, C.A., BASIC CLIN. PHARMACOL. TOXICOL., vol. 96, 2005, pages 156 - 61
BIOCHEM. J., vol. 219, 1984, pages 345 - 373
BIRR, C.; LOCHINGER, W.; STAHNKE, G.; LANG, P., JUSTUS LIEBIGS ANN. CHEM., vol. 763, 1972, pages 162 - 172
BLASKOVICH, M. A.; EVINDAR, G.; ROSC, N. G. W.; WILKINSON, S.; LUO, Y.; LAJOIE, G., J. ORG. CHEM., vol. 63, 1998, pages 3631
BOBO, G. ET AL., HEPATHOLOGY, vol. 46, 2007, pages 122 - 129
BOWERS, C.Y., CURR. OPIN. ENDOCRINOL. DIABETES, vol. 7, 2000, pages 168 - 174
CAMANNI, F.; GHIGO, E.; ARVAT, E., FRONT NEUROSCI., vol. 19, 1998, pages 47 - 72
CARPINO, P.A., EXP. OPIN THER. PATENTS, vol. 12, 2002, pages 1599 - 1618
CARPINO, P.A.; HO, G., EXP. OPIN. THER. PAT., vol. 18, 2008, pages 1253 - 1263
CHENG, K.; WEI, L.; CHAUNG, L.-Y. ET AL., J. ENDOCRINOL., vol. 152, 1997, pages 155 - 158
CHOLLET, C.; MCYER, K.; BECK-SICKINGER, A.G., J. PEPT. SCI., vol. I5, 2009, pages 711 - 730
CONSTANTINO, L.; BARLOCCO, D., FUT. MED. CHEM., vol. 1, 2009, pages 157 - 177
CORDIDO, F.; ISIDRO, M.L.; NEMINA, R.; SANGIAO-ALVARELLOS, S., CURR. DRUG DISC. TECH., vol. 6, 2009, pages 34 - 42
CRISP, G.T.; MEYER, A.G., TETRAHEDRON, vol. 51, 1995, pages 5831 - 5845
CROWLEY, V.E.F.; YEO, G.S.H.; O-RAHILLY, S., NAT. REV. DRUG DISC., vol. 1, 2002, pages 276 - 286
CUMMINGS, D.E.; CLEMENT, K.; PURNELL, J.Q. ET AL., NAT., vol. 8, 2002, pages 643 - 644
DAVENPORT, A.P. ET AL., PHCIRMACOL. REV., vol. 57, 2005, pages 541 - 546
DEGHENGHI R; BROGLIO F; PAPOTTI M ET AL., ENDOCRINE, vol. 22, 2003, pages 13 - 18
DEGHENGHI R; PAPOTTI M; GHIGO E; MUCCIOLI G; LOCATELLI V., ENDOCRINE, vol. 14, 2001, pages 29 - 33
DELTWILER; J.E.; LUBELL, W.D., J. ORG. CHEM., vol. 68, 2003, pages 177 - 179
DEPOORTERE, I., REGUL. PEPT., vol. 156, 2009, pages 13 - 23
DEZAKI, K.; SONE, H.; YADA, T., PHARMACOL. THER., vol. 118, 2008, pages 239 - 249
DHARANIPRAGADA, R.; VAN HULLE, K.; BANNISTER, A.; BEAR, S.; KENNEDY, L.; HRUBY, V., J. TETRAHEDRON, vol. 48, 1992, pages 4733 - 4748
DI MARZO, NATURE, vol. 410, 2001, pages 822 - 825
DIANO, S.; FARR, S.A.; BENOIT, S.C. ET AL., NAT. NEUROSCIENCE, vol. 9, 2006, pages 381 - 388
DODGE, J.A.; HEIMAN, M.L., ANN. REP. MED. CHEM., vol. 38, 2003, pages 81 - 88
EGECIOGLU, E.; JERLHAG, E.; SALOME, N. ET AL., ADDICT. BIOL., vol. 15, 2010, pages 304 - 311
EGGENWEILER, H.-M., DRUG DISCOVERY TODAY, vol. 3, 1998, pages 552 - 560
ENDERS, D.: "Asymmetric Synthesis", vol. 3, 1984, ACADEMIC PRESS, article "Alkylation of Chiral Hydrazones", pages: 275 - 339
EUR..J. BIOCHEM., vol. 138, no. 9-37, 1984, pages 152
EVANS, D. A.; ELLMAN, J. A.; DOROW, R. L., TETRAHEDRON LETT., vol. 28, 1987, pages 1123 - 1126
FEHRENTZ, J.-A.; MARTINEZ, J.; BOEGLIN, D.; GUERLAVAIS, V.; DEGHENGHI, R., DRUGS, vol. 5, 2002, pages 804 - 814
FRCUDC, S.; SCHUBERT, M., DRUG DISC. TODAY: DIS. MODELS, vol. 4, 2007, pages 9 - 16
FRECHET, J.M.J.; HAQUE, K.E., TETRAHEDRON LEFT., vol. 16, 1975, pages 3055
GHIGO, E; ARVAT, E.; CAMANNI, F., ANN. MED., vol. 30, 1998, pages 159 - 168
GUTIERREZ, J.A.; SOLENBERG, P.J.; PERKINS, D.R. ET AL., PROC. NATL. ACAD. SCI., vol. 105, 2008, pages 6320 - 6325
HALEM, H.A.; TAYLOR, J.E.; DONG, J.Z. ET AL., EUR. J. ENDOCRINOL., vol. 151, 2004, pages S71 - S75
HALEM, H.A.; TAYLOR, J.E.; DONG, J.Z.; SHEN, Y.; DATTA, R.; ABIZAID, A.; DIANO, S.; HORVATH, T.; ZIZZARI, P.; BLUET-PAJOT, M.-T., EUR. J. ENDOCRINOL., vol. 151, 2004, pages 71 - 75
HANSEN, D. W., JR.; PILIPAUSKAS, D., J. ORG. CHEM., vol. 50, 1985, pages 945 - 950
HELMLING, S.; MAASCH, C.; EULBERG, D. ET AL., PROC. NATL. ACAD. SCI USA, vol. 101, 2004, pages 13174 - 13179
HIGGINS, S.C.; GUEORGUIEV, M.; KORBONITS, M., ANN. MED., vol. 39, 2007, pages 116 - 136
HOJO, H.; AIMOTO, S., BULL. CHEN?. SOC. JPN., vol. 64, 1991, pages 111 - 117
HOLST, B.; CYGANKIEWICZ, A.; HALKJAER, T.; ANKERSEN, A.; SCHWARTZ, T.W., MOL. ENDOCRINOL., vol. 17, 2003, pages 2201 - 2210
HOLST, B.; CYGANKIEWICZ, A.; JENSEN, T.H.; ANKCRSCN, M.; SCHWARTZ, T.W., MOL. ENDOCRINOL., vol. 17, 2003, pages 2201 - 2210
HOLST, B.; HOLLIDAY, N. D.; BACH, A.; ELLING, C.E.; COX, H.M.; SCHWARTZ, T.W., J. BIOL. CHEM., vol. 279, 2004, pages 53806 - 53817
HOLST, B.; SCHWARTZ, T., J. CLIN. INVEST., vol. 116, 2006, pages 637 - 641
HOLST, B.; SCHWARTZ, T.W., TRENDS PHARMACOL. SCI., vol. 25, 2004, pages 113 - 117
HORVATH, T.L.; CASTAÑEDA, T.; TANG-CHRISTENSEN, M.; PAGOTTO, U.; TSCHOP, M.H., CURR. PHARM. DESIGN, vol. 9, 2003, pages 1383 - 1395
HOWARD, A.D.; FEIGHNER, S.D.; CULLY, D.F. ET AL., SCIENCE, vol. 273, 1996, pages 974 - 977
HUNT, S.: "Chemistry and Biochemistry of the Amino Acids", 1985, CHAPMAN AND HALL
INT.J. PEPT. PROT. RES., vol. 24, 1984, pages 84
INUI, A.; ASAKAWA, A.; BOWERS, C.Y.; MANTOVANI, G.; LAVIANO, A.; MEGUID, M.M.; FUJIMIYA, M., FASEB J., vol. 18, 2004, pages 439 - 456
ISHII, S.; KAMEGAI, J.; TAMURA, H.; SHIMIZU, T.; SUGIHARA, H.; OIKAWA, S., ENDOCRINOLOGY, vol. 143, 2002, pages 4934 - 4937
ISIDRO, M.L.; CORDIDO, F., COMB. CHEM. HIGH THROUGHPUT SCREEN, vol. 9, 2006, pages 178 - 180
J. BIOL. CHEM., vol. 247, 1972, pages 977 - 983
J. BIOL. CHEM., vol. 260, 1985, pages 14 - 42
JAMES, I.W., TETRAHEDRON, vol. 55, 1999, pages 4855 - 4946
JCBN/NC-IUB NEWSLETTER, vol. 1986, 1985, pages 1989
JENSEN, A.A. ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 29547 - 29555
JERLHAG, E.; EGECIOGLU, E.; DICKSON, S.L.; ENGEL, J.A., PSYCHOPHARMACOL., vol. 211, 2010, pages 415 - 422
JERLHAG, E.; EGECIOGLU, E.; LANDGREN, S. ET AL., PROC. NALL. ACAD. SCI..USA, vol. 106, 2009, pages 11318 - 11323
KAIYA, II.; MIYAZATO, M.; KANGAWA, K.; PETER, R.E.; UNNIAPPAN, S., COMP. BIOCHEM. PHYSIOL., vol. 149, 2008, pages 109 - 128
KAUR, S.; RYABININ, A.E., ALCOHOL. CLIN. EXP. RES., vol. 34, 2010, pages 1525 - 1534
KOJIMA, K.; KANGAWA, K., NAT. CLIN. PRACT. ENDOCRINAL. METAH., vol. 2, 2006, pages 80 - 88
KOJIMA, M.; HOSODA, H. ET AL., NATURE, vol. 402, 1999, pages 656 - 660
LASSETER, K.C.; SHAUGHNESSY, L.; CUMMINGS, D. ET AL., J. CLIN. PHARMACOL., vol. 48, 2008, pages 193 - 202
LEGGIO, L., DRUG NEWS PERSPECT., vol. 23, 2010, pages 157 - 166
LEPOUL, E. ET AL., J. BIOMOL. SCREEN., vol. 7, 2002, pages 57 - 65
LI, A.P., DRUG. DISC. TODAY, vol. 6, 2001, pages 357 - 366
LIPINSKI, C.A.; LOMBARDO, F.; DOMINY, B.W.; FEENEY, P.J., ADV. DRUG DELIVERY REV., vol. 23, 1997, pages 3 - 25
LIU ET AL., J. MED. CHEM., vol. 46, 2003, pages 2093 - 2103
LIU, B.; LIU, G.; XIN, Z. ET AL., BIOORG. MED. CHEM. LETT., vol. 14, 2004, pages 5223 - 5226
LOCATELLI, V.; TORSELLO, A., PHARMACOL. RES., vol. 36, 1997, pages 415 - 423
MALAGUAMERA, M.; DI ROSA, M.; NICOLETTI, F.; MALAGUARNERA, L., J. MOL. MED., vol. 87, 2009, pages 679 - 695
MARTIN, G.E.; ZEKTZER, A.S.: "Performance,and Interpretation", 1988, JOHN WILEY & SONS, article "Two-Dimensional NMR Methods for Establishing Molecular Connectivity: A Chemist's Guide to Experiment Selection"
MELDAL, M., TETRAHEDRON LETT., vol. 33, 1992, pages 3077 - 3080
MEYER, S.D.; S.L. SCHREIBER, J.ORG.CHEM, vol. 59, 1994, pages 7549 - 7552
MINUTI, L., TETRAHEDRON ASYMM., vol. 14, 2003, pages 481 - 487
MUEGGE, 1., MED. RES. REV., vol. 23, 2003, pages 302 - 321
MUNIYAPPA, R.; LEE, S.; CHEN, H.; QUON, M.J., AM. J. PHYSIOL., vol. 294, 2008, pages E15 - E26
MURAKAMI, N.; HAYASHIDA, T.; KUROIWA, T. ET AL., J. ENDOCRINOL., vol. 174, 2002, pages 283 - 288
NAKAZATO, M.; MURAKAMI, N.; DATE, Y. ET AL., NATURE, vol. 409, 2001, pages 194 - 198
NANDI, A. ET AL., PHYSIOL. REV., vol. 84, 2004, pages 623 - 647
NARGUND, R.P.; PATCHETT, A.A.; BACH, M.A.; MURPHY, M.G.; SMITH, R.G., J. MED. CHEM., vol. 41, 1998, pages 3103 - 3127
NICOLAS, E.; RUSSELL, K. C.; KNOLLENBERG, J.; HRUBY, V. J., J. ORG. CHEM., vol. 59, 1993, pages 7565 - 7571
ORG. SYNTH. COLL., vol. 5, 1973, pages 179
PALUCKI, B.L. ET AL., BIOORG. MED. CHEM. LETT., vol. 11, 2002, pages 1955 - 1957
PALUCKI, B.L. ET AL., BIOORG. MED. CHERN. LETT., vol. 11, 2001, pages 1955 - 1957
PANTEL, J.; LEGENDRE, M.; CABROL, S. ET AL., J. CLIN. INVEST., vol. 116, 2006, pages 760 - 768
PASTERNAK, A; GOBLE, S.D.; DEJESUS, R.K. ET AL., BIOORG. MED. CHEM. LETT., vol. 19, 2009, pages 6237 - 6240
PERELLO, M.; SAKATA, I.; BIRNBAUM, S. ET AL., BIOL. PSYCHIATRY, vol. 67, 2010, pages 880 - 886
PERLEMUTER, G.; BIGORGNE, A.; CASSARD-DOULCIER, A.-M.; NAVEAU, S., NAT. CLIN. PRACT. ENDOCRINOL. METAB., vol. 3, 2007, pages 458 - 469
PINILLA, L.; BARREIRO, M.L.; TENA-SEMPERE, M.; AGUILAR E., NEUROENDOCRINOLOGY, vol. 77, 2003, pages 83 - 90
PULKKINEN, L.; UKKOLA, O.; KOLEHMAINEN, M.; UUSITUPA, M., INT. J. PEPT., 2010
PURE APPL. CHEM., vol. 45, 1976, pages 13 - 30
PURE APPL. CHERN., vol. 56, 1984, pages 595 - 624
RAPP, W.; ZHANG, L.; BAYER, E.: "Peptides, Polypeptides and. Oligonucleotides", SPCC LTD., article "Innovations and Persepctives in Solid Phase Synthesis", pages: 205
RASMUSSEN; HUSKINSON, BEHAVIORAL PHARMACAL., vol. 19, 2008, pages 735 - 742
REUTER, T.Y., DRUG DISC. TODAY: DIS. MODELS, vol. 4, 2007, pages 3 - 8
ROMERO, A.; KIRCHNER, H.; HEPPNER, K. ET AL., EUR. J. ENDOCRINOL., vol. 163, 2010, pages 1 - 8
SARTOR, 0. ET AL., ENDOCRINOLOGY, vol. 117, 1985, pages 1441 - 1447
SHAFRIR, E.; ZIV, E., AM J. PHYSIOL., vol. 296, 2009, pages E1450 - E1452
SHAH, P.; JOGANI, V.; BAGCHI, T.; MISRA, A., BIOTECHNOL. PROG., vol. 22, 2006, pages 186 - 198
SHAO, H.; GOODMAN, M., J. ORG. CHEM., vol. 61, 1996, pages 2582
SHEARMAN, L.P.; WANG, S.P.; HELMLING, S. ET AL., ENDOCRINOLOGY, vol. 147, 2006, pages 1517 - 1526
SIBILIA, V.; MUCCIOLI, G.; DEGHENGHI, R. ET AL., J. NEUROENDOCRINOL., vol. 18, 2006, pages 122 - 128
SINDCLAR, D. K.; MYSTKOWSKI, P.; MARSH, D. J.; PALMITER, R. D.; SCHWAI-TZ, M. W, DIABETES, vol. 51, 2002, pages 778 - 783
SMITH, R.G.; SUN, Y.X.; BEATANCOURT, L.; ASNICAR, M., REST PRACT. RES. CLIN. ENDOCRINOL. METAB., vol. 18, 2004, pages 333 - 347
SOARES, J.-B.; RONCON-ALBUQUERQUE, R., JR.; LEITE-MOREIRA, A., EXP. OPIN. THER. TARGETS, vol. 12, 2008, pages 1177 - 1189
SPANSWICK, D.; LEE, K., EXP. OPIN. EMERGING DRUGS, vol. 8, 2003, pages 217 - 237
STILL, W. C.; KAHN, M.; MITRA, A., J. ORG. CHEM., vol. 43, 1978, pages 2923 - 2925
SUN, D.; YU, L.X.; HUSSAIN, M.A.; WALL, D.A.; SMITH, R.L.; AMIDON, G.L., CURR. OPIN. DRUG DISCOV. DEVEL., vol. 7, 2004, pages 75 - 85
SUN, Y.; ASNICAR, M.; SMITH, R.G., NEUROENDOCRINOL., vol. 86, 2007, pages 215 - 228
SUN,Y.; AHMCD, S.; SMITH, R.G., MOL. CELL BIOL., vol. 23, 2003, pages 7973 - 7981
SUN,Y.; AHMED, S.; SMITH, R.G., MOL. CELL BIOL., vol. 23, 2003, pages 7973 - 7981
SVENSSON, J. EXP. OPIN. THER. PATENTS, vol. 10, 2000, pages 1071 - 1080
TACKE, F.; BRABANT, G.; KRUCK, E.; HORN, R. ET AL., J. HEPALOTOGY, vol. 38, 2003, pages 447 - 454
THCODORIDIS, G., TETRAHEDRON, vol. 56, 2000, pages 2339 - 2358
THEODORA W. GREENE AND PETER G. WUTS,: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS
THOMSEN, W. ET AL., CURR. OPIN. BIOTECHNOL., vol. 16, 2005, pages 655 - 665
TONG, J.; PRIGEON, R.L.; DAVIS, H.W. ET AL., DIABETES, vol. 59, 2010, pages 2145 - 2151
TOZAWA-TAKAHASHI F ET AL., 11TH SBS ANNUAL CONFERENCE, September 2005 (2005-09-01)
TRINQUET, E.; FINK, M.; BAZIN, H. ET AL., ANAL. BIOCHEM, vol. 358, 2006, pages 126 - 135
TURPEINEN, M.; KORHONEN, L.E.; TOLONEN, A. ET AL., EUR. J. PHARM. SCI., vol. 29, 2006, pages 130 - 138
UCHIKAWA, O., J. MED. CHEM., vol. 45, 2002, pages 4212 - 4221
UCHIKAWA, O., J. MED. CHEM., vol. 45, 2002, pages 4222 - 4239
UKKOLA, O., CURR. PROT. PEPT. SCI., vol. 10, 2009, pages 2 - 7
VAN DER LELY, A.J.; TSCHOP, M.; HEIMAN, M.L.; GHIGO, E., ENDOCRINE REV., vol. 25, 2004, pages 426 - 457
VAN MAARSCVCCN, J.H., COMB. CHEM. HIGH THROUGHPUT SCREEN., vol. 1, 1998, pages 185 - 214
VEBER, D.F.; JOHNSON, S.R.; CHENG, H.-Y.; SMITH, B.R.; WARD, K.W.; KOPPLC, K.D., MED. CHEM., vol. 45, 2002, pages 2615 - 2623
VEDEJS, E.; LIN, S.; KLAPARA, A.; WANG, J., J. AM. CHEM. SOC., vol. 118, 1996, pages 9796 - 9797
WANDLESS, T.J. ET AL., J. AM. CHEM. SOC., vol. 11S, 2003, pages 6864 - 6865
WELLS, T., PROG. LIPID RE.S., 2009
WERMUTH, C.G. AND STATIL, P.H.: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VERLAG HELVETICA ACTA
WHITE, R.E., ANN. REV. PHARMACAL. TOXICOL., vol. 40, 2000, pages 133 - 157
WILKINSON, G. R.: "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL, article "Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination"
WORTLEY, K.E.; ANDERSON, K.D.; GARCIA, K. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 8227 - 8232
WURST, F.M.; GRAF, I.; EHRENTHAL, H.D. ET AL., ALCOHOL. CLIN. EXP. RES., vol. 31, 2007, pages 2006 - 2020
XIAO, N.; JINAG, Z.-H.; YU, Y.B., BIOPOLYMERS (PEPT. SCI.), vol. 88, 2007, pages 781 - 796
XIN, Z.; ZHAO, H.; SERBY, M.D. ET AL., BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 1201 - 1204
YADA, T.; DEZAKI, K.; SONE, H. ET AL., CURR. DIAB. REV., vol. 4, 2008, pages 18 - 23
YANG, J.; ZHAO, T.J.; GOLDSTEIN, J.L. ET AL., PROC. NATL. ACAD. SCI., vol. 105, 2008, pages 10750 - 10755
YOUNOSSI, Z.M., ALIMENT. PHARMACOL. THER., vol. 28, 2008, pages 2 - 12
ZDRAVKOVIC M.; OLSE, A.K.; CHRISTIANSEN, T. ET AL., EUR. J. CLIN. PHARMACOL., vol. 58, 2003, pages 683 - 688
ZHANG, L.; TAM, J., J. AM. CHEM. SOC., vol. 121, 1999, pages 331 - 3320
ZHAO, H.; XIN, Z.; LIU, G. ET AL., J. MED. CHEM., vol. 47, 2004, pages 6655 - 6657
ZHAO, H.; XIN, Z.; PATEL, J.R. ET AL., BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 1825 - 1828

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119800A1 (en) * 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US9821042B2 (en) 2012-02-07 2017-11-21 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
US10450286B2 (en) 2013-03-13 2019-10-22 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10399951B2 (en) 2013-03-13 2019-09-03 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10800750B2 (en) 2013-03-13 2020-10-13 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10457655B2 (en) 2013-03-13 2019-10-29 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10472342B2 (en) 2013-03-13 2019-11-12 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US10995078B2 (en) 2013-03-13 2021-05-04 Forma Therapeutics, Inc. Compounds and compositions for inhibition of FASN
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
US11098080B2 (en) 2015-10-27 2021-08-24 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US10030047B2 (en) 2015-10-27 2018-07-24 Hoffmann-La Roche Inc. Peptide macrocycles against acinetobacter baumannii
US12012466B2 (en) 2015-10-27 2024-06-18 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
EP3432874B1 (en) * 2016-04-14 2021-01-13 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods and compositions for treatment of prader-willi syndrome
US11066443B2 (en) 2017-04-10 2021-07-20 Hoffmann-La Roche Inc. Anti-bacterial peptide macrocycles and use thereof
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US10875848B2 (en) 2018-10-10 2020-12-29 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US11299484B2 (en) 2018-10-10 2022-04-12 Forma Therapeutics, Inc. Inhibiting fatty acid synthase (FASN)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US11267805B2 (en) 2018-10-29 2022-03-08 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl) piperazine-1-yl)(1-hydroxycyclopropyl)methanone

Also Published As

Publication number Publication date
JP2013509434A (en) 2013-03-14
US20110105389A1 (en) 2011-05-05
EP2493910A1 (en) 2012-09-05
AU2010313282A1 (en) 2012-05-24
CN102812037A (en) 2012-12-05
CA2778990A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
WO2011053821A1 (en) Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
JP5219509B2 (en) Use of macrocyclic modulators of ghrelin receptor
JP5363726B2 (en) Use of macrocyclic modulators of ghrelin receptor
EP2644618B1 (en) tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
US20090275648A1 (en) Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
JP5122446B2 (en) Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of use thereof
USRE42013E1 (en) Macrocyclic modulators of the ghrelin receptor
USRE42624E1 (en) Methods of using macrocyclic modulators of the ghrelin receptor
US20090198050A1 (en) Macrocyclic Modulators of the Ghrelin Receptor
WO2006046977A1 (en) Macrocyclic ghrelin receptor antagonists and methods of using the same
US20180110824A1 (en) Macrocyclic Modulators of the Ghrelin Receptor
US9493505B2 (en) Macrocyclic modulators of the ghrelin receptor
WO2011146845A1 (en) Modified macrocyclic ghrelin receptor modulators and methods of using the same
JP5739766B2 (en) Use of macrocyclic modulators of ghrelin receptor
JP5730835B2 (en) Use of macrocyclic modulators of ghrelin receptor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080060081.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10774101

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010313282

Country of ref document: AU

Ref document number: 2778990

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012537129

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 4233/CHENP/2012

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2010313282

Country of ref document: AU

Date of ref document: 20101029

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010774101

Country of ref document: EP